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To be effective, a drug must be efficiently delivered in sufficient quantities over a period of time 
long enough for it to carry out its desired effect. A major challenge in this sense is poor retention 
and bioavailability of drugs, particularly those that display poor solubility. The number of newly 
discovered drugs is disproportionate to the number that make it to market because of less than 
desirable solubility and permeability profiles, but smart drug delivery systems, such as lipid-based 
systems, are capable of overcoming these challenges. One particular system, the amphiphilic, 
biocompatible, and biodegradable lipid cubic phase, has shown promise as an effective carrier 
system for the controlled release of drugs varying in solubility. This work explores the behaviour 
of a variety of industrially relevant small molecule pharmaceuticals in lipid cubic phases 
formulated with different host lipids for potential controlled delivery applications. An 
understanding of the molecular mechanisms underlying the process of dissolution/diffusion from 
these phases was elucidated to support the field of controlled drug delivery using in silico 
molecular dynamic modelling and empirical approaches.  A comprehensive characterization 
approach was taken both macroscopically and microscopically using small-angle X-ray scattering 
and polarized light to ascertain the mesophase accessed upon incorporation of molecules of 
varying solubilities and size. 
 
In the first instance, the influence of environmental conditions on the release profile of four 
antihistamine molecules was studied to establish in vitro models that might assist in predicting the 
dissolution behaviour of a given pharmaceutical with known physicochemical properties. Two 
model first-generation and two model second-generation H1 antagonist antihistamine drugs were 
selected and formulated in two separate monoacyglycerol-derived matrices. The impact of 
encapsulating the molecules in the lipid cubic systems on their mucoadhesive properties was 
demonstrated using multi-parametric surface plasmon resonance (MP-SPR). With a potential 
application in developing therapies for the treatment of allergic reactions, the ability of the 
formulations to inhibit mediator release utilizing RBL-2H3 mast cells with the propensity to 
release histamine upon induction was presented.  
 
Lipid cubic formulations can enhance the intestinal solubility and subsequent bioavailability of 
notoriously hydrophobic drug entities by reducing drug precipitation and facilitating mass 
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transport to the intestinal surface for absorption. In this context, the aims of the second study were 
twofold: to evaluate an approach to regulate the rate of degradation of lipid cubic phase drug 
delivery systems by targeting the enzyme interactions responsible for their demise; and to study 
the subsequent drug release profiles from bulk lipid cubic gels using model drugs of contrasting 
hydrophobicity. In a novel approach, monoacylglycerol cubic phases were formulated with a 
potent lipase inhibitor tetrahydrolipstatin displaying controlled degradation with at least a 4-fold 
longer release compared to the blank systems. Sustained release of a model hydrophobic 
pharmaceutical (a clofazimine salt) was studied over 30 days to highlight the advantage of 
incorporating an inhibitor into the cubic network to achieve tunable lipid release systems.  
 
The final aspect of this thesis deals with the interplay between the lipolysis rate and the 
interfacial interaction of porcine pancreatic lipase with lipid cubic substrates encapsulating the 
THL.  In the final chapter, inhibitor-modified monoolein lipid cubic formulations designed to 
encapsulate and control the release of a model BCS class IV drug paclitaxel (PTX) were examined 
under simulated lipolysis in the presence of lipase and its cofactors colipase and calcium. We 
present a combination of thermodynamic and molecular dynamics simulations of the competitive 
inhibition with experimental dynamic digestion studies to reveal the role and mode of action of 
the studied lipase effectors in designing a degradation-controlled release system for the poorly 
soluble drug PTX. These studies facilitated a deeper understanding of the approach described in 
the previous chapter, expanding the study to open new important possibilities in the field of 

















i. Dully, M., Brasnett, C., Djeghader, A., Seddon, A., Neilan, J., Murray, D., Butler, J., 
Soulimane, T. and Hudson, S.P., 2020. Modulating the release of pharmaceuticals from 
lipid cubic phases using a lipase inhibitor. Journal of Colloid and Interface Science. 
ii. Dully, M., Ceresnakova, M., Soulimane, T. and Hudson, S.P. A Lipid Cubic System 
for prolonged delivery of antihistamine drugs. Under review 
iii. Dully, M., Bhattacharya, S., Verma, V., Murray, D., Thompson, D., Soulimane, T. and 
Hudson, S.P. Probing the mechanism behind inhibitor-controlled degradation of lipid 
cubic formulations. In progress 
iv. Ceresnakova, M., Dully, M., Soulimane, T. and Hudson, S.P. Stent conditioned media 
for in vitro evaluation of hydrophobic stent coatings. In progress 




i. Outside front cover artwork for Journal of Colloid and Interface Science Volume 574 
August 2020 (Appendix D) 
ii. BOC gases bursary for outstanding researcher recipient 2019 
iii. Published Case study “Modulating API release with a tuneable lipid carrier” for 
Diamond Light Source, Didcot, United Kingdom (Appendix E) 
iv. Bernal Research Day Illustration award 1st place  
v. YESBernal Writing competition First place for article titled “Teaching reimagined – 




WORKSHOPS & CONFERENCES 
 
i. Dissolution workshop at the School of Pharmacy and Pharmaceutical Sciences, TCD 
ii. Poster presentation at COST Imaging School at the Hamburg Centre for Ultrafast 








List of Acronyms and Abbreviations  
 




Active pharmaceutical ingredient 
Azelastine hydrochloride 

















Critical packing parameter 
Cryogenic transmission electron microscopy 
Cetirizine dihydrochloride 
Double-barrelled syringe 
Drug delivery system 
DI Deionized 
DLS Dynamic light scattering 





EB Ethidium bromide 
ESI-MS Electrospray ionization mass spectroscopy 






Fasted state simulated gastro fluid 





Food and Drug Administration 
Free fatty acids 
Generally regarded as safe 










Liquid chromatography - mass spectroscopy 
Lipid cubic phase 
Lyotropic liquid crystal 
 10 





MCEC Mouse cardiac endothelial cells 
MeOH Methanol 
MO Monoolein (9.9 MAG) 
MPL 
MP-SPR 
Monopalmitolein (9.7 MAG) 








Monovaccenin (11.7 MAG) 
New chemical entities 
Nanostructures lipid carrier 
NMR Nuclear magnetic resonance 


























Rotations per minute 
Solvent accessible surface area 
Small-angle X-ray scattering 
Standard deviation 
Simulated intestinal fluid 
Solid lipid nanoparticles 



















gtot The calculated free energy of a given system 
gp The packing frustration of a given system 
gc The curvature of a system calculated using CPP 
lmax The maximum lipid chain length 
v Volume 
∅aq The volume fraction of the aqueous portion of a liquid crystalline 
phase 
∅MAG The lipid volume fraction 
caq The water weight fraction 
ρaq The density of water (0.997 g cm-3) 
ρMAG  The density of the MAG host lipid  (0.942 g cm
-3[1, 2] for 
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EA-B The single point energy of a given dimer 
EA and EB The respective single point energies of isolated monomers 
ps Pico second 
ns Nano second 
DEbinding The total binding energy of a ligand-receptor complex 
DEbinding, vacuum DEbinding, vacuum = DEMM (molecular mechanics energy = electrostatic 
energy + vdW energy in vacuum) 
DGsolv, complex The free energy of solvation of a given ligand-receptor complex 
DGsolv, ligand The solvation energy of a given ligand 
DGsolv, protein The solvation free energy of a given enzyme receptor 




DGpolar The polar solvation free energy or electrostatic component of 
solvation free energy 
DGnonpolar The nonpolar solvation free energy approximated by the solvent 
accessible surface area (SASA) times a constant factor 
W0 The initial gel weight before immersion in media 
W1 The weight of the submerged gel at a measured time point 
wt% The weight of a component of a system as a % of the total weight of 
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Λmax Maximum absorption wavelength 
cP Measure of viscosity 
px Pixel 
kV Kilo Volts 





























Table of Contents 
Declaration ............................................................................................................................ 2 
Dedication .............................................................................................................................. 3 
Acknowledgments ................................................................................................................... 4 
Abstract .................................................................................................................................. 6 
Key words ............................................................................................................................... 7 
Contributions ......................................................................................................................... 8 
JOURNAL CONTRIBUTIONS ..................................................................................................... 8 
AWARDS ....................................................................................................................................... 8 
WORKSHOPS & CONFERENCES .............................................................................................. 8 
List of Acronyms and Abbreviations ....................................................................................... 9 
Nomenclature ....................................................................................................................... 11 
Chapter I: Introduction & Scientific Background ................................................................. 17 
1.1 Introduction to Drug delivery strategies ................................................................................. 17 
1.2 Lipid based drug delivery systems .......................................................................................... 23 
1.3 Self-assembled Lipid Liquid Crystalline Phases ..................................................................... 29 
1.4 The Cubic Phase: Structure and properties ........................................................................... 33 
1.5 LCP for Drug delivery ............................................................................................................ 39 
Lipid nanosystems in solution ........................................................................................................................... 45 
1.6 Lipid Digestion and its role in drug absorption ...................................................................... 47 
Digestion of MAGs by biological enzymes ...................................................................................................... 47 
Improving oral bioavailability of lipophilic drugs ............................................................................................. 49 
1.7 Concluding Remarks and Identified Research objectives ...................................................... 51 
1.8 Thesis outline .......................................................................................................................... 53 
Chapter II: Lipid Cubic System for the controlled delivery of pharmaceuticals of varied 
solubility. A Case Study: Antihistamine delivery ................................................................... 54 
2.1 Introduction ............................................................................................................................ 54 
2.2 Background ............................................................................................................................. 54 
2.3 Materials and Methods ........................................................................................................... 60 
2.3.1 Materials ................................................................................................................................................... 60 
2.3.2 Preparation of bulk Antihistamine-LCP matrix formulations ................................................................... 60 
2.3.3 Preparation of cubic dispersions (cubosomes) .......................................................................................... 61 
2.3.4 Mesophase characterization ...................................................................................................................... 61 
SAXS data collection ........................................................................................................................................ 61 
SAXS data processing and analysis .................................................................................................................. 62 
Lipid cubic phase structural dimensions calculations ........................................................................................ 62 
Mucoadhesion studies ....................................................................................................................................... 64 
 14 
2.3.5 Particle size estimation and zeta-potential studies [348] .......................................................................... 65 
2.3.6 Drug release studies .................................................................................................................................. 65 
PXRD ................................................................................................................................................................ 65 
Encapsulation efficacy ...................................................................................................................................... 66 
2.3.7 Cell culture methods ................................................................................................................................. 68 
2.3.8 Cell viability study: Cytotoxicity ............................................................................................................. 68 
2.3.9 Cellular uptake of cubosomal formulations .............................................................................................. 69 
2.3.10 Anti immunoglobulin E- (IgE-) induced histamine release studies ........................................................ 69 
2.4 Results and Discussion ............................................................................................................ 70 
2.4.1 Mesophase characterization ...................................................................................................................... 70 
2.4.2 Properties of Cubic dispersions: Zetasizer Studies, encapsulation efficacies ........................................... 74 
2.4.3 Cellular uptake of cubosomes [375] ......................................................................................................... 76 
2.4.4 Cytotoxicity study .................................................................................................................................... 78 
2.4.5 Mucoadhesion studies .............................................................................................................................. 79 
2.4.6 Drug release studies .................................................................................................................................. 83 
2.4.7 RBL-2H3 inhibitory effect study .............................................................................................................. 94 
2.5 Conclusion and leading research questions ............................................................................ 97 
Chapter III: Modulating the Release of Pharmaceuticals from Lipid Cubic Phases using a 
Lipase Inhibitor .................................................................................................................... 99 
3.1 Introduction ............................................................................................................................ 99 
3.2 Background ............................................................................................................................. 99 
3.4 Materials and Methods ......................................................................................................... 103 
3.4.1 Materials ................................................................................................................................................. 103 
3.4.2 Preparation of MAG LCP matrix formulations ...................................................................................... 104 
3.4.3 Mesophase characterization .................................................................................................................... 104 
3.4.4 Enzyme stock preparation ...................................................................................................................... 106 
3.4.5 Swelling and degradation Behaviour ...................................................................................................... 106 
3.4.6 Drug release studies ................................................................................................................................ 107 
3.4.7 High Performance Liquid Chromatography ........................................................................................... 108 
3.4.8 UV-visible Spectroscopy ........................................................................................................................ 108 
3.4.9 Drug release kinetics .............................................................................................................................. 108 
3.5 Results and Discussion .......................................................................................................... 109 
3.5.1 Mesophase characterization .................................................................................................................... 109 
3.5.2 Swelling and degradation ....................................................................................................................... 119 
3.5.3 Drug release studies ................................................................................................................................ 128 
3.6 Conclusions and Leading Research Questions ...................................................................... 136 
Chapter IV: Probing the mechanism behind the inhibitor-controlled degradation of lipid cubic 
formulations ........................................................................................................................ 138 
4.1 Introduction ............................................................................................................................................... 138 
4.2 Background ............................................................................................................................................... 139 
4.3 Materials and Methods ......................................................................................................... 143 
4.3.1 Materials ................................................................................................................................................. 143 
4.3.2 Mesophase characterization .................................................................................................................... 143 
4.3.3 Preparation of PTX-LCP matrix formulations ........................................................................................ 143 
4.3.4 Mesophase characterization .................................................................................................................... 144 
4.3.5 PTX binding energy with lipid and lipase inhibitor using DFT calculations .......................................... 146 
 15 
4.3.6 In silico predictive modelling of enzyme, lipid substrate, and inhibitor interactions ............................. 146 
4.3.7 Digestion Studies .................................................................................................................................... 149 
4.3.8 Solubility study of PTX to facilitate in vitro drug release studies .......................................................... 150 
4.3.9 Degradation controlled in vitro drug release studies .............................................................................. 150 
4.4 Results and Discussion .......................................................................................................... 151 
4.4.1 PTX-LCP matrix formulation and characterization ................................................................................ 151 
4.4.2 PTX binding energy with lipid and lipase inhibitor using DFT calculations .......................................... 158 
4.4.3 Modelling of interactions and binding affinities between the components of lipid cubic formulation via 
atomistic molecular dynamics simulations ...................................................................................................... 161 
4.4.4 Enzyme-driven degradation behaviour ................................................................................................... 168 
4.4.5 In vitro drug release studies .................................................................................................................... 172 
4.5 Conclusions ........................................................................................................................... 175 
Chapter V: Formulation strategies for the lipid cubic phase ................................................ 177 
5.1 Introduction .......................................................................................................................... 177 
5.2 Background ........................................................................................................................... 177 
5.3 Materials & Methods ............................................................................................................ 180 
5.3.1 Materials ................................................................................................................................................. 180 
5.3.2 Double-barrelled syringe method ........................................................................................................... 180 
5.3.3 ‘In situ’ forming cubic phases: studying the effect of swelling buffer ................................................... 181 
5.3.4 SAXS for mesophase assignment ........................................................................................................... 182 
5.4 Results & Discussion ...................................................................................................... 182 
5.4.1 Double-barrelled syringe method ........................................................................................................... 182 
5.4.2 ‘In situ’ forming cubic phases: studying the effect of swelling buffer ................................................... 184 
5.5 Conclusions ........................................................................................................................... 187 
Chapter VI Conclusions & Future directions ...................................................................... 189 
6.1 Conclusions ........................................................................................................................... 189 
6.2 Final words and future directions ......................................................................................... 195 
References ........................................................................................................................... 197 
Appendices .......................................................................................................................... 226 
Appendix A ......................................................................................................................... 227 
Appendix A ......................................................................................................................... 228 
A.1. Calibration Curves .............................................................................................................. 228 
A.2. Host lipid selection .............................................................................................................. 230 
A.3. Cell Culture ......................................................................................................................... 233 
A.4. Mucoadhesion Studies: MP-SPR investigation ................................................................... 233 
A.5. PXRD of antihistamine drugs ............................................................................................. 236 
A.6. SAXS patterns of antihistamine-loaded LCP ...................................................................... 237 
Appendix B ......................................................................................................................... 239 
 16 
Appendix B ......................................................................................................................... 240 
Appendix C ......................................................................................................................... 263 
Appendix C ......................................................................................................................... 264 
Appendix D ......................................................................................................................... 272 







































Chapter I: Introduction & Scientific Background 
 
1.1 Introduction to Drug delivery strategies 
 
The in vivo effectiveness and efficiency of pharmaceuticals in the treatment of a wide range of 
disease states is often related to, or limited by, the administration route and the chosen dosage form 
for a particular therapy. To attain the desired therapeutic effect, the drug must first reach the target 
site of action following administration. Despite the enormous amount of new chemical entities 
discovered yearly with therapeutic potential, the vast majority, even with strategic formulation, are 
unable to localize at the target disease site (especially Class IV drugs, figure 1.1). The result is a 
distinct imbalance between those entities that gain regulatory approval, and those that do not 




Figure 1.1. Four classes of pharmaceuticals according to the Biopharmaceutical Classification 
System (BCS) recreated from [4] 
 
In overcoming this imbalance, the design of a drug delivery strategy may first look at the 
selection of the most suitable route of administration, a decision that is limited by the nature of the 























challenges associated with each route are laid out in figure 1.2 and careful consideration should be 
given in assessing these aspects. For one, obtaining and maintaining optimal drug plasma 
concentrations after administration (through oral, intravenous, intramuscular routes) is 
problematic due to rapid normal body metabolism. Dilution of the administered dose to 
concentrations below the therapeutically effective concentration can induce drug resistance in 
target cells [5]. Variations in drug absorption and concentration related to individual administration 
routes mean that more concentrated dosages or multiple dosages over the treatment period may be 
required to compensate for these inconsistencies, bringing with it a plethora of other complications 
(including a risk of toxicity). Further, the site-specific bioavailability of drugs is also severely 
limited by the presence of physical barriers in vivo that must be passed.  The extent of the restrictive 
barricade varies between tissues and the therapies given, which govern the suitability of potential 
approaches to overcome the obstacles. Such physical barriers may include tissues and/or the 
materials they produce (including enzymes). While those such as the skin and the blood-brain 
barrier present more distinct barriers to flux, others such as connective tissue surrounding a nerve 
or plaque deposits may be less obvious in their ability to impede the exchange of pharmaceutical 







✓ Overcome oral delivery issues. 
 
✗ Risk of infection and invasive. 
 
Transdermal Delivery 
✓ Non-invasive, painless, possibility 
of patient self-administration. 
 
✗ Favours low MW, low dosage 
(mg), lipophilic drugs [9-11], drugs 
must be capable of crossing the 
impermeable barrier at low flux [12]. 
 
Vaginal Delivery 
✓ Local delivery to infection site, 
mucosal membrane [13], convenient 
access, high permeation area and  
vascularization, relatively low 
enzymatic activity, avoidance of 
first-pass metabolism. 
 





✓ Reduced infection risk vs IV [14, 
15], delivery of poorly soluble drugs 
in solvent. 
 
✗ Pain, aqueous solubility issue 




✓ Local delivery to infection site 
[16], possible self-administration 
 
✗ Localized pain, volume 
restrictions, tissue backpressure, 
leakages [17]. 




Figure 1.2 Drug administration routes and their 
associated benefits and challenges 
 
Nasal Delivery 
✓ Readily accessible, large surface area, 
porous endothelial membrane and high 
blood flow, access to blood brain barrier 
[18]. 
 
✗ Mucociliary clearance and filtration 
mechanisms [19, 20], low deliverable 
volumes (<200 µl) and molecular weight 
cut off (~1 kDa) [21]. 
 
Oral Delivery 
✓ Economical benefits, patient 
compliance, flexibility and reduced sterility 
concerns, variations in pH for responsive 
delivery. 
 
✗ pH and enzymes directly influence the 
behaviours of drugs within the 
gastrointestinal tract [12]. 
 
Pulmonary Delivery 
✓ Large surface area, plentiful alveoli, thin 
tissue lining [22], low hydrolytic enzyme 
concentration [23-26]. 
 
✗ Inefficient drug delivery, requirement 
for frequent administration, liquid 
formulations include environmentally 
unfriendly chlorofluorocarbons [27].  
 
Bone Delivery 
 ✓ Local delivery, concomitant scaffold 
and drug delivery [28-30]. 
 
✗ Bisphosphonates colloids or calcium 
salt/complex precipitates of in plasma [31]. 
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Following administration, it is necessary for the drug to reach the desired site of action in order 
to achieve a favourable therapeutic index, while preferably having minimal interaction with 
healthy tissue along the way. Localized or ‘smart’ targeted delivery alleviates unwanted side 
effects often seen in non-specific systemic and conventional delivery such as with intravenous or 
oral routes, and serves to maximise the drug’s efficacy at the desired organ or tissue. Here, the 
design of tailored drug delivery systems (DDS) is an attractive approach to improve the 
pharmaceutical biodistribution, retention time [32], tissue uptake, pharmacokinetics and 
therapeutic index of existing drug entities  [33-36] and conventional free dosage forms [37]. 
Further, many DDS have the added advantages of impeding early metabolism and elimination of 
the drug by shielding it from digestive enzymes and in vivo environments and also lend themselves 
to the possibility of associating the drug moieties with a specific intracellular component.  
 
For the numerous routes of administration that exist, matching the drug formulation strategy 
with the preferred route of administration must be considered. Here, ‘formulation’ applies not only 
to the inputs and processes of the drug manufacturing process, but also the final form of the dosage 
product, which is ultimately what a patient receives. This encapsulates all dosage forms and DDS; 
from tablets to capsules, ointments and liquids, reservoir and matrix type systems, sustained 
release drug delivery systems to emulsions, solid dispersions, drug conjugates and organic, 
inorganic and metal organic frameworks among countless others [38, 39]. Currently, the vast 
majority of research in this field is directed towards polymeric systems, ceramics, plastics, and 
inorganic materials. In that context, drug molecules can be incorporated into a DDS by simple 
mixing approaches, chemically through covalent attachment, or through encapsulation of the drug 
in the final formulation. Depending on the ultimate aim and desired site of action, countless 
materials for DDS exist, and the selection of the most suitable in terms of chemical characteristics, 
geometry and release properties as well as biocompatibility and immunogenicity is an important 
stage in the design process [40, 41]. These will be looked at these in more detail to highlight the 
relationship between the design of a drug delivery strategy and the challenging properties of (i) 
the drug molecule (either chemical or physical properties), (ii) the target site in the body and (iii) 
the preferred route of administration.   
 
Polymeric systems (including biodegradable and nondegradable polymers) are non-corrosive 
and can demonstrate density values close to those of natural tissue such as collagen and hyaluronic 
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acid making them attractive materials in drug delivery applications [42]. The benefits of these 
systems are related to the properties of the materials selected which could be of natural origin 
(chitosan, dextran [43], etc.) or synthetic (block co-polymers, etc.). Commonly used synthetic 
polymers include polymethylmethacrylate, polyvinyl alcohol, polylactides, polyanhydrides among 
many others [42] and are easily fabricated into many forms. Polymeric nanoparticles such as 
PLGA nanoparticle systems have been studied for the delivery of drugs in managing infection 
[44]. These systems offer a number of advantages in: overcoming the biological barriers and 
transport drugs at high local concentrations [45, 46] within a desirable time [47, 48]; enhancing 
pharmacological activity and overcoming issues of solubility and toxicity, for example with plant 
bioactive compounds in curcuminoids [49, 50]. Although synthetic polymer systems constitute a 
large range of DDS, the requirement for essential fabrication additives such as anti-discolouring 
agents, plasticizers and antioxidants in many cases pose a toxic risk if additive leaching was to 
occur [42]. Further, the low modulus of elasticity and viscoelastic characteristics of these polymer 
make them unsuitable for load bearing applications. Not only that, but the acidic nature of the 
degradative products of certain polymers such as poly(glyco1ic acid) (PGA) and poly(L-lactic 
acid) (PLA) can induce unwanted side effects in vivo [51]. Certain polymers such as polylactides 
and glycolides are highly susceptible to harsh environmental conditions such as low pH, high 
temperature and radiation which can dramatically alter the mode of degradation and action 
potentially ruling them out for certain applications [52].  
 
Other polymeric DDS, including naturally occurring polymers, can be designed such that 
physicochemical modifications of the formulation can provide stimuli-responsive systems [53-58], 
garnering tighter control of the release kinetics under certain conditions of pH [59], hydration or 
temperature [60], or through the use of external stimuli such as light [61, 62]. The DDS may be 
present as free-flowing liquids at room temperature, that swell or gelate at physiological pH and 
temperature, increasing their mesh size to facilitate drug release [63]. The most widely studied 
class of swellable delivery systems are hydrogels, hydrophilic networks that swell rapidly in 
aqueous solvents [64-66]. An in situ swelling hydrogel with a polyelectrolyte complex, was shown 
to sustain the release of proteins (insulin and Avidin) over two weeks [67]. The natural polymer 
xyloglucan (1.5% w/w) has also been used to formulate in situ gels, specifically for ocular delivery 
in a rabbit model [68]. Various other polymers such as alginic acid [69], chitosan [70] and 
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Carbopol [71] have also been investigated in these applications. Hydrogel nanoparticles combine 
the advantages of both hydrogels and nanoparticles [72-76]. They comprise 3D crosslinked 
polymeric networks that are formed upon self-assembly of amphiphilic copolymers, giving rise to 
nanostructures with a hydrophilic exterior and hydrophobic core. The minimal associated toxicity 
and serum stability [77, 78], and their small size makes them injectable and easily internalized by 
cells [64, 79, 80]. Mucoadhesive polymeric systems have been designed to improved drug 
retention [81], including hydrogels, microspheres (including those formulated from alginate for 
the delivery of hypertension drug carvedilol [82] and dextran [83], albumin and degradable starch 
for the delivery of insulin [84]); and in situ gelling formulations [85-87]. The advantage of 
naturally occurring polymer systems over other polymer type DDS is that they usually do not 
require the use of organic solvents or chemical crosslinking agents, reducing associated toxicity. 
However, the hydrated systems usually exhibit poor mechanical properties and stiffness. Further, 
the high hydration capacity of the hydrophilic polymers, such as Carbopol®, sodium alginate, 
Poloxamer®, hydroxypropylmethylcellulose, and hydroxyethylcellulose, accelerate erosion of the 
system in aqueous media leading to rapid drug release [88-90]. 
 
Composite materials [91, 92] such as composite nanofibers [93], and ceramics [94] are also 
utilized as DDS. While they can be hard and brittle, they can also demonstrate high compressive 
strength which may be more attractive for load bearing applications [94, 95]. Commonly used 
ceramic materials include hydroxyapatite ceramics [96] and tricalciumphosphate ceramics [97, 
98]. In recent years, “bone-seeking” agents with osteotropic properties such as bisphosphonates 
[31] have been investigated to enhance and prolong pharmacological effects in osteo-applications 
to deliver gentamicin and other antibiotics to combat osteomyelitis, as well as anti-inflammatory 
drugs and bisphosphonates, and growth factors [99]. However, these bisphosphonate conjugates 
can form colloids or calcium salt/complex precipitates in plasma that cause a major 
pharmacokinetic drawback sometimes leading to renal or hepatosplenic accumulation [31]. 
Magnetic nanoparticles have also demonstrated potential for different biomedical applications, 
including oncology [100]. The small magnetic particles can be modulated to react to certain 
magnetic field gradients to elicit a controllable desired effect in the body. The versatile systems 
have been used in therapies such as drug delivery, magnetic hyperthermia, photodynamic and 
photothermal therapy [101-103]. Fe3O4 nanoparticles combined with PEG-based hydrogel 
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magnetic nanoparticles have demonstrated efficient delivery of paclitaxel to glioma cells [100], 
however, toxicity of other magnetic nanoparticles, such as manganese nanoparticles, may be an 
issue [104] in the clinical applicability of these systems.  
 
1.2 Lipid based drug delivery systems 
 
Several commonly studied DDS have now been introduced, and in doing so a number of 
challenges associated with them have been highlighted, including: associated toxicity (of the 
material itself or of solvents in their manufacture), rapid release, environmental factors and 
mechanical properties among others. A final group of DDS that are the topic of this thesis, are 
biocompatible and biodegradable lipid systems. Lipid-based DDS have gained interest from the 
pharmaceutical industry due to their potential to enhance the bioavailability and therapeutic index 
of otherwise problematic formulations. A resurgence over the last number of years in the interest 
in these materials is owed to the proven commercial success of lipid systems in the delivery of 
HIV protease inhibitor ritonavir (Table 1.1). 
 
Table 1.1. Commercially available lipid-based products for oral administration [105] with 
additional information. Most are formulated in gelatin capsules or coated tablets.  
Trade 
name 
Company Molecule Therapeutic use Formulation 
Rocaltrol® Roche Calcitriol Calcium regulator triglyceride of 
coconut/palm oil 








Accutane® Roche Isotretinoin Anti-comedogenic triglycerideS 
Kaletra® Abott Lopinavir and 
Ritonavir 
HIV antiviral Sorbitan 
monolaurate 















Convulex® Pharmacia Valproic acid Anti-epileptic glycerol 
monostearate 44-
55 Type II 
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Current trends in the pharmaceutical industry are moving towards an increasing number of new 
potent, lipophilic chemical entities emerging as potential drug candidates [106, 107]. Not only that, 
but as the discovery and clinical approval of new drug candidates is a lengthy and expensive 
process, the pharmaceutical industry now put a greater emphasis on directing research toward the 
resolution of previously abandoned and problematic candidates through the use of biocompatible 
carrier systems that enhance the bioavailability and biodistribution of difficult drug molecules 
[108]. Lipid based systems may serve to improve gastrointestinal solubilization and absorption 
through selective lymphatic uptake of these problematic drugs [109-112] to improve 
bioavailability and reduce associated toxicity. 
 
In terms of selecting the lipid excipient itself, there exists a wide range of options; from mono-, 
di- or triglycerides to oils constituting a combination of any of them, and phospholipids to 
sphingolipids, and ever emerging novel and modified oils and tailorable lipids. Selection of a 
suitable excipient can lead to the development of novel biomaterials useful in drug delivery 
applications. Further, various types of formulations/lipid assemblies can be implemented in 
improving the bioavailability of drugs, most of which are delivered orally. Table 1.2 outlines a 
working model of lipid formulation classification that facilitates the prediction of a formulations 
in vivo behaviour [113, 114]. Most of the marketed products are Type III systems, which are 




Table 1.2. The lipid formulation classification system: characteristic features, advantages, and disadvantages of the four essential 

















I Oils without 
surfactants (e.g., 






Crucial GRAS status; simple; and excellent 
capsule compatibility 
Formulation has poor solvent capacity 
unless drug is highly lipophilic 
 








100–250 nm Not crucial, 
but likely 
to occur 
Unlikely to lose solvent capacity on 
dispersion 
 
Turbid o/w dispersion (particle size 
0.25–2 !m) 










100–250 nm Not crucial, 
but may 
be inhibited 
Clear or almost clear dispersion, drug 
absorption without digestion 
 
Possible loss of solvent capacity on 







to form a micellar 
solution 
50–100 nm Not required 
and not likely 
to 
occur 
Formulation has good solvent 
capacity for many drugs 
Likely loss of solvent capacity on 
dispersion may not be digestible 
*SEDDS is self-emulsifying drug delivery system; SMEDDS is self micro-emulsifying drug delivery system 
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Numerous formulation approaches exist producing different types of lipid based drug 
delivery systems and assemblies. In general these can be categorized into three different types 
of systems: Emulsions, vesicular systems, and lipid particulate systems.  
 
 
Figure 1.2. Representation of different lipid carrier systems 
 
Traditionally, emulsion systems are formulated from a blend of oil, surfactant and co-
surfactant that is dispersed in aqueous phase. They can be designed to meet the specifications 
of the physicochemical properties of drug substances [116]. SEDDS are the most advanced 
approach of emulsion based drug delivery systems and relies on physiological fluids for the in 
situ formation of the micro/nanoemulsion. This formulation strategy comprises the drug 
dissolved in oils and stabilized by surfactants and co-surfactants, which upon exposure to the 
aqueous environment under gentle agitation leads to the spontaneous formation of an emulsion 
[117]. 
 
Solid lipid nanoparticles (SLNs) are an alternative version to emulsions in which the liquid 
oil is replaced by solid lipids. Nanostructured lipid carriers (NLCs) are the advanced generation 
of SLNs with increased drug loading capacity and stability (oil versus solid lipid) [118]. Both 
SLNs and NLCs have proven themselves to be effective drug delivery systems incorporating a 
host of biologically active ingredients [119]. Enhanced oral paclitaxel bioavailability was 
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reported after encapsulation and administration in loaded lipid nanocapsules as a suspension in 
saline solution. This eliminates the need for harmful castor oils used in intravenous delivery of 
this highly water-insoluble drug [120].  
 
Vesicular systems can be classified into two categories: Rigid vesicles (liposomes and 
niosomes) and elastic or ultra-deformable vesicles (transferosomes and ethosomes) [121]. 
Liposomes are spherical shaped vesicles produced from non-toxic phospholipids. The 
nanocarriers have exhibited extensive potential for use in the delivery of drugs, proteins and 
even genetic material [122]. The response of the amphiphilic lipids when placed in aqueous 
solution is to rearrange themselves into a sealed, circular lipid bilayer encapsulating an aqueous 
phase [123] where bio-/pharmaceuticals may be transported. In other cases however, different 
three dimensional phases can result after this lipid reorganization [123-126]. They are often 
utilized in reducing systemic toxicity and stabilization of the encapsulation drugs which might 
otherwise be rapidly degraded. A number of routes have been explored to improve their blood 
circulation time by introducing polymers such as PEG into the system. One of the major 
drawbacks with liposomes as drug carriers is their inherent physical instability [127], as 
liposomes are composed of biodegradable materials that are easily metabolized in vivo. 
Additionally, with the exception of transferosomes, liposomal formulations are generally 
unsuitable for transdermal delivery as they become trapped in the superior layers of stratum 
corneum preventing them reaching the deeper layers of the skin [128-130].  
 
Examples of each of these different systems and the advantages they hold are described in 
table 1.3.
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Table 1.3. Examples of implemented lipid based drug delivery formulations 
 



























Small droplet size,  
 
High industrial scalability 
- low energy 
requirements for 
manufacturing 
Microemulsion of dimethyl isosorbide, 









Solid self-nanoemulsifying oily 
formulations (S-SNEOFs) [134] 
 

































2-fold higher drug permeation & higher antifungal 
properties 
 
3.2-fold increase in the oral bioavailability 
 
 
Significant enhancement in absorptivity 
 
 



















and lipophilic drug 
substances within them 
[135, 136]  
Mannosylated liposomes [137] 
 
Chitosan coated liposomes [138] 
 
Phospholipid based ethosomes [121] 
 
















Improvement in anti-parasitic activity (+35%) 
 
Eight-fold increase in FUR permeability 
 
Increased transdermal flux (15-fold), prolonged 
drug release 

















drug release, increased 
drug stability, exclusion 
of organic solvents from 
the manufacturing 
process, manufacturing 
scalability and industrial 
adaptability [140] 
 
Higher solubility of drugs 
in oils as compared to 
solid lipids 










































5-fold increase in oral bioavailability  
 
3.5-fold enhancement of SQV transport across 
Caco-2 monolayers 
Increased potency in vitro and in vivo (murine) 
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Other examples of lipid based systems include novel hybrid systems, such as one that relies on 
the use of a commercially available methoxyPEG-liposome encapsulated doxorubicin (DOX) to 
produce a thermoreversible hydrogel for the treatment of glioma [143]. Another example is the 
innovative hydrogel formed by lipid nanocapsules (LNC) and lauroyl-gemcitabine (GemC12), 
intended to be injected inside the tumour or in the tumour resection cavity [144].  
 
In more recent years, an intriguing family of self-assembled lipid systems known as liquid 
crystalline mesophases have emerged as potential drug delivery systems. Originally developed to 
facilitate the crystallisation of difficult to crystallize membrane proteins, these mesophase systems 
mimic those of naturally existing membranes and present a means for effectively delivering drugs 
and therapeutic proteins [145]. The versatility of these systems in the encapsulation and delivery 
of drugs and biopharmaceuticals of different size, charge and solubility has been extensively 
studied and may provide a means to overcoming issues seen with other lipid based systems such 
as poor stability, and toxicity [123]. The remainder of this chapter will present a detailed 
description of these interesting systems and aims to highlight the reasons for selecting this family 
of carrier systems for the delivery of industrially relevant drugs within this thesis.   
 
1.3 Self-assembled Lipid Liquid Crystalline Phases  
 
Amphiphilic lipids, in their solid state, exhibit a defined architecture that comprises a bundle of 
planar molecular bilayers stacked to form the lipid framework. The polar lipid heads surround the 
outer surface of the tightly packed hydrocarbon chains [146]. It is the hydrophobic effect, acting 
to reduce the interface between the aqueous phase and the hydrocarbon tails of the amphiphilic 
lipid that drives the instinctive self-assembly of these lipids in water [147]. Exclusive to a certain 
subset of lipid molecules is a physical or structural property that drives a spontaneous association 
in aqueous environments to form highly organized structural units which exhibit long-range order. 
A number of polymorphs exist for each of these lipids in aqueous media, whereby, under defined 
environmental conditions of pH, pressure, temperature, and water content, different complex 
liquid-crystalline phases of defined geometries can be accessed [1, 148]. These highly viscous 
mesophases are so named lyotropic “liquid crystals” due to their short-range disorder despite the 
fact that they are considered to be plastic crystals [146]. The lipid molecules are dynamic in these 
liquid crystalline systems, behaving like a viscous lipid while still maintaining a global degree of 
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order characteristic of a crystalline solid, owing to the unique rheological properties of these 
interesting systems.  
 
The influence of the key environmental conditions on the lipid mesophase formed is 
demonstrated on corresponding phase diagrams, which have been defined for a number of 
functional lipids. The three most understood phases on these diagrams are the lamellar, hexagonal 
and cubic phases: 
 
Lamellar (Lα) phase – This liquid-crystalline phase displays one dimensional long range order, 
where the lipid molecules can diffuse laterally. A linear arrangement of interchanging lipid 
bilayers and aqueous channels make up the three dimensional structure of the phase [123, 146].  
This phase demonstrates relatively low viscosity compared to phases observed through an increase 
in water content and is commonly formed in an aqueous environment above the associate 
hydrocarbon chain Tm. Above that temperature the water can penetrate the polar portion of the 
lipid and form the Lα phase which displays higher mobility than the other corresponding 
mesophases [146]. By raising the temperature or hydration of a system, the hydrocarbon chain 
disorder becomes more apparent and geometrical reorganization ensues causing a transition from 
the lamellar phase to the three dimensional cubic phase.  
 
The cubic phase (Q) – This interesting phase is commonly seen sandwiched between the lamellar 
and reversed hexagonal phase on the phase diagram. It is observed as the water content is raised 
[123]. A further increase in the influential environmental factors sees a collapse of the mesophase 
geometry and a transition beyond the cubic phase to the highly curved hexagonal phase. 
 
Reversed Hexagonal (HΠ) phase – An arrangement of limitless water rods divided by lipid 




Figure 1.3. Schematic representation of the various lyotropic liquid crystalline phases including: 
solid (lamellar), mesophase (lamellar phase; cubic- Pn3, -Ia3d and -Im3m phases; inverted 
hexagonal phase), and liquid (fluid isotropic phase) states spontaneously formed upon contact with 
an aqueous environment. Water is represented by the coloured regions [149]. 
 
The formation of an additional phase was also noted during the course of mesophase 
compatibility studies, and is now referred to as the ‘sponge phase’.  This phase was observed when 
test components caused swelling of the cubic phase under particular conditions. It is said to evolve 
from the LCP possibly as a result of the added component reducing the structures bending rigidity 
and lowering the bilayer interfacial curvature and thus allowing the mesophase to absorb more of 
the aqueous solution [150]. The sponge phase still maintains its bicontinuity despite this phase 
transition [145] and may be advantageous for applications with large proteins or pharmaceuticals, 
as the aqueous channels in the swelled phase are dilated and have the capacity to incorporate larger 
molecules [145].  
 
The free energy of the system is a critical factor in the assembly of inverse mesophases. It is 
reported that both the instinctive formation of the phase and the thermodynamic stability of the 
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liquid crystalline phases are driven by an opposition between a pair of free energy terms. When 
this competition between the curvature energy of the individual monolayers and stretching energy 
of the lipid chains exists in its least frustrated state, it is suggested to be responsible for the nature 
of the solid state phase and its position on the phase diagram (equation 1.1) [151-153].  
 
!"#$%&'(	*. *:										g./. = 12 + 14 
 
Where gtot is the calculated total free energy of the system, which is defined as the sum of the free 
energies associated with the system curvature, (gc, calculated for each lipid using critical packing 
parameter (CPP)) and, that of the packing frustration (gp).  
 
As the free energy of curved geometries is always in the frustrated state, changes in 
environmental conditions or additional stresses imposed by factors including temperature, pH, 
pressure or the addition of additives may induce global changes in the curvature of the system or 
result in a phase transition in a bid to compensate and relive the frustration. While these 
environmental factors greatly govern the behaviour of amphiphilic lipids in aqueous media, 
various other structural and chemical factors such as lipid chain length, molecular shape, and lipid 
concentration dictate the polymorph accessible for a particular lipid system under these conditions 
[148, 154]. The molecular shape of the lipid is one of the most influential factors in determining 
whether a lipid system favours lamellar or non-lamellar structures. The literature utilizes the 
relationship between the contribution of the hydrophobic and hydrophilic moieties. Here, the shape 
of the lipid components are considered, where the ratio of the volume (v) and maximum chain 
length (lmax) of the incompressible hydrocarbon chain to the effective cross-sectional area the head 
group can assume (acs) defines the phase behaviour of a lipid. This theoretical ratio is referred to 







When the contribution of the two different moieties reaches near equal, the value of the CPP 
approaches 1. In this case, a normal type (type I) self-assembled structure is preferred, where the 
surfactant molecules favour the formation of planar membranes with a cylindrical critical packing 
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shape. When the CPP value is less than 1, micellar structures are favoured, with an interface of 
convex curvature. For these assemblies, water content greatly influences the stability of the 
structures and their geometry is highly sensitive to dilution rendering them rather unsuitable for 
biological applications. On the other hand, for inverted type structures (type II), the CPP value 
exceeds 1 and the self-assembled structures bear an interface that is concave with respect to their 
hydrophilic domains, favouring non-lamellar structures such as the inverted hexagonal and micelle 
phases, as well as the cubic phase [156, 157].  
 
While CPP values are considered semi-quantitative at best, estimating this parameter provides a 
means for predicting the mesophase accessible in a particular sample, and may serve in 
qualitatively studying phase transitions when laying out a phase diagram. If one were to increase 
the temperature of a cubic lipid-water system for example, the cross-sectional area of the head 
group is reduced due to a dehydration of the polar domain, in turn increasing the value of the 
associated CPP and transitioning out of the cubic phase toward the inverted hexagonal or micellar 
architectures [154, 156]. The complex architecture of the liquid crystalline phases involves 
numerous energies and interactions, and for this reason calculation of the CPP value alone would 
not be sufficient in determining the phase behaviour of these amphiphilic lipid systems. To provide 
a detailed description of the complex systems and how they behave in aqueous environments 
requires high resolution techniques combined with mathematical modelling.  
 
1.4 The Cubic Phase: Structure and properties  
 
The intrigue around the lipid cubic phase (LCP) in recent decades can be owed to its unique 
microstructure [158] which has been defined after extensive study by means of different 
spectroscopic approaches including X-ray diffraction [1], freeze-fracture electron microscopy 
[159], resonance Raman spectroscopy [160] and NMR [161]. The microstructure agreeably 
resembles that of the naturally occurring physiological lipid bilayer [125, 146] displaying flawless 
long-range three dimensional periodicity [146]. Two different classes of cubic phases are known 
to exist, both of which are macroscopically stable, completely transparent and solid-like viscous 
materials [162, 163]. The first of these is the micellar cubic phase which comprises a cubic lattice 
of lipids which are packed into micelles. These micelles assemble when the critical micellar 
temperature (Krafft temperature) is less than or equal to the experimental temperature [164]. The 
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second class, of interest in this thesis, is the bicontinuous cubic phase which comprises a curved, 
extended bilayer which spreads in three dimensions [165] and is accessed upon hydration of the 
system upon which the lamellar phase undergoes structural reorganization.  
 
These bicontinuous phases can assume architectures of varying surface symmetry, forming 
different cubic structures of  primitive (Im3m or 	ABBC  ), gyroid or (Ia3d or QEEF ), or double-diamond 
(Pn3m or QEEG) symmetry with associated values of 229, 230, and 224 respectively. The latter two 
symmetries, listed in order of increasing hydration, are of particular interest in the areas of drug 
delivery and applied sciences as they are inherently thermodynamically stable even in excess water 
[148, 166, 167]. Despite these differences in space group geometry, they share distinct structural 
features of a set of identical interpenetrating, congruent aqueous channels which never intersect, 
delineated by a lone, uninterrupted, and highly curved lipid bilayer [123, 165, 168]. The size of 
the aqueous pores in a fully swollen cubic phase is said to range from approximately 4-5 nm in 
diameter and forms the diffusion space [123, 169]. 
 
The cubic phases themselves are distinguishable by their discrete crystallographic space groups, 
optical isotropy and its non-birefringent refraction. A range of characterization techniques can be 
applied in the distinction and characterization of these systems outside of the cell environment. In 
the first instance, characterization of the structural properties of the lipid cubic formulations is 
carried out using techniques such as polarized light microscopy (PLM).  Small angle X-ray-
scattering (SAXS) is applied in distinguishing between cubic space groups and is utilized in 
dimensional analysis. Lipid cubic phases typically give rise to diffraction patterns similar to those 
of powder X-ray diffraction; characterized by a series of sharp, clearly defined concentric rings 
owing to their randomly orientated domains of cubic symmetry [170]. More traditionally, DSC, 
NMR and fluorescence microscopy were applied in the characterization of the formulations. 
Beyond that, electron microscopy approaches are utilized to study the topography of the 
formulations, specifically cryo-TEM is utilized to visualize the structural organization of the cubic 
systems [171].   
 
A wide range of lipids have the ability to form different cubic and other mesophases including: 
monoacylglycerols (MAGs); phospholipids; alkyl glycerates; PEGylated phospholipids; and 
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glycolipids, [161, 167, 172-175] and the selection of a suitable host is key in developing the cubic 
phase for drug delivery applications. 
 
Monoacylglycerols, are a class of esters of the trihydric alcohol glycerol with one of the hydroxyl 
groups esterified with a long-chain fatty acid. They are commonly used as surfactants (emulsifiers) 
and in the food and cosmetic industries to prevent oil-water mixtures from separating and also as 
antistaling agents [176]. Two different monoglycerides can be formed depending on the alcohol 
group attached to the fatty acid. Glycerols may provide both primary (1-monoacylglycerols) and 
secondary alcohols (2-monoacylglycerols) (Figure 1.4). 2-monoacylglycerols are one of the 
primary digestive products of dietary fats (triacylglycerols and diacylglycerols). 
 
 
Figure 1.4. Chemical structures of 1- and 2-monoacylglycerols stereoisomers  
 
In this context, cis-monoacylglycerols (MAGs) are a widely studied class of amphiphilic lipids 
that demonstrate anomalous polymorphism favourable for drug delivery and fundamental 
applications. Arguably the most extensively studied polar lipid in lyotropic liquid crystal 
applications is Monoolein (MO) for its rich and unique polymorphism [177]. Other 
monoacylglycerides of interest in this study are monopalmitolein (MPL) and monovaccenin (MV) 
(Figure 1.5), while others such as monoelaidin [172], monoeicosenoin [158], and various 
phospholipids [161, 178] have also demonstrated the ability to form biocompatible cubic phases 
under different conditions of temperature and water content [174]. All of the cis-
monoacylglycerols exhibit differences in hydrocarbon chain length, location of unsaturation and 
in cis double bond count. Synthesis of these lipids follows an enzymatic hydrolysis of naturally 













1-Glyceryl residue 1-Glyceryl residue
1-monoacylglycerol 2-monoacylglycerol
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head and a cis unsaturated fatty acid chain bridged together via an ester bond that is critical in 
assuming the correct curvature and rotational and translational motions crucial in the formation of 




Figure 1.5. Chemical structures of the cis-monoacylglycerols used in this investigation: 
monoolein (a); monopalmitolein (b); and monovaccenin (c). 
 
Monoolein was introduced into the food industry in the 1950s as an emulsifying agent and a 
food additive and is also a commonly used ingredient in the cosmetic industry today. It has since 
exploded into the pharmaceutical world as a biocompatible transporter for various drugs [180] as 





















Figure 1.6. Temperature-composition Liquid crystalline phase diagram for Monoolein 
[182]. 
 
The amphiphilic molecule displays spontaneous self-assembly into the various thermostable 
lyotropic and thermotropic phases with different rheological properties in environments of varying 
water content and temperature. MO is insoluble in water, however the cubic liquid crystalline 
phase formed with MO above 17°C  with 40% hydration and has the ability to co-exist in 
equilibrium with excess water [1, 123, 146, 183, 184]. These cubic symmetries are metastable and 
collapse at temperatures below 17°C [177]. The cubic region of the Monoolein-water phase 
diagram (Shown in Figure 1.6) comprises two different cubic phases - Ia3d and Pn3m phases [182]. 
The fact that the Monoolein cubic phase can be prepared at water concentrations from 55 to 85% 
with 15%-45% MO lipid, means that drugs with very different polar nature and different dosages 
can be incorporated [123]. The phase has demonstrated the ability to protect drugs, such as peptide 
drugs, from enzymatic cleavage making it an attractive carrier for easily degraded molecules [126] 
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and is itself subject to biodegradation (lipolysis) by the various esterases and lipases in biological 
tissues [1].  
 
The lipid-water phase diagrams of the other monoacylglycerols of interest in this study share 
similarities with that of monoolein. Diffraction patterns from monopalmitolein samples prepared 
at hydration levels of 50 wt% exhibited a distinct cubic region of pure Pn3m symmetry [173]. 
Again, the phase diagram of monovaccenin is comparable with that of MO. Here, the pure Pn3m 
phase is identified between 48% and 52% (w/w) hydration  at 20°C [185] while the less hydrated 
Ia3d phase precedes the Pn3m at 48% hydration under room temperature. Increasing the 
temperature reduces the water content necessary to access this mesophase to between 23 and 38%. 
Although the phase diagrams are relatively similar in terms of the location of the cubic region, 
their slight differences highlight how the lipid molecular shape influences the polymorph 
behaviour of the systems. Lipid chain length, and shape, governed by the position of the ester 
bond, control the microstructure of the associated mesophases. The importance of the location of 
the ester bond is best highlighted when comparing the MO and MV systems, both of which possess 
hydrophobic chains 18 carbon atoms in length. The shift in cis double bond location further away 
from the polar headgroup to position 11 from 8 in the MO increases the hydration capacity of the 
system, reported to be influenced by a stabilizing effect on a less curved interface at the polar-
nonpolar boundary [185]. Not only does the location of this bond greatly influence the layout of 
the mesophase phase boundaries, structural parameters such as water channel diameter are 
affected. This may become relevant when matching up APIs to the most appropriate system, 
where, for example, molecular size or concentration is an issue.  
 
Additionally there are sugar-phytane lipids which enter the cubic phase within a wide range of 
temperatures. A fully hydrated cubic phase is achieved with the right ratios of water and lipid from 
10°C  to 70°C [175]. Phytantriol (3,7,11,15-tetramethyl-1,2,3-hexadecanetriol), is a biocompatible 
surfactant which finds frequent application as an ingredient in the cosmetic industry [186, 187]. It 
is a small, non-ionic amphiphile which undergoes self-assembly into inverse micellar, lamellar, 
cubic phase Ia3d, and cubic phase Pn3m and an inverse hexagonal phase under certain conditions 




Figure 1.7. Chemical structure of Phytantriol  
 
The phase transitions undergone by phytantriol are qualitatively similar to those observed in 
monoolein [127, 167]. Importantly, the cubic phase again exists in equilibrium with excess water 
[127]. Unlike MAGs, phytantriol does not possess a hydrolysable ester bond on its backbone [127, 
167] and so is not susceptible to hydrolysis in vivo. While this may be more useful for drug delivery 
to degradative environments such as tumours, as exemplified in a comparative study for the 
delivery of oridonin, this may result in incomplete release of encapsulated drugs [188]. 
Additionally, the phases differ in water channel diameter; 3 nm versus 4-5 nm in PHY and MAGs 
respectively [189]. This feature may become important when selecting the most appropriate lipid 
system for the API of interest, as size may dictate. As a key focus of this thesis was on the delivery 
of hydrophobic drugs whose release is controlled by the degradation of the lipid cubic phase, 
phytantriol was ruled out in the early stages of the investigation.  
 
1.5 LCP for Drug delivery 
 
The use of LCP in controlled drug release applications is owed to its unique microstructure and 
physio-chemical properties as well as its amphiphilic character and the biodegradable, 
biocompatible nature of the lipids used [167, 168]. The phase geometry and symmetry can be 
manipulated at nanoscale to design compatible systems for a given application [190]. Not only 
that, but the inherent ability of the system to transition between phases by ramping up temperature 
and hydration, subsequently modifying the structural properties of the system, and in turn its 
diffusion coefficient. It is well studied that the release kinetics of the mesophases phase are 
governed by the phase identity (3D LCP>> 2D Lamellar >> 1D Hexagonal phase) [191, 192] and 
the capacity of the aqueous channels [191, 192].  In terms of commercialization, the uncomplicated 
manufacturing requirements of the systems, which generally do not necessitate the use of organic 





thermostability and resistance against dilution, make the cubic phase and its dispersions appealing 
for drug delivery applications [195, 196].  
 
In order to serve as a functional delivery system, a matrix is required to have the ability to 
dissolve or disperse drugs of different concentrations and solubility. LCP possesses both 
hydrophilic and hydrophobic areas which aid its function [168] and serve to modulate the release 
of actives from its network by different phenomena [197].  There are a number of different 
mechanisms by which sequestration of pharmaceutical moieties from DDS can occur, often related 
to the nature of the DDS, but also the properties of the drugs themselves (size, charge, 
hydrophilicity etc.). These mechanisms include: 1) diffusion of the drug either through or from the 
carrier; 2) liberation of the drug through the degradation of the carrier system by chemical 
(hydrolytic) or enzymatic digestion; 3) solvent activation (through swelling of the system or 
osmotic effect); and 4) more obscure activation by externally applied forces such as magnetic 
fields or ultrasonic technology. Various mathematical models are used to study the complex and 
often multifactorial kinetics of release for a particular system for comparative reasons and in their 
design to better predict the behaviour of a system in vivo. The relationship studied in each model 

















Table 1.4 Summary of commonly used mathematical models for studying release kinetics 






Drug release rate is independent of the analyte 
concentration. Same amount of drug is released per unit 







) 	= KI 
Drug release rate is dependent on analyte concentration. 










Drug release by dissolution not diffusion, combined with 
changes in matrix surface area and inner diameter [199]. 
 
Not suitable for hydrogel systems as dependent on 





	= KI1/2 Drug release follows diffusive mechanisms. 
 
Release kinetics from ointments, films, and planar 
transdermal systems and three-dimensional dosage forms.  








Drug release is erosion and diffusion controlled.  
 
For n<0.49 Quasi Fickian diffusion,  
n=0.49 drug smaller than mesh size and rapid Fickian 
diffusion,  
0.49 >n<0.89 non-Fickian diffusion and swelling 
controlled release [206, 207] 
Where Mt is the total amount of drug released at a time t, M∞ is the total amount of loaded drug, n 
is the diffusivity exponent, W0 is the initial drugload in the DDS, Wt is the unreleased drug in the 
DDS at time t, and k is the kinetics constant [199, 208]. 
 
Since drug release is complex and often governed by more than one factor (eg. diffusion, 
swelling, erosion etc.) fitting distinct models to more sophisticated systems is not always possible. 
However, several of these mathematical models are applied in defining the release kinetics from 
LCP, the most commonly referred to model is the Higuchi square root of time release kinetics, 
which defines the release of pharmaceuticals from the cubic phase as diffusion controlled in the 
case of hydrophilic drugs [123].  The Higuchi equation is based on a pseudo-steady-state and it 
provides a mathematical means of demonstrating a direct proportionality between the total quantity 
of released drug and the square root of time, allowing one to understand the release mechanism of 
a material [202]. The lipid cubic phase’s aqueous nanochannels exhibit regular structure and 
 42 
repetition enabling the carriage of hydrophilic drugs and proteins with suitable dimensions [209]. 
Here, their release is diffusion controlled where an exchange of water from the media into the 
internal matrix and simultaneous transfer of incorporated drug and water from the matrix to the 
external environment are the proposed events occurring during hydrophilic drug release from the 
cubic phase [123].  
 
Hydrophobic molecules on the other hand are embedded in, or loosely bound to, the lipid bilayer 
portion of LCP as solid dispersions meaning that their liberation is limited by the breakdown of 
the lipid envelope surround them. Owing to the highly viscous and mucoadhesive nature of the 
LCP [210] the formulations encapsulating the hydrophobic agents can be retained at the site for a 
greater length of time compared to the free drug which are often rapidly washed away. There they 
are protected against the aqueous environment thus limiting their exposure to oxidative and 
degradative processes and their dissolution is slowed down. In a study using hydrophobic model 
drug cinnarizine the solubility of the drug was increased by 2 x 105 fold over the drug in aqueous 
buffer, and the same study demonstrated a prolonged release of the drug from the cubic phase 
compared to a lamellar system over a 4 hour testing period [211]. Further, comparison of in vivo 
plasma profiles after administration highlighted significantly slower absorption from the cubic 
phase compared to a lipid suspension of the drug (~10 times slower) proving the system as an 
improved lipid based sustained-release delivery systems for lipophilic drugs [211]. Other 
mathematical models such as the Korsemeyers Peppas model relate matrix degradation and erosion 
to the release kinetics of hydrophobic APIs in these cases.  
 
 In addition to the effect the structure and properties of the matrix itself have on the diffusion of 
the drug, both the physical and chemical properties of the drug being incorporated into the cubic 
phase, including the shape and molecular size of the drug itself, also influence the transport 
properties of the matrix [168, 212]. It is also imperative to ensure that the incorporated drug does 
not disrupt the assembly of the cubic phase lattice structure which may in turn affect its function. 
In some cases this may limit the use of the cubic phase as a drug delivery matrix. The location and 
effect of an incorporated active agent can be distinguished by monitoring induced changes in the 
structure of the mesophase upon the additives introduction. More traditionally, DSC, NMR and 
fluorescence microscopy were applied in the characterization of the formulations. Beyond that, 
electron microscopy approaches are utilized to study the topography of the formulations, 
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specifically cryo-TEM is utilized to visualize the structural organization of the cubic systems 
[171].   
 
 
Figure 1.8. Schematic representation of a bicontinuous lipid cubic phase of generic single chain 
lipid, water and encapsulated drugs. The magnified image on the right demonstrated the matrix 
lipid bilayer which is the insertion site for the hydrophobic drugs and envelopes a water conduit 
where hydrophilic drugs can be encapsulated. 
 
Lipid cubic-based formulations have been investigated in the literature for use in numerous drug 
delivery applications [123, 181], including topical [209, 213], oral routes [214], and parenteral 
routes for a range of pharmaceutical agents of different aqueous solubilities [169, 174, 197, 215-
217]. The literature reports how the cubic phase maintains its nanostructure and controlled release 
capabilities when subcutaneously injected [218] or orally dosed [219] in vivo. Bicontinuous lipid 
cubic phases are said to exist within numerous biological systems, where their presence may be 
related to the cell’s pathological state and health [220]. For this reason, they have been applied as 
transporters of both small molecules and larger proteins through both oral and parenteral routes as 
well as in local delivery applications including subcutaneous and intramuscular routes [123, 158]. 
Sustained release of hydrophilic drugs from medical implants has been achieved primarily through 
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the use of comparably hydrophilic lipids in their solid state [123].  The lipid cubic system’s 
applicability as a sustained release system has been investigated for a range of pharmaceutical 
agents of different aqueous solubilities [169, 174, 197, 215-217], the majority of which 
demonstrate diffusion-controlled release that follows first order kinetics, with total release 
observed within 24 hours. These studies have shown the system’s ability to sustain a controlled 
release of various antibiotics including: Clindamycin phosphate [221]; Cefuroxime [222]; 
Benzylpenicillin [223]. Sustained release has also been demonstrated for a range of pharmaceutical 
agents such as acetyl salicylic acid (aspirin) [169], antihistamine chlorpheniramine maleate [215], 
corticosteroid budesonide [223], pyrimethamine [216] and decongestant pseudoephedrine [217], 
all of which demonstrate diffusion-controlled release that is follows first order kinetics.  
 
Moreover, the stabilizing effect of the cubic phase on incorporated drugs makes it an attractive 
vehicle for use in drug delivery. It has demonstrated its ability to stabilize small molecule labile 
drugs from the destabilizing effects of reactions such as hydrolysis and oxidation, thus slowing 
down their degradation [222]. Its applications are however somewhat limited as a consequence of 
the matrix’s shorter release profile which is often less than 24 hours for hydrophilic agents [123] 
and its highly viscous consistency which has been likened to thick sticky toothpaste [145]. It is 
this viscous and mucoadhesive nature however that makes the lipid cubic phase suitable for the 
delivery of poorly soluble, lipophilic molecules that would otherwise be washed away before they 
could elicit a response [210].  
 
The selection of a suitable host lipid is key in developing the cubic phase for drug delivery 
applications [145].  Significant research has been directed towards synthesising novel lipid cubic 
systems capable of forming the lipid cubic phase for drug delivery [224, 225]. Additionally, it is 
useful to highlight research carried out in the way of manipulating the cubic phase rheology and 
phase behaviour through the addition of additives such as ethanol , PG, PEG [150], cholesterol 
and fatty acids [145] to name a few. In addition, several groups have reported success in 
incorporating other lipids and lipid derivatives into a host lipid system to achieve modified, tailored 
cubic phase matrices. Nazaruk and colleagues recently reported the incorporation of charged 
monoolein derivatives to modulate the control of a positively charged chemotherapeutic agent 
based on electrostatic interactions between the drug and the negatively charged modified LCP 
[226]. Wadsten-Hindrichsen et al. in the Swedish Chalmers University of Technology described 
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the addition of Monoolein lipid as an additive to Phytantriol LCP to create cubic phase gels with 
modified properties for topical drug delivery [189].  
 
Lipid nanosystems in solution 
 
Bulk liquid crystalline mesophases lend themselves to dispersion, allowing for the formulation 
of nano-sized drug delivery systems. In the case of lamellar, hexagonal, and cubic phases, 
researchers have coined the terms liposomes, hexosomes, and cubosomes to describe these 
nanoparticles. Importantly, the nanostructured lipid systems maintain the internal structures of the 
bulk mesophases and present an opportunity to deliver a variety of drugs with reduced system 
viscosity compared to their bulk counterparts.  
 
Lipid cubic nanostructures, cubosomes, can be readily produced from the bulk lipid system when 
a suitable stabilizer is present to support the internal structure of the liquid crystal [190, 227, 228]. 
All of the physicochemical features of the cubic phase that control the drug release kinetics are 
retained and preserved in these dispersions [227, 229], eliminating issues associated with handling 
and injecting the sticky bulk formulation. By fragmenting the bulk cubic phase through high-shear 
mechanical approaches or chemical techniques, liquid-crystalline nanodispersions ranging in size 
from 100-140 nm are formed in solution [230, 231]. Such fragmentation approaches include high 
pressure homogenization and sonication of bulk gel [232-234] or chemical approaches which 
involve use of a solvent precursor and dilution of an isotropic lipid-ethanol mixture [235, 236]. 
 
Typically, drugs are added prior to dispersion of the phase (pre-loaded cubosomes), either in the 
molten lipid, or the water phase depending on their solubility properties. However, the harsh 
fragmentation methods are often unsuitable for sensitive proteins and peptides such as those 
discussed above. In the case of these delicate bioactives, other formulation methods that employ a 
post-loading approach are favoured [237]. For example, growth hormone-inhibiting hormone 
(GHIH) somatostatin was post-loaded to liquid crystalline nanoparticles to improve its otherwise 
short half-life in vivo [238]. The common strategy takes advantage of the slightly negative zeta-
potential of the cubosomes to attract and adsorb water soluble drugs onto their surface by 
electrostatic and hydrophobic interactions.  
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Cubosomes are a widely studied and utilized for the delivery of hydrophilic active agents. Their 
structure differs from that of liposomes as it can encapsulate hydrophilic, lipophilic and 
amphiphilic molecules all at once [239]. Cubosomes have been employed to stabilize numerous 
biologically active substances through their encapsulation in the particles [219]. Some examples 
include vitamins [239], anti-inflammatory agent Indomethacin [240], insulin [241], ocular 
treatment [213], and a variety of peptides and proteins [152, 236, 238, 242-244] all of which 
showed promising results in terms of bioavailability, sustained release compared to free drug and 
improved half-life. Furthermore, nanosized carrier systems (smaller than 200 nm) have 
demonstrated their efficient accumulation and retention in tumorous tissue compared to healthy 
tissues due to the pathological architecture of the diseased state tissues [245-247]. The system’s 
proven ability in sustained release and in protecting the molecules it encapsulates from degradation 
demonstrate the potential of these cubosomes as versatile drug delivery  vehicles  for  various 
active pharmaceutical agents.  However it should be considered that, as the surface area of these 
cubosomes is much too high to maintain the controlled delivery that the bulk phase can, these 
nanosystems may be better suited to rapid release applications as they often exhibit burst release 
[248].  
 
Although not the topic of this thesis, hexosomes should not be disregarded as promising drug 
delivery systems. Owed to the closed nature of the water channels in the hexagonal phase, that are 
shielded from the external environment [249, 250], hexosomes have the potential to slow the of 
release of hydrophilic drugs compared to cubosomes. The release of hydrophilic drugs takes place 
through these discontinuous water rod-like compartments [251] and generally follows Higuchi 
order diffusion kinetics. Despite their promise, the limited number of lipids capable of forming 
hexagonal mesophases, coupled with the harsh preparation conditions required (eg. high 
temperatures), means hexosomes are historically less frequently reported in a drug delivery 
capacity. In more recent years however, groups have focused on synthesising a new class of 
materials with glycerate headgroups to form the hexagonal lyotropic liquid crystal. Among these 
materials, oleyl glycerate and phytanyl glycerate were found to form hexagonal phase in excess 
water at physiological temperature [252]. The dispersed matrices were applied as delivery systems 
for a range of model hydrophobic and hydrophilic drugs, such as paclitaxel, doxorubicin,  
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irinotecan, glucose, histidine, and octreotide [214, 253-256] where the distribution of the drugs 
within the system was not dissimilar to that of the cubic systems.  
 
1.6 Lipid Digestion and its role in drug absorption 
 
The amphiphilic nature of the lipid cubic phase, and its ability to deliver active ingredients of 
varied solubility has been presented. While the release of hydrophilic drugs that are incorporated 
into  the  cubic network  has  been  shown  to  be  a  diffusive  process, the release of hydrophobic 
agents is  regulated  by  the  digestion of the lipid bilayer envelope that encapsulates the drug. For 
this reason, and the significant impact digestion of the lipid carrier will have on the performance 
of lipid-based drug delivery systems, understanding the digestion behaviour of the system is 
pivotal in predicting the dissolution behaviour of this class of drugs in vivo. 
 
Digestion of MAGs by biological enzymes 
 
The importance of the ester bond on the backbone of MAG lipids in the self-assembly of liquid 
crystalline mesophases [179-181] has already been discussed, however these bonds render 
mesophases formulated with this class of lipid highly susceptible to the lipolysis by biological 
enzymes in vivo [257]. These MAG lipid systems are subject to slow hydrolysis at the ester linkage 
connecting the acyl chain (oleic acid) to the glycerol backbone by a family of enzymes, lipases, 
that are found in the body, often accompanied by other offending abettors such as esterases [257-
259]. Lipases are water-soluble and act at an oil-water interface during lipolysis of glycerides in 
any aqueous system through a series of intricate steps [257], with the surface area being the rate 
limiting factor [258, 260]. Briefly, pancreatic lipases employ a surface loop system that controls 
access of its various substrates to its serine active site [261]. In the presence of lipid substrates and 
other amphiphiles, the surface loop, or ‘lid’, undergoes a conformational change thus exposing the 
enzyme’s putative catalytic site [262]. The adapted schematic in figure 1.9 summarizes the action 
of pancreatic lipase on MAGs [263].  
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Figure 1.9. Lipase attack on the ester bond present on the Monoacylglycerol lipid chain bridging 
the oleic acid component to the glycerol backbone breaking the lipid down into its constituents. 
Adapted from [263]. 
 
Colipase is an important non-enzymatic lipase cofactor that is secreted by the pancreas in an 
inactive form to be activated by trypsin cleavage [264, 265]. It facilitates the action of the enzyme 
by first binding at the oil-water interface to anchor the lipase to the substrate [266]. Furthermore, 
colipase stabilises the enzyme in its active conformation through hydrogen bonding with the over-
laid polypeptide chain ‘lid’ sealing the active site [264, 265]. Upon binding at the oil-water 
interface, the α-helical surface loop is opened to expose the serine-histidine-aspartic acid triad 
active site [267] and the co-factor serves to maintain this conformation thus facilitating catalysis. 
Unlike the majority digestive lipases however, gastric lipases’ hydrolytic function is independent 
of cofactors or bile salts [268-270].  
 
It is reasonable to assume that the action of these enzymes and cofactors [174, 257, 258] is likely 
to influence the in vivo release kinetics of any membrane-embedded reconstituted hydrophobic 
drug as has been described for numerous hydrogel systems [271]. These release of these poorly 
soluble drugs is limited by their portioning into the aqueous channels of the phase, and issues with 
solubility mean they cannot be transported by simple diffusive processes. As such, they are 
liberated only when the lipid network surrounding it is disassembled. Within this thesis we delve 
further into understanding this mechanism of lipolytic action on our MAG cubic phase systems 
(Chapters 3 & 4) and explore methods for controlling the digestions as a means of establishing 




Improving oral bioavailability of lipophilic drugs 
 
Lipids are assimilated in the body through a multi-step process that beings in the stomach [268, 
269, 272]. However, the upper intestine is the major site for the lipolysis and absorption of lipid 
excipients (and the drugs they carry). The mixtures have been homogenized in the stomach and 
are then delivered to the duodenum that contains a mixture of bile and pancreatic juice containing 
an enzyme cocktail of trypsinogen, chymotrypsinogen, elastase, carboxypeptidase, α-amylase, 
phospho-lipase A, pancreatic lipase, and colipase [273, 274]. In combination with these, a complex 
mixture of amphiphilic species, including bile salts, phospholipids, lipolytic and other digestive 
products from the stomach facilitates further emulsification in the upper small intestine [275-277].  
 
To be absorbed, lipid transporters delivered orally must overcome the intestinal diffusion barrier 
(aka the unstirred water layer) that separates the enterocytes’ apical membrane from the bulk 
aqueous fluid in the intestinal lumen. Micellar solubilisation is said to increase the uptake of 
molecules by the enterocytes, in comparison to the poorly soluble fatty acids which struggle to 
overcome the barrier [273, 276, 278-280]. Although the mechanism of lipid molecule uptake is 
not completely understood, it has been suggested that the micelles are broken down by the acidic 
environment of the barrier in the process [279, 281] allowing the lipolytic molecules to be absorbed 
across the membrane; either by means of a carrier system when extracellular lipid concentrations 
are lower than inside the cell or by straight-forward passive diffusion at higher fatty acid 
concentrations outside the cell [109, 277, 278, 282]. The transport from micelles to the membrane 
may also be driven by vesicular-mediated uptake or alternatively, it may be driven directly by a 
collisional mechanism [109]. Several transporters of the ATP binding cassette family of proteins 
(ABC proteins) have been identified as being responsible for the efflux of material back in to the 
intestinal lumen post-absorption. Arguably the most widely studied of this family is p-glycoprotein 
(P-gp), whose action is notoriously linked to challenges in the bioavailability of drug compounds. 
There are many reports in the literature on the use of lipid and polymeric excipients to modulate 
the activity of P-gp in a bid to increase gastrointestinal absorption and oral bioavailability of a 
variety of drugs [283-287]. In these studies, the lipid excipients decreased or inhibited P-gp protein 
expression, thus impeding and reducing PGP-mediated efflux of target molecules [283, 288]. Once 
the lipid molecules have been taken up by the intestinal absorptive cells enterocytes, they may 
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simply diffuse across the cytosol independently or through interactions with intracellular lipid-
binding proteins [289-292] for further processing.  
 
An important step in the way of lipid secretion is their transport to the endoplasmic reticulum 
(ER). Following their transport to the ER, monoacylglycerols are esterified with FFAs by 
monoacylglycerol acyltransferases to re-synthesize diacylglycerols, which may then be converted 
to triacylglycerols by a group of proteins called diacylglycerol acyltransferases [277, 293] or 
combined with choline and ethanolamine to synthesize phospholipids by choline and ethanolamine 
transferases.  The re-synthesis of triacylglycerols is achieved through one of a pair of two 
pathways: 1) within the smooth endoplasmic reticulum by means of the 2- monoglyceride (2-MG) 
pathway; or 2) the α–glycerol-3-phosphate pathway (G3P) associated with the rough endoplasmic 
reticulum. The reassembled lipids face two possible fates: they may become part of lipid droplets 
for storage, accumulating ER lumen or in the cytosol of enterocytes to be mobilized and secreted 
during fasting state in enterocytes [294, 295]; or transported to the ER to be secreted. The lipids 
are packaged into large, spherical triacylglycerol-rich lipoproteins (LP) called chylomicrons or 
into very low density lipoproteins (VLDLs). The enterocytes export the lipoproteins into the 
lamina propria containing capillaries and central lacteal (lymph vessel) via exocytosis. 
Chylomicrons are released and enter systemic circulation at the thoracic duct. The LP cross the 
highly permeable lymphatic endothelium [109, 110]. In a similar way, drug molecules can also 
enter the general circulation through uptake into the portal vein or via the mesenteric lymphatic 
system. Highly lipophilic drugs with log P values that exceed 5 are said to partition into the LPs 
during their assembly which facilitates their access to the intestinal lymph [109] dodging first pass 
metabolism in the process. On the other hand, drug entities with lower lipophilicity tend to access 
general circulation via the liver through the portal vein in a similar manner to medium to short-
chain fatty acids [273, 276].  
 
In this way, lipids can influence oral drug absorption in numerous ways. Lipids present in the 
GI tract stimulate the gall bladder to secrete bile into the small intestine which aids the 
solubilization of poorly water soluble drugs.  Further, the digestive products of lipids produce a 
variety of amphiphilic colloidal species including micelles, mixed micelles and vesicles increase 
the solubilisation capacity of the intestinal milieu [109, 296]. Drugs that are pre-solubilized in 
amphiphilic colloidal species demonstrate a higher mass transport across the unstirred water layer 
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compared to  solute drug molecules who’s diffusion is retarded by their unfavourable aqueous 
solubility. The lipid excipients influence the enterocyte-based transport of drug molecules through 
the apical brush border membrane through a number of mechanisms including: increasing 
membrane fluidity enabling transcellular absorption; facilitating paracellular transport by opening 
of the tight junction and; through the previously discussed targeted inhibition of P-gp and/or 
CYP450 efflux to increase intracellular residence time and concentration  [109, 110]. Lipophilic 
drug absorption through the lymphatic pathway can also be influence by co-administering lipid 
molecules which may trigger the assembly of LPs in the duodenal cell facilitating drug absorption; 
entering systemic circulation by bypassing the liver in the intestinal lymph and subsequently 
dodging first pass metabolism to improve bioavailability. The incorporation of lipophilic drug 
molecules into lipid-based delivery formulations has been shown to improve oral bioavailability 
[120, 297-301].  
 
1.7 Concluding Remarks and Identified Research objectives 
 
The ever-increasing number of drugs emerging from discovery posing challenges of poor 
solubility and permeability present a need for the development of bio-enabling formulation 
approaches to tackle the issue of reduced bioavailability akin to these troublesome drugs. 
Emerging trends in lipid-based formulation design focus on the structure and stability of these 
systems, and on their ability to overcome these complications. As discussed, lipid-based delivery 
formulations have been shown to improve the oral bioavailability of otherwise problematic drugs 
(Table 1.3) by increasing solubilization and facilitating the mass transport of these drugs to the 
intestinal surface for absorption [120, 297-301]. There, the lipid excipients have the ability to 
maximise intestinal drug solubilization and have been explored as a vehicle for improving 
enterocyte-based transport [109, 110]. The sustained release of poorly soluble drugs from the lipid 
cubic network compared to other lipid-based drug delivery systems has already been discussed, a 
process that is driven by the breakdown of the lipid matrix. Understanding these lipolytic processes 
may present opportunities for modulating the degradation of the systems for local delivery 
applications, where different lipases are present in vivo. This would be particularly for those 




Within this work, liquid crystalline lipid formulations of bicontinuous cubic symmetry have 
been selected and explored as potential drug delivery systems. Their resemblance to biological 
membrane structures [220, 302], biocompatibility and amphiphilic nature makes these cubic 
phases attractive contenders in the race to optimise bio-enabling formulations. Additionally, the 
fully swollen bicontinuous cubic phases studied here are resistant to dilution lending themselves 
to dispersion into nanoparticles (cubosomes) that maintain the unique internal microstructure of 
the bulk phase. In this context, the effect of  loading a selection of drug molecules differing in 
solubility properties on the internal structure of bulk and dispersed cubic formulations was 
evaluated through high resolution approaches such as small-angle X-ray scattering and cryo-TEM, 
and assess the feasibility of both bulk and dispersed (cubosomes) cubic systems to encapsulate and 
deliver a range of small molecule drugs.  
 
This work aimed to investigate the impact of active pharmaceutical ingredients with contrasting 
physicochemical and solubility properties on the application of the lipid cubic phase as a controlled 
release drug delivery system. In this context, the following four research questions have been 
addressed:  
 
1. What influence do the physicochemical properties, specifically solubility and size, of the 
passenger drug loaded into the lipid phase, have on the stability and liquid crystalline 
structure of the phase? and what are their implications on its subsequent release kinetics? 
2. Do environmental factors of the body, including pH and ionic composition, impact the 
internal structure of the phase or influence the kinetics and duration of loaded drug release 
from the phase and its dispersions relevant in potential local drug delivery applications? 
3. Can the rate of release of hydrophobic or hydrophilic drug molecules be tuned beyond the 
rate of degradation of the lipid cubic phase through lipolysis by naturally occurring lipases? 
4. Could predictions on the rate of release, and degradation of the lipid phase, in vivo be 
made based on relative binding energies of the lipid, drug and lipase and inhibitor 





1.8 Thesis outline 
 
The research outlined within this thesis is presented as four distinct experimental chapters, each 
outlining contributions that have led to published or compiled research manuscripts with additional 
results included for clarity.  
 
In the interest of transparency, it is declared that all experimental data was collected by the author 
unless otherwise specified. Specifically, molecular dynamics simulations in Chapter IV were 
carried out by Dr Shayon Bhattacharya and Dr Damien Thompson at the University of Limerick 
to compliment the experimental results and used in support of hypotheses presented in relation to 
the lipolysis of the system. DFT calculations were facilitated by Dr Vivek Verma, University of 
Limerick. MP-SPR data was collected by Radek Bombera at BioNavis, Tampere, Finland. Cryo-



















Chapter II: Lipid Cubic System for the controlled delivery of 
pharmaceuticals of varied solubility. A Case Study: Antihistamine 
delivery  
 
2.1 Introduction  
 
The work outlined in this chapter has been compiled into a research manuscript to be submitted 
for publication titled “Lipid Cubic System for nasal/topical delivery of antihistamine drugs”. The 
aim of this initial study was to establish the controlled release properties of the QEEG-type lipid cubic 
system and its dispersions by studying the dissolution properties of a selection of small molecule 
antihistamine drugs differing in physicochemical properties in release media of varying pH and 
ionic composition. Here, the MP-SPR data was collected by Radek Bombera at BioNavis, 
Tampere, Finland. The author wished to acknowledge Miriama Ceresnakova at the University of 




Histamine, a biogenic amine whose synthesis in tissue mast cells is driven by the 
decarboxylation of the free amino acid histidine [303], is released in mammals in an inflammatory 
response to tissue injury or allergic reactions through a complex cascade of mediator release and 
interactions [303]. Should an imbalance between accumulated histamine and the rate of its 
degradation occur, histamine intolerance induces a number of unwelcome side effects [304, 305]. 
In the case of dermatological conditions such as urticaria and atopic/contact dermatitis exorbitant 
accumulations of histamine induce skin wheals and itchy flare-ups through direct contact, 
ingestion, or inhalation of allergens  [306-308].  In allergic rhinitis, which is purported to affect 
over 1/3 of the world’s population [309, 310], histamine imbalance induces symptoms such as 
itching, watery eyes, and rhinorrhoea (nasal discharge).  
 
Currently, the primary course of treatment for managing such allergies is oral dosage forms of 
antihistamines which target the histamine receptors present on the various cells in the body, of 
which four have been identified; H1-4. Of the four, H1 and H2 receptors are currently the most 
clinically relevant when it comes to treating histamine related disorders. H1 is a receptor present 
on endothelial and smooth muscle cells that is the target of the majority of marketed and identified 
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antihistamine molecules. More than 45 H1-antihistamines are commercially available worldwide 
[311]. They are referred to as inverse agonists [312] which bind these receptors without effecting 
a response, thus inhibiting the action of histamine through competitive or pharmacological 
antagonism [313]. However, more recent research has shown that they also exert their effect 
through transcription factor nuclear factor-kB to decrease antigen presentation, reduce 
proinflammatory cytokine expression, and downregulate cell adhesion molecules and chemotaxis. 
They have also proven their ability to inhibit mast cell activation and subsequent histamine release, 
likely through the downregulation of calcium ions in the cell, although the mechanism is still not 
fully understood [311, 314-316]. All function in a concentration-dependent manner, where the 
concentration of the antihistamine molecule must be maintained at sufficient levels over the 
required time to effectively compete with histamine. The use of a controlled-release drug delivery 
system is therefore an attractive approach to improving the efficacy of these molecules.  
 
These H1-antihistamines are further classified into 2 groups based on their ability to cross the 
blood-brain barrier. First-generation antihistamines refer to the group of molecules that because of 
their lipophilic nature, relatively low molecular weight and lack of recognition by the P-
glycoprotein efflux pump, readily cross this barrier and readily interact with H1 receptors through 
the central nervous system (CNS) [314, 317-319]. As a result of their lack of selectivity, this class 
of molecules may also induce deleterious effects such as sedation and reduced psychomotor 
performance [320]. To overcome these unwanted side-effects,  second-generation antihistamines 
have been developed. These molecules are poorly lipophilic, bind more specifically to H1 receptors 
and display a strong affinity for surface P-glycoprotein expressed on vascular endothelial cells 
reducing the likelihood of their penetration into the CNS [320, 321] thus cause less side-effects.  
Having said that, second generation antihistamine cetirizine used in this study has been shown to 
occupy CNS H1 receptors to a certain extent [322]. Due to their clinical relevance H1 receptor 
blockers varying in structure and solubility have been chosen for investigation. Table 2.1 
summarises the key physicochemical properties, indications and delivery routes associated with 
the four selected antihistamines investigated and their chemical structures are shown in figure 2.1.  
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For the most part, these inverse agonists are delivered through oral dosage forms, however, a 
major drawback of administering required dosages of antihistamines through the oral route are a 
list of unwanted side effects [334, 335]; including nausea, dry mouth, and drowsiness and sedation. 
To overcome these effects, other delivery routes can be used. Local delivery to the skin or nasal 
passage for atopic/contact allergic reactions would confine the effect to the delivery area, 
eliminating the adverse side effects induced upon non-specific systemic delivery and absorption 
while still delivering effective concentrations to the affected organ for sustained action.   
 
Numerous formulation approaches have been investigated and described in the literature in the 
realm of effective antihistamine delivery including [308, 336, 337]: nasal delivery through 
chitosan-derived microspheres [329, 338-342]; delivery by ethosomes [329], liposomes [340], 
poly(4-methyl-1-pentene), ethylene-vinyl acetate membranes and matrices [341]; and surfactants 
[343]. While these systems demonstrated desirable therapeutic effects, the formulations 
demonstrated rapid release within the first 24 hours, with some reporting the highest concentration 
after only 2 hours [340]. Further, the requirement for harmful and carcinogenic excipients such as 
plasticizers in the formulation approach [341], poor stability [127-130], and the low encapsulation 
efficacy, sometimes as low as 33% [329] reported for these formulations, leaves room for the 
development of sustained and more biocompatible delivery systems. Given what has already been 
discussed in section 1.5 of this thesis, the lipid cubic phase (LCP) systems may present an 
advantageous approach over traditional non-specific systemic delivery of such antihistamine 
molecules, especially those first generation and poorly soluble H1 antagonists that are highly 
lipophilic in nature and can induce unwanted side-effects. The amphiphilic nature of the lipid cubic 
phase and its dispersions means it has the potential to encapsulate and release organic drugs and 
bioactives of different solubilities.  Ibuprofen-loaded phytantriol systems demonstrated a relative 
oral bioavailability increase of 222% compared to the free drug with evidence of a longer half-life 
[344]. The mucoadhesive nature of the system should serve to improve the local retention time of 
the formulation to allow for sustained release [210]. Not only that, but LCP systems have been 
shown to enhance transdermal permeation of drugs [345], while the precursor lipids display 
inherent biocompatibility [1, 346]. The formulations are themselves non-allergenic with low 
toxicity of their digestive products [123]. Further, the uncomplicated manufacturing requirements 
of the systems, which generally do not necessitate the use of organic solvents [193, 194], mean 
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production costs may be reduced. These features, coupled with its thermostability and resistance 
against dilution, make the cubic phase and its dispersions appealing for drug delivery applications 
[195, 196].  
 
The cubic phase has previously been investigated for its capabilities in transdermal and ocular 
delivery of active ingredients as a topically applied formulation [209, 213, 347] and have been 
shown to enhance transdermal permeation of drugs such as diclofenac sodium formulated in cubic 
systems of glyceryl monooleate [345]. This may be particularly relevant for CZH as it has proven 
effective in dermatological and nasal aspects [313, 348]. The nose has previously been investigated 
as an entry route for delivery of odorranalectin-loaded cubosomes, as a more direct route to the 
blood-brain barrier demonstrating an enhanced therapeutic effect [349]. However, little has been 
done in the way of a topical lipid delivery system to be applied on the mucosal lining on the surface 
of the inner nasal cavity. The aim of this investigation was to study the potential of the cubic phase, 
in its bulk and dispersed form, for use in the controlled delivery of various commercially available 
antihistamine molecules for potential use as a topical/local delivery system. In vitro drug 
dissolution was applied to study the extent and release rate of two model first-generation and two 
model second-generation H1 antagonist antihistamine drugs from two monoacyglycerol-derived 
models (Figure 2.1). To optimize the formulation approach, the systems were characterized 
macroscopically and microscopically by small-angle X-ray scattering and polarized light to 
ascertain the mesophase accessed upon incorporation of the antihistamines of varying solubilities 
and size. The impact of encapsulating the antihistamine molecules in the lipid cubic systems on 
their mucoadhesion was also investigated using multi-parametric surface plasmon resonance (MP-
SPR). Facilitated by a model cell system, the internalization and associated cytotoxicity of the 
dispersed cubic forms are discussed. With the ultimate goal of developing therapies for the 
treatment of allergic reactions, the ability of the formulations to inhibit histamine release from 




Figure 2.1. Chemical structures of: a) monoolein (9.9 MAG) and b) monopalmitolein (9.7 MAG) 
both possessing an ester linkage linking the oleic acid chain to the glycerol backbone; 
antihistamines c) diphenhydramine hydrochloride (DPH); d) azelastine hydrochloride (AZL); e) 
carbinoxamine maleate (CBX) and, f) cetirizine dihydrochloride (CZH) 
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All solvents were analytical grade and purchased from FisherScientific; Monoolein 9.9 MAG 
(1-(9Z-octadecenoyl)-rac-glycerol) and Monopalmitolein 9.7 MAG (1-(9Z-hexadecenoyl)-rac-
glycerol) were acquired from JenaBioscience, Germany at >99% purity; Phosphate buffered saline 
(PBS) tablets were purchased from Merk (Saint Louis, MO); FaSSGF (Fasted state simulated 
gastric fluid) powder was purchased from Biorelevant.com Ltd; Water was purified in the lab using 
a Milli-Q Water System (Millipore Corporation, Bedford, MA); Lipase isolated from porcine 
pancreas was purchased from Merck, Germany (Type II, 100-500 units/mg protein (using olive oil 
(30 min incubation)); cetirizine dihydrochloride, azelastine hydrochloride, carbinoxamine maleate 
and, diphenhydramine hydrochloride were purchased from Merck, Germany at ≥98 % purity; 
Rabbit monoclonal [RM122] to IgE, rabbit IgG monoclonal [EPR25A] – isotype control, native 
human IgE protein (Azide free) and, the Histamine ELISA kit used were purchased from Abcam 
(Netherlands); RBL-2H3 rat basophilic leukemia cells (ATCC-CRL-2256) and Eagle's minimum 
essential medium (EMEM) were purchased from ATCC (United Kingdom). 
 
2.3.2 Preparation of bulk Antihistamine-LCP matrix formulations 
 
For preparation of LCP containing the water-soluble antihistamines (DPH, and CBX), the APIs 
were first dissolved in water with sonication to ensure complete dissolution. Fusion of dry lipid 
crystals to the melt was achieved between 40 - 45 °C in an oven to allow for more facile delivery 
of the lipid to sample vials.  Appropriate volumes of molten lipid (Monoolein (MO) 60 mg/sample 
or Monopalmitolein (MPL) 50 mg/sample) were added to glass vials. The API-water mixture was 
then added to molten lipid in appropriate concentrations to access the lipid cubic phase and to 
deliver API at a concentration of 1 mg per 100 mg hydrated gel. The API-water mixture acted as 
the aqueous phase (≥40 wt% and ≥50 wt% for MO and MPL LCP respectively) according to their 
respective phase diagrams [1-3]. The more hydrophobic antihistamine molecules AZL and CZH 
(1 wt%) were added to the molten lipid prior to addition of MilliQ water acting as the aqueous 
phase. The samples were then subjected to vortex mixing for no less than 15 minutes. The 
homogeneous mixtures were stored in sealed glass vials and allowed to equilibrate in the dark for 
at least 48 hours. 
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Preparation of empty gels followed the same approach, without the addition of the respective 
APIs to the lipid/aqueous phase. 
 
2.3.3 Preparation of cubic dispersions (cubosomes)  
 
The method for the preparation of the cubosomes in this study followed that of Boge et al. with 
some minor modification [350]. MO LCP was formulated with the various antihistamines at a 
loading concentration of 1 wt% as described previously, before being subjected to fragmentation. 
The pre-loaded bulk gel (500 mg) was added to 20 ml of 1 wt% stabilizer Pluronic® F-127 solution 
prepared in PBS.  Fragmentation was achieved by subjecting the LCP-stabilizer mixture to mixing 
using a magnetic stir bar followed by high shear homogenization at 14,000 rpm using a T25 digital 
ULTRA-TURRAX® disperser (IKA®-Werke GmbH & Co. KG, Germany) for 2 minutes. The 
samples were subjected to further fragmentation with an ATPIO ultrasonic microwave combined 
reaction system sonication probe operating at 40% of its maximum power on pulse mode (3 second 
pulses followed by a 7 second break) for an additional 5 minutes. The resultant opaline dispersions 
were stored in sealed glass vials. Antihistamine-loaded cubic phases were also dispersed in the 
absence of stabilizer to assess changes in physical properties of the systems.  
 
2.3.4 Mesophase characterization 
 
SAXS data collection  
 
SAXS measurements were carried out after sample preparation (as described in sections 2.3.2 
and 2.3.3) at the Solution State SAXS B21 beam line at Diamond Light Source on the Harwell 
Campus, Didcot, UK.  The experiments used a beam of wavelength λ = 13.1 keV (~0.94644 Å) 
with a beam size at the sample of 1 mm x 1 mm. Data collection was performed at ambient 
temperature (20 °C). B21 utilizes a bending magnet source with a typical flux of approximately 4 
x 1012 photons per second delivered directly to the sample. The photons were distributed over a 
large 0.8 x 2 mm cross-section which served to minimize radiation damage while also enhancing 
the signal of the particles. 2D diffraction images were recorded on an Eiger X 4M detector, with a 
detector face size of 155.2 mm x 162.5 mm and pixel size of 75 µm x 75 µm. The beam size at the 
detector was 50 µm x 50 µm. The detector was configured to measure a scattering vector (q) range 
from 0.0032 to 0.38 Å-1. Samples were loaded into a custom 3-D printed sample holder designed 
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especially for viscous samples. The holder was 3-D printed from a mixture of methacrylic acid 
esters and photoinitiator comprising a window in which the sample was filled. The sample holder 
was made from stainless steel and had mica windows. Each sample was subjected to a 1 second 
X-ray exposure for 15 frames at one location and required manual loading.  
 
SAXS data processing and analysis  
 
Exposure of the lipid samples to the X-ray beam produced small angle diffraction images. The 
detector images were azimuthally reduced using DAWN, an eclipse-based workbench for carrying 
out scientific data analysis [351] and subsequently analysed using the lipidsaxs toolkit developed 
by Christopher Brasnett, University of Bristol, available at 
https://github.com//csbrasnett/lipidsaxs. The scattering intensity I (q) was represented as a function 
of the magnitude of the scattering vector according the equation: 
 




where 2θ is the total scattering angle. 
 
Lipid cubic phase structural dimensions calculations 
 
Taking into account the space group, lattice parameter and water volume fraction of each of the 
different samples, the monolayer thickness and size of the water channels separating the lipid 
framework were determined as outlined by Szlezak, Nieciecka [212] and according to the 
following equations:  
 
To compute the lipid volume fraction, first the water volume fraction was calculated according 
to:     
23456789	:. ::	∅>? =
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Where ∅aq is the volume fraction of the aqueous portion (0.386 and 0.496 for fully hydrated 
QKK
L	phase	of	MO and MPL respectively. and 0.416 and 0.584 when the dehydrated QKKR  phase is 
seen for MO and MPL respectively [352, 353]), caq is the water weight fraction, ρaq denotes the 
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density of water (0.997 g cm-3), and ρMAG represents the density of the MAG host lipid  (0.942 g 
cm-3[1, 2] for monoolein and 0.982 g cm-3 for monopalmitolein) [354].  
 
By subtracting the water volume fraction from 1, the lipid volume fraction ∅MAG was determined 
[1]:  
23456789	:. S:	∅GHI = 1	 − ∅>?	 
 
From there the lipid monolayer thickness (l ) could be extrapolated [354]:  
 










Where Ao and the Euler characteristic χ are constants specific to the type of bicontinuous cubic 
phase related to the minimal surface area given in 2.2, d is the lattice parameter determined by 
SAXS for the phase in nm, and l is the lipid chain length or thickness of the assembled lipid 
monolayer.  
 
Table 2.2. Surface area constants [151, 354] 














Ultimately, the radius of the congruent aqueous channels (raq) within the network was calculated 
utilizing the calculated lipid chain length according to the following equation based on minimal 
surfaces [151, 212]:   
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Mucoadhesion/bioadhesion of the cubosomes was evaluated using surface plasmon resonance 
(SPR; SPR Navi 200, BioNavis) in a similar manner to that described previously to investigate the 
mucoadhesive properties of block copolymer micelles [355]. Data was collected by instrument 
scientists at Bionavis, Tampere, Finland. Mucin-coated sensors were prepared using mucin from 
bovine submaxillary gland (M3895 SigmaAldrich). The coating was prepared according to the 
protocol proposed by Prosperi-Porta et al [355]. In brief, bare Au sensors for MP-SPR 
measurements were firstly cleaned using 1:1:5 (v/v) solution of H2O2/NH3/H2O (10 min, 90°C). 
After thorough rinsing in MilliQ water and drying under nitrogen stream, the sensors were 
incubated in 100 µg/ml mucin solution for 24 h at room temperature in the dark. Mucin deposition 
was performed and measured in situ by MP-SPR (Appendix A). Based on the registered full SPR 
curves (not shown), the LayerSolver software by BioNavis enabled calculation of the optical 
thickness of the layers formed on the sensor surface. The calculated layer thickness was 3.88nm 
(± 0.11) resulting in surface coverage of 2.8 ng/mm2 and refractive index of 1.41 (± 0.002) at 670 
nm, which is typical for a glycoprotein layer. After mucin adsorption, the sensors were rinsed in 
water to remove any unbound residual mucin and sensors were stored dry until use.  
 
Figure 2.4. Schematic of SPR set-up for mucoadhesion studies showing the introduction of drug-
loaded cubosomes onto the mucin-coated gold layer  
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Tests were performed using the MP-SPR 2-channel Navi 220A NAALI system equipped with 
two detection wavelengths (670 nm and 785 nm) with instrument injection loops set to 1000 µL 
volume. Samples were run at 37°C in PBS (pH 7.4) as running buffer. Empty cubosome test 
samples were added to PBS (pH 7.4) at a concentration of ~15 mg gel/mL. The flow rate was set 
to 20 µL/min for injection of cubosome samples and 50 µL/min for all washing steps. Before 
loading the samples, the sensor surface was pre-conditioned with short washing in CHAPS (3-[(3-
cholamidopropyl)dimethylammonio]-1-propanesulfonate) detergent (20 mM, 1 min injection) 
followed by a 10 min baseline stabilization. Samples at a concentration of 1 mg/mL were 
subsequently loaded over a 40 min injection time to reach steady-state signal followed by 40 min 
PBS buffer flow to assess the dissociation phase. Samples were loaded in at least 3 repetitions, 
each injection separated by rejuvenation of the sensors by washing with CHAPS 20 mM solution 
(2 x 1 min injections at 50 µl/min). CHAPS provided sufficient surface regeneration and stable 
baselines between the samples.  
 
2.3.5 Particle size estimation and zeta-potential studies [356] 
 
Dynamic light scattering was utilized to estimate the particle size distribution (Z-average) and 
polydispersity (PDI) as well as the zeta potential (mV) of the cubic dispersions using PBS as the 
dispersant on a Zetasizer (Malvern Panalytical, United Kingdom) equipped with a 4 mW He–Ne 
laser (633 nm) which applies Brownian motion theories in its measurement. The viscosity of the 
dispersant was set at 0.8872 cP and the system was maintained at 25°C.  Three measurements of 
50 runs were taken for each sample and the mean value, along with the calculated standard 
deviation for particle size estimation (nm) were recorded using the Malvern Panalytical zetasizer 
software.  
 




PXRD data were collected in reflection mode with an Empyrean diffractometer (PANalytical, 
Phillips) equipped with CuKα1,2 radiation (γ = 1.5406 Å) operating at 40 kV and 40 mA at room 
temperature. Samples were scanned between 2θ values of 5 and 40° at a step size of 0.01313° 2θ/s, 
73 s per step. 
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Encapsulation efficacy  
High performance liquid chromatography was used to quantify the encapsulation efficacy 
(EE%) of the antihistamine-loaded cubosomes. Freshly made cubosomes were removed from the 
dispersion media by centrifugation at 10 000g for 30 min. The concentration of free drug in the 
supernatant was then quantified by means of a chromatographic approach described below. The 
encapsulated drug could then be calculated as a % of the total added drug according to the 






Different buffers were investigated to study the release profiles of the four antihistamines from 
the LCP under different conditions of pH. Fasted-state simulated gastric fluid (FaSSGF) was 
prepared by dissolving pre-prepared simulated intestinal fluid (SIF) powder (Biorelevant.com) in 
acidic buffer (1.997 g NaCl in 1L water) adjusting the pH to 1.6 using 1M HCl with stirring 
according to the manufacturers guidelines. Simulated nasal fluid (SNF) was prepared as 
previously described by Farid et al. [357] (7.45 mg/mL NaCl; 1.29 mg/mL KCl; 0.32 mg/mL 
CaCl2.2H2O; made up to volume with deionised water) to give a solution pH of 6.4. The final 
buffer was phosphate buffered saline, prepared at pH 7.4.  
 
The solubility of the four antihistamines were determined in the different release media studied. 
Excess amounts of each drug was added to 10 mL of media at 37 ºC with shaking at 150 rpm 
overnight. Undissolved drug was removed by filtration before the concentration of drug in each 
sample was determined after appropriate dilution by HPLC under the chromatographic separation 
conditions specified below.  
 
The HPLC system used in this investigation was an Agilent 1200 Infinity Series (Agilent 
Technologies, Palo Alto, USA) comprising: G1311B 1260 quaternary pump, G1329B 1260 ALS 
autosampler, G1316A 1260 TCC (thermostated column compartment) and a G1365D 1260 MWD 
VL diode-array detector. The acquired data was processed with the Agilent OpenLAB CDS 
software. Chromatographic separations of antihistamine-containing samples were achieved using 
an Agilent Poroshell 120 PFP (3 x 100 mm, 2.7 µm) column fitted with a UHPLC Poroshell 120 
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guard module (3 x 5 mm, 2.7 µm). The system was maintained at 21°C with mobile phase delivered 
under isocratic conditions of 0.4 mL/min. The separation conditions for each antihistamine is 
described in 2.3. In all cases, mobile phase was delivered to the column at a flow rate of 0.5 
mL/min. Samples were filtered through a 0.2 µm nylon filter (Fisherbrand®) and 8 µL injections 
were made.  
 











Acetonitrile: 25 mM 
KH2PO4 
(0.1 % Formic acid) 
25:75 210 ~ 4.8 
Cetirizine Dihydrochloride 
(CZH) 
Acetonitrile: 25 mM 
KH2PO4 
(0.1 % Formic acid) 
25:75 230 ~ 14 
Carbinoxamine maleate 
(CBX) 
Acetonitrile: 25 mM 
KH2PO4 
(0.1 % Formic acid) 
20:80 260 ~ 4.1 
Azelastine Hydrochloride 
(AZL) 
Acetonitrile: 50 mM 
KH2PO4 
 
40:60 215 ~ 4.9 
 
All in vitro drug release testing of the antihistamines from the lipid formulations/dispersions was 
carried out in triplicate at 37 ± 0.1 ºC under shaking at 150 rpm. For bulk samples, over the course 
of the investigation at predetermined time-points the entire release media was withdrawn and the 
media was immediately replenished with freshly made stock. Release of the antihistamines from 
the cubosomal dispersions was tracked via dialysis. For this, the drug-loaded cubosomal 
dispersions were placed in Pur-A-LyzerTM dialysis devices with a molecular weight cut-off of 6-8 
kDa. Drug release was followed in 15 mL of each of the selected release media, where 1 mL of 
the sample media was removed at the predetermined time-points and immediately replenished with 
the same volume of fresh media. The dissolution samples were analyzed by means of a high 
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performance liquid chromatography (HPLC) method described previously to quantify the 
accumulated drug in solution.  
 
Dissolution testing of the as-received free drug was carried out in parallel under the same 
conditions of temperature and agitation in Duran flasks containing 100 mL of the various 
biorelevant media under sink conditions. At pre-determined timepoints,  2 mL aliquots of the 
dissolution media were removed using preheated syringes (37 ºC) and immediately replaced with 
pre-warmed fresh media. Drug concentration was determined by means of HPLC after filtration 
through 0.2 μm filters and calculations took dilution factor into consideration.      
                                                 
2.3.7 Cell culture methods 
 
NIH-3T3 cells were grown in Dulbecco’s Modified Eagle’s Medium (DMEM) (with sodium 
pyruvate) supplemented with 10% v/v fetal bovine serum (FBS), 1 % v/v L-glutamine, and 1 % 
penicillin-streptomycin at 37°C in humidified air containing 5 % CO2. RBL-2H3 cells were 
cultured Eagle's Minimum Essential Medium (EMEM) (ATCC® 30-2003™) supplemented with 15 
% v/v heat-inactivated fetal bovine serum (FBS) and 1% penicillin-streptomycin at 37°C in 
humidified air containing 5% CO2. 
 
2.3.8 Cell viability study: Cytotoxicity  
 
The cytotoxic effect of the monoolein-based cubosomes formulated with and without the four 
antihistamine molecules was assessed by an MTT assay in NIH-3T3 and RBL-2H3 cells. Cells 
were plated in 96-well plates at a seeding density of 5 x 103 cells/well. Cells were allowed to reach 
confluence over 2 days before the experiments were carried out. The cells were then treated with 
cubosomes at a concentration of 100 µg/mL and incubated at 37°C for 24 h and 48 h. After the 
incubation period, the MTT reagent (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromidefor) was added to samples for 2 h at 37°C. The MTT formazan crystals were then dissolved 
by solubilisation buffer (10% SDS in 0.01 M HCl) followed by further incubation for 4 h at 37 °C. 
The absorbance was read using a multi-well microplate spectrophotometric reader at 570 nm. Cell 
viability was determined as the percentage of absorbance values of treated cells to absorbance 
values of untreated control cells. A ratio of percentage reduction of cell viability relative to that of 
 69 
control cells was used to express the obtained data. All measurements were carried out in at least 
triplicate.  
 
2.3.9 Cellular uptake of cubosomal formulations 
 
The difference in zeta potential between mammalian cells and the drug-loaded cubosomes was 
utilized to track the fusion and uptake of the lipid nanoparticles over time. Mammalian fibroblast 
cells (NIH-3T3) were selected as the model system. Cells were seeded in 6-well plates at a seeding 
density of 3 x 105 cells/well. Cells were allowed to reach confluence over 2 days before the 
experiments were carried out. The cells were then incubated in the presence of the various 
antihistamine-loaded MO cubosomes at a concentration of 100 µg/mL for different lengths of time 
(30 minutes, 2 hours, and 12 hours). The cells were harvested after this predetermined time by 
trypsinization, and the cell pellets were resuspended in 1mL of fresh DMEM media. The zeta 
potential of the treated cells was measured as previously described and compared against that of 
the untreated cells.  
 
2.3.10 Anti immunoglobulin E- (IgE-) induced histamine release studies 
 
RBL-2H3 cells were exposed to blank and antihistamine loaded cubosome formulations after 
IgE treatment and histamine release was tracked in a manner similar to that described previously 
[358]. Cells were seeded in 24-well plates at a seeding density of 1 × 106 cells/well. Cells were 
allowed to reach 90% confluence overnight before treatment. After this period, the media was 
aspirated away and replenished with fresh media containing 0.2 μg/mL IgE. Cells were incubated 
in the antibody media for 1 hour at 37°C. The media was once again aspirated away and cells were 
washed with release buffer (1 mM CaCl2, 40 mM NaOH, 0.1% BSA, 119 mM NaCl, 5 mM KCl, 
5.6 mM glucose, 25 mM piperazine-N, N-bis (2-ethanesulfonic acid) (PIPES), and 0.4 mM 
MgCl2). The washed cells were subsequently treated with release buffer containing 1.25 μg/mL 
anti-IgE along with 100 μg/mL of the blank or antihistamine-loaded cubosome formulations . Cells 
were incubated for a further 10 minutes at which point the media was removed and the 
concentration of released histamine was determined by means of a competitive histamine enzyme-
linked immunosorbent assay (ELISA) kit. Samples were diluted appropriately before analysis. 
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2.4 Results and Discussion  
 
2.4.1 Mesophase characterization  
 
There currently exists a wide range of host lipids capable of forming the cubic phase available 
commercially [161, 167, 172-175]. In this study two naturally occurring monoacylglycerol lipids, 
monoolein (MO) and monopalmitolein (MPL) have been selected to form cubic systems. Both 
host lipids are GRAS (Generally regarded as safe) listed digestive products of triglycerides present 
in the gastrointestinal tract, and were selected here on account of their biodegradable nature and 
inherent ability to maintain the cubic phase under physiological conditions [173, 352].   
 
As described in chapter I, section 1.4, cubic phases are distinguishable by their discrete 
crystallographic space groups. Three inverse bicontinuous cubic phases exist; primitive (ÅÇÇÉ  ), 
gyroid (QKKR ), and double-diamond (QKKL) with symmetry values of 229, 230, and 224 respectively. 
The MAG-water system typically accesses two types of cubic phase under equilibrium at room 
and body temperature depending on the level of hydration [177]. At lower water concentrations 
the gyroid or ‘QKKR  ’ cubic phase is accessed and when hydration levels are increased the phase 
transitions to the more swelled and stable diamond cubic (QKKL ) phase. The QKKL  phase is stable 
against dilution and maintains its architecture when the water content is increased further to excess 
levels. The SAXS data collected at Diamond Light Source in the UK was analysed for mesophase 
characterization and dimensional analysis of the bulk and dispersed systems, with and without 
incorporated antihistamine molecules (at a loading concentration of 1 wt%) to investigate if the 
incorporation of the antihistamine molecules had altered the internal structure of the lipid systems. 
All samples, with and without the drug molecules, were found to exist in the cubic phase (Table 
2.4 and Appendix A). Compatible reflections in the collected data were utilized and the absolute 
values were indexed to calculate the lattice parameter of bicontinuous cubic phase samples. As 
discussed in the introduction, CBX and DPH, being quite soluble in water, may preferentially 
reside in the water channels of the cubic phase, while the more lipophilic agents CZH and AZL 





Table 2.4. Phase identification and lattice parameters of assigned mesophases for bulk LCP loaded 
with different antihistamine APIs (1 wt%) from SAXS experiments with calculated dimensional 















MO - QKKL 10.3 1.75 4.55 - 










MO CBX QKKL 11.818 2.01 5.22 - 
MO CZH  QKKL 10.467 1.78 4.61 - 










MPL - QKKL 11.41 1.56 5.8 - 










































Table 2.4 reports the assigned mesophases and their structural parameters for bulk antihistamine-
loaded systems calculated from the collected 1 and 2D SAXS patterns, where sharp Bragg 
reflections indicative of long-range order were seen. For the majority, a cubic phase of 
crystallographic space group	QKKL was accessed, with slightly larger lattice parameters (L) identified 
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than those previously reported [359, 360]. The more hydrophilic drugs, DPH and CBX, were 
expected to locate comfortably in the aqueous channels of the phases, defined as 4.55 nm and 5.8 
nm for blank MO and MPL LCP respectively, both of which were prepared with water only. 
Hydrophobic molecules have the potential to disrupt the lipid bilayer network and induce phase 
transitions [361, 362] by integrating into the lipid bilayer and altering the liquid crystalline 
structure. The data collected for the MPL_CZH formulation highlighted coexisting inner cubic 
structures of QKKL	+	QKKR   spacegroup upon the incorporation of the hydrophobic molecule. However, 
when hydrophobic AZL was incorporated in the lipid cubic network QKKL symmetries prevailed.  
These bicontinuous cubic phases both conform to minimal periodic surfaces and their 
identification is achieved with the mid-plane of the membrane bilayers [146, 363, 364]. When 
equilibrium is reached, the average Gaussian curvatures of both phases should approach equal. A 
ratio known as Bonnet relation/ratio relates the unit cell parameters of the coexisting bicontinuous 
cubic phases with a theoretical value of 1.279 for	QKKR/QKKL  [363, 365-368]. In the case of the 
observed coexistence here where CZH is encapsulated in the lipid bilayer of the MPL system, the 
calculated Bonnet ratio of 1.27 is in excellent agreement with this proposed theoretical value.  
 
Larger water channels were noted across all specimen relative to the blank systems, indicating 
swollen lipid systems. A more pronounced effect was noted when the highly water soluble DPH 
and CBX were incorporated into the aqueous conduits of the phase, with a lesser effect noted in 
the more hydrophobic molecules AZL and CZH. The presence of small and broad unassignable 
peaks in some samples could not be related to any cubic symmetry so it is unclear whether these 
relate to an intermediate/transitioning phase as has previously been described in a monoolein 
system [369]. Such intermediates exist at temperatures below 33ºC and are not accounted for in 
the lipidsaxs script .  
 
The fully hydrated lipid cubic phase is resistant to dilution, maintaining its structural integrity 
even in excess water. However, when the bulk phase is fragmented, the resulting cubosomes are 
not stable long-term in aqueous solution because of the hydrophobic portions that are exposed at 
the particle surface as a minimal surface. Introducing amphiphilic copolymers that adsorb to the 
cubosome’s surface reduces the interfacial free energy between the cubic phase and the water 
phase while maintaining the internal nanostructure of the phase [370]. Further, the weak 
electrostatic charge on the surface of the cubosomes (discussed later) lends a need for a suitable 
 73 
stabilizer to reduce agglomeration of the dispersions. The accumulation of Pluronic F-127 on the 
external surface of the cubosomes has demonstrated enhanced steric stabilization of cubosomes in 
aqueous solution dispersions  [146, 233, 234], and in particular those produced using monoolein, 
where a small amount of the stabilizer can also be incorporated into the internal labyrinth of the 
water channels  [371]. 
 
In this investigation, pre-loaded sub-micron particles were produced through high energy 
homogenization and sonication of the bulk phase.  As the differences in release properties between 
MPL and MO was minor, monoolein alone was selected to investigate the behaviour of 
antihistamine cubosomes, on account of its slightly more controlled release properties overall 
(section 2.4.6 below).  In a similar way to that described for the bulk systems, SAXS was employed 
to reveal the architecture of theses MO lipid dispersions (Table 2.5) of predicted cubic symmetry. 
A similar trend in lattice parameter changes was seen across the cubosome samples compared to 
the corresponding bulk formulations, where calculated lattice parameter followed the trend 
CBX>DPH>AZL>CZH. 
 
Table 2.5. Phase identification and lattice parameters of assigned mesophases for MO cubosomes 














MO CBX QKKL 10.79 1.83 4.77 - 
MO DPH QKKL 10.66 1.82 4.69 - 
MO CZH  QKKL 9.43 1.61 4.15 - 











A single QKKL	symmetry was assigned for the DPH, CZH and CBX systems. The cubosomes 
maintained the cubic phase  of the bulk systems from which they were conceived, with only minor 
reductions in unit cell parameter values calculated. An efficient concentration of the stabilizer can 
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halt transitions between the QKKL	and	QKKR  structures [234, 372] while co-existence has been widely 
observed in cubosomal dispersions owed to the fluid and dynamic nature of their inner 
organization when fully hydrated [171, 372]. However, coexisting inner cubic structures of  
QKK
L	+	QKK
R   symmetries were identified upon indexing of the diffraction peaks for the MO_AZL 
cubosomes, with the calculated Bonnet ratio (1.28) in agreement with the theoretical values laid 
out. This coexistence may be influenced by the addition of the stabilizer which has been shown to 
stabilize the other cubic symmetries in some systems [192, 370, 373].  Pluronic F127 is a triblock 
copolymer consisting of two poly(ethyleneoxide) blocks as hydrophilic parts and a poly(propylene 
oxide) block as a hydrophobic part. It is possible that hydrophobic interactions between the F127 
and the AZL destabilise portions of the QKKL leading to dehydration of the system and a transition 
to the QKKL	+	QKKR   symmetries. Several other suitable stabilizers have been reported in the literature 
and Pluronic 108 for example, was reported to coat only the surface of cubic nanoparticles without 
penetrating the internal structure of the system [374]. This may be a suitable alternative in this case 
to avoid potential interactions between the stabiliser and the drug that may induce unwanted phase 
transitions.  
 
2.4.2 Properties of Cubic dispersions: Zetasizer Studies, encapsulation efficacies  
 
The monoolein cubosomes were loaded with the antihistamines at a theoretical concentration of 
1 wt%. HPLC was used to quantify the encapsulation efficacy (Table 2.6) by quantifying the 
amount of free drug in solution after the dispersion process. Encapsulated drug was then estimated 
according to equation 2.6. It is apparent that a better association between the lipid system and drug 
is seen in the cases of the hydrophobic agents, where loading efficacies of  >93% were calculated 
for both AZL and CZH. Slightly lower encapsulation efficacies (87-90%) were calculated for the 
hydrophilic drugs which are mainly present in the water channels of the cubic network with little 
interaction at the lipid bilayer.  
 
The particle size and zeta potential of the antihistamine-loaded cubosome formulations prepared 
with and without stabilizer Pluronic® F-127 are shown in table 2.6. Evaluation of the zeta potential 
of lipid nanoparticles aids in the prediction of their stability, tendency to aggregate (greater charge 
means stronger electrostatic repulsion between particles) [375, 376],  performance, and cellular 
uptake in vivo. Modification of the cubosomes through incorporation of additives/APIs, or 
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alterations in surface chemistry, can alter the surface charge of the dispersions and, by default, 
their performance.  
 
Samples prepared in the absence of Pluronic® F-127, demonstrated a large variation in 
nanoparticle size between the different samples encapsulating the four antihistamine molecules. 
The zeta potential results showed that both the blank and antihistamine-loaded cubosomes carried 
a negative charge. This has previously been associated with trace free fatty acids contaminating 
commercially available MAG lipids. These may carry a negative charge when ionized and alter 
the overall cubosome charge upon adsorbing onto its surface [377]. The lipids used here report 
purity >99%, but the potential of free oleic acid is still there. Zeta potential is taken as the overall 
charge the cubic nanoparticles acquire in a given dispersant and is a measure of the magnitude of 
repulsive/attractive forces between nanoparticles and serves as an efficient indicator of the storage 
stability of nanoparticles. The overall zeta potential of the samples was less than 30 mV in 
magnitude across the board and so the stability of the samples is likely reduced  [378, 379].  
 









Size ± SD 
(nm) 





- - - 182.7 ± 0.1 0.237 -6.86 ± 0.15 
DPH 1 87.48 ± 1.4 301 ± 23 0.38 -11.8 ± 0.96 
CBX 1 90.5 ± 1.2 289.3 ± 9.8 0.225 -2.94  ± 0.99 
AZL 1 93.12 ± 0.7 271.3 ± 19.6 0.199 -25.87 ± 0.54 




- - - 133.9 ± 0.1 0.247 0.969 ± 0.05 
DPH 1 87.48 ± 1.4 135.4 ± 1.2 0.193  7.54 ± 0.27 
CBX 1 90.5 ± 1.2 140.6 ± 4.5 0.165 4.6  ± 0.14  
AZL 1 93.12 ± 0.7 140.1 ± 2.3 0.169  17.4 ± 0.01  
CZH 1 94.85 ± 0.7 147.1 ± 4.9 0.225  2.08 ± 0.22 
 
Particle size and ZP data was also collected for samples prepared with the commonly used 
stabilizing additive F127 (Table 2.6). The particle sizes of all cubosomes generated were in the 
nanosized range. The size varied slightly among the different encapsulated APIs compared with 
the blank system, with larger particle size ranging between ~ 135 and 147 nm. All samples 
displayed PDI values less than 0.23 and a size reduction of up to half with greatly reduced standard 
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deviation compared with the systems prepared without F-127. This result is in agreement with 
published data [234, 380, 381]. The surface charge  also varied between the cubosomes loaded 
with different antihistamines, and in stark contrast to the negative charge recorded for the 
unstabilized samples, the study revealed positively charged cubosomes in all cases.  This study 
identifies the positive impact of including the stabilizer on achieving cubic dispersions within the 
desired size range as nanoparticles of size <200 nm have shown improved cellular uptake over 
larger systems [245-247] and distribution displaying a reduced propensity to aggregate in solution. 
The stability of the cubosome-stabilizer systems was confirmed over a 5-day storage period, where 
no change is nanoparticle size was observed. Pluronic® F-127 has previously been shown in the 
literature to physically stabilize the colloidal cubic phase for months [382] so it is reasonable to 
predict a more lengthy stability period than shown here.  The positive surface charge associated 
with the samples was predicted to further improve cellular uptake of the drug-loaded samples as 
cationic polymers form complexes and bind with the negatively charged plasma membrane of the 
cells to a higher degree than negatively charged or neutral molecules [383].  
 
2.4.3 Cellular uptake of cubosomes [384] 
 
As a means of studying the time-dependant interaction and possible uptake of the formulated 
cubosomes by cells, changes in the zeta potential of NIH-3T3 fibroblast cells incubated with the 
formulations were tracked over 12 hours. It has been described that positive or weakly negative 
charged nanoparticles should show enhanced cellular uptake [385, 386] on account of the negative 
zeta potential on the cell surface giving rise to strong electrostatic interactions with the with the 
negatively charged membrane. Previous reports showed that a 12 hour incubation with 
nanoparticles was sufficient for the cells to fully take up the dispersions; identified by an initial 
change and then stabilization of the  of the cells back to that of the untreated cells after the 
nanoparticles were bound and subsequently internalized [384]. In this study, the cells were 
incubated with MO cubosomes for 30 minutes, 2 hours, and 12 hours before the zeta potential was 





Figure 2.3. Zeta potential of NIH-3T3 cells treated with 10 µg/ml of MO cubosomes formulated 
with antihistamine molecules measured in DMEM media after 30 minutes, 2 hours, or 12 hours  
 
 
Figure 2.3 shows the shifts in zeta potential of the NIH-3T3 cells incubated with the cubosomal 
formulations. After 30 minutes, a shift towards a less negative surface charge was noted across all 
samples compared to that of the untreated cells. This shift may signify the binding of the positively 
charged cubosomes at the cell surface, reducing the overall negative charge of cell membrane 
through electrostatic interactions [387]. When nanoparticles interact and adsorb onto the cell 
membrane, changes in zeta potential are seen as the adsorption of ions surrounding their surface 
and the surface of hydrodynamic shear and particle mobility are altered [384]. Uptake through the 
cell’s plasma membrane after adsorption can occur by means of different mechanisms including 
phago- or endocytosis [384, 388]. Endocytosis is the process commonly observed in the 
internalization of nanoparticles, soluble molecules, proteins, and lipids [389-391] and is an energy 
dependent process [390, 392, 393]. The mechanism may be either non-specific or receptor 






































































exposure to the cubosomes, the zeta potential returned to a more negative value and approached 
that of the untreated cells, suggesting that the adsorbed cubosomes could have been taken up by 
the cells after this time. While these alterations in zeta potential suggest the uptake of the 
cubosomes by the cells, it is important to acknowledge that a volume of drug may be released prior 
to internalization, as described in the release profiles in section 2.4.6. In this case, the drugs would 
likely disperse in the surrounding tissue at the delivery site [390].  
 
2.4.4 Cytotoxicity study  
 
Monoolein-based cubosomes formulated with each of the four studied antihistamines were 
evaluated for cytotoxic effect in NIH-3T3 fibroblast cells and RBL-2H3 basophilic leukemia cells 
as a model by means of an MTT assay. While positively charged nanoparticles have been reported 
to improve drug delivery efficacy, an increase in the cytotoxic effect of these formulations has also 
been reported [397].  
 
 
Figure 2.4.  Cell viability, expressed as percentage of the control absorbance at 570 nm, induced 
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cubosomes (delivered at ~100 µg/mL).  formulated with and without antihistamine molecules. 
Data are expressed as a mean ± standard deviation (SD) of three independent experiment 
(minimum n=3). 
 
Treatment with the lipid cubic dispersions containing antihistamine molecules did not appear to 
significantly negatively impact cell viability in the case of the RBL-2H3 samples, Figure 2.4 in 
agreement with published data [398, 399]. Similar results were observed in the case of the NIH-
3T3 cells with the exception of those treated with CZH-loaded cubosomes when compared to the 
control system after 24 or 48 hours, at which point approximately 20 % of the loaded drug should 
have been released into solution (Figure 2.9 – drug release curve). Treatment with CZH at similar 
concentrations has previously been shown to be cytotoxic against epithelial cell lines [400]. 
However, a separate study by Salimi et al. studied the cytotoxic effect of a gradient of CZH 
concentrations on Chang cell lines and showed that concentrations of almost 200 times more than 
were studied here were required to induce cytotoxicity to the degree reported here [401]. That said, 
the Chang cells were only assessed over a 6 hour exposure period, where a reduction in viability 
over time was seen. These published studies further serve to highlight the variation in cell line 
sensitivity to the antihistamine, in agreement with the differences in tolerability shown here. 
Further, it is possible that the cubosomes have facilitated improved cellular uptake of the drug as 
reported in the literature [241, 396] and may also explain the increased toxic effect here. 
Regardless, the obtained results are in agreement with literature confirming the biocompatibility 
of monoolein-based cubosomes [396, 402] and the reduction in viability is likely owed to the 
encapsulated drugs.  
 
2.4.5 Mucoadhesion studies  
 
The high viscosity of the in situ formed cubic phase may facilitate its bioadhesive properties, 
which were demonstrated by Nielsen et al. [210] in proposing cubic phases of glyceryl monooleate 
(GMO) and monolinoleate as bioadhesive mucosal drug delivery systems. GMO itself is readily 
digested in the gastrointestinal tract presenting its bioadhesive properties [403]. In fact, the 
literature reports that GMO-based cubic phase gels have proven their ability to adhere to rabbit 
jejunum and have also been found to interact at a surface level in the vaginal cavity for a period of 
6 h [210]. Targeting mucosal layers for targeted delivery has the advantage of overcoming the first 
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pass effect otherwise seen with enteral delivery routes to improve bioavailability and would 
provide a means for local delivery of antihistamine molecules to overcome the associated 
unwanted side effects of these molecules when systemically administered (especially 1st generation 
H1 antihistamines) [404-408]. 
 
Here, MP-SPR was used to investigate the mucoadhesive nature of the antihistamine-cubosomes 
by studying their interaction with a mucin protein coated surface using unloaded monoolein 
cubosomes as a positive control for mucoadhesive comparison (Figure 2.2). Mucin is a highly 
glycosylated polymeric protein excreted [409] by goblet and submucosal glands and constitutes 
between 2-5% of the composition of the protective mucosal layer [410]. The highly entangled 
network of the mucin fibres are responsible for the sticky adhesive nature of the mucus [411] and 
provide a means for modelling the adhesive nature of our systems in vitro. The results obtained 
from this in vitro mucoadhesion investigation provide an estimate of cubosome residence time at 
a given mucosal site of administration [88].  
 
The cubosomes formulated with or without antihistamine molecules exhibited relatively 
reproducible adsorption kinetics profile as observed from triplicate injections of the dispersed 
samples over mucin-coated sensors (Appendix A). Figure 2.5 represents an overlay of average 
sensograms registered for each sample. Equilibrium is reached within 40 minutes of injection. The 
data presented quite distinct behaviour between the different cubosomal formulations toward the 
mucin layer. The MO_AZL samples displayed the highest binding level at a constant concentration 
of 1 mg/mL even as compared to the reference MO_Blank (unloaded cubosomes) suggesting 
greater mucoadhesion. The MO samples loaded with DPH displayed a much lower binding 
capacity to mucin – displaying an equilibrium state signal 3-fold lower than the strongly bound 
MO_AZL sample. Compared to the MO_blank sample, the MO_CBX formulation also displayed 
reduced binding and, despite slower association, the MO_CZH could be considered to have similar 
binding efficiency to the reference. Differences in zeta potential were also thought to play a part 
in the variations in mucoadhesion, as the oligosaccharide chains of the mucin glycoprotein confer 
negative charge to the protein through carboxyl and sulfate groups [412]. The AZL system 
displayed the strongest positive charge, which also represented the strongest binding. Based on  
surface charge, the mucoadhesivity trend was expected to follow that DPH > CBX > CZH. 
However, it appears that DPH system displayed the lowest degree of binding and CZH cubosomes 
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were second in line to the AZL system. Based off these findings, the differences may be attributed 
to the nature and effect of the encapsulated antihistamine molecules themselves, with the 
hydrophilic molecules seemingly causing a greater reduction in binding when compared to the 
blank system. This may be due to the additional bonding and hydrophobic interactions between 
the lipophilic drugs and hydrophobic segments on the mucin glycoprotein.   
 
 
Figure 2.5. Kinetics of adsorption onto mucin-coated sensors measured for 5 tested cubosome 
formulations. Each sensogram is average MP-SPR signal from triplicate sample injections 
measures at 670 nm. 
 
Despite a higher binding intensity observed in the case of the AZL loaded cubosomes, a faster 
rate of dissociation indicated by the slope of the reduction in relative intensity after the washing 
step was noted compared to the other formulations. This decline in intensity can be taken as 
representative of the stability of the adsorbed layer [413]. Regardless, the mucoadhesive nature 
demonstrated for these formulations support their potential to prolong the retention of an 
encapsulated drug molecule at the target site for improved bioavailability and is comparable to the 
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The kinetic profiles showed various binding level at equilibrium but also different behaviour in 
association/dissociation phases. Although the cubosome injection concentration was not varied, 
an attempt was made by the team at Bionavis at calculating local kinetic parameters (KD, ka and 
kd) using the TraceDrawer™ software for BioNavis. The obtained values (Table 2.7) confirm 
differences in maximum binding levels (Rmax) and distinct association/dissociation constants 
between the various monoolein samples. It is noted that in common practice, kinetic parameters 
should ideally be calculated against multiple concentration responses which will be the object of 
further studies. 
 
Table 2.7. Calculated kinetic values obtained from TraceDrawer™ for MP-SPR instruments*. 
Fitting was performed according to One-to-Two interaction model on the measured sensogram for 
1mg/mL concentration i.e., 2.8mM (monoacylglycerol lipid content) 
 
 MO_Blank MO_DPH MO_CZH MO_AZL MO_CBX 
Rmax [mdeg] 330 173 433 525 247 
ka1 (1/(M*s)) 1,27E+00 4,46E-01 1,10E-01 4,07E-01 3,19E+07 
kd1 (1/s) 4,65E-05 4,04E-04 1,31E-04 2,17E-05 9,15E-05 
KD1 (M) 4,70E-05 9,06E-04 1,19E-03 5,34E-05 2,86E-12 
ka2 (1/(M*s)) 1,02E+00 4,09E-01 6,64E-01 1,06E+00 4,97E-01 
kd2 (1/s) 2,08E-04 5,40E-04 2,91E-04 3,78E-04 3,01E-04 
KD2 (M) 2,29E-04 1,32E-03 4,38E-04 3,57E-04 6,05E-04 
Chi2 (mdeg^2) 8,71 24,16 15,26 27,85 29,29 
 
*The best fitting was obtained for One-to-Two binding model which might be the closest 
theoretical model considering mucin layer with virtually different binding sites to the injected 
analyte. In this context a model where one ligand would bind at least two different binding sites 
on the surface is considered.  
 
SPR studies were performed initially at 37°C but to investigate the impact of temperature on the 
mucoadhesion of samples, two samples (MO-CZH and MO-DHP) were run under conditions 
closer to room temperature (22°C). The resultant sensogram (Appendix A) highlights the direct 
effect of experimental temperature on cubosome binding to the mucin layer. Both tested samples 
exhibited reduced binding as a result of the decrease in temperature that may be explained by 
changes in the mucin-layer structure and properties. Through hydrogen bonding, electrostatic and 
hydrophobic interactions, and weak Van der Waal forces, mucin molecules cross-link in solution 
 83 
to form aggregates. As the number of these cross-links increase, the protein aggregates form 
viscous adhesive gels, an effect that is greatly influenced by temperature [416, 417]. 
 
Adhesion of the systems to the mucosal layer increases drug residence time for absorption that 
might otherwise be cleared through mucociliary clearance [19, 405, 418, 419].  
 
 
2.4.6 Drug release studies 
 
The solubility of the antihistamine molecules at 37°C was studied in the different biorelevant 
media, and the variations in solubility at different pH are shown in table 2.8. There is an obvious 
increase in solubility of the drugs as the pH becomes more acidic from the PBS at 7.4, to the SNF 
at pH 6 and further to FaSSGF at pH 1.6. This trend is seen across all of the antihistamine 
molecules as determined by HPLC. This may be related to their associated pKa values (Table 2.8). 
AZL [420], DPH [421], and CBX [422] are weak bases and under acidic conditions are protonated 
and in turn are more polar thus increasing their solubility. This trend is shown in Table 2.8, where 
decreasing the pH towards a more acidic environment increases the saturated solubilities of the 
drugs. CZH is considered a weak acid [423] but under acidic conditions is considered to be 
zwitterionic.  
 











Buffer   pH 
~6.4      
(mg/mL)  
Solubility in 
FaSSGF Buffer pH 

















2.19, 2.93 and 
8.00 
(weak acid [423]) 







1.33 ± 0.01 
 
1.4 ± 0.02 6.3 ± 0.04 
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Based on these marked variations in solubility, it was hypothesized that the pH of the dissolution 
medium would likely influence the release rates of the antihistamines into the dissolution medium. 
In vitro release data of the H1 receptor antagonists into biorelevant media was obtained over a two 


































































Figure 2.6. In-vitro dissolution profiles of as-received (free) antihistamine drug at 37°C in 
phosphate buffered saline media at pH ~ 7.4, SNF at pH 6.4 or FaSSGF at pH ~ 1.6. Each point 
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The as-received drugs were all crystalline (PXRD diffractogram, appendix A) and in agreement 
with structures reported in the literature [424-427]. They all rapidly dissolved, under sink 
conditions, in all three aqueous media, Figure 2.6. In most cases complete solubilization was 
recorded within the first 10 minutes (Figure 2.6) with only AZL showing a more prolonged release 
as the pH increased due to its hydrophobic nature and lower solubility. Even so, almost 80% of 
AZL was in solution after the first 10 minutes and 100% within the first hour. 
 
The dissolution profiles of the antihistamines from the bulk MAG systems at 37°C into the 
dissolution media are depicted in Figure 2.7. The dissolution profiles of the selected antihistamines 
demonstrated extended release profiles into the dissolution media maintained at 37°C over a 216 
hour investigation when compared to the free as-received drugs (Figure 2.6). The release followed 
a biphasic pattern for most of the loaded systems, with an initial burst release in the first 8 hours 
(with the exception of CBX in FaSSGF that was rapidly released). Although the release in this 
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Figure 2.7. In-vitro antihistamine release profiles from bulk lipid cubic formulations prepared with 
monoolein or monopalmitolein incubated at 37°C in phosphate buffered saline media at pH ~ 7.4, 
SNF at pH 6.4 or FaSSGF at pH ~ 1.6. Each point represents the mean (±SD) of three 
determinations. 
 
The dissolution profiles from MO and MPL LCP systems exhibited comparable controlled 
release properties, with a slightly prolonged API release profile seen with the MO LCP systems 
compared to the MPL lipid system. The variations in release, although relatively small, may be 
considered to be related to observed differences in the structural dimensions of the cubic phases 
of both systems, where differences in water channel diameter were calculated (Table 2.4). This 
results in variations in water uptake capacity where the osmotic effect is pertinent to the ratio of 
the size of the incorporated molecule to the water channel diameter [170]. It is clear from the 
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At physiological pH (7.4), the cumulative release of the two hydrophilic molecules within the 
first 24 hour testing period was 47.5 ± 0.7 and 55.6 ± 1.8 % for the DPH and, 62.7 ± 2.3 and 64.3 
± 1.6 % for the CBX from MO and MPL respectively within the first 24 hours. The more 
hydrophobic agents (CZH and AZL) displayed much more prolonged accumulation profiles from 
both systems, which was to be expected as the release of such lipophilic molecules from the lipid 
cubic phase has been shown to be degradation controlled [428]; and in the absence of lipolytic 
enzymes [257, 428], the breakdown of the cubic phases is retarded. At the end of the testing period, 
no significant degradation of the LCP in PBS was observed, suggesting that the release of the drug 
from its network was limited by the breakdown of the lipid cubic network and not driven solely 
by simplistic diffusive mechanisms. This supports the theory that the release of the hydrophobic 
compounds from LCP is substantially degradation-driven.  
 
Based on available literature and the solubility studies conducted here, an increase in release rate 
was expected across the samples when a more acidic environment was created. SNF was chosen 
to represent the conditions of the nasal passage of relevance for topical application of the 
antihistamine-LCP formulation. The pH of the simulated nasal fluid was slightly lower than that 
of the PBS buffer at pH 6.4 and followed the same pattern in the cases of the AZL and DPH, while 
the dissolution rate is relatively constant in this pH range for CBX.   
 
A medium representing the fasted conditions in a human stomach, so-called FaSSGF, was 
selected to study the release behaviour of the antihistamines from the lipid formulations into media 
at low pH for potential oral delivery applications. For both hydrophilic antihistamines, DPH and 
CBX , between 70 and 97% of the encapsulated drug had gone into solution within the first 8 hours 
of testing, as shown in the magnified portions displayed on the dissolution curves, with the 
difference in profiles between the two different host lipid systems of different water channel 
diameter noted once again. Similarly in the case of the hydrophobic drugs, the release was greatly 
accelerated in the acidic medium where twice the concentration of AZL was released into FaSSGF 
compared to PBS, and almost 3-fold more in the case of CZH over the testing period. The stability 
of lipid cubic gels was monitored in FaSSGF over the testing period and a loss of 21.6 ± 5.7 % of 
its original mass was recorded after 10 days. This loss in mass shown in figure 2.8 likely 
contributed to the drug release rate.  Although this increase in release rate was observed for CZH 
at the most acidic pH (although it has been described as a weak acid [423]), where the COOH 
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functional group potentially remained un-ionized while both tertiary amines (Figure 2.1) were 
likely protonated and positively charged owing to the jump in solution concentration, the trend 
deviated from that of the other molecules when considering the rate of release into SNF and PBS. 
Variations in ionic strength of the buffers may explain this deviation, where the salinity effect of 
the various ions in terms of their kosmotropic/chaotropic [429-431] properties as defined by the 
Hofmeister series may serve to stabilize/destabilize the system (see also chapter V), in turn 
affecting its controlled release properties [432]. 
 
 
Figure 2.8. Degradation behaviour (mass lost) of MO lipid cubic formulations in simulated 
FaSSGF solution at 37°C and 150 rpm 
 
The duration of release from antihistamine-loaded cubosomes of MO were significantly shorter 
than its bulk predecessor, where complete release was noted within the first 48 hours across all 
samples likely owed to an increased surface area or the dissolution of drug on or near the surface 
of the cubosomes. Similar trends to those of the bulk systems were noted in the dissolution curves 
across all four cubosomes formulations (Figure 2.9), with further accelerated release observed in 
the case of the samples immersed in FaSSGF compared to PBS. Although release from the 
cubosomes was notably faster than that observed from the bulk gel systems, the dissolution rates 
are obviously slower than the free drug in solution, figure 2.6. The more lipid soluble drugs (AZL, 
















































































































































Figure 2.9. In-vitro antihistamine release profiles from dispersed lipid cubic formulations 
(cubosomes) prepared with monoolein incubated at 37°C in phosphate buffered saline media at 
pH ~ 7.4, SNF at pH 6.4 or FaSSGF at pH ~ 1.6. Each point represents the mean (±SD) of three 
determinations. 
 
Variations in the pH or ionic strength of a dissolution medium have been shown in the literature 
to greatly influence the  release behaviour of active ingredients from the lipid cubic phase causing 
significant changes in their profiles [56, 58, 215]. For some drugs, the release was accelerated 
under acidic conditions when compared to its behaviour at neutral pH [58, 215]. This has been 
attributed not only to differences in the solubility of the encapsulated drug within certain pH ranges 
as seen previously, but also to changes in the lipid matrix itself. It has been suggested that the 
ionization of the fatty acid chain under neutral conditions may be responsible for the slowed-down 
release of the encapsulated drugs, whereas the acid chains are unionized in acidic environments 
[215, 434]. “Relocation” of encapsulated drugs when different pH stresses are applied have be 
described where the formation of less soluble ion pairs between positively charged drugs and the 
negatively charged fatty acid chains of the lipids may impede their dissolution. This has been 
demonstrated for drugs including doxorubicin [359] where at neutral pH the drugs may reside in 
the lipid portion owed to hydrophobic tendencies, but once the pH is altered, and subsequently the 
solubility and ionization state of the molecule, the drug may partition into the aqueous channels or 
vice versa. This will directly impact the rate of drug release which is directly correlated with  its 
location in the matrix [435]. It is acknowledged that the recommended dosage requirements vary 
for the individual drugs tested (Table 2.1) but the lipid cubic formulations were prepared at the 
same loading concentration (1 wt%) to minimize the number of variables potentially affecting drug 
release [216]. 
 
2.4.7 RBL-2H3 inhibitory effect study  
 
Antihistamine molecules delivered in high concentrations have demonstrated the ability to 
impede IgE-mediated histamine release from basophilic and mast cells in vitro [436, 437]. The 
RBL-2H3 cell-line can be activated to secrete histamine by aggregation of their high affinity IgE 
receptors or with calcium ionophores [438, 439]. In this study, the ability of the encapsulated 
antihistamines (delivered at a cubosome concentration of ~100 µg/mL corresponding to ~1 µg/mL 
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of drug) to inhibit histamine release from a basophilic leukemia cell line (RBL-2H3) with known 
IgE-induced histamine degranulation properties was investigated. The inhibitory effect of the 
antihistamine formulations was quantified using a histamine ELISA kit and the resultant profiles 
are displayed in figure 2.10.  The antihistamine molecules CZH and AZL belonging to this group 
have previously shown selective HI-receptor antagonism and the ability to inhibit mediator release 
and inhibition of eosinophil migration or degranulation [440]. Similarly, free CZH has been shown 
to inhibit histamine release in RBL-2H3 cells at concentrations as low as 15 ng/mL [358]. 
 
 
Figure 2.10. Histamine release induced in RBL-2H3 cells after incubation for 10 minutes in the 
presence of MO cubosomes (100 µg/mL) formulated with and without antihistamine molecules. 
Samples were read at 450 nm and are expressed as percentage of the control. Data are expressed 
as a mean ± standard deviation (SD) of duplicated experiments. 
 
The cells were most sensitive to cetirizine dihydrochloride (CZH), showing that incubation with 
the cubosomal formulation for as little as 10 minutes was sufficient in reducing histamine release 
by over 60% compared to the control. The ability of CZH to inhibit mediator release upon pre-
treatment has been reported in the literature, with studies claiming that at high dosage 
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results to those seen here have been reported for free CZH treatment at the same concentration, 
where a reduction in histamine release of almost 80% from the RBL-2H3 cell model was reported 
[358].  AZL and DPH loaded in cubosomes exerted a similar inhibitory effect on the histamine 
release, with a reduction of approximately 30% observed in each case. The inhibitory effect of 
first-generation antihistamine DPH against antigen-induced IgE mediated histamine release has 
previously been shown, where the released histamine was halved when the drug was present in 
concentrations up to 0.5 mM [437]. Similarly, AZL has been found to significantly inhibit anti-
IgE-stimulated basophil histamine release [445], specifically in animal models [446-448]. The 
smallest effect was observed in the case of the hydrophilic CBX formulation, with just over 10% 
less histamine quantified in those samples, an effect that was found not significant (at p<0.05). To 
our knowledge, CBX has not been reported in similar studies monitoring IgE-stimulated histamine 
release. This insignificant reduction in mediator release may be explained by differences in in vivo 
mediator release suppression between certain models where the role of histamine in inflammatory 
response is dependent on the organ and complemented by the effects of other mediators such as 
leukotrienes and prostaglandins - which are reported to be site-specific [313, 348].  
 
These results serve to highlight the non-interfering effect of the cubosomal carrier on the effect 
of these molecules and, given the muco-adhesiveness and the prolonged release profiles discussed 
above, Figure 2.10 also highlights the long acting potential of these antihistamine cubosome 
formulations. Efficient accumulation of drug carriers smaller than 200 nm has previously been 
demonstrated in cells of certain pathologies [245-247]. It is possible that the response seen in this 
study is a cumulative result from the effect of antihistamine drug that has been released from the 
cubosomal dispersions before cellular uptake as well as unreleased encapsulated drug where cells 
may retain or internalize the lipid nanoparticles. Importantly, the lipid cubic system and its 
associated nanodispersions, cubosomes [380], have been classified as a potential intermediates in 
membrane fusion [146, 449]; where after adsorption of the material on the cell membrane, the two 
lipid bilayers fuse  thus mitigating toxicity and enhancing the cellular delivery of the targets (A 
process also described in the internalization of viruses [450]). These fusogenic drug carriers are 
capable of evading endocytic internalization to effectively deliver targets. An important 
consideration in the study of drug release and uptake, is the rate at which fusion occurs versus drug 
release. Whether or not release after adsorption of the system to the cell surface outpaces fusion is 
 97 
an important consideration. In this context both must be fully understood and would require further 
studies in this case. It has been demonstrated here that the rate of release is highly dependent on 
the physicochemical properties and location of the drug molecule within the lipid system (Figures 
2.7 and 2.9 dissolution profiles). It is therefore reasonable to assume that both factors may 
contribute to drug delivery, with one factor or the other dominating in specific circumstances and 
for specific lipid formulations.  
 
2.5 Conclusion and leading research questions  
 
In this study MAG lipid cubic phases and their dispersions have shown potential as 
mucoadhesive controlled release systems for the delivery of four commercially available 
antihistamine molecules. Through high resolution SAXS and dynamic light scattering the impact 
of incorporating these molecules on the lipid cubic structure, its toxicity, bioactivity and 
mucoadhesivity has been studied. Lipid cubic systems have been hailed for its mucoadhesive 
nature [403]. The impact on the degree of mucoadhesion of encapsulating the antihistamine 
molecules in the lipid cubic dispersions was tracked on mucin-coated MP-SPR sensors. Here, this 
approach has proven to be an efficient tool to investigate the adhesion of lipid-based nanoparticles 
to mucin layers and have confirmed the mucoadhesive nature of the systems. The results presented 
distinct binding profiles depending on the properties of the drug incorporated into the cubic 
network, with the most favourable adhesion seen with AZL, an effect that may be attributed to 
surface charge and hydrophobic interactions. The bioadhesive nature of these systems presents an 
opportunity for tapping into improved retention, absorption, and subsequently bioavailability of 
the molecules through local delivery of antihistamines to mucosal membranes facilitating retention 
of the active ingredients within the nasal mucosal cavity or at gastrointestinal sites for the treatment 
of allergic reactions (this could be extended to other mucosa including buccal, vaginal [123], 
pulmonary, and those of the renal system). Likely owing to their increased surface area, cubosomes 
are said to be more bioadhesive in nature than bulk gels so that they can be conveniently used in 
topical and mucosal delivery of different drugs. A major challenge in the area of bioadhesive drug 
delivery systems is uncontrollable hydration of bioadhesive formulations at the delivery site [403]. 
The system’s resistance to dilution beyond a maximum hydration level eliminate the need for 
overcoming this obstacle as far as the cubosomal formulations are concerned.  
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Changes in zeta potential were used to track the efficient cellular uptake of positively charged 
cubosomes stabilized with commonly used surfactant Pluronic® F-127. By studying the changes 
in zeta potential, cubosomes were found to interact at the surface of the cell surface and suspected 
internalization of the dispersions was observed after a 12 hour incubation of a model fibroblast 
cell line where the zeta potential returned to that of untreated cells. In this time, no cytotoxic effect 
was observed in two model cell lines, with the exception of CZH that appeared to reduce cell 
viability by half after a 48 hour incubation in fibroblast cells. With the ultimate application in 
therapies for the treatment of allergic reactions, the formulations were shown to inhibit mediator 
release from basophilic mast cells by more than half in some cases compared to the untreated 
control. Furthermore, prolonged release of both sets of first and second generation antihistamine 
molecules from the bulk and dispersed systems compared to the free drugs were shown, 
highlighting the prolonged release capabilities of the lipid matrix. The impact of drug solubility 
and environmental pH on the dissolution properties were studied. The changes in the release 
pattern of the antihistamines at lower pH may be relevant in the treatment of gastric-related allergic 
reactions including acid-reflux, which occurs as a result of histamine release and interaction from 
parietal cells which stimulate acid production in the lining of the stomach. It is important to note 
however that it is primarily H2 receptor antagonists that are indicated for this type of application, 
but regardless the system described here may be of potential use in this area.  
 
From this work, it is apparent that the physicochemical properties of a given molecule govern 
its location within the cubic network, with hydrophobic molecules residing in the lipid bilayer 
while water soluble molecules inhabit the congruent water channels of the mesophase. Chapter III 
will explore a novel approach to garnering further control of the liberation of different active 









Chapter III: Modulating the Release of Pharmaceuticals from Lipid 




This chapter has been modified from a published manuscript titled “Modulating the release of 
pharmaceuticals from lipid cubic phases using a lipase inhibitor” published in The Journal of 
Colloid and Interface Science, Vol. 573 in 2020. In this chapter, a novel approach to controlling 
the lipolytic degradation of the lipid system to garner further control of the release of a hydrophobic 
model drug, a clofazimine salt, is introduced.  
 
3.2 Background 
The monoacylglycerol lipid family has been widely studied for their ability to form the lipid 
cubic phase (Chapter I, section 1.4). These formulations are susceptible to lipolysis by a variety of 
enzymes, including lipases and esterases, which attack the ester bond present on the lipid chain 
bridging the oleic acid component to the glycerol backbone (Chapter I, section 1.6).  The release 
of poorly soluble molecules residing in the lipid membrane portions of the phase is limited by the 
breakdown of the matrix, thus presenting a potential means for further controlling and sustaining 
the release of  therapeutic agents by targeting the matrix stability and its rate of degradation. The 
aims of the present study were twofold: to evaluate an approach to regulate the rate of degradation 
of lipid cubic phase drug delivery systems by targeting the enzyme interactions responsible for 
their demise; and to study the subsequent drug release profiles from bulk lipid cubic gels using 
model drugs of contrasting hydrophobicity. Here, hybrid materials consisting of cubic phases with 
monoacylglycerol lipids of different chain lengths formulated with a potent lipase inhibitor 
tetrahydrolipstatin were designed. Modulation of the release of a hydrophobic model 
pharmaceutical, a clofazimine salt, was obtained by exploiting the matrices’ enzyme-driven 
digestion. A stable cubic phase is described, displaying controlled degradation with at least a 4-
fold improvement compared to the blank systems shown in inhibitor-containing cubic systems. 
Sustained release of a model hydrophobic pharmaceutical was studied over 30 days to highlight 
the advantage of incorporating an inhibitor into the cubic network to achieve tunable lipid release 
systems. This is done without negatively affecting the structure of the matrix itself, as shown by 
comprehensive small-angle x-ray scattering experiments.  
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The challenges in the delivery of therapeutic agents in vivo include controlling and maintaining 
their release at therapeutically effective doses over a sustained period of time, long enough for 
them to exhibit their desired effect. Smart design of delivery systems can help overcome these 
challenges. This is particularly applicable in the design of delivery matrices for pharmaceuticals 
of poor water solubility, which is believed to account for between 70 and 90% of new drugs in 
development [106, 107]. Lipid carrier systems have proven their potential in controlled delivery 
applications on account of their unique microstructure [161, 162, 165, 231] and amphiphilic 
character, as well as the biodegradable and biocompatible nature of the lipids used [167, 168].  
 
The lipid cubic matrix’s application in sustained release, while proven to be very promising, is 
somewhat limited as a consequence of its shorter release profile which is often less than 24 hours 
for hydrophilic agents [123, 174] (as shown in Chapter II, section 2.4.6) and its highly viscous 
consistency which has been likened to toothpaste [145]. Additionally, the integrity of 
monoacylglycerol derived cubic phase (MAG LCPs) gels in particular are greatly compromised 
by the presence of lipolytic enzymes [174, 257, 258] capable of hydrolysing the ester linkage 
connecting the acyl chain (oleic acid) to the glycerol backbone [257-259]. This likely influences 
the release kinetics of any membrane-embedded hydrophobic drugs with which it is formulated as 
has been described for numerous hydrogel systems [271]. The main perpetrators are a family of 
enzymes, lipases, that are found in the body, often accompanied by other offending abettors such 
as esterases. Lipases are water-soluble and act at an oil-water interface during lipolysis of 
triglycerides in any aqueous system through a series of intricate steps [257], with the surface area 
being the rate limiting factor [258, 260].  
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Figure 3.1. Chemical structures of: a) monoolein (9.9 MAG) and b) monopalmitolein (9.7 MAG) 
both possessing an ester linkage linking the oleic acid chain to the glycerol backbone; c) lipase 
inhibitor tetrahydrolipstatin (THL); d) hydrophobic model active pharmaceutical ingredient (API) 











































The inhibition of lipase interactions through steric approaches has previously been described as 
a means to impede the digestion of lipid-based formulations for drug delivery [451-455]. 
Additionally, a class of lipids exist that have been synthesized such that their structure greatly 
resembles that of monoolein, except that the glyceryl ester group is replaced by a glycerate [252]. 
As an alternative approach here, a novel chemical approach to achieve regulated degradation and 
subsequent controlled drug release from bulk lipid cubic systems is presented by targeting these 
lipase enzyme interactions through the incorporation of a known inhibitor into the lipid network. 
The stability of two bulk LCP matrices is examined over time in the presence of a hydrophilic or 
a hydrophobic active pharmaceutical ingredient (API) and in the presence of tetrahydrolipstatin 
(THL), a potent active site-directed lipase inhibitor [456-460]. THL is FDA approved and 
indicated for the treatment of obesity at concentrations that well exceed those used in this study 
[461]. A surface loop system employed by pancreatic lipases controls access to their active site. In 
the presence of lipid substrates and other amphiphiles, the surface loop, or ‘lid’, undergoes a 
conformational change thus exposing the enzyme’s catalytic site [262]. Upon exposure, 
tetrahydrolipstatin exerts its inhibitory effect upon binding the pancreatic lipase at its catalytic 
serine residue as it forms a stable monolayer at the oil-water interface [453, 462, 463]. Following 
a nucleophilic attack of the serine active site on the b-lactone group [464, 465], the THL forms a 
stoichiometric acyl-enzyme complex with the various lipases [456, 457, 466] to impede the 
catalytic degradation of the lipid formulation (Schematic displayed in appendix B).  
 
Lipolysis and its inhibition are considered to be a set of competitive processes, often occurring 
simultaneously both in vitro and in biological systems when an inhibitor and a lipid substrate co-
exist [467]. The efficacy and rate of the individual processes are dependent on factors including 
concentration and surface area and are related to the ratio of lipid substrate to enzyme inhibitor. 
The inhibitor selected in this investigation was incorporated into the lipid cubic gels at different 
concentrations in a bid to stabilize and control their digestion by pancreatic lipase. A range of THL 
loadings from 0.35 to 2.5 wt% were selected to demonstrate the relationship between inhibitor 
concentration and the rate of competitive lipolysis, subsequently allowing for the tunable 
degradation-driven release of hydrophobic pharmaceuticals from their network. Within this range 
of inhibitor concentrations, the cubic phase is accessed and maintained under the experimental 
conditions described in this investigation, without any observed phase transition.  
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THL is practically insoluble in water [468] and so was expected to reside mainly in the lipidic 
domain of the cubic phase, while its hydrophilic portions may partition into the aqueous channel 
compartment. In a similar way that a lipid/water interface is necessary for lipase catalysis, 
inhibition of the enzyme by THL is possible at this boundary [260, 462]. This means that most 
likely only the THL available at the surface of the lipid network in the LCP can carry out its 
inhibitory function while the THL integrated in the inner bilayers would serve as a reservoir, 
reaching the lipid/water interface upon the degradation of the gel [451, 469, 470]. This repository 
provides fresh inhibitor to the system for the entirety of its life, where continuous, controlled 
degradation at the surface of the gel exposes encapsulated THL to the lipolytic enzyme. A 
clofazimine citrate salt and caffeine were selected as model APIs for release studies based on their 
different propensities to dissolve in water (~40 mg/L [471] and ~51 g/L [472] at 37°C  for the 
CFZ-citrate and caffeine respectively). Their structures are shown in Figure 3.1. .  
 
3.4 Materials and Methods 
 
3.4.1 Materials  
 
All solvents were analytical grade and purchased from FisherScientific; Monoolein 9.9 MAG 
(1-(9Z-octadecenoyl)-rac-glycerol) and monopalmitolein 9.7 MAG (1-(9Z-hexadecenoyl)-rac-
glycerol) were acquired from JenaBioscience, Germany at >99% purity; Phosphate buffered saline 
(PBS) tablets were purchased from Merk (Saint Louis, MO); Water was purified in the lab using 
a Milli-Q Water System (Millipore Corporation, Bedford, MA); Clofazimine (CAS registry 
number 2030-63-9) was purchased from Beijing Mesochem Technology Co., Ltd. The 
clofazimine-citrate salt form was produced previously by our group [471]; Lipase isolated from 
porcine pancreas was purchased from Merck, Germany (Type II, 100-500 units/mg protein (using 
olive oil (30 min incubation)), 30-90 units/mg protein (using triacetin), L3126 SIGMA); 
Pancreatin isolated from porcine pancreas was purchased from Merck, Germany (4x USP 
Specifications L1750 SIGMA), 30-90 units/mg protein (using triacetin), L3126 SIGMA); Caffeine 





3.4.2 Preparation of MAG LCP matrix formulations 
 
Viscous lipid cubic phase formulations were obtained by dispensing appropriate volumes of 
molten monoacylglycerol (MAG) (Monoolein (MO) ≥60 mg/sample or monopalmitolein (MPL) 
≥50 mg/sample) in glass vials. Fusion of dry MAG crystals to the melt was achieved at 40 °C.  
This was followed by the addition of the aqueous solution in excess volumes (≥45 wt% and ≥55 
wt% for MO and MPL LCP respectively) according to their respective phase diagrams [173, 177, 
352]. The samples were then subjected to vortex mixing for at least 15 minutes and equilibrated 
and stored in sealed glass vials out of direct light at room temperature until an optically clear and 
visually homogenous sample was achieved and for no longer than three weeks.  
 
A range of MAG lipidic mixtures with 0.35, 0.7, 1.5 and 2.5 wt% THL were prepared by first 
dissolving the inhibitor in the appropriate weighed amounts of molten lipids. Homogeneous blends 
were achieved by subjecting the molten solution to brief vortex mixing with gentle heating. 
Mesophase samples were then generated by mixing weighed quantities of MAG lipid-THL 
formulations with Milli-Q water corresponding to ratios at excess hydration according to the MAG 
lipid-water phase diagrams (≥ 40% - 50% w/w).  
 
The same approach was taken for the incorporation of the hydrophobic API (CFZ-citrate salt) 
into the LCP whereby the API crystals were dispersed in the molten MAG at the desired percentage 
weight before the introduction of water to the system to form the cubic phase. For the hydrophilic 
API, caffeine, the caffeine was dissolved in the water used to prepare the cubic phase and this was 
added to the blank molten lipid. Both the caffeine and the CFZ-citrate salt samples were prepared 
at concentrations of 1 and 3 wt% API. 
 
3.4.3 Mesophase characterization 
 
Polarizing Light Microscopy   
 
Polarized light was utilized to assign the predicted liquid crystalline mesophase accessed. A 
spatula tip of the generated mesophase was transferred to a glass microscope slide and immediately 
covered with a glass coverslip. The sample was examined under normal and cross polarized light 
at room temperature on a Zeiss AxioScope Optical microscope equipped with polarized light filter 
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and a cross-polarizer. Image acquisition was carried out using an AxioVision 4.8 imaging system 
by Carl Zeiss Ltd. Non-birefringence in refraction was identified by the appearance of a black 




Small angle X-ray scattering was performed to confirm mesophase assignments for the 




Mesophase samples with discrete composition were prepared as previously described for various 
concentrations of tetrahydrolipstatin within the range of 0 to 2.5 wt%. To study the metastability 
of the phases over a prolonged period of time, samples were prepared 3 weeks, 4 days, 2 days and 
1 hour prior to SAXS data collection. Samples were stored in sealed vials until just before data 
acquisition to avoid any sample dehydration through atmospheric exposure. Another set of samples 
were tested to determine the loading capabilities of the phase with the model APIs, prepared as 
previously described at concentrations of 1 and 3 wt%. 
 
SAXS measurements were carried out after sample preparation at the Solution State SAXS B21 
beam line at Diamond Light Source on the Harwell Campus, Didcot, UK as previously described 
[428]. The relative positions of the distinct Bragg peaks were indexed and served in distinguishing 
the space groups and lattice parameters, correlating with Miller indices [473] of the bulk cubic 
phases and their dispersions. The water channel diameter and lipid chain length were calculated as 
previously described [428], where surface area constants Å and Euler Poincare constant (χ) were 
utilised [151, 354] according to equations 2.2 through 2.5.   
 
A further calculation was applied in this study where the area at the interface per lipid molecule 















Where MWMAG is the molecular weight (g.mol-1) for the host lipid, taken as 356.6 and 328.5 g.mol-
1for MO and MPL respectively. 
  
From there, the area at the interface per lipid molecule was calculated according to the following 
equation:  





Where Aêdé + 2πχlé	is equal to the area at the head group at the interface integrated over a single 
monolayer 
 
3.4.4 Enzyme stock preparation  
 
A 5 mg/mL solution was prepared by dissolving the lipase in 0.1 M phosphate buffered saline 
(PBS), pH 7.4 ± 0.2. The preparation was carried out on ice to avoid denaturation or premature 
activation of the enzyme. Enzyme solutions were stored on ice or in the fridge and only used for 
up to one hour after preparation. New solutions were prepared for experiments thereafter. It is 
acknowledged that at this concentration, proteins displaying interfacial activity are prone to 
aggregation, however all samples were treated identically in this investigation under the same 
experimental conditions of enzyme exposure.  
 
For the clofazimine salt, ultrapure water was substituted for the PBS in the preparation of the 
enzyme solution to prevent ion displacement from the citrate salt form of the API leading to 
reduced aqueous solubility [471]. 
 
3.4.5 Swelling and degradation Behaviour  
 
To investigate the time-dependent swelling and degradation behaviour of the lipid cubic phase 
gels prepared with different commercial lipids, pharmaceuticals and THL, dynamic swelling 
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studies were performed. After sufficient equilibration the gels were weighed before submersion in 
1ml of phosphate buffered saline solution (pH 7.4 ± 0.2), both in the presence and absence of 
enzyme. The sample vials were tightly capped and maintained at 37°C. The samples were shaken 
at 200 rpm throughout the investigation to ensure homogenous exposure of the sample to the 
enzyme. Porcine pancreatic lipase was selected for the study. For the clofazimine salt, ultrapure 
water was again substituted for the PBS to prevent ion displacement from the citrate salt form of 
the API leading to reduced aqueous solubility [471]. 
 
The swelling and degradation ratios of the gels were studied by means of a standard gravimetric 
method. The gels were removed from the media at regular intervals and their liquid uptake and 
mass loss was characterized by measuring the change in their mass. The gels were rinsed with 
purified MilliQ water to remove any residual salts potentially deposited on the surface of the gel 
from the swelling media and lipase solution debris. The excess surface water was then removed 
from samples by gentle blotting with lint-free Kimwipes™ before the samples were weighed on 
an analytical balance.  
 
The swelling ratio and rate of degradation in terms of relative weight % were calculated against 
the initial sample mass as per the following equation:  
 




Where W0 is the initial gel weight before submersion in the media and W1 is the weight of the gel 
at a measured time point after immersion in the media. 
 
3.4.6 Drug release studies  
 
The release of the model pharmaceuticals CFZ-citrate and caffeine from the LCP was tracked at 
timed intervals for up to 31 days in PBS or water for caffeine and CFZ-citrate respectively. Drug 
release measurements consisted of removing the entire solution from the sink and immediately 
replenishing it with fresh release media. Throughout the measurement, the samples were shaken 
at 200 rpm in an incubator at 37°C. The concentration of CFZ-citrate and caffeine in the sink were 
measured by UV-vis spectrometry for CFZ-citrate and high performance liquid chromatography 
(HPLC) for caffeine, due to interference from the lipids in solution.  
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3.4.7 High Performance Liquid Chromatography  
 
The HPLC system used in this investigation was an Agilent 1200 Infinity Series (Agilent 
Technologies, Palo Alto, USA) comprising: G1311B 1260 quaternary pump, G1329B 1260 ALS 
autosampler, G1316A 1260 TCC (thermostated column compartment) and a G1365D 1260 MWD 
VL diode-array detector. The acquired data was processed with the Agilent OpenLAB CDS 
software. 
 
Chromatographic separations of caffeine-containing samples were achieved using an Agilent 
Poroshell 120 PFP (3 x 100 mm, 2.7 µm) column fitted with a UHPLC Poroshell 120 guard module 
(3 x 5 mm, 2.7 µm). The system was maintained at 20°C with a run time of 10 minutes. The mobile 
phase which comprised A: HPLC Analytical grade Acetonitrile (Fisher Scientific) and B: 
deionized water (A:B 15:85, v/v) was delivered to the column at a flow rate of 0.64 mL/min which 
yielded a column back pressure of ~290 bar. Samples were filtered through a 0.2 µm nylon filter 
(Fisherbrand®) and 8 µl injections were made. UV detection was conducted at a wavelength of 
274 nm. 
 
3.4.8 UV-visible Spectroscopy  
 
The concentration of CFZ citrate was determined by means of UV-vis spectrophotometry. A full 
spectrum was obtained on a double beam UV-1800 Shimadzu UV-Visible spectrophotometer to 
ascertain λmax for the drug, which was determined as 488 nm. Absorbance values of release samples 
were then obtained with appropriate dilution at this wavelength and Beer-Lambert’s Law was then 
utilized to calculate the concentration of the API in the sample. 
 
3.4.9 Drug release kinetics 
 
The release data obtained for the release of caffeine and clofazimine citrate in the presence or 
absence of the THL inhibitor from the two MAG LCP formulations were treated according to a 
number of release models: zero-order (cumulative % drug released v time (min)); first order (Log 
cumulative % drug released v time (min)); Higuchi (cumulative % drug released v square root of 
time);  Hixson-Crowell (cube root % total drug - cube root of % unreleased drug v time (min)); 
and Korsmeyer-Peppas (log cumulative % drug released v log time) to obtain the correlation 
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coefficient. The diffusion coefficient (n) was estimated from the linear regression line of the 
Korsmeyer-Peppas model for each sample. 
 
3.5 Results and Discussion 
 
3.5.1 Mesophase characterization 
 
In this study, lipid cubic phases were successfully formed using monoolein and monopalmitolein 
in the presence of hydrophobic and hydrophilic pharmaceutical compounds as well as a lipase 
inhibitor, the chemical structures of which are shown in Figure 3.1. A range of characterization 
techniques can be applied in the distinction of these phases. This investigation utilized simple 
polarizing light microscopy and more thorough small-angle X-ray scattering approaches to assign 
mesophase properties to the test formulations. One can determine whether a test material is 
anisotropic or isotropic in nature and measure its birefringence simply by using cross-polarized 
microscopy (CPLM) [474]. As the highly ordered cubic phase exhibits optical isotropy and its 
refraction is non-birefringent in nature, it gives rise to a dark background between crossed polars 
as the phase is essentially ‘invisible’ against the dark stage [475]. The lamellar and hexagonal 
liquid crystalline phases on the other hand, are anisotropic and optically birefringent thus split the 
plane of the incident light appearing as textured multi-coloured patterns. This distinction allowed 
for the identification of the phases of our formulations. Indeed, when the fresh formulations under 
investigation in this study were exposed to cross-polarized light, a dark image was observed with 
no obvious signs of birefringence suggesting a structure of cubic architecture.  
 
While CPLM allows for differentiation between mesophases, its usefulness is limited by an 
inability to distinguish between the various types of discrete cubic phases and it provides no means 
for dimensional analysis. Small angle X-ray scattering investigations enabled the lattice 
dimensions and unambiguous space group symmetry to be assigned to each sample. They also 
allowed for the effect of THL and API loading on the phase properties, and its impact on the 
stability of the phase to be tracked. With a favourable effect in terms of stability against lipolytic 
enzymes anticipated, phase identification was required to confirm the loading capabilities of the 
MAG LCP systems. Lipid cubic phases typically give rise to diffraction patterns similar to those 
of powder X-ray diffraction; characterized by a series of sharp, clearly defined concentric rings 
owing to their randomly orientated domains of cubic symmetry [170]. Figure 3.2 shows the 1D 
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azimuthally integrated SAXS patterns of freshly made MAG LCP systems of MO and MPL. Bragg 
peaks have been indexed according to the Miller indices of the reflection plane to assign the 
mesophase. The relative positions of the reflection lines indicated the presence of highly ordered 
bicontinuous cubic phases in our samples. As expected, in all of the systems for both host lipids, 
the phase in equilibrium with excess water was of the cubic-QKKL type with lattice parameters (Table 
3.1) slightly higher than those referenced in the literature [359, 360]. The calculated water channel 
diameter dimensions however (Table 3.1) were in agreement with published values [123, 169] 
with larger values for channel diameter calculated for the MPL system as expected [353].  
 
 
Figure 3.2 1D azimuthally integrated SAXS patterns of fresh monoolein (MO) and 
Monopalmitolein (MPL) of blank cubic mesophases. The peaks of both patterns have been indexed 
according to the ÅÇÇõ  mesophase. Repetitions (see appendix B) demonstrated no impact on the 
mesophase from radiation damage. 
Samples prepared below excess hydration levels saw a transition from the QKKL to QKKL + QKKR   that 
occurred across all specimen, even in those prepared fresh on the day of testing (data not shown). 
In these dual-phase regions, the individual lattice parameter of the respective phases should remain 
constant with little influence from the sample make-up as a whole. In Table 3.1, the transition from 
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a single phase to the co-existence of two bicontinuous cubic phases in the monoolein/water system 
is seen as dehydration of the sample occurs [177, 352], likely occurring during transferal to the 
sample stage and also during storage [476]. It is also possible that the fresh formulations had not 
yet fully equilibrated to a homogeneous hydration state at the time of testing, which could explain 
the coexistence of two cubic phases. The coexistence between the ÅÇÇõ	and ÅÇÇI	 is supported by the 
Bonnet ratio between the lattice parameters: the ratio of unit cell dimensions of coexisting cubic 
phases related through Bonnet transformations [368]. In the case of coexistence between ÅÇÇõ	and 
ÅÇÇ
I	mesophases, the Bonnet ratio should be 1.57. It should also be noted at this point, that in 
utilizing X-rays for sample research, the impact of radiation damage on any given specimen, 
especially those soft biomaterials such as lipid mesophases, is a justified concern. However, the 
work of Cherezov and colleagues attests that the radiation dosage and exposure time used in this 
investigation is not likely to have a significant impact on the MAG mesophases under examination 
[477]. Here, 15 frames per sample recorded sequentially in one single location were analyzed and 


















Table 3.1. Phase identification and lattice parameters of assigned mesophases at varied THL 
loadings from SAXS experiments with calculated dimensional values for lipid chain length (L) 



















MO 0 F QKKL 10.17 1.74 4.475 - 
MO 0 21 n/a* - - - - 
MO 0.7 F QKKL 9.92 1.69 4.369 - 























MO 2.5 F QKKL 9.24 1.58 4.064 - 
MPL 0 F QKKL 10.8 1.48 5.482 - 
MPL 0 21 n/a* - - - - 
MPL 0.7 F QKKL 10.47 1.43 5.320 - 
























MPL 2.5 F QKKL 9.88 1.35 5.025 - 
 
CE samples that presented the coexistence of two mesophases; a *one single peak detected i.e. no 
mesophase; storage time of sample in sealed vial prior to SAXS 
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Table 3.1 reports the mesophases assigned for samples doped with varying concentrations of 
THL, the lipase inhibitor, up to 2.5 wt% obtained from SAXS experiments. The formulations of 
both MO and MPL at increasing concentrations of THL present cubic structures almost identical 
to those of the blank matrices. Figure 3.3 shows the effect of incorporating increasing 
concentrations of the hydrophobic THL in MAG LCP systems of MO and MPL on the SAXS 
patterns.  The addition of the lipase inhibitor appeared to bear no major effect on the peak 
positioning with only minor shifts in scattering vector q observed. The integrated SAXS patterns 
demonstrated how increasing the concentration of the THL lipstatin saw a shift towards higher q 
for the LCP systems. This is directly related to the swelling of the phase; with higher q indicating 
a smaller lattice parameter of the mesophase. The lattice spacing and space group assignment 
provide a metric for the estimation of cubic phase structural dimensions, which can aid in host 
lipid selection and loading capacity determination. The volume fraction of the lipid component 
along with d-spacing values were essential parameters in estimating the internal dimensions of the 
mesophases [354]. Values pertaining to the structural dimensions of the cubic formulations were 
calculated utilizing these parameters as well as the phase identity obtained from the SAXS 
experiments according to equations 2.2 through 2.5. In bicontinuous cubic phases, under 
conditions of equilibrium, the characteristic lattice spacing is directly related to the diameter of its 
penetrating water channels; and an increase in parameters is observed with increasing hydration. 






Figure 2.3. Azimuthally integrated SAXS patterns of monoolein (MO, a) and monopalmitolein 
(MPL, b) mesophases doped with increasing concentrations of THL from 0 (fresh) – 2.5 w/w %. 
The patterns have been indexed according to the ÅÇÇõ mesophase. 
In the case of the monoolein LCP system, the amount of the hydrophobic THL added appeared 
to be inversely related to the aqueous channel diameter; reducing by a little over 0.4 nm as the 
weight percent of THL increased from 0 to 2.5 % w/w, Table 3.1. A decrease in water channel 
diameter is also evidenced by higher q values as shown in Figure 3.3 This coincided with a slight 
reduction in lattice parameter for these samples. A similar relationship was seen in the LCP 
systems prepared with the shorter chain monopalmitolein host lipid whereby an increase in THL 
loading saw a reduction in both the water channel diameter and lipid layer depth. Indeed, the 
reduction in this case was slightly higher than that in the MO 9.9 MAG monoolein system, with a 
reduction of almost 0.5 nm observed.  
 
The impact of THL on the stability of the LCP systems over time was also investigated where 
the metastability of the phase structure over 3 weeks was studied. Diffraction patterns were 
examined in relation to those samples freshly prepared on the day of testing. A phase transition, 
similar to that observed in the samples prepared below excess hydration, was seen in those samples 
stored over a 3 week period when prepared with the inhibitor, where peak broadening and the co-
existence of two cubic systems (QKKL + QKKR  ) was presented (Figure 3.4 (a) and (b)). However, in 
samples prepared without the THL, the initial phase transitioned even further beyond the liquid 
crystalline region entirely, highlighting the stabilizing effect of the THL inhibitor on the LCP 
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mesophase. Smooth, sharp diffraction rings corresponding to discrete cubic phase symmetry are 
highlighted in the 1D azimuthally integrated SAXS patterns for the fresh samples in Figure 3.4 (a) 
and (b).  
 
 
Figure 3.3. The effect of incorporating the hydrophobic THL lipstatin on the stability of 
monoolein (a) and monopalmitolein (b) lipid systems over 3 weeks at 37° C. Bragg peaks have 
been indexed according to the Miller indices of the reflection plane to assign mesophase. 1D 
azimuthally integrated SAXS patterns of  blank mesophases and those doped with 1.5 w/w % THL 
in order of decreasing storage time prior to analysis. The patterns have been indexed to either the 
ÅÇÇ
õ (black text) or ÅÇÇI  (red text) mesophase. 
The observed increase in stability of the MAG LCP systems over time owed to the presence of 
the inhibitor may be related to changes in the packing frustration of the phases. When considering 
the phase behaviour of pure monoacylglycerols such as MO and MPL, there are really only two 
major influential parameters at play – temperature and water content. However, when you venture 
outside of pure lipid systems and begin to consider how their behaviour is affected or driven by 
other compositional factors such as the inclusion of additive molecules, one might find that the 
phase behaviour changes, potentially deviating from their classical binary behaviour. The impact 
of introducing a third contributing factor stretches the system beyond this simplistic model to a 
much more complex ternary system [478]. The introduction of hydrophobic molecules in particular 
has been shown to induce changes on the molecular level, subsequently altering the morphology 
of the phase. These studies described the effect on packing frustration (the energy cost associated 
MO_THL_1.5_FRESH MO_THL_1.5_3 WEEK 
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with deviation from the favoured shape in a particular phase) of MO cubic phases induced by the 
addition of a hydrophobic long chain alkane tricosane [153]. They have demonstrated the 
relationship between the packing frustration and cubic phase stability, whereby the introduction of 
the hydrophobic molecules reduced the frustration by partitioning into the hydrocarbon chain 
domains [152, 479], subsequently stabilizing the mesophase [480]. The stabilizing effect may also 
be explained by an interaction between the hydrophilic moieties of the tetrahydrolipstatin molecule 
and the water present in the penetrating channels. It is possible that hydrogen bonding between 
water and the carbonyl or amide groups of THL, Figure 3.1, could retain water molecules in the 
matrix, thus maintaining the cubic phase over the three week storage period investigated, where 
dehydration of the blank systems resulted in the disassembly of the mesophase. More thorough 
SAXS investigations into the exact location of the inhibitor in the phase would be required to 
corroborate this theory.  
 
Ultimately, the objective of this study was to control the rate of release of hydrophobic drugs 
from LCP systems. To assess the suitability of the THL-containing LCP systems as controlled 
drug delivery matrices, two model pharmaceutical agents (caffeine and CFZ-citrate salt) were 
selected based on their propensity to dissolve in water. Samples were prepared with increasing 
amounts of both APIs (1 and 3 wt%) in a bid to establish the carrying capacity of the cubic phase 
for APIs located in different regions of its network. The resulting mesophases and their 
corresponding dimensional estimations are shown in Table 2.2. As with samples without added 











Table 2.2. Phase identification and lattice parameters of assigned mesophases for varied THL and 
model API loading from SAXS experiments with calculated dimensional values for lipid chain 





























































































































MO 0 Caff 
1% 
2 QKKL 10.07 1.72 4.432 - 
MO 0 Caff 
3% 
2 QKKR  15.09 1.99 3.502 - 
MO 1.5 Caff 
1% 














































MPL 1.5 Caff 
1% 
2 QKKL 10.46 1.43 5.316 - 
CE samples that presented the coexistence of two mesophases *one single peak detected i.e. no 
mesophase; storage time of sample in sealed vial prior to SAXS 
 
The incorporation of the hydrophobic CFZ citrate salt into the lipid matrices lead to an increase 
in the lattice parameter, and the width of the water channels. This effect was more pronounced in 
the case of the upper loading of 3 wt% API. In the MPL system, the coexistence of a second double 
diamond cubic phase structure is observed with larger structure parameter values at both API 
loadings (+ 0.91 to 1.32 Å). In the MO LCP-THL system, a phase coexistence was observed, with 
reduced water channel diameter and shift to higher q (Å) noted. The incorporation of hydrophilic 
caffeine at 1 wt% loading into the MO LCP formulations did not significantly affect the lattice 
parameter and size of water channels. The relatively small size of the molecule (0.243 nm3) [481] 
meant that it could be easily accommodated in the aqueous channels (4.48 ± 0.03 and 5.48 ± 0.13 
nm in MO and MPL LCP respectively, shown as the mean value of 3 samples ± standard deviation) 
of the matrix and therefore the QKKL structure was preserved. The presence of the caffeine (1 wt%) 
in the 1.5 wt% THL LCP system left the phase seemingly unaffected, with a single QKKL space group 
maintained for both MO and MPL host lipid LCPs that were comparable to the blank systems. It 
is clear that the structural parameters of the QKKL regions are greater than those of the QKKR  . This is 
expected as the QKKL phase is accessed at a higher hydration point than the QKKR   region, which in turn 
influences the physical dimension of the unit cell [177, 352]. The presence of an unassignable peak 
between 0.134 and 0.136 Å-1 in the MO samples containing the caffeine API may be owed to API 
precipitation or formation of a caffeine hydrate in the system as the sharp Bragg peak was not 
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observed in the blank system and could not be assigned to any mesophase. Its presence does 
however allude to the existence of a crystal of some sort.  
 
The release kinetics of the cubic phase are governed by the phase identity and the capacity of its 
aqueous channels. In addition to the effect the physio-chemical properties of the matrix itself have 
on the diffusion of the API, the properties of the API being incorporated also influence the 
transport properties of the matrix and have been reported to induce phase transformations upon 
formulation [123, 168, 212]. It is therefore imperative to ensure that the incorporated API does not 
disrupt the assembly of the cubic phase lattice structure which may in turn affect its function. In 
some cases, this may limit the use of the cubic phase as a drug delivery matrix. While some 
dimensional changes in the crystallographic unit cell were observed upon the incorporation of both 
model drugs, the conclusion was drawn that the molecular distribution of the lipid cubic phases 
was not significantly altered by their presence at concentrations below 3 wt%. Additionally, the 
incorporation of the lipase inhibitor THL did not induce a phase transition and both systems have 
shown the ability to preserve the cubic structures at room temperature, showing only a small 
increase of the crystallographic unit cell parameter. This is important as major changes in the phase 
properties or transitions out of the cubic region caused by the incorporation of an API, may render 
the system unsuitable for certain applications as their release kinetics are governed by the 
mesophase of the lipid delivery system.  
 
3.5.2 Swelling and degradation  
 
As previously discussed, the integrity of lipid cubic systems, especially those generated from 
MAG host lipids, is vulnerable in the presence of a family of enzymes referred to as lipases [482]. 
This in turn may directly impact the release of the APIs that it encapsulates. In humans three major 
lipases exist, where their role is in the digestion and catabolism of dietary fatty intake [463, 483, 
484]. The lipase family of enzymes display significant sequence homology between species and 
this investigation utilized a model lipase from porcine pancreas to which tetrahydrolipstatin has 
the ability to bind and inhibit through irreversible interactions [485]. The lipolysis of the cubic 
phase in solution was followed both visually and gravimetrically. At predetermined time points, 
the mass of the gel was measured and the residual weight % was calculated (equation 3.3). The 
degradation could also be tracked visually, and its initiation was indicated by the formation of an 
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off-yellow oil layer on the outer surface of the gel. The digestion eventually resulted in an entirely 
cloudy solution with the oily layer sitting on top. 
 
For both MAG LCP systems, those exposed to lipolytic enzyme in the incubation medium saw 
a rapid decline in original mass for the blank MAG lipid cubic systems compared to those 
incubated in enzyme-free PBS buffer. The integrity of the MO LCP was compromised, and the 
enzyme action broke down the entire gel after a 7 day exposure. The gel that was spared lipase 
exposure maintained almost half of its original mass over the testing period of 12 days. Similarly, 
in the MPL LCP system, the gel maintained 94 ± 0.53 % of its original mass after 17 days in the 
enzyme free buffer, while the cubic gel exposed to lipase was digested to its oleic acid and glycerol 
components over the course of 10 days. In fact, the gel incubated in lipase-free buffer was subject 
to a loss of only 13 ± 2.5 % over a testing period of 36 days.  
 
Tetrahydrolipstatin is a potent lipase inhibitor and the lipophilic molecule exerts its inhibitory 
effect upon binding the pancreatic lipase at its serine active site as previously mentioned in the 
introduction to this study. THL was incorporated into cubic formulations generated from both host 
lipids at increasing concentrations to study its effectiveness in impeding their lipolysis. 
Concentrations of 0.35, 0.7, 1.5 and 2.5 wt% were chosen to study the potential tunability of the 
systems in terms of the LCP lifespan compared to the blank systems as a means of further 
controlling the rate of release of hydrophobic APIs in particular, which is concomitant with 




Figure 3.5. Swelling and degradation profile of: a) Monoolein and b) Monopalmitolein LCP 
formulations (Blank or formulated with THL) in Physiological Buffer (1X PBS) incubated at 37°C 






























































Figure 3.5 (a) shows the enzyme-driven hydrolysis of the monoolein LCP gels, both with and 
without THL up to 2.5 wt% embedded in its network. Increasing the concentration of the THL in 
the lipid network incrementally decreased the degradation rate of the gels by almost 6 fold at the 
highest loading compared to the LCP without inhibitor. Even at the lowest inhibitor concentration 
(0.35 wt%), the loss in original mass was slowed down and the systems maintained 49.7 ± 9.5 % 
of their original mass after 7 days when the blank LCP had been fully digested into their soluble 
oleic acid and glycerol components.  
 
A control group was also studied, where MO LCP was incubated with lipase and free THL in 
solution at a concentration of 1.5 mg/mL. Here, an increase in stability was observed as the samples 
were fully degraded after 15 days compared to the degradation rate of the MO LCP with lipase, 
where they had fully degraded by day 7. The rapid loss in mass may have occurred as a result of a 
combination of phase change and mass depletion rather than solely the lipolysis of the lipid 
component itself. In this control group, the THL in solution was replenished with each change of 
media at least every 24 hours, and yet the MO LCP with the THL incorporated into its network 
displayed greater stability and did not fully degrade until day 24. These latter samples only had 
the initial 1.5 mg/ml of THL added for the duration the experiment and the depletion in mass 
occurred with little initial swelling observed, possibly on account of the hydrophobic effect of the 
membrane bound inhibitor pointing towards a predominantly surface-driven digestion pattern. 
 
The same experimental conditions were tested on the MAG LCP of shorter chain length, 
monopalmitolein, Figure 3.5 (b). Once again, an increase in stability was noted in the presence of 
the THL, even at the lowest loading of 0.35 wt% where the LCP samples maintained between ~31 
- 33 % of their original mass at 10 days by when the blank gels were completely broken down.  
There was no observed swelling between tested time-points indicating that the diffusion of enzyme 
solution into the phase did not outpace the degradation. The 0.35 wt% samples were not fully 
digested until after 15 days in incubation.  
 
Both systems were considered to be comparable in terms of tunable stability, and for the majority 
the error, while still relatively small, between samples may be generally explained by the variation 
in distribution of the lipstatin between gel formulations. Although all samples were prepared 
following identical protocols of manual and vortex mixing, the hydrophobic inhibitor is suspended 
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rather than dissolved within the formulation and is likely not completely homogeneous. While the 
two LCP systems appear to follow similar digestive trends, the incorporation of the THL showed 
a more prolonged stability period in the MO LCP versus the MPL system compared to the samples 
prepared without the inhibitor in their respective profiles. This difference may be attributed to the 
difference in water channel diameters and lipid packing described already in the SAXS section of 
this investigation, where the wider diameter of aqueous channels in the MPL system allowed for 
a higher penetration of the external lipase solution into the phase’s aqueous network, in turn 
speeding up the degradation process. The SAXS data clearly showed a lower degree of swelling 
of MO LCP in the presence of THL under conditions of excess water (shown by higher q values) 
suggesting that lower volumes of lipase solution could penetrate and diffuse into the phase.  
 
The faster degradation of the MPL LCP system may therefore be attributed to the higher surface 
area associated with the lipid portion of the phase. The interfacial area per lipid molecule of both 
MAG LCP systems was calculated using equation 3.2 which utilized the lattice parameter and 
calculated lipid chain length obtained from the SAXS data. The calculated surface area was shown 
to be larger in the shorter chain MPL system (Table 3.3). This provides the lipase with a larger 
access area at the interface required for it to carry out its lipolysis. On the contrary, the surface 
area is seen to increase as the water channel diameter decreases with higher THL loadings. Despite 
this, the degradation is clearly slowed down by the THL’s presence which may seem counter-
intuitive. It is however hypothesized that with the larger associated surface area of the lipid portion, 











Table 3.3. Calculated interfacial area per lipid molecule (ai) of MAG LCP generated at different 
THL loadings 
Host Lipid THL % Storage 
(days) 
mesophase ai (nm2) 
MO 0 F QKKL 3.13 x 10-22 
MO 0.7 F QKKL 3.22 x 10-22 
MO 1.5 F QKKL 3.32 x 10-22 
MO 2.5 F QKKL 3.45 x 10-22 
MPL 0 F QKKL 3.43 x 10-22 
MPL 0.7 F QKKL 3.54 x 10-22 
MPL 1.5 F QKKL 3.73 x 10-22 
MPL 2.5 F QKKL 3.75 x 10-22 
 
Once again, the digestion of the LCP samples was easily trackable upon visual inspection. After 
prolonged lipase exposure, the sample appearances became cloudier in colour, with a brittle core 
covered in a more viscous outer layer. The samples prepared with the inhibitor maintained the 
characteristically clear colour of the lipid cubic phase for longer than those blank samples; with 
the change in appearance noted after only 3 days in incubation for the blank gels compared to 7 
days in the doped gels.  
 
To confirm that the THL-containing samples maintained the cubic phase as well as the system 
mass in the presence of the lipase solution, LCP samples were prepared for both host lipid systems 
with and without THL at 1.5 wt% incorporated into the membrane and were exposed to lipase 
solution for 3 days before SAXS analysis was conducted. In both cases, the QKKL  structure was 





Table 3.4. Phase identification and lattice parameters of assigned mesophases for varied THL 


























MO 1.5 3 QKKL 9.68 1.65 4.265 
MPLCE 0 3 QKKL 
 























L is the lipid chain length/monolayer thickness (nm); DH20 is the diameter of the water channels 
(nm);CE samples that presented the coexistence of two mesophases; storage time of sample in 
sealed vial prior to SAXS 
 
In the more readily digested MPL system in the absence of THL, the SAXS data demonstrated 
a transition of the LCP to what appears to be a hexagonal phase (HII) within the network after 
exposure to the lipase. It is described in the literature that both the instinctive formation of the 
phase and the thermodynamic stability of the LCP are driven by an opposition between a pair of 
free energy terms. When this competition between the curvature energy of the individual 
monolayers and stretching energy of the lipid chains exists in its least frustrated state, it is 
suggested to be responsible for the nature of the solid state phase and its position on the phase 
diagram [151]. The hexagonal phase comprises an arrangement of limitless water rods divided by 
lipid bilayers in a two dimensional lattice and the transition to the phase upon lipase interaction 
has previously been reported where the presence of the lipase in solution served to increase the 
curvature of the system, subsequently altering the molecular structure inducing a phase transition 
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[146, 257]. This was not seen in the MO system although the presence of a second QKKL lattice was 
noted where only one existed in the sample containing the inhibitor. The same phenomenon was 
seen in the MPL system even in the sample formulated with the inhibitor.  
 
Additionally, the immediate impact of lipolytic enzymes on the structure of the phase was also 
studied by swelling the lipids in an enzyme solution at a concentration of 5 mg/mL (Table 3.5, 
appendix B).  
 
Table 3.5. Phase identification and lattice parameters of assigned mesophases for LCP formulated 
with various biologically enzymes from SAXS experiments. Enzyme stock solutions were 












MO Lipase QKKL 10.37 1.77 4.56 
MO Pancreatin QKKL 10.29 1.76 4.53 
MPL Lipase QKKL 11.34 1.55 5.76 
MPL Pancreatin QKKL 11.23 1.54 5.7 
 
While changes in internal dimensions were noted (reduced water channel diameter) compared 
to those systems swelled in water, both MO and MPL systems formed the QKKL phase in the presence 
of the enzymes. This was unsurprising as the lipid cubic phase is commonly used in protein 
crystallization techniques [145] and readily incorporates proteins of different sizes and charge. 
These results prove that the phase changes and break down of the system over time in the enzyme 
media are not caused by disruption caused by the size or shape of the proteins when taken up by 
the mesophase, but solely the hydrolysis of the individual lipid molecules by the enzymes.  
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Figure 3.6. Stability plots for a) MO-THL and b) MPL-THL LCP-inhibitor systems showing 
increasing THL concentration plotted against the stability (days) of the cubic phase in lipase 
solution. 
 
From the stability tests conducted in the presence of lipase, it may be possible to control the 
duration of the prolonged release of hydrophobic molecules from LCP matrix networks using 
lipase inhibitors, allowing for the selection of the most suitable system for a given clinical drug 
delivery application. Figure 3.6 shows stability plots for both of the LCP-inhibitor formulations; 
where increasing THL concentration was plotted against the stability of the phase in lipase 










































solution. These models may provide researchers with a mode of predicting the phase stability 
against lipase digestion up to 40 or 36 days for the MO- and the MPL- THL LCP systems 
respectively across a range of inhibitor concentrations from 0 to 2.5 wt%.  
 
3.5.3 Drug release studies  
 
Numerous approaches have been described to modulate the kinetics of drug release to 
systematically control or prolong the drug delivery period of hydrophilic agents [168, 170, 435, 
486, 487]. This study sought to investigate the impact of addressing the rate of degradation of the 
phase as a means to control the release of model APIs. A particular interest lay with understanding 
in its impact on hydrophobic pharmaceuticals. It was hypothesized that the incorporation of the 
inhibitor would have greater influence on the predicted degradation-driven release of hydrophobic 
agents and little to no effect on more water-soluble molecules.  
 
Clofazimine (CFZ), an antimycobacterial agent indicated for the treatment of leprosy, was 
selected as a model drug on account of its Biopharmaceuticals Classification System (BCS) class 
II properties of low aqueous solubility. Our group has previously developed a number of novel salt 
forms of clofazimine in a bid to improve the uptake of the drug in vivo [471]. One of these salts, 
co-formed with a citrate ion, was selected for this study on account of its enhanced aqueous 
solubility (~40 mg/L) which made studying its release possible. Not only that, but the API itself 
has shown high uptake in micelles and liposomes [488] and so its highly lipophilic nature [489] 
render CFZ a perfect subject to profile the release of membrane anchored molecules from our 
LCP-inhibitor systems.  
 
The release of CFZ-citrate from the MAG systems, with and without THL and in the presence 
of lipase at 37°C, is displayed in Figure 3.7. Upon initiation of significant digestion of the LCP 
matrices after approximately 24 hours in both systems in the absence of the inhibitor, CFZ-citrate 
release appears to be inversely proportional to the residual mass of the matrix. In the case of 
lipophilic APIs such as CFZ citrate which are thought to be predominantly located in the lipid 
bilayer, the rate of their diffusion is believed to be limited by their partitioning into the bilayers 
and is controlled by the erosion and breakdown of the carrier [174]. The release of the CFZ salt 
was found to be slower in the MO-based LCP compared to the MPL system under identical 
conditions. This result was expected from the faster degradation observed for MPL (Figure 3.5) in 
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the absence of THL and presence of lipase, where the gel was entirely digested into its core 
constituents. The oil layer maintained the characteristic red colour of the CFZ indicating that some 






















Figure 3.7. Dissolution profiles of the hydrophobic model drug Clofazimine-citrate salt (1 wt%) 
from a) MO and b) MPL LCP formulations (Blank or formulated with 1.5 % w/w THL) into water 
incubated at 37°C in the presence of lipase enzyme showing the corresponding swelling and 
degradation behaviour of the gels. (Water replaced PBS for the release study with CFZ-citrate.) 
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The influence of THL on the dissolution profiles is also clearly represented in Figure 3.7 
compared to the samples without the inhibitor; showing the prolonged release of the hydrophobic 
model drug upon its addition to the mesophases. The release rates were significantly slower in the 
systems that had the THL in their network with less than 20% cumulative release in both host lipid 
formulations after the testing period, indicating that its incorporation can control the rate at which 
the drug is eliminated from the gels. As discussed, this control is believed to be owed to the 
interaction of the THL with the lipase, thus inhibiting the degradation of the cubic mesophase. In 
the absence of the inhibitor, the lipase acts at the lipid/water interface to breakdown the matrix into 
an oily emulsion enabling the CFZ-citrate to partition into the media while this effect is delayed 
by the presence of the THL.  
 
In the MO system formulated with 1.5 wt% THL, the CFZ salt continued to be released into 
solution at a steady rate over a 3 week testing period. After a 21 day incubation at 37°C and 200 
rpm approximately 25% of the drug was released. 40% of the original CFZ salt loading in the 
MPL-THL system was released from the bulk phase after this period. The MO-based gel mass had 
not reduced beyond 20% of its original weight and the MPL system maintained almost 60% of its 
original mass after this time. These results highlight the influence of tunable degradation of the 
cubic phase on controlled release of hydrophobic agents.  
 
The release data for these hydrophobic API systems was fitted to a number of theoretical and 
empirical drug release models to study the effect the incorporation of the inhibitor had on 
controlling the release of CFZ-citrate (appendix B). The literature indicates the Korsmeyers-
Peppas, first-order kinetics and Higuchi models as the most representative of release from cubic 
phases [359]. These mathematical models, among others, were applied. However, in this case, the 
release data did not appear to fit well with these fundamental models described, although the best 
fit was indeed seen with zero-order and Korsemeyer-Peppas release kinetics indicating an 
anomalous non-Fickian diffusion transport that is both diffusion and swelling/erosion controlled. 
In examining the coefficient values (n) obtained for the CFZ salt from the Korsemeyer-Peppas 
model, values pointing towards non-Fickian case 2 relaxation or super-case transport-2 mechanism 
were calculated (n > 0.45) on account of the hydrophobic salt’s location in the lipid membrane. 
This supported the theory that erosion was a driving force in its release [359].  In both cases, higher 
coefficient values were observed in the gels without the inhibitor, where significant degradation 
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was observed over the testing period directly related to the release of the drug into solution. These 
values allude to deviation from straight-forward diffusive transport and the results reiterate the 
influence the swelling and erosion of the matrix has on release of CFZ and serves to further affirm 
the concept of targeting degradation as a reasonable approach to extend the control inherently 
offered by the cubic phase itself without altering its phase structure.  
 
While it is generally accepted that release of APIs from bioerodible polymers, such as lipid-
based systems, is biphasic, driven by both diffusion and matrix effect [271], it is clear from the 
model plots and the respective r2 values obtained (appendix B) that the release from these LCP-
inhibitor formulations is not simplistic, nor two-dimensional. While these mathematical models 
provided us with an indication of the release kinetics at play, there are several influential factors 
in this ternary system that drive the liberation of the hydrophobic API from its network. This makes 
it difficult to apply the existing simplistic mathematical models to its release, most of which 
assume a spherical-shaped system, which of course is not this case here. The release profile is, 
without dispute, complex with a combination/opposing effect of the variables on water uptake and 
digestion responsible.  
 
As the release kinetics of APIs from LCP depend on their location within the matrix [271], it 
was expected that the dissolution of the two model agents would follow different kinetics. To 
highlight the influence of the APIs location within the matrix on its release profile, caffeine was 
reconstituted in MAG LCP formulations to act as a model hydrophilic agent and the effect of 
encapsulation with lipase inhibitor THL on its release was studied. Release data was obtained and 
quantified using HPLC. The dissolution profiles of the hydrophilic model drug from these systems 




Figure 3.8. Dissolution profiles of the hydrophilic model drug Caffeine (1 wt.  %) from a) MO 
and b) MPL LCP formulations (Blank or formulated with 1.5 % w/w THL) into Physiological 
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corresponding swelling and degradation behaviour of the gels. Each point represents a mean value 
± standard deviation of three determinations. 
 
It was seen that the MO and MPL LCP systems were comparable as far as the release of the 
caffeine is concerned, although a slightly slower release was observed from the MO LCP system. 
The variations in release may once again be attributed to differences in the water channel diameter 
of the two systems owing to an osmotic effect; whereby different volumes of water can enter the 
respective network of channels, and is related to the ratio of the molecule size to water channel 
diameter [170]. It is obvious from the dissolution profiles of these formulations that the release of 
caffeine was not greatly influenced by the introduction of THL into MAG systems, as simple 
diffusive mechanisms were driving its release and were largely independent of matrix effect. A 
decrease in water channel diameter of almost 0.65 nm calculated in the MPL-inhibitor system upon 
the addition of caffeine may account for the slighter slower elution observed in the inhibitor system 
[170]. The theories put forward by Clogston and Caffrey suggested that as the size of the water 
channel approaches the size of the molecule that it encapsulates, the diffusion of said molecule is 
slowed or prevented. However, the narrower water channel diameter in our systems still well 
exceeded that of the caffeine molecule, even if it were to exist as a dimer or trimer and so explains 
the relatively analogous release profiles with and without the THL inhibitor. The SAXS data 
showed only minor reductions in water channel diameter upon the addition of 1 wt% caffeine to 
the monoolein LCP-inhibitor system evidenced in the largely comparable release profiles with and 
without THL. However, the MO-THL samples did display slightly faster diffusive transport 
compared to the blank MO-caffeine system despite a decrease in water channel diameter of ~0.6 
nm, which contradicts the aforementioned theory. It is most likely explained by the fluid nature of 
the phase as it has been suggested that the inherent flexibility of the liquid crystalline phase may 
provide evolving fluid channels that facilitate the movement of molecules through the network 
[170].  
 
The release data collected from the caffeine system was also treated against a number of 
mathematical models to obtain a correlation coefficient (r2), which allowed for evaluation of the 
kinetics of release of the hydrophilic model API from LCP. The more simplistic release profile 
was seen to fit better with the linear models compared to the vastly complex elution behaviour 
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seen in the CFZ salt model. The results (appendix B) indicate that the caffeine does indeed 
predominantly partition into the aqueous channel network from which it diffuses into the media 
with little influence from the digestion of the matrix itself. In contrast to the kinetics of CFZ 
release, when the release data from the various caffeine systems were fitted to the zero-order 
kinetic equation, the relatively small regression values suggested that the system did not obey the 
model. However, the dissolution results were found to have a better fit with first order kinetics. 
The correlation coefficient in this case was closest to unity suggesting that the release of caffeine 
from LCP most likely follows first order kinetics. This data strongly confirms the expected 
diffusion-controlled kinetics. In first-order release, the rate of drug diffusion is dependent on the 
concentration of the API incorporated in the formulation.  
 
Ultimately, this confirms the hypothesis that the incorporation of THL would likely not affect 
the release kinetics of the hydrophilic agent as its release is, for the most part, independent of the 
breakdown of the matrix. For this reason, the system would be suitable for a combined therapy 
application, whereby two or more active agents with opposite solubility properties could be 
incorporated into the lipid system with the hydrophilic agent being released within the first few 
days and more controlled, sustained release of a hydrophobic agent could be achieved.  
 
While this investigation focused primarily on an application with bulk lipid cubic gels, there is 
recognizable scope to extend this approach further to its cubic nanodispersions. In this case, the 
inhibitor may be encapsulated within the cubosomal network, either pre- or post-fragmentation. 
The technique of controlling release using inhibitors may be particularly appropriate for these 
formulations, as cubic nanosystems are more readily degraded by enzymes owing to their 
increased lipid-media interfacial area. In this instance, the rate of enzymatic digestion versus the 
length of time required for these nanoparticles to bind with, and be taken up through the cell 
membrane will determine the release kinetics of an encapsulated drug in a given environment. 
Here, factors such as pH and enzyme concentration will contribute to these interactions governing 
the rate at which both occur. Depending on proposed application, one may be interested in tailoring 
a system that favours one or the other. For example, a cubosomal-inhibitor hybrid system may be 
attractive where overcoming the blood-brain barrier is desired, as cubosomes have readily 
demonstrated their ability to do so [473, 490]. Here the inhibitor may serve to maintain the 
nanoparticle architecture for sufficient time to allow successful transition across the barrier to 
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deliver the desired drug at the target site.  Future work will focus on defining these interactions to 
distinguish the dominating action, if any.  
 
3.6 Conclusions and Leading Research Questions 
 
Lipid cubic systems derived from biodegradable MAG lipids are highly susceptible to lipolytic 
degradation by lipase enzymes in vivo, potentially limiting their application in drug delivery. In 
this study, it has been demonstrated that controlled release of hydrophobic APIs can be achieved 
with a novel formulation approach through the incorporation of small doses of lipase inhibitors, 
using tetrahydralipstatin as a model. Comprehensive SAXS experiments have shown, 
notwithstanding some minor alterations in structural parameters, that the incorporation of the 
inhibitor bore no negative impact on the phase behaviour of our lipid cubic formulations below 
loading concentrations of ≤ 2.5 wt%.  
 
The influence of hydrolytic enzymes on the stability of the cubic phase has been widely 
demonstrated [257-259]. The true effect of these enzymes responsible for catalyzing the hydrolysis 
of lipid membranes was studied here to better predict the degradation rate of the formulated LCP 
in vivo. Phase stability in the presence of these enzymes was found to control the degradation-
driven drug elution. Through the incorporation of THL, the lipid vehicles have demonstrated finely 
tunable rates of degradation that can be optimally coordinated to release hydrophobic 
pharmaceutical, and biological molecules over a desired period of time before the gel succumbs to 
complete digestion. Using CFZ citrate as a model drug, the LCP-inhibitor systems could extend 
its release profile beyond the one week duration in the blank LCP systems to weeks, and potentially 
even months through interactions with the lipases responsible for matrix digestion. These hybrid 
lipid cubic systems may also provide means of delivering inhibitors to control the action of these 
enzymes. Tetrahydralipstatin is a potent inhibitor of many other lipolytic enzymes additional to 
the pancreatic lipase studied here. These include gastric lipase, and carboxyl ester lipases. Thus, 
the approach described here may have a more far-reaching relevance. Should dosage requirements 
be defined and applied in the formulation, our LCP-inhibitor system could potentially be applied 
in a variety of drug administration routes with numerous possible target delivery sites where 
different lipolytic enzymes may be at play. Leading on from the promising results shown here, 
Chapter IV delves further into the interactions at play between the enzyme inhibitor and the lipid 
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ligand with the hydrolytic enzyme assisted by in silico techniques, with an aim of understanding, 











































Chapter IV: Probing the mechanism behind the inhibitor-controlled 




In this chapter the interactions and cofactors that influence the digestion of MAG derived lipid 
cubic phases are investigated and within this framework the inhibitory and stabilizing action of the 
encapsulated THL inhibitor is explored. Unlike regular enzymes that transform soluble substrates, 
lipolytic enzymes act at the interface between their aqueous medium and the insoluble lipid 
substrate. Compounds that bind or interact at this interface, including endogenous factors and ions, 
have the ability to enhance or inhibit the activity of these enzymes to varying extents. This study 
deals with the interplay between the lipolysis rate and the interfacial interaction of porcine 
pancreatic lipase with lipid cubic substrates encapsulating a known lipase inhibitor 
tetrahydrolipstatin (THL) that also acts at this interfacial region.  In the present work, inhibitor-
modified monoolein lipid cubic formulations designed to encapsulate and control the release of a 
BCS class IV drug paclitaxel (PTX) were examined under simulated lipolysis in the presence of 
lipase and its effectors colipase and calcium. Here, thermodynamic measurements and molecular 
dynamics simulations of the competitive inhibition of pancreatic lipase by THL have been 
combined with experimental dynamic digestion studies to reveal the role and mode of action of 
the studied lipase effectors in designing a degradation-controlled release system for the poorly 
soluble drug PTX.  
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Figure 4.1. Graphical depiction of the incorporation of THL into the lipid bilayer of the lipid cubic 
phase and its subsequent controlled lipolytic degradation through interaction at the lipase serine 
active site. 
 
In the interest of transparency, the author wished to credit Dr Shayon Bhattacharya and Dr 
Damien Thompson at the University of Limerick for their contribution to this chapter in carrying 
out molecular dynamics simulations and Dr Vivek Verma for carrying out DFT calculations. Cryo-




Recent advances in drug discovery by automated synthesis, combinatorial chemistry and high 
throughput screening have identified a large number of poorly soluble, high molecular weight drug 
candidates with presumed poor ability to permeate biological membranes [491]. Their 
physicochemical properties place them in the most difficult class IV category of the 
Biopharmaceutical Classification system (BCS) (Figure 1.1) [4]. Efforts to improve their 
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bioavailability may require reverting back to the lead optimisation phase to alter the chemical 
structure in an attempt to improve the physicochemical properties of the Active Pharmaceutical 
Ingredient (API) [492]. Currently, almost half of marketed drugs can be characterized as poorly 
soluble [493, 494] and it is reported that the proportion of new chemical entities (NCEs) in drug 
development displaying poor solubility may be upwards of 75% [106, 495, 496], highlighting 
issues with solubility as a major obstacle in drug development [497]. Resorting to changing the 
chemical structure is costly and may not resolve issues with poor membrane permeability. Thus, 
significant effort has been expended towards developing carrier systems to deliver poorly soluble 
drugs [215, 252, 435, 486, 487], which can be engineered to also achieve a targeted release in 
response to environmental stimuli and changes [58, 498-501].  
 
In this work, paclitaxel has been selected as the model hydrophobic BCS IV drug [502] to 
investigate its release via a novel carrier system. Paclitaxel (PTX) is a widely used and effective 
anti-tumour agent that carries out its function by binding tubulin and impeding DNA duplication 
[503] but displays very low solubility in aqueous phases [504] and poor permeability across 
biological barriers [505]. Further, PTX is a known substrate of P-glycoprotein (P-gp) [506], which 
actively transports PTX back into the extracellular space, reducing effective absorption, 
permeability, and retention of the drug within the cell [507]. Currently, PTX is reconstituted in 
mixed solvents composed of polyethoxylated castor oil and dehydrated alcohol for intravenous 
administration. The known side effects of this formulation, including allergic reaction, 
neurotoxicity, and nephrotoxicity [508], have motivated development of nanostructured 
alternatives for PTX delivery [509-512] including lipid-based carrier systems [513-516].  
 
The incorporation of lipophilic drug molecules into lipid-based delivery formulations has been 
shown to improve the bioavailability of otherwise problematic drugs [120, 297-301]. They do so 
in a number of ways: increasing drug solubilization by stimulating the secretion of bile into the 
small intestine, facilitating the solubilization capacity in the intestines through the assembly of 
micellar structures, and by improving enterocyte-based transport including inhibition of the P-gp 
efflux system [109, 110]. Among the plethora of lipid-based formulations, it has been discussed 
earlier in Chapter I section 1.5 why the lyotropic liquid crystalline phases stand out due to their 
non-toxic, biocompatible and biodegradable nature as well as their bioadhesive properties [1] and 
thermostability [167, 177, 371, 517]. For this particular application, their autonomous assembly 
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that is independent of organic solvent is attractive as it eradicates the need for harmful carriers 
such as polyethoxylated castor oil.  
 
As previously demonstrated in chapter III, an important consideration in the design of these 
carrier-based drug delivery systems is the degradation behaviour of the host system. In this context, 
the digestion of the lipid component can significantly impact the performance of lipid-based drug 
delivery systems. Hence, in vitro tests are an important first step in gaining predictive information 
about the physicochemical changes to the host that will occur in vivo. Dietary lipids such as 
monoolein (MO) shown in figure 4.2 and other MAGs are rapidly digested in vivo by the lipase 
family of enzymes [257], disassembling the liquid crystalline matrix, as described in chapter II. 
This process has been shown to be accelerated by the presence of a number of cofactor molecules 
including calcium [518-520] and colipase, an important polypeptide cofactor of the pancreatic 
lipase (Figure 4.2) [521]. The colipase functions by anchoring the lipase at the lipid-water interface 
[522, 523], a prerequisite for the digestion of any lipid substrate by lipolytic enzymes. While this 
rapid enzymatic digestion limits the ability of current MAG LCP to provide sustained release over 
very long periods [123], particularly following oral administration, it provides a novel means of 
controlling drug release by targeting and modulating the biological lipolytic degradation process. 
It has been shown that lipolytic enzyme interactions can be modulated through the incorporation 
of known lipase inhibitor tetrahydrolipstatin (THL) into the lipid cubic phase to modulate the 
release of the model small hydrophobic drug clofazimine (CFZ) from LCP (Chapter II). 
 
In this study, monoolein-based lipid cubic formulations designed to encapsulate and control the 
release of the notorious BCS class IV drug PTX were examined under simulated lipolysis with the 
aim of better understanding the mechanisms of lipid digestion in vivo. A combination of 
experiments probing the effect of PTX on the lipid cubic structure and examining the degradation 
profiles of PTX monoolein based lipid formulations with molecular dynamic simulations are 
conducted to elucidate the role of the lipase cofactor colipase in the competitive inhibition of 
pancreatic lipase by THL and in the degradation of the lipid cubic system and subsequent release 
kinetics of PTX. Here this hybrid system is presented as an approach to resolve the issues of low 
bioavailability of poorly water-soluble drugs by encapsulating the lipophilic drug in the lipid-based 
matrix. This deeper understanding of the mechanisms at play may guide us towards the design of 
a broadly applicable, tunable carrier for a wide range of poorly soluble APIs, while overcoming 
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the issues of instability associated with the lipid mesophase through the inclusion of THL in the 
formulation. 
   
 









4.3 Materials and Methods 
 
4.3.1 Materials  
 
All solvents were analytical grade and purchased from Fisher Scientific. Monoolein 9.9 MAG 
(1-(9Z-octadecenoyl)-rac-glycerol) was acquired from JenaBioscience, Germany at >99% purity. 
Phosphate buffered saline (PBS) tablets and heptakis(2,6-di-O-methyl)-β-cyclodextrin (HCD) 
were purchased from Merk (Saint Louis, MO). Water was purified in the lab using a Milli-Q Water 
System (Millipore Corporation, Bedford, MA). Lipase isolated from porcine pancreas was 
purchased from Merck, Germany (Type II, 100-500 units/mg protein (using olive oil (30 min 
incubation)). Anhydrous Paclitaxel was provided by Yunnan Hande Bio-Tech Co. Ltd., China 
(Lot: CP-160301) and Tetrahydrolipstatin (Orlistat/THL) (99% purity) was purchased from 
Sigma-Aldrich. 
 
4.3.2 PTX characterization 
 
PXRD was used to confirm the crystallinity of the as-received PTX prior to reconstitution within 
the lipid cubic phase. Data was collected in reflection mode with an Empyrean diffractometer 
(PANalytical, Phillips) equipped with CuKα1,2 radiation (γ = 1.5406 Å) operating at 40 kV and 
40 mA at room temperature. Samples were scanned between 2θ values of 5 and 40° at a step size 
of 0.01313° 2θ/s, 73 s per step. 
 
4.3.3 Preparation of PTX-LCP matrix formulations 
 
Anhydrous paclitaxel was first dissolved in ethanol at a concentration of 40 mg/mL. Fusion of 
dry lipid crystals to the melt was achieved in an oven at 40–45°C. Appropriate volumes of molten 
monoolein (MO) (~60 mg/sample) were added to glass vials and calculated volumes of the PTX 
solution were added to the lipid to deliver various concentrations of PTX up to a maximum of 6 
mg. The mixture was once again heated above 40°C and gently vortexed for 5 minutes to ensure a 
homogenous blend. The ethanol was evaporated in a vacuum oven before the addition of the 
aqueous solution (MilliQ water) to initiate the formation of the lipid cubic phase. Water was added 
in excess to alleviate dehydration of the samples during storage (~45 wt%) according to its phase 
diagram [173, 177, 352]. The samples were then subjected to further vortex mixing for no less than 
15 minutes. The homogeneous mixtures were stored in sealed glass vials and left to equilibrate in 
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the dark for at least 48 hours. Final PTX concentrations of between 1 to 6 mg/100 mg gel were 
achieved.  
 
For the preparation of inhibitor-containing LCP formulations, the THL was first physically 
mixed in the appropriate volume of molten lipid before PTX was added followed by the mixing, 
evaporation, water addition, and equilibration steps outlined above. The THL-lipidic formulations 
were prepared at a concentration of 1.5 wt%. Preparation of empty gels followed the same 
approach, without addition of either drug or inhibitor to provide a control dataset. 
 
The method for the preparation of the cubosomes for cryo-TEM analysis of the effect of 
encapsulating PTX followed that of Boge et al. with some minor modification [350]. LCP was 
formulated with PTX and/or THL as already described, before being subjected to fragmentation. 
The pre-loaded bulk gel (500 mg) was added to 20 ml of 1 wt% stabilizer Pluronic® F-127 solution 
prepared in water.  Fragmentation was achieved by subjecting the LCP-stabilizer mixture to 
mixing using a magnetic stir bar followed by high shear homogenization at 14,000 rpm using a 
T25 digital ULTRA-TURRAX® disperser (IKA®-Werke GmbH & Co. KG, Germany) for 2 
minutes. The samples were subjected to further fragmentation with an ATPIO ultrasonic 
microwave combined reaction system sonication probe operating at 40% of its maximum power 
on pulse mode (3 second pulses followed by a 7 second break) for an additional 5 minutes. The 
resultant opaline dispersions were stored in sealed glass vials.  
 




Small angle X-ray scattering was performed to confirm the mesophase nature of the bulk 
formulations. SAXS measurements were carried out after sample preparation at the Solution State 
SAXS B21 beam line at Diamond Light Source on the Harwell Campus, Didcot, UK [428]. Small 
angle diffraction images were processed and the relative positions of the distinct Bragg peaks were 
indexed and used to deduce the space groups and lattice parameters by correlating with Miller 
indices [473] as already described. Similarly, the water channel diameter and lipid chain length 
were calculated as previously described [428], with surface area and Euler Poincare constant (χ) 
used [151, 354] to track any changes induced upon drug loading.   
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Differential scanning calorimetry (DSC) 
 
The thermal behaviour of mixtures of monoolein and PTX was examined on a Netzsch Polyma 
214 calorimeter (Netzsch, Germany). DSC analysis was performed by heating the sample from 
25°C to 280°C at a rate of 10°C/min to determine the sample melting point (endothermic peak), 
melting range and onset temperature. Samples tested included (i) 6 wt% PTX-LCP, (ii) PTX-pure 
monoolein blend (1:2), (iii) blank monoolein LCP and (iv) free PTX to identify changes in the 
crystalline structure of the PTX upon formulation with the host lipid carrier system. Where PTX 
was formulated with lipid, samples (i) and (ii), the PTX was first dissolved in ethanol and the 
solvent was evaporated before thermal analysis was conducted.  
 
Particle size estimation and zeta-potential studies 
 
Dynamic light scattering (DLS) was utilized to estimate the particle size distribution (Z-average) 
and polydispersity (PDI) as well as the zeta potential (mV) of the cubic dispersions for cryo-TEM 
using PBS as the dispersant on a Zetasizer (Malvern Panalytical, United Kingdom) equipped with 
a 4 mW He–Ne laser (633 nm) which applies Brownian motion theories in its measurement. The 
viscosity of the dispersant was set at 0.8872 cP and the system was maintained at 25°C.  Three 
measurements of 50 runs were taken for each sample and the mean value, along with the calculated 
standard deviation for particle size estimation (nm) were recorded using the Malvern Panalytical 
zetasizer software.  
 
Cryo-TEM  
For the cryo-TEM analysis, vitrified cubosome samples formulated with PTX or THL were 
prepared in a similar manner to those methods described by Nilsson et al. [524]. For comparative 
purposes blank monoolein cubosomes were also studied. 3 microliter aliquots of the investigated 
sample were applied with a pipette onto Quantifoil R 1.2/1.3 holey carbon grids (Quantifoil Micro 
Tools GmbH, Großlöbichau, Germany) maintained at 22°C and 80 % relative humidity in a sample 
chamber of a Leica EMGP vitrification device (Leica Microsystems, Wetzlar, Germany). The grids 
were then vitrified by rapid plunging into liquid-nitrogen cooled ethane. The samples were 
observed in a Talos Arctica transmission electron microscope (Thermo Fisher Scientific) at 200 
kV under low-dose conditions (~15 e/A2) at a constant temperature of ~-190 °C. The images were 
recorded at a nominal magnification of 120 000x resulting in a final image sampling of 1.24 Å/px. 
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4.3.5 PTX binding energy with lipid and lipase inhibitor using DFT calculations 
 
The binding energy of PTX-lipid and PTX-lipase inhibitor dimer was calculated using the 
method that has been successfully applied for small and medium sized API molecules such as 
risperidone [525], tolbutamide [526], and carbamazepine [527]. The equilibrium geometries of the 
1:1 PTX-PTX, PTX-lipid, and PTX-lipase inhibitor dimer in isolation (gas phase) were calculated 
with Density Functional Theory (DFT) using a B97-D3 Grimme’s functional [528], and a 
Gaussian-type 6-31G(d, p) basis set [529]. Single point energies for the fully optimised structures 
were calculated using a double hybrid B2PLYP-D3 [530] functional combined with an exact 
Hartree Fock exchange with an MP2-like correlation and long-range dispersion corrections with a 
basis set of quadruple-ζ valence quality (def2-QZVPP) [531]. Single point energy calculations for 
PTX-PTX dimer was calculated using B97-D3 Grimme’s functional due to large heavy atoms 
along with number of atoms exceeding 200, which was possible with B2PLYP-D3 functional. The 
binding energy was calculated as follows: 
 
Equation 4.1:  
 
where, EA-B is the single point energy of the given PTX-lipid and PTX-lipase inhibitor dimer, while 
EA and EB are the respective single point energies of the isolated monomers, A and B, in the gas 
phase.   
 
4.3.6 In silico predictive modelling of enzyme, lipid substrate, and inhibitor interactions 
 
Structure of pancreatic lipase and its catalytic pocket 
 
The starting conformation of the full-length lipase enzyme was obtained from the 2.8 Å 
resolution crystal structure of the porcine pancreatic triacylglycerol lipase/colipase complex (PDB 
code 1ETH [532]). The lipase structure has two identical subunits. One subunit was used for this 
study. A mobile domain flap (or lid or loop; Cys238-Cys262) controls enzyme activity [533] by 
regulating entry of substrates/inhibitors (see Fig. C1A), . The cofactor colipase (shown as licorice) 
opens the flap by binding to the smaller C-terminal ú-sheet-rich domain which activates the 
catalytic site on the larger N-terminal ù-helix-rich domain [534]. The active site at the N-terminal 
( )bind A-B A BE E E ED = - +
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domain houses the catalytic triad Ser153 (green)-His264 (blue)-Asp177 (red) responsible for the 




In order to generate physically realistic potential starting structures of complexes for molecular 
dynamics (MD) simulations, molecular docking of lipase with inhibitor THL and with native 
ligand MO was performed. The crystal structure of pancreatic lipase (PDB code 1ETH) was used 
as a template for the generation of pancreatic ligand/inhibitor complex models using AutoDock 
4.2 [536]. Fig. C1B shows the 3D structures of THL and MO that were obtained from ChemSpider 
[537]. As static docking incorporates torsional degrees of freedom only in the ligand molecule, 
structures of complexes using flexible docking with AutoDock were generated, where the lipase 
Ser153 side chain was allowed to reorient in response to the THL or MO binding. A 50 X 50 X 50 
Å3 grid was used to accommodate all possible THL or MO poses and centered on the Ser153 
catalytic site of the lipase (Fig C1C). 26 torsions in the THL structure and 21 torsions in the MO 
structure were rendered flexible, and four side chain torsions in the Ser153 of the lipase were 
rotatable. A Lamarckian genetic algorithm [538] was used as a search algorithm to explore the 
docking space. Four best docked complexes ranked according to their binding energies are 
provided in Tables C1 and C2, and their corresponding poses are shown in Figs. C1D and C1E for 
THL and MO as ligands, respectively. The most favourable complex from each of the THL-lipase 
and MO-lipase docked poses was selected as the starting structure for the MD simulations. The 
same docked poses of substrate and inhibitor with lipase were further used to perform MD 
simulations with the inclusion of colipase in the systems.   
 
Atomistic molecular dynamics simulations 
 
For simulations with inclusion of the enzyme cofactor colipase (THL-lipase/colipase and MO-
lipase/colipase), the same THL and MO poses were used in the starting structures. In order to 
compare the affinity of inhibitor to lipase in presence of Ca2+ and in the presence of colipase/Ca2+, 
we considered the native PDB structure (PDB 1ETH) with the Ca2+ intact and incorporated the 
same docked THL poses in each complex to produce the initial structures for MD. The lipase, 
colipase and Ca2+ were represented by CHARMM36m forcefield parameters [539] and the 
CHARMM General Force Field (CGenFF) [540, 541] was used to represent the topology and 
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parameters for THL and MO. The six systems THL-lipase, THL-lipase/colipase, THL-lipase/Ca2+, 
THL-lipase/colipase/Ca2+, MO-lipase and MO-lipase/colipase, were solvated in cubic simulation 
cells with water molecules represented by the CHARMM-modified TIP3P [542] water model and 
a minimum distance of 20 Å between any protein atom and any box edge. MD simulations were 
carried out using the Gromacs 2018.4 [543, 544] package with an integration time step of 2 fs 
implemented in the leapfrog integrator [545] with bond lengths to hydrogen constrained using the 
LINCS [546] (protein) and the SETTLE [547] (water) algorithms. Snapshots were saved every 2 
ps. Background ions were added to neutralize protein formal charges and to mimic physiological 
ionic strengths (0.15 M NaCl). Long-range electrostatics were treated by the Particle mesh Ewald 
(PME) method [548]. Protein and non-protein molecules (water and ions) were coupled separately 
to an external heat bath (310 K) with a coupling time constant of 1 ps using the velocity rescaling 
method [549]. All systems were minimized for 100 ps, and equilibrated for 1 ns in constant volume 
NVT ensemble followed by another 1 ns of NPT equilibration with the reference pressure at 1 bar 
and a time constant of 4 ps using the Berendsen barostat [550]. The production runs were carried 
out in constant pressure NPT ensemble using the Parrinello-Rahman barostat [551]. All 
simulations were run for 500 ns (in all, two microsecond dataset of equilibrated molecular 
dynamics), and all reported values were generated using structures sampled during the last 200 ns 
(based on the convergence of the time evolution of cumulative average secondary structure of 
lipase; Figs. C1F-I). All analyses of interaction energies, interaction distances, and secondary 
structures were performed with Gromacs tools and trajectories were visualised using VMD [552] 
and UCSF Chimera [553]. 
 
Computation of binding energy by MM/PBSA 
 
The binding energies (DEbinding) between the ligand (native MO or inhibitor THL), and lipase or 
lipase/colipase, written lipase(colipase) for short below, were calculated using the molecular 
mechanics energies combined with Poisson–Boltzmann continuum solvation (MM/PBSA) [554] 
method implemented in Gromacs (g_mmpbsa) [555]. The binding energies include the solvation 
effect of interfacial water in addition to the non-covalent van der Waals (vdW) and electrostatic 
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where DEbinding, vacuum = DEMM (molecular mechanics energy = electrostatic energy + vdW energy 
in vacuum), DGsolv, complex = free energy of solvation of the ligand-lipase(colipase) complex, DGsolv, 
ligand = solvation energy of the THL or MO, DGsolv, protein = solvation free energy of lipase(colipase), 
DGpolar = polar solvation free energy or electrostatic component of solvation free energy, and 
DGnonpolar = nonpolar solvation free energy approximated by the solvent accessible surface area 
(SASA) times a constant factor. It should be noted that although the DGsolv is a free energy term, 
the DEbinding, vacuum does not consider the change in entropy due to binding, and hence is not a free 
energy term. Therefore, the total binding energy (DEbinding) only approximates the free energy, with 
entropy contributions considered minimal in the present case as the THL and MO ligands both 
bind to the same site and are similar in size (typical of competitive native vs. inhibitor ligand 
binding) [556].  
 
4.3.7 Digestion Studies  
 
Dynamic degradation studies were carried out on the lipid cubic preparations formulated with a 
monoacylglycerol lipid, the antineoplastic agent paclitaxel, and lipase inhibitor THL using 
previously described methods (Chapter II, section 2.3.4) Equilibrated samples were submersed in 
1 mL of digestion media and the sample was maintained at 37°C with continuous mixing at 150 
rpm. 
 
The influence of lipase cofactor colipase on the reaction was investigated using digestion media 
at pH 7.4. For samples studied in the presence of colipase, enzymes were first dissolved in distilled 
water at a lipase concentration of 8 mg/mL (100-500 units/mg protein (using olive oil (30 min 
incubation)) and 50 mg/mL of colipase separately. The digestion media was prepared by mixing 
the enzyme and cofactor in PBS buffer at pH 7.4 at a volume ratio of 1:0.6:0.4 
lipase:colipase:buffer. One sample group was also exposed to CaCl2 present in the buffer at 5 mM 
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concentration. The media was allowed to equilibrate for 10 minutes at 37°C before being added to 
the LCP sample vial and media was replenished with freshly prepared media throughout the 
duration of the experiment.  
 
The swelling ratio and rate of degradation in terms of relative weight % were calculated against 
the initial sample mass as per the following equation:  
 
Equation 4.4:  îïvXXy}|	ñzxyw	we	ñvãyY{zX	âvy|ℎx	% = 	óòôóö
óö
	× 	100%                       
where W0 is the initial gel weight before immersion in the media and W1 is the weight of the 
submerged gel at a measured time point. 
 
As a control experiment, free PTX was incubated in the digestion media and subsequently 
analyzed through HPLC for any degradation or changes in structure indicated by split peaks and 
additional or reduced peaks. The test demonstrated that the enzymes did not interfere with 
detection of the drug peak. 
 
4.3.8 Solubility study of PTX to facilitate in vitro drug release studies  
 
Excess amounts of anhydrous PTX were added to glass vials containing 10 mL of a range of 
dissolution media; phosphate buffered saline (PBS), water, acetonitrile, ethanol, methanol, or 2% 
heptakis(2,6-di-O-methyl)-β-cyclodextrin (HCD, previously used as dissolution media to enhance 
PTX solubility [557]). Upon addition of PTX to the dissolution medium, sample vials were 
inverted several times to ensure all of the poorly wettable drug particles were suspended. The 
samples were stirred using PTFE magnetic stirrers at 150 rpm on a submersible stirrer plate in a 
water bath maintained at 37°C overnight. After the 16 hour incubation period, 5 mL of sample was 
withdrawn and centrifuged for 10 minutes at 13,000 rpm. The supernatant was then passed through 
a pre-heated nylon filter (0.22 µm). The first 2 mL was discarded and HPLC analysis was carried 
out on the remaining filtrate under the previously described separation conditions.   
 
4.3.9 Degradation controlled in vitro drug release studies  
 
The in vitro dissolution profiles of paclitaxel from LCP matrices were tracked by quantifying 
the drug remaining in the matrix after incubation in PBS containing lipolytic enzyme. The gels 
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were solubilized in acetonitrile at time intervals up to 30 days, and the concentration of unreleased 
drug was subsequently quantified using high performance liquid chromatography (HPLC). 
Dissolution samples were maintained at 37°C under shaking at 150 rpm for the duration of the 
investigation. 
 
The HPLC system used in this investigation was an Agilent 1200 Infinity Series (Agilent 
Technologies, Palo Alto, USA) comprising: G1311B 1260 quaternary pump, G1329B 1260 ALS 
autosampler, G1316A 1260 TCC (thermostated column compartment) and a G1365D 1260 MWD 
VL diode-array detector. The acquired data was processed with the Agilent OpenLAB CDS 
software. 
 
Chromatographic separation of paclitaxel-containing samples was achieved using an Agilent 
Poroshell 120 PFP (3 x 100 mm, 2.7 µm) column fitted with a UHPLC Poroshell 120 guard module 
(3 x 5 mm, 2.7 µm). The system was maintained at 25°C with a run time of 18 minutes. The mobile 
phase which contained HPLC Analytical grade Acetonitrile (Fisher Scientific) and deionized water 
(A:B 13:87, v/v) was delivered to the column at a flow rate of 1 mL/min which yielded a column 
back pressure of ~260 bar. Samples were filtered through a 0.2 µm Nylon filter (Fisherbrand®). 
The volume of analyte injected was within the range of 0.5 to 10 µl. Column effluent was detected 
at a UV detector wavelength of 228 nm.  
 
4.4 Results and Discussion  
 
4.4.1 PTX-LCP matrix formulation and characterization 
 
The highly hydrophobic nature and aggregation propensity of paclitaxel made it necessary to 
first dissolve it in organic solvent prior to incorporation in the lipid to ensure its homogeneous 
distribution in an aqueous based system. Within this system, there was the potential for the 
formulation approach and physicochemical properties of PTX to affect the behaviour of the matrix 
due to PTX’s large size (853.9 g/mol) and highly hydrophobic nature. For this reason, small-angle 
X-ray scattering (SAXS) was employed to study the effect, if any, of PTX encapsulation on the 
cubic internal structure to decipher the loading capacity of the system.  
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Figure 4.3.  Representative azimuthally integrated SAXS intensity versus scattering vector, q plot 
of blank monoolein system (left) and paclitaxel-loaded monoolein at 4 wt% loading (right). The 
peaks of the pattern has been indexed according to the ÅÇÇõ mesophase and highlight the stability 
of the phase against the introduction of PTX into its lipid network.  
Three bicontinuous cubic phases exist; primitive (ÅÇÇÉ  ), gyroid (QKKR ), and double-diamond (QKKL) 
varying in internal organization and distinguishable by their discrete crystallographic space 
groups. However, only two of these cubic phase (ÅÇÇõ	and ÅÇÇI	 ) are typically accessed in the 
monoolein-water system under equilibrium [177]. The more stable and swelled QKKL  phase is 
accessed when hydration levels are increased by a transition through the QKKR  phase. These lipid 
cubic mesophases give rise to diffraction patterns reminiscent of powder X-ray diffraction; 
characterized by a series of sharp and clearly defined concentric rings [170]. Here, Bragg peaks 
have been indexed according to the Miller indices of the reflection plane to assign the mesophase. 
The relative positions of these reflection lines from our samples confirms highly ordered 
bicontinuous cubic phases. Table 4.1 displays the assigned mesophases and calculated lattice 
parameters of the formulations encapsulating PTX up to a concentration of 6 wt%. The dominating 
phase in equilibrium across our samples was of the cubic-QKKL type to an upper limit of 5 wt%. At 
the highest loading concentration (6 wt%) however, the onset of a phase transition is observed, 
where a coexistence of both the ÅÇÇõ	and ÅÇÇI	 type symmetries is noted. Lipophilic molecules have 
previously been shown to induce such phase transitions in lipid cubic samples [361, 362] by 
integrating into the lipid bilayer and altering the liquid crystalline structure. Complexation of the 
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This effect is dependent on the ratio of the solubilized guest component to lipid and is controlled 
also by the water content. The PTX loading capacity of the QKKL  cubic phase described here is 
similar or slightly higher compared to those described in the literature for other highly hydrophobic 
agents such as vitamin K [360] and tea tree oil [558].  
 
Table 4.1. Phase identification and lattice parameters of assigned mesophases from SAXS 
experiments with calculated dimensional values for lipid chain length (L) and water channel 




















MO - - QKKL 10.31 1.75 4.55 - 
MO - 1 QKKL 10.91 1.86 4.81 - 
MO - 2 QKKL 10.9 1.86 4.8 - 
MO - 3 QKKL 10.83 1.84 4.78 - 
MO - 4 QKKL 10.72 1.83 4.72 - 
MO - 5 QKKL 10.72 1.83 4.72 - 













MO 1 - QKKL 9.5 1.62 4.18 - 
MO 1 1 QKKL 10.7 1.82 4.72 - 
CE samples that presented the coexistence of two mesophases 
 
 
Dimensional analysis was conducted to calculate the water channel diameter and the monolayer 
thicknesses were determined using the method of Szlezak, Nieciecka [212].  It is clear that the 
incorporation of PTX into the lipid system has an effect on the internal dimensions of the cubic 
formulations. The calculated dimensions for the lipid chain length at all PTX loadings are almost 
0.1 nm larger than those calculated for the blank system, and an increase of up to 0.24 nm is seen 
for the PTX-LCP formulations compared to the THL-containing system without PTX. As the % 
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loading of PTX is increased, a slight reduction in both the water channel diameter and monolayer 
thickness is observed. This change, may be caused by the portioning of the drug between individual 
lipid molecules, “closing the gap” between the lipid chains in the cubic framework. 
 
Figure 4.4. Diffractogram of the as-received PTX 
 
PXRD of the as-received PTX was carried out to determine the crystallinity of the drug prior to 
encapsulation in the lipid cubic phase. Figure 4.4 shows the collected diffractogram that presents 
sharp diffraction peaks indicating crystallinity in the as-received drug. The solid-state behaviour 
and extent of hydrogen bonding exhibited within a crystal structure has a direct impact on the 
physical properties of the material [559]. This is of particular relevance in the drug delivery, as it 
influences the dosing, solubility, and bioavailability of the drug [560]. For this reason, a DSC study 
was carried out to study the blending behaviour and degree crystallinity of PTX throughout the 






















Figure 4.5. Thermograms of paclitaxel and lipid bulk formulations: MO PTX-LCP is loaded at a 
PTX concentration of 6 wt%; MO PTX blend is 50 wt% PTX dissolved in pure monoolein; blank 
monoolein LCP contains no PTX; and as received PTX. 
 
The as-received free PTX produced a sharp endothermic peak at approximately 225°C, 
confirming it exists in its crystalline form (that is likely the anhydrate form  [504, 561, 562]), 
supported by the PXRD diffractogram (Figure 4.4). At approximately 35°C, a single endotherm 
indicates the melting peak of the MO [174].When the molten lipid is blended with PTX in the 
absence of water and after ethanol removal, the endothermic peak corresponding to the crystalline 
form of PTX is still absent, likely indicating the presence of an amorphous form of the drug [561]. 
Upon addition of water to form the LCP the absence of this characteristic peak was also noted. 
Similar behaviour has been reported in the literature for a variety of drugs including diclofenac 
sodium, penciclovir, and poorly soluble clozapine when incorporated into lipid matrices [345, 563-
565]. Generally, amorphous materials possess higher saturation solubility than crystalline 
materials, resulting in their better behaviour in terms of drug delivery and bioavailability. The 














same can be said for paclitaxel which has been reported to demonstrate an increased dissolution 
rate in its non-crystalline form when compared to its crystalline counterparts [562, 566]. The 
indication of an amorphous form of PTX in the lipid formulation may therefore be advantageous 
in terms of its in vivo performance. It is noted however, that the risk of spontaneous 
recrystallization and subsequent reduction in bioavailability is always a concern for amorphous 
formulations upon delivery. 
 
Lipid cubic dispersions (cubosomes) were prepared and the effect of incorporating the drug into 
the particles was investigated by cryo-TEM. The internal structure of the lipid cubic phase is said 
to be resistant to dilution [230], and so lends itself to dispersion into nanoparticles that maintain 
the structural integrity of the lipid cubic phase as shown with the monoolein system in chapter II. 
This allows us to visually track the effect of introducing these highly hydrophobic drugs into the 
lipid matrix. The particle size and zeta potential of these paclitaxel and inhibitor-loaded cubosome 
formulations are shown in Table 4.2. The particle size of the different formulations demonstrated 
a successful fragmentation approach for producing nanosystems in solution, with the blank 
cubosomes being larger than those described in the literature at 188.2 ± 4.1 nm compared to 
reported sizes of 131.5 ± 10 nm [567] and 133.9 ± 0.1 (Chapter II, Table 3.1). This may be 
attributed to the formulation approach, where the bulk LCP was formulated in stabilizer solution 
prepared in water here versus PBS for the antihistamine-loaded cubosomes. The size increased 
slightly with the addition of THL and PTX compared with the blank system, with PTX responsible 
for a larger increase in particle size, attributed to the relatively large size of the molecule. All 
samples displayed PDI values less than 0.23. 
 
Table 4.2. Properties of paclitaxel and/or tetrahydrolipstatin loaded cubic dispersions for cryo-





Size ± SD 
(nm) 
PDI Zeta potential ± SD 
(mV) 
--- - 188.2 ± 4.1 0.141 - 1.6 ± 0.18 
- 1.5 202.2 ± 3.9 0.181 - 1.54 ± 0.2 
1 - 211.8 ± 3.9 0.188 - 0.99 ± 0.16 
1 1.5 210.1 ± 6 0.187 -1.14 ± 0.2 
 
In addition to the dimensional and zeta analysis, the submicron dispersed cubic particles were 
investigated by cryo-TEM. The obtained images (Figure 4.6) reveal the internal structure of blank 
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and loaded cubic dispersions that have been stabilised with Pluronic® F-127. The nanoscale 
structures displayed the expected onion-like geometry and organization for particles of cubic 
structure [244, 568] with lattice periodicity and densely packed nanochannels. 
 
The majority of the particles visible in the cryo-TEM images are highly ordered of size 100-200 
nm in agreement with the DLS size analysis.  
  
   
 
Figure 4.6. Cryo-TEM images of selected samples after vitrification from 37°C. A) Blank 
monoolein cubosomes (MO_Blank); B) monoolein cubosomes formulated with 2 wt% PTX 
(MO_PTX); and C) monoolein cubosomes formulated with 1.5 wt% THL (MO_THL). All 
cubosomes were stabilised with Pluronic F-127. Scale bars represent 100 nm.  
 
While structures indicating the formation of highly ordered nanoparticles were confirmed by 
cryo-TEM, the images obtained also showed the presence of surface-attached vesicles that 
appeared lamellar in structure. Although the high shear techniques used here to disperse the cubic 
phase results in the desired size reduction of the cubic dispersion, the approaches have the downfall 
of concurrently producing lipid vesicles. In particular, these large surface vesicles have previously 
been reported in monoglyceride cubosomes for which Pluronic® F-127 was employed in the 
stabilization approach [234, 235]. The number of these non-cubic vesicles is likely related to 
stabiliser concentration [234]. Heat-treatment has been reported to reduce the number of vesicles 
present in a sample [569], however for the purpose of this study the presence of these vesicles was 
not of great concern.  
 
As established by SAXS, the low concentration of PTX added to the lipid formulations for cryo-
TEM analysis does not induce major changes in the Pn3m internal structure. Such is the case at 
A)                                            B)                                             C) 
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concentrations at or below 5 wt%. Similarly, the incorporation of the THL inhibitor at the studied 
concentration (1.5 % w/w) did not induce an unwanted phase transition. The cryo-TEM results 
obtained here further demonstrate no clear obstruction in the repetitious texture of the internal 
network that might otherwise be induced by the formation of large PTX crystals within the 
membrane. That said, further analysis of these nanoparticles would be required to categorise the 
periodicity to either cubic or hexagonal space groups as previously described by Sagalowicz et al. 
[570].  In their study Sagalowicz et al. employed a controlled tilting of the specimen to observe 
different orientations of the same particle providing a 3D representation of the particles. This 
coupled with fast Fourier transform (FFT) analysis [524] would provide a clearer picture of the 
nature of the nanoparticles formed from cubic bulk systems.  
 
4.4.2 PTX binding energy with lipid and lipase inhibitor using DFT calculations 
 
The absence of thermal peaks from DSC analysis, combined with the changes in dimensional 
parameters observed in the SAXS investigation of the PTX formulated with monoolein point 
toward an interaction between the lipophilic PTX and the lipid excipient of the cubic system 
inhibiting the recrystallisation of the PTX once encapsulated. To corroborate this, binding energies 
of the formulation constituents were calculated with Density Functional Theory (DFT). Figure 4.7 
presents the DFT-calculated (1:1) MO-MO, PTX-MO, PTX-PTX, and PTX-THL interaction 
energies for the most favourable interaction sites. The PTX-PTX dimer binding appears to be 
stronger (-145.3 kJ/mol) compared to that of the PTX-MO binding (-42 kJ/mol). In theory, this 
would suggest that the PTX would preferentially bind a second PTX molecule to recrystallise in 
the formulation approach. However, assuming that after solvent evaporation the PTX is soluble at 
the molecular level in MO, where it is bound through multiple hydrogen bonding of PTX with the 
hydroxyl (-OH) group on MO, the inherent insolubility of PTX in aqueous media may prevent 
dissolution of the molecules into water inhibiting the recrystallization event from happening. 
Given the similarities in the MO-MO and the PTX-MO binding energies, it is reasonable to assume 
that the PTX is energetically able to disrupt the MO-MO interaction and insert itself into the MO 
membrane, potentially in a MO-PTX-MO system. This result is in agreement with the thermal 
analysis data which demonstrates the absence of any ordered arrangements of the drug when 
formulated with monoolein, even in the presence of water – an advantageous feature in terms of 
drug dissolution and bioavailability [562, 566].  
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Additionally, although less favourable in terms of relative binding energy, hydrogen bonding 
exists between the hydroxyl (-OH) group of PTX with the aldehyde oxygen of THL. While the 
concentration of THL in the formulation is relatively low, there is the potential for further 
inhibition of PTX re-crystallization through these interactions.  
 
Further, the DFT data supports the theory that the lipophilic PTX interacts with the lipid 
membrane of the cubic network, potentially sandwiching between the individual lipid molecules 
to evade the water present in the swollen channels. This may explain why at the higher loading 
concentrations studied here phase transitions in the system were induced as the lipid bilayer may 
be “pushed apart” by the incorporation of high concentrations of the large hydrophobic drug 




              
 
System MO-MO dimer PTX-MO PTX-PTX dimer PTX-THL 
Binding energy 
(kJ/mol) 
-56  -42 -145.3 -13.7 
 
Figure 4.7. Optimized geometry of A) MO dimer; B) MO-PTX; C) PTX dimer; and D) PTX-THL at B97-D3/6-31G(d,p) level. Binding 
energy in kJ mol-1, calculated at B2PLYP-D3/def2-QZVP level for A, B, and D, and with B97-D3 Grimme’s functional for C. Hydrogen 
– white, carbon – grey, oxygen – red, nitrogen – blue; intra and inter molecular hydrogen bonds are shown with dotted green lines.
A                                       B                                         C.                                                              D. 
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4.4.3 Modelling of interactions and binding affinities between the components of lipid cubic 
formulation via atomistic molecular dynamics simulations 
 
For sustained delivery of PTX from LCP matrices, control over the enzymatic degradation rates 
by pancreatic lipase, can potentially be achieved by a lipase inhibitor, tetrahydrolipstatin (THL), 
as indicated in chapter III. However, this relies on the preferential binding of THL to the lipase 
active site over the lipid components of the monoolein (MO)-based LCP matrix. In order to gain a 
deeper understanding of the atomic-level interactions and relative binding affinities of the lipid 
substrate MO and inhibitor THL with the enzyme lipase, fully atomistic molecular dynamics (MD) 
simulations of MO-lipase and THL-lipase complexes (with/without colipase) were designed from 
a preliminary screening of the most plausible binding poses of these complexes via 
macromolecular docking.  
 
MD simulations (Aappendix C) show that the active site of the lipase (involving the catalytic 
triad Ser153-Asp177-His264) is more accessible to the natural substrate MO than the inhibitor 
THL. A hinge-like motion of the mobile flap domain (Cys238-Cys262) closing access of THL to 
the catalytic pocket of lipase (Figure 4.8, A, left panel) is observed, whereas the flap presents an 
open configuration in the presence of MO (Figure 4.8, A, right panel). The more favourable 
interactions of MO over THL (by ~6.5 kJ/mol averaged over the last 200 ns) are predominantly 
vdW in nature (Figure 4.8, B, left panel; see also Appendix C for running averages), highlighting 
the dominant lipophilic nature of both THL and MO. However, minor improvement in electrostatic 
charged interactions also boosts MO recognition, as the negatively charged acidic group in MO is 
stabilized by the positively charged imidazole group of His264 in the catalytic pocket of lipase 





Figure 4.8. (A) Representative snapshots from MD simulations of the inhibitor Tetrahydrolipstatin 
(THL) with pancreatic lipase (left panel) and substrate lipid Monoolein (MO) with lipase (right 
panel) in the absence of cofactor colipase. The catalytic triad Ser153, Asp177 and His264 are 
coloured in green, red and blue, respectively with the mobile flap domain shown in orange. (B) 
Interaction energies between THL/MO and the catalytic pocket in lipase without (left panel) and 
with (right panel) colipase. (C) Representative snapshots of THL-lipase (left panel) and MO-lipase 
(right panel) complexes in the presence of colipase. (D) Binding energies between THL/MO and 
lipase in the absence of colipase (left) and in the presence of colipase (right).  
 
The influence of the cofactor colipase [534, 571] on binding specificity is revealed in a 500 ns 
MD simulation in the presence of colipase (Appendix C) which reveal that THL is now able to 
access the lipase catalytic pocket while keeping the mobile flap open throughout (Figure 4.8, C, 
left panel). This cofactor induced loop dynamics which promote favourable THL interactions with 
the catalytic pocket (Appendix C). By contrast, access of the MO substrate to lipase is slightly 
more restricted as the flap closes the catalytic pocket during binding in the presence of the colipase 
(Figure 4.8, C, right panel and Appendix C). The average interaction energies (Figure 4.8, B, right 
panel) indicate that THL interacts more favourably with the catalytic pocket than MO (by ~2.5 













kJ/mol dominated again by vdW interactions) when colipase is present. In order to substantiate the 
involvement of colipase in facilitating the movement (opening or closing) of the mobile flap 
domain in lipase, which in turn might modulate the molecular recognition of THL over MO, the 
interaction energies of the mobile flap domain with colipase were computed for the first 300 ns 
and the last 200 ns of simulations (Appendix C). The flap-colipase interactions are clearly more 
favourable for the last 200 ns with THL binding than with MO binding, confirming the 
participation of colipase in stabilising the open configuration.  
 
To further probe the contribution of water in binding of both THL and MO to lipase, the binding 
energies were computed using the MM/PBSA [554] method (refer to section 4.3.6) in the absence 
and presence of colipase. It should be noted that the binding energies here were calculated with 
the full-length lipase enzyme and not just the residues in the catalytic triad, as was done previously 
in the calculation of the interaction energies. Therefore, the involvement of other residues in lipase 
(apart from the catalytic pocket) are taken into account when considering binding energies. In the 
absence of colipase, it was observed that the overall predicted binding of THL to lipase (Figure 
4.8, D) is favoured over MO-lipase binding energy (by ~13 kJ/mol, averaged over the last 200 ns). 
The vdW component is the major contributor of binding energy in line with the observation from 
interaction energies with the catalytic pocket (Figure 4.8, B, left panel), although diametrically 
opposing the favourability of THL over MO, which identifies the involvement of residues in vdW 
interactions other than those belonging to the catalytic pocket. The overall improvement in binding 
of THL over MO with lipase thus originates from a concerted contribution from direct vdW and 
non-polar solvation energies. The binding energies are more favourable for THL-lipase in the 
presence of colipase too, with contributions majorly from vdW component (Figure 4.8, D), also in 
agreement with the catalytic pocket interactions (Figure 4.8, right panel). However, the Coulomb 
electrostatics contribute more for THL-binding than MO-binding in this case, coupled with an 
equally proportional penalty from polar solvation energy. The binding of THL to lipase is 
improved in the presence of colipase (by ~11 kJ/mol), while MO bound to lipase less favourably 
when colipase is present (Figure 4.8 D), which may point towards time-dependent modulation by 
loop dynamics. 
 
Additionally, the residue-wise energy decomposition contributing towards the overall binding 
energy was accounted for (Appendix C S2E-H). Without colipase, the more favourable THL 
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binding over MO binding is primarily facilitated by Ile79 and Ile252 in the flap domain of lipase 
(Figure 4.8, D), while Thr256 in the flap penalises binding of THL. With regards to the residues 
in the catalytic pocket, Gly151 (in the vicinity of Ser153), Leu176 (close to Asp177) and His264 
also penalise binding of THL. In the presence of colipase, Ile79 penalises binding of THL with 
negligible contribution from Ile252, and stabilising contribution from Thr256 along with Gly114 
(Figure 4.8). Leu176, Pro178 (close to Asp177) and His264 in the catalytic pocket also contribute 
favourably towards THL binding. Although the contributions from colipase indirectly binding to 
THL/MO is negligible as expected given the X nm separation, the altered loop dynamics with 
colipase co-bound (Appendix C S2D, S2F) influences MO vs. THL binding specificity. 
 
Calcium has been shown to significantly increase the activity of lipase against lipid substrates 
[518-520], although the exact role of calcium in the activation of pancreatic lipase is still not fully 
elucidated. Given the reported influence of calcium ions on the lipolytic activity of the enzyme, 
preliminary studies have been carried out to probe the influence, if any, of Ca2+ on the inhibitory 















      
 
Figure 4.9. (A) Representative snapshot of PDB structure 1ETH, showing the Ca2+ coordinated to 
residues Glu188, Arg191, Asp193 and Asp196 with the measured distances from the catalytic triad 
Ser153, Asp177 and His264 shown (B) Representative snapshot from MD simulations of the 
inhibitor tetrahydrolipstatin (THL) with pancreatic lipase in the presence of cofactors colipase and 
calcium (Ca2+). In both (A) and (B) the catalytic triad Ser153, Asp177 and His264 are coloured in 
green, red and blue, respectively with the mobile flap domain shown in orange. (C) Interaction 
energies between THL and the catalytic pocket in lipase without (left panel) and with colipase 
(middle panel), and interaction energies between THL and the catalytic pocket in lipase with 
colipase and Ca2+ (right panel). 
 
In the PDB structure 1ETH, the Ca2+ is coordinated to residues Glu188, Arg191, Asp193 and 
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far away from the catalytic triad in the initial PDB structure (14.2 Å from Ser153, 15.1Å from 
Asp177 and 20.9 Å from His264). Although the Ca2+ site is not likely to be directly involved in 
catalysis, it appears to play a structural role in maintaining the conformation of the loop connected 
between Ca2+ site and Asp177. The simulations for 500 ns revealed that the Ca2+ remains intact in 
position and bound to its coordinated residues in lipase both in presence and absence of colipase. 
The flap (Cys238-Cys262) enclosing the active catalytic triad (Ser153, Asp177 and His264) 
remains in an open conformation throughout the course of simulation facilitating favourable access 
of the THL to the catalytic pocket. The THL in the Ca2+-colipase-lipase system presents a less 
favourable interaction with the enzyme compared to the THL in the colipase-lipase system. From 
the interaction data, the THL may inhibit lipase less efficiently in presence of Ca2+ and colipase 
than in their absence, but the most profound inhibition would be expected where calcium is 
excluded from the lipase-colipase system. The predicted rank order for inhibiting propensity of 
THL may then be summarized as: lipase &  colipase > lipase & colipase & Ca2+ > lipase. However, 
more comprehensive binding energy studies with the inclusion of the effect and contribution of 
solvation are required to give a clearer representation of the true effect of calcium on the system 
using the MM/PBSA [554] method (refer to section 4.3.6). There, the binding energies would be 
calculated for the full length enzyme, including all residues and not solely the catalytic triad. 
Changes in the relationships of calculated interaction energies between the various systems 
without the inclusion of calcium have already been noted, so it is expected that is will influence 
the conclusions drawn here. These calculations, as well as interaction energy calculations for the 
MO-lipase-colipase system in the presence of calcium, are required to predict the effect of calcium 
on the degradation kinetics of the cubic phase containing the inhibitor. The presence of calcium 
may influence the competitive nature of the binding of the lipase for its natural MO substrate and 
the THL inhibitor, impacting the degradation kinetics.  
 
In summary, the predicted interactions and binding profiles from MD simulations suggest that 
the significant inhibition of pancreatic lipase by THL can impede the catalytic degradation of MO 
in lipid formulations by lipase. Altered loop dynamics in the presence of the cofactor colipase 
raises the predicted inhibitory activity of THL but further modelling is required to predict the 
impact of calcium on this inhibitory activity.  
 
 168 
4.4.4 Enzyme-driven degradation behaviour  
 
To support the in silico predictions of the binding energies between the lipase (w and w/o 
colipase) and the lipid or inhibitor molecules, the enzyme-driven degradation behaviour of the 
LCP matrix in vitro was examined experimentally. Based on the simulations of MO-lipase and 
THL-lipase complexes it was predicted that the THL should inhibit the lipolytic activity on the 
MO, an effect that would be enhanced in the presence of the enzyme’s cofactor colipase. In line 
with the predicted altered loop dynamics in the presence of colipase, the binding of the inhibitor 
at the active site would be enhanced and subsequently would hinder the binding of the lipolytic 
enzyme to the lipid substrate. Based on these predictions, a controlled and prolonged digestion of 
the cubic lipid phase containing THL was anticipated under simulated lipolysis.  
  
The concentration of lipase taken in these studies was in excess of those described in normal 
human serum in order to predict its behaviour at the upper limit of enzyme exposure [572]. Here, 
a gravimetric approach was taken to track the digestion of the formulated phases. The depletion in 
mass was followed and quantified using equation 4.4 until the samples were completely broken 





                     
 
Figure 4.10. Degradation behaviour of paclitaxel-lipid controlled-release formulation in  lipase-
containing PBS or lipase and co lipase containing PBS with and without THL at 37°C and 200 
rpm. 
 
The PTX loaded cubic phases formulated without the inhibitor saw a relatively rapid chemical 
degradation over a 14 day period for both systems with and without colipase. At that timepoint, 
the lipid systems were completely digested to leave behind only an oily layer. For future studies it 
is important to note that reduction in the chain length of the lipid substrate to medium and short 
chain lipids (from the C18 MO used in these studies) could increase the rate of degradation [573, 
574]. At 14 days, where the samples in the absence of the inhibitor were fully digested, the gels 
incorporating THL maintained upwards of 84% of their original mass. This improvement in 
stability can be ascribed to the presence of the THL, which is a potent inhibitor of a number of 
lipolytic enzymes [453, 462, 463]. These results support the explanation that the anchoring of the 
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inhibitor [575-577]. THL is hydrophobic in nature [468] and as a consequence resides mainly in 
the lipidic domain of the cubic phase. THL acts at the oil/water interface during lipolysis [260, 
462] and so it is reasonable to assume that the THL integrated in the inner bilayers likely serves 
as a reservoir, carrying out its inhibitory function upon reaching the lipid/water interface 
throughout the progressive degradation of the lipid matrix [451, 469, 470].  
 
Inclusion of the cofactor in digestion media has previously been reported to improve the activity 
of lipase on glyceride substrates several fold [521]. As clearly demonstrated in figure 4.10, the 
digestion process was, as expected, accelerated by the inclusion of the enzyme cofactor colipase 
(L+C). With THL incorporated, the lipase and colipase (L+C) samples were found to degrade 
faster over the first 24 days, compared to those in the presence of lipase alone. However, after the 
24 day period, the inhibitor containing samples exposed to the colipase (L+C) showed a more 
sustained stability. The systems exposed to lipase alone displayed an initial extended lag phase 
where limited hydrolysis was seen finally followed by an accelerated digestion where the 
remaining lipid substrate was consumed rapidly. Despite displaying a faster digestion rate in the 
early stages of the study, the digestion curve demonstrates a more controlled lipolysis over the 
testing period when THL is present, especially upon exposure to the enzyme-cofactor mix – an 
important feature of a controlled drug delivery system which serves to reduce the risk of burst 
release and minimise possible toxicities associated with same.  
 
Based on the MD simulations (section 4.4.3), the inclusion of calcium in the digestion media 
was expected to influence the stabilising effect of the inhibitor on the MO system. For this reason, 
the digestion medium was supplemented with calcium as a further lipase activation approach 




         
 
Figure 4.11. Degradation behaviour of paclitaxel-lipid controlled-release formulation in  lipase 
digestive media showing the impact of including calcium in the media with and without THL and 
colipase at 37°C and 200 rpm. 
 
The predicted rank order for inhibiting propensity of THL was estimated from MD simulations 
to be lipase &  colipase > lipase & colipase & Ca2+ > lipase. Although the stability of the system 
was indeed prolonged compared to the lipase & colipase sample, the addition of the calcium was 
shown to further accelerate the digestion of the lipid cubic samples in the presence of THL (within 
24 days (Figure 4.11) compared to 30 when exposed to lipase alone). When THL was excluded 
from the MO LCP, the inclusion of calcium in the lipase-colipase media resulted in the fastest 
matrix digestion after only 7 days, compared to 10 and 14 days for the lipase & colipase, and lipase 
only systems respectively. This indicates that the presence of calcium may increase the binding 
affinity of lipase to MO and may reduce the ability of THL to competitively bind with the lipase. 
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lipase-colipase and the THL-lipase-colipase systems in the presence of calcium . Calcium has been 
shown to significantly increase the activity of lipase against lipid substrates [518-520], potentially 
be impeding its inhibition by the digestive products of the reaction (fatty acids) which block access 
of the lipase at the activity interface [575, 578]. It is predicted, at this stage, that a more favourable 
competitive interaction of the lipase with MO over THL in the presence of calcium will be 
observed from the in silico modelling studies. 
 
Paclitaxel has previously been shown to interact with lipid membranes in small unilamellar lipid 
vesicles composed of 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) [579]. Here 
DFT and thermal analysis have been utilised to demonstrate that the PTX interacts with the 
hydrophobic region of the lipid. The highly lipophilic BCS IV drug resides within the lipid portion 
of the cubic network where it loosely interacts with bicontinuous lipid layer away from water. The 
inclusion of PTX in the formulation approach directly impacts the internal dimensions of the 
system such that larger water channel dimensions (DH2O) of up to 0.26 nm wider than the blank 
were observed in the SAXS analysis. This increase in water channel diameter could in theory serve 
as an accelerating effector of digestion, whereby the wider diameter of aqueous channels in the 
MO_PTX system might allow for a higher penetration of the external lipase solution into the 
phase’s aqueous network compared to a blank system. However, previous studies by our group 
have shown that in the presence of lipase, blank monoolein cubic mesophase systems are rapidly 
digested by the enzyme within 7 days (Figure 3.5) [428]. This suggests that the PTX itself exhibits 
an inhibitory effect on digestion when incorporated into the system, possibly owing to a 
hydrophobic effect of the membrane bound drug. Additionally, the positioning of the drug within 
the membrane may shield or block access of the lipase hindering the surface-driven digestion.  
 
4.4.5 In vitro drug release studies 
 
Solubility studies were carried out on PTX to assess the most appropriate dissolution media to 
determine its release kinetics from the lipid cubic phases. The calculated saturated solubility of the 
drug in the various dissolution media (appendix C), highlighted the practically insoluble and 
undetectable nature of PTX in aqueous-based media compared to organic solvents. While 
information reported in previous studies on the dissolution behaviour of hydrophobic drugs such 
as paclitaxel in organic solvents is useful [580], these studies may not be representative of the true 
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dissolution behaviour of the drug under physiological conditions [494] and would not be useful 
for predicting the release behaviour from a lipid matrix, due to the rapid dissolution of the lipid 
matrix in organic solvents. For these reasons, the decision was made to focus solely on aqueous-
based physiologically relevant media.  
 
Due to the apparent inherent insolubility of paclitaxel, and its propensity to precipitate upon 
contact with aqueous media, an accurate quantification of its slow degradation-controlled release 
into biorelevant media was not directly measurable. Solubility limits of highly hydrophobic drugs 
must be taken into account as an underestimation of drug release can occur, where liberated drug 
may precipitate and go undetected, resulting in false sustained drug release behaviour being 
reported [581].  For this reason, an alternative approach was taken to study the dissolution of 
paclitaxel from the lipid cubic phase. Samples of PTX loaded lipid cubic phases, formulated with 
or without THL, were exposed to lipase enzyme over 30 days. Over the course of the study, at pre-
determined time-points the reaction was stopped, the cubic phase was removed from the release 
media, dissolved in acetonitrile and the % of PTX remaining in individual samples was quantified 
using HPLC. The compiled release profiles are represented in figure 4.12, where the calculated % 
of drug release is plotted along with the % of mass loss according to the mass of the starting 









Figure 4.12. In vitro dissolution profile of paclitaxel from LCP (formulated at a concentration of 
2 wt%) with/without THL (loaded at a concentration of 1.5 wt%)  into PBS in the presence of  
lipase  measured by quantifying unreleased drug using HPLC. Samples were shaken at 150 rpm at 
37°C 
 
These profiles demonstrate the direct correlation between the release of a hydrophobic agent and 
the stability/digestion of the lipid cubic phase. As shown in the degradation studies, the presence 
of the inhibitor in the system has the ability to greatly extend the stability of the LCP-PTX system 
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the ability to predict and tune the duration of release of a hydrophobic molecule from a lipid cubic 
systems with any given inhibitor concentration [428]. 
 
4.5 Conclusions  
 
Lipid cubic delivery systems provide a route for improving the in vivo behaviour of hydrophobic 
drugs by tapping into the intestinal absorption pathways of dietary glycerides. The complex cubic 
lattice network of the systems provide a versatile means to control and sustain the release of the 
encapsulated payload. Water-immiscible drugs such as paclitaxel studied in this investigation will 
reside in the lipid portion of the cubic network, meaning that their liberation from the mesophase 
is governed by the hydrolysis rate of the surrounding lipid matrix.  
 
This study sought to characterise the modulation of the lipolysis of a lipid cubic phase by 
unravelling the impact and mode of action of lipase inhibitors, colipase, calcium ions and 
hydrophobic therapeutic agents on the enzymatic activity of lipases. In doing so, it was possible to 
decipher the impact on the digestion rate of the matrix and subsequent release of the encapsulated 
drug. In this context, it has been demonstrated that controlled release of the highly hydrophobic 
drug PTX through the concurrent incorporation of small doses of lipase inhibitor 
tetrahydralipstatin in the lipid cubic matrix without significantly impacting the internal structure 
of the lipid cubic matrices as shown by high resolution techniques such as SAXS and cryo-TEM. 
Through a combination of experimental and in silico approaches the significant inhibition of 
pancreatic lipase by THL has been demonstrated, whereby it can impede the catalytic degradation 
of monoolein and in turn garner further control of the release of PTX without significantly 
disrupting the internal structure of these systems. MD simulations confirmed that the catalytic triad 
of the pancreatic lipase is more accessible to the natural substrate MO than the inhibitor THL, 
where a surface loop exposes the active site to its lipid substrate while the mobile flap domain 
closes to hinder access of THL to the catalytic pocket of the enzyme. In contrast, the presence of 
the lipase cofactor colipase presents the inhibitor with a more favourable binding at this catalytic 
site compared to that of its lipid substrate. When the full length of the lipase enzyme  is taken into 
account, beyond the isolation of the catalytic triad, our simulations identified a more favourable 
predicted binding of the inhibitor compared to its lipid counterpart. In this context, the stability of 
the PTX-containing lipid cubic samples under simulated lipolysis were extended at least two-fold 
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when THL was included in the formulation. Preliminary in silico studies have presented calcium 
as a further influential factor in the interactions between THL and the lipase enzyme, where the 
potential degree of the THL’s inhibitory action is reduced its presence.  More comprehensive 
calculations are required along with further simulations to establish the influence of calcium on 
the binding of lipase with its natural substrate MO to draw comparisons between both systems in 
establishing the nature of the perceived competitive process. The results discussed here evidence 
the capabilities of the inhibitor system to modulate and extend the degradation-controlled release 
properties of the PTX from lipid cubic mesophases, which have the potential to overcome issues 
of bioavailability associated with the notorious BCS IV drug along with others that present similar 



































The high viscosity and stiffness of the fully swollen lipid cubic phase may limit its potential for 
drug delivery applications. In this work, a double-barrelled syringe apparatus is explored for 
generation of the lipid cubic phase for surgical and controlled drug-delivery applications. 
Additionally, as an alternative formulation approach, the impact of in situ formation in a range of 
physiological media on the internal structure of the cubic-Q""#  type mesophase in vitro is 
investigated. Lipid cubic phases were formed directly in phosphate buffered saline, simulated 
gastric fluid and simulated nasal fluid with the aim of predicting in situ gelling behaviours of the 
system for site-directed drug delivery applications to overcome delivery issues and systemic 
toxicity.  
 
5.2 Background  
 
Within this thesis, a commonly used [582, 583] and straight forward melt-hydration approach 
for generating the lipid cubic has been employed. The approach simply involves introducing water 
to molten lipid containing the bio-/pharmaceutical of interest in glass vials or ampules with 
agitation to ensure formation of a homogeneous mixture followed by incubation in sealed vials to 
allow complete equilibration of the system. Although the stiffness and viscosity of the fully 
assembled cubic phase prove beneficial in slowing down the diffusion of drugs through its network 
for controlled delivery, the highly viscous consistency of the lipid cubic phase makes handling the 
gel post-formation a challenge. It is therefore desirable to improve the ease of handling and to 
define the stability of the phase in the approach. In many cases, dispersion of the phase into lipid 
cubic nano-suspensions (cubosomes) may overcome the challenge of viscosity for oral or spray 
delivery routes and also for topical applications. However, the bulk cubic phase should not be 
overlooked for its potential in prolonged and controlled topical drug delivery to enhance 
permeation of a range of drugs [209, 584, 585].  Further, the cubic phase is a self-gelling system, 
which eliminates the need for additional gelling agents (eg.  tragacanth, carbomer, sodium alginate, 
gelatin, polyvinyl alcohol clays, etc. [586]) in the formulation approach. However, the fully 
swollen system is easily dehydrated during storage (Chapter IV, figure 3.4) inducing unwanted 
phase transitioning over time, so due consideration should be given to designing tools for real-time 
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formation of the cubic phase in a clinical setting. For this reason, alternative strategies for 
formulating the lipid cubic phase have been explored to facilitate its applicability in a clinical 
setting. In this context, the aims of the present study were twofold: (i) to demonstrate a double 
barrel syringe assembly with water in one syringe, and lipid in the other to rapidly form the cubic 
phase through a mixer unit attachment, and (ii) to demonstrate the in situ forming properties of the 
system through injection of molten lipid from a single barrel syringe into simulated body fluid. 
 
Custom tools and procedures have previously been developed to formulate and handle the lipid 
cubic phase. The coupled syringe mixer is a well-known mixing assembly which was designed for 






Figure 5.1. Homogenization and spontaneous self-assembly of the lipid cubic phase using the 
coupled syringe mixing aparatus. Image 1 shows the apparatus before assembly and image 2 shows 
the assembled system where the compound-containing lipid component would be present in one 
of the syringes and the aqueous phase in the other in appropriate ratios. 
 
The mixer apparatus itself comprises a set of glass positive displacement Hamilton® syringes 
(Figure 5.1). The micro-syringes are linked by a narrow-bore coupler unit. Molten lipid is loaded 
within one of the syringes and the water component in the other at a known ratio (w/w). The cubic 
phase is achieved by repeatedly passing the contents of the syringes back and forth, blending the 
mixture until homogenous and until the desired phase is observed [588]. The micro-syringes are 




Lipid portion  Aqueous portion  
Plunger 
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achieving a homogenous mixture of gel volumes required for drug delivery applications through 
the narrow coupler unit would require a significant amount of mixing. In this study, commercially 
available syringe-mixer units already used to accurately mix and dispense viscous biomaterials in 
surgical procedures were investigated.  
 
Further, the potential for in situ forming lipid cubic systems are discussed here as an alternative 
approach to overcoming issues with handling. As already discussed, the location of the cubic phase 
on the MAG-water phase diagram, where it lies sandwiched between the lamellar and reversed 
hexagonal phases respectively (Chapter I, section 1.4), facilitate its in situ formation. By raising 
the temperature or hydration of a lamellar system, geometrical reorganization ensues inducing a 
transition from the inherently fluid and injectable lamellar phase to the stiff three dimensional 
cubic phase. This presents an alternative approach to delivery of the viscous cubic phase where it 
may be possible to deliver a lipid-drug mixture in the absence of water or a less viscous lamellar 
formulation containing the desired pharmaceutical ingredient to subsequently form the viscous 
cubic phase upon contact with excess water in biological fluid.  
 
Previous work has demonstrated the feasibility of the MAG-water systems as excellent in situ 
forming biodegradable matrix type drug delivery systems [589-592]. However, these studies fell 
short in detailed studies of the impact of biological fluids on in the internal structure of the phase 
upon contact. Esposito et al. investigated a glycerol monooleate-poloxamer system for delivery of 
tetracycline for a periodontal application, where the lipid mixture was delivered directly to the 
periodontal pocket. The in situ forming system demonstrated prolonged release in vivo and clinical 
efficacy [591]. The results presented by Esposito et al. were important in understanding the 
capacity of the cubic phase for such applications but no details of the structural properties and state 
of the lipid formulation upon contact with biological fluids were described. Similarly, a study 
carried out on the in situ formation of the cubic phase are oral administration of cubic precursor 
molecules neglected these structural studies [590]. Geraghty et al. reported a lamellar system 
formed upon the incorporation of muscarinic drugs that could be delivered to a vaginal delivery 
site where upon imbibing water would transition to the viscous cubic phase [592]. However, this 
study did not provide in vivo data, and the media used to swell the system was water which is not 
entirely representative of biological conditions. As has been shown in chapters II and IV, as well 
as from the literature [191, 192], the release rate of drugs from mesophase systems is highly 
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dependent on both the phase present and the capacity of the aqueous channels. Additionally, 
variations in ionic strength where the salinity effect explained by the kosmotropic/chaotropic 
properties of the ions present in the swelling media [429-431] have been shown to stabilize or 
destabilize the system, in turn affecting its controlled release properties [432].  In this framework, 
understanding the swelling and mesophase properties of MAG systems formed in situ is important 
to understand the controlled release capabilities of the system. For this reason, three biologically 
relevant buffers have been selected as the swelling media for the formulations. The buffer effect 
on the internal structure of MAG mesophases compared to the systems swelled in water was 
established by means of SAXS. In this sense, understanding these structural changes is important 
in the design of these systems, as changes in their phase structure/symmetry directly influences 
the release kinetics  [191, 192]. 
 




Monoolein 9.9 MAG (1-(9Z-octadecenoyl)-rac-glycerol) and monopalmitolein 9.7 MAG (1-
(9Z-hexadecenoyl)-rac-glycerol) were acquired from JenaBioscience, Germany at >99% purity; 
Phosphate buffered saline (PBS) tablets were purchased from Merk (Saint Louis, MO); FaSSGF 
(Fasted state simulated gastric fluid) powder was purchased from Biorelevant.com Ltd; Water was 
purified in the lab using a Milli-Q Water System (Millipore Corporation, Bedford, MA). 
 
5.3.2 Double-barrelled syringe method 
 
A FibriJet® double-barrelled syringe (3 mL, 1:1 ratio) coupled with a mixer unit (3 cm, stream 
output with 2.03 mm inner diameter) suitable for high viscosity samples (Figure 5.2) was studied 
as a tool for rapid generation and dispensing of the cubic phase. Lipid (monoolein or 
monopalmitolein) was added to one side of the applicator assembly and the aqueous phase was 
contained within the other in a similar manner to the Hamilton® syringe set up [587]. The two 
components were simultaneously and slowly dispensed at equal volumes through the mixer unit 




Figure 5.2.  FibriJet® double-barrelled syringe (DBS) coupled with 3 cm mixer unit for fast cubic 
phase formulation 
 
Monopalmitolein is liquid at room temperature and so required no pre-heating to achieve fluid 
molten lipid. Monoolein was heated in an oven at 35ºC to facilitate its transferal to the syringe unit 
as it is waxy at room temperature. Prior to mixing with the aqueous phase, the loaded syringe unit 
was once again heated to 35ºC to allow the lipid to easily travel through the syringe into the mixer 
unit.  
 
5.3.3 ‘In situ’ forming cubic phases: studying the effect of swelling buffer 
 
Different buffers were investigated to study their effect on the formation of the lipid cubic phase 
in situ. Fasted-State Simulated Gastric Fluid (FaSSGF) was prepared by dissolving pre-prepared 
FaSSGF powder (Biorelevant.com) in acidic buffer (1.997 g NaCl in 1L water) with an adjusted 
pH of 1.6 reached using 1M HCl with stirring according to the manufacturers guidelines. 
Simulated nasal fluid (SNF) was prepared as previously described by Farid et al. [357] (7.45 
mg/mL NaCl; 1.29 mg/mL KCl; 0.32 mg/mL CaCl2.2H2O; made up to volume with deionised 
water) to give a solution pH of 6.4. The final buffer was phosphate buffered saline, prepared at pH 
7.4 (137 mM NaCl, 2.7 mM KCl and 10 mM phosphate buffer solution (Na2HPO4 & KH2PO4)). 
To simulate the formation of the cubic phase ‘in situ’, the molten lipid was delivered to 1 mL of 
the three simulated body buffers and left to equilibrate for 48 hours in sealed glass vials.  
 
 
Syringe 1: Lipid component 
Syringe 2: Aqueous/water component 
Mixer unit 
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5.3.4 SAXS for mesophase assignment 
 
Small angle X-ray scattering was performed to confirm the mesophase nature of the lipid cubic 
samples prepared by means of (i) the double-barrelled syringe method, and (ii)  when molten lipid 
was injected directly into the various biorelevant media. SAXS measurements were carried out 
within 10 minutes after sample preparation at the Solution State SAXS B21 beam line at Diamond 
Light Source on the Harwell Campus, Didcot, UK [428]. Small angle diffraction images were 
processed and the relative positions of the distinct Bragg peaks were indexed and used to deduce 
the space groups and lattice parameters by correlating with Miller indices [473] as already 
described. Similarly, the water channel diameter and lipid chain length were calculated as 
previously described [428], with surface area and Euler Poincare constant (χ) used [151, 354] to 
track any changes induced upon drug loading.   
 
5.4 Results & Discussion  
 
5.4.1 Double-barrelled syringe method 
 
A dehydration effect in the stored lipid cubic phase over time has been demonstrated (Chapter 
IV, figure 3.4), which induces a phase transition. For topical drug delivery applications, it may be 
more effective to prepare the cubic phase at the time of administration. Samples were prepared 
here using a double-barrelled syringe unit to investigate the suitability of existing biomaterial 
applicators. A mixer unit specified for viscous samples was chosen and SAXS was employed as 







Figure 5.3. 1D azimuthally integrated SAXS patterns of monoolein (MO) and monopalmitolein 
(MPL) cubic mesophases prepared by means of the double-barrelled syringe fitted with mixer-
unit. Samples were analysed within 10 minutes after dispensing through the mixer unit. The peaks 
of the patterns have been indexed according to the $%%& mesophase 
 
Here, the distinct Bragg peaks have been indexed according to the Miller indices of the reflection 
plane to assign the mesophase (Figure 5.3). The relative positions of these reflection lines from 
our samples confirm highly ordered bicontinuous cubic phases of the cubic-Q""#  type formed 
through hydration in the mixer unit. Table 5.2 displays the assigned mesophases and calculated 
lattice parameters of these formulations. 
 
Table 5.2. Phase identification and lattice parameters of assigned mesophases for LCP formulated 













MO Q""# 9.82 1.67 4.33 
MPL Q""# 11.85 1.32 6.62 
 
 
The cubic formulations shown here are comparable to the cubic systems formulated by the 














[123, 169, 353, 359, 360]. This highlights the potential of real-time generation of the cubic phase 
for clinical application without the need for pre-formulation and lengthy equilibration times. 
Although pharmaceuticals were not included in the studied formulations here, it would be possible 
to introduce hydrophilic agents in the aqueous phase and lipophilic molecules within the lipid 
either dissolved or in suspension.  Further, this approach would allow for personal and tailored 
dosing, where unique drug loading concentration could be made for a given patient by simply 
varying the amount of drug added to either the lipid or aqueous components. 
 
Monopalmitolein is particularly attractive for this approach, as the lipid is fluid at room 
temperature facilitating easy delivery through the syringe to the mixer unit. Other lipids such as 
monoolein that are solid or waxy at room temperature require pre-heating to facilitate transferal to 
the syringe and for ease during mixing. This can be done in an oven, water-bath or simply using 
the warmth of the palm of your hand. Further, monoopalmitolein forms Q""#  phase at 50 wt% 
hydration, and the Q""# phase is accessed at 40 wt% hydration in the monoolein system, beyond 
which it exists in excess water. Therefore, the DBS assembly that dispenses equal volumes of lipid 
and aqueous media are ideal for these lipids and any of those that form the cubic phase at hydration 
levels at or below 50 wt%. Lipids that require a higher degree of hydration to assemble the fully 
swollen cubic phase may not be suitable, unless they were to be delivered to an internal delivery 
site where the system would further swell in biological fluid.  
 
5.4.2 ‘In situ’ forming cubic phases: studying the effect of swelling buffer 
 
In order to assess the impact of salts and other components present in biologically relevant media 
on the lipid mesophase formed, the swelling capacity and internal dimensions of the molten lipid 
swelled in excess media of varying pH and composition were monitored by means of SAXS 
analysis.  The resultant 1D azimuthally integrated SAXS patterns of MO cubic mesophases 
swelled in PBS buffer at pH ~ 7.4, SNF at pH 6.4, or FaSSGF at pH ~ 1.6 are shown in figure 5.3 
and 5.4 where the distinct Bragg peaks have been indexed according to the $%%& mesophase. The 
collected data identified the fully swollen cubic phase in all swelling media samples, and therefore 









Figure 5.3. 1D azimuthally integrated SAXS patterns of monoolein (MO) cubic mesophases 
swelled in a variety of bio-relevant media of varied pH (PBS buffer at pH ~ 7.4, SNF at pH 6.4 or 
FaSSGF at pH ~ 1.6). The peaks of the patterns have been indexed according to the $%%& mesophase 
and the MO_SNF figure highlights the stability of the system against the X-ray exposure over 15 
frames.   
 
Once the resistance of the $%%& mesophase to environmental pH was shown, it was important to 
study the ionic effect on the systems as it has been reported that ions in solution have the ability to 
expand or reduce the lattice constant of the phase [593]. Subsequently, the internal dimensions of 
the phase, including water channel diameter, are altered which can directly impact the controlled 
release properties of the system [191, 192]. This is an important consideration where local delivery 
or in situ forming gels are concerned, as behavioural predictions made in the design of these 
systems using water alone are likely not representative of the true biological effect. For this reason, 
the internal dimensions of the phase were calculated and the results are reported in table 5.3.  
 






















Table 5.3. Comparison of phase identity and lattice parameters of assigned mesophases for LCP 
formulated in water and with various biologically relevant buffers of different pH (PBS buffer at 













MO Water Q""# 10.3 1.75 4.55 
MO PBS Q""# 10.45 1.78 4.61 
MO SNF Q""# 10.49 1.78 4.64 
MO FaSSGF Q""# 10.26 1.75 4.49 
 
 
The results show that the cubic phases formed from the various buffers differ in their internal 
diameter although MO in SNF and PBS are seen to be comparable. The composition of SNF and 
PBS buffers does not differ drastically, although PBS does include phosphate salts which may 
affect the stabilization of the system [593]. A reduction in lattice parameter and therefore internal 
dimensions is seen when the sample is prepared in FaSSGF. This may be influenced by the 
presence of components other than salts in the simulated gastric fluid, such as the 
glycerophospholipid mixture lecithin which is lipid soluble and pepsin which is a water soluble 
protein. Previous studies carried out by Chang et al. identified a decrease of over 10% in swelling 
capacity in the cubic phase of a MyverolTM derived system at media with lower pH (0.1M HCl) 
compared to PBS at pH 7.4 [215]. Myverol is a monoglyceride mixture, made up predominantly 
of monoolein (>86%) while the remainder is composed of other monoglycerides such as 
monostearin, monopalmitin and monoarachidin [594]. The group related this effect to the presence 
of free fatty acids in the lipid mixture with the hypothesis being that at normal biological pH, these 
fatty acids are ionized and thus interacting and absorbing more water. In acidic pH however, these 
fatty acids are thought to be non-ionized and are therefore more readily solubilized in the lipid 
membrane of the mesophase ultimately decreasing the capacity for water uptake [215]. While the 
study carried out by Chang et al. did not calculate the internal dimensions of the systems studied, 
it is reasonable to assume that changes in water channel diameter seen across the samples prepared 
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in the three buffers here would contribute to differences in the swelling capacity of the system in 
the same way.  
 
It would be remiss to overlook the potential impact of the ionic composition of the media used 
here [432]. Across the samples, an increase in lattice parameter of the PBS and SNF samples 
compared to the control sample is seen. X-ray diffraction data suggests that kosmotropic solutes 
reduce the interfacial area of the Q""# cubic phase of MAGs by stabilizing the structure of bulk 
water, thus reducing the amount of water molecules present at the lipid/water interface [595]. 
Chaotropic solutes however, present the opposite effect, where chaotropes expand the interfacial 
area [593, 596, 597]. Given what is known about the geometrical relation of the lipid cubic 
structure [598], the relationship between an increase or decrease of the area at the water/lipid 
interface of Q""#  cubic phases with an observed increase and decrease of the lattice constants 
respectively has been reported in a similar manner to that observed for lamellar and inverted 
hexagonal phases  [596, 599]. Specifically, these reports suggest that kosmotropes reduce the 
interfacial area at this boundary and thus reduce the lattice parameter for cubic phases [593] while 
chaotropes have the opposite effect (assuming negligible effect on lipid molecular length caused 
by solute composition). FaSSGF contains NaCl, a known kosmotropic solute with strong hydration 
behaviour [600, 601], however, it also contains sodium taurocholate, which along with other 
sterols has been shown to directly affect the Q""# cubic reducing the lattice parameter when present 
in a salt solution [478]. The sterols, also including cholesterol, possess a large headgroup and 
reduce the negative curvature of the system altering the rigidity of the bilayer of the cubic phase 
through hydrogen bonding [602] and have been shown to induce a phase transition from the Q""# to 




Although pre-formed bulk lipid cubic phase may have limited applicability in parenteral drug 
delivery due to its viscous and stiff nature, alternative delivery strategies exist where the cubic 
phase can be delivered to the body more efficiently. Taking advantage of the location of the lipid 
cubic phase on its phase diagram and the ability of the MAG-water system to transition between 
the various liquid crystalline mesophases, in situ formation of the cubic phase upon contact of the 
molten lipid with aqueous biological fluids presents an attractive route for localized or enteral drug 
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delivery. Although not relevant for MO (which form the Q""#  cubic phase between room 
temperature (RT) and body temperature), other cubic phases (for example phytantriol [167]) are 
sensitive to changes in temperature between RT and body temperature, further facilitating this 
putative in situ gelling system. In this study the impact of ions, small molecules and proteins 
present within biological fluids on the lipid phase behaviour swelled in various biologically 
relevant media in place of water have been investigated. By means of SAXS the collective impact 
of ionic effect and composition on the lattice parameter and subsequent water uptake of the Q""# 
cubic phase has been calculated. Changes in internal dimensions not only impact the drug release 
kinetics but also the stability of the phase in enzymatic environments, where systems with larger 
water channels may imbibe more enzymatic media, potentially accelerating the digestive process 
due to a larger interfacial surface area for lipolysis. Understanding these effects of biologically 
relevant ions and small molecules on the phase behaviour of this complex system is of great 
importance from a biological and medical viewpoint in order to make predictions on the 
performance of the system in vivo. 
 
Here also, the feasibility of a single-use double-barrelled syringe equipped with a mixer unit has 
been explored as a suitable set up for rapidly forming the viscous cubic phase of MO and MPL in 
potential medical applications. This approach overcomes the need for storage of the easily 
dehydrated lipid cubic phase system and would facilitate personal and tailored dosing, where 
variations in drug loading concentration could be made for a given patient by simply concentrating 












Chapter VI Conclusions & Future directions 
 
This PhD thesis focused on the study of lipid cubic phases and their dispersions as encapsulating 
matrices for the controlled delivery of active pharmaceutical ingredients. This chapter summarises 
the key conclusions that may be drawn from the research carried out within this extensive and 




The development of effective carrier systems that are capable of delivering sustained and 
therapeutically relevant doses of drugs has earned its place at the forefront of research over the last 
decade. The introduction to this thesis has provided an extensive discussion on the numerous and 
expansive challenges these systems are tasked with overcoming to effectively improve the 
therapeutic index of existing and new drug entities. The amphiphilic, biocompatible, and 
biodegradable nature of the lipid cubic phase has merited the system as a worthy and versatile 
candidate for controlled drug delivery.  
 
The first aspect of this thesis investigated the capabilities of two MAG derived (MO and MPL) 
lipid cubic phases and its dispersions in a controlled release capacity using a selection of four 
antihistamine molecules of varied physicochemical properties, specifically varying degrees of 
aqueous solubility. Through high resolution analytical techniques including SAXS, coupled with 
dynamic light scattering the impact of incorporating these molecules into the cubic network has 
been studied. Decelerated and biphasic release of both sets of first and second generation 
antihistamine molecules was observed from the bulk and dispersed systems compared to the free 
drugs, highlighting the prolonged release capabilities of the lipid matrix. A clear focus was given 
the impact of drug solubility and environmental pH on the dissolution properties and have 
presented a greatly reduced release rate for the hydrophobic AZL and CZH compared to the freely 
water soluble DPH and CBX. The pH of the selected biorelevant dissolution media was shown to 
impact the release rates of these drugs from the system, with the acidic environment created by the 
FaSSGF media greatly accelerated the release of the molecules from the lipid matrix, an effect that 
has been widely reported in the literature [58, 215]. This change in dissolution rate may be 
attributed to a matrix effect where the fatty acid chain may be ionized or unionized under certain 
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conditions dictating the release of the encapsulated drugs [215, 434] which is directly correlated 
with  its location in the matrix [170, 435]. 
 
In this thesis the lipid cubic phase and its dispersions have also been highlighted as potential 
mucoadhesive controlled release systems, an area that to our knowledge has not been extensively 
explored to date. MP-SPR has been shown to be an efficient tool to investigate adhesion of lipid 
cubic systems to mucin layers as an alternative approach to studying the mucoadhesive nature of 
the systems without the need for tissue samples. A potential real-world application in the mucosal 
delivery of antihistamine molecules through the mucosa of the nasal cavity was discussed and the 
impact of four commercially available molecules on the mucoadhesive nature of the system has 
been explored. The need for these in vitro tests in matrix design and in predicting their behaviour 
in vivo was highlighted by the distinct binding profiles of the systems, directly affected by the 
passenger molecule and its properties. The bioadhesive nature of these systems should prove an 
important tool in improving retention time and absorption of passenger drugs at a target delivery 
site, reducing systemic toxicity, increasing bioavailability of the drug and enabling long-acting 
therapeutic effects. While hydrophilic compounds and large polar molecules follow paracellular 
diffusion, lipophilic molecules rely on transcellular transport across lipid bilayers in cell 
membranes [603]. As a consequence, the bioadhesive nature of the lipid cubic phase is particularly 
influential in improving the bioavailability of poorly soluble and lipophilic drugs, that can be 
rapidly absorbed when delivered and retained at the mucosal membrane due to its high surface 
area and contact with the heavily vascularised anatomy. Where antihistamine molecules are 
concerned, in particular the first-generation molecules having the ability to cross the blood brain 
barrier and elicit unwanted side effects, mucosal delivery has the added bonus of containing the 
molecules at a target site while efficiently delivering effective concentrations to the affected organ. 
Efficient cellular uptake of the drugs reconstituted in cubosomes has been demonstrated by 
monitoring changes in zeta potential at the surface of fibroblast model cells over 12 hours. With 
the aid of competitive ELISA, the ability of the drug formulations to inhibit mediator release has 
been illustrated, by more than half in some cases, from basophilic mast cells (RBL2H3 cells) with 
the propensity to release histamine upon IgE induction [358, 604]. In this time, metabolic assays 
identified no cytotoxic effect caused by the systems in the two studied cell lines, with the exception 
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of one of the hydrophobic drugs CZH, that appeared to reduce cell viability by half after a 48 hour 
incubation in fibroblast cell line.  
 
While this initial investigation answered a number of questions, the results also brought forward 
several additional research objectives towards the design of effective drug carrier systems. For 
one, additional studies were required to clarify the relationship between the location of the drug 
molecule in the system leads and the varied release kinetics. Further, there was a keen interest in 
identifying and optimising formulation approaches to further control the release through targeting 
lipolysis of the system. It is understood that the solubility properties of a given molecule govern 
its location within the cubic network, with hydrophobic molecules residing in the lipid bilayer 
while water soluble molecules inhabit the congruent water channels of the mesophase. As a result, 
the release kinetics of water-soluble molecules is limited by their diffusion through the water 
channels of the system, with little effect from the lipid bilayer itself. Hydrophobic drugs on the 
other hand, rely on the depletion of the lipid bilayer surround them to be liberated into solution. 
Lipid cubic systems such as those studied in this thesis that are derived from biodegradable MAG 
lipids are highly susceptible to lipolytic degradation by lipase enzymes in vivo. While this is 
important in achieving total release of the encapsulated drugs, the rate at which this digestion 
occurs may limit their application in drug delivery. In the second research study reported in this 
thesis, the controlled release of hydrophobic APIs was achieved by means of a novel formulation 
approach through the incorporation of small doses of lipase inhibitors, using tetrahydralipstatin as 
a model. Exploiting the biodegradable nature of MAG lipids in lyotropic liquid crystalline 
mesophases in this way, presents a means of establishing further control of the release kinetics of 
poorly soluble molecules reconstituted within the lipid envelope. However, the interactions 
between the lipid excipient and the molecules that it encapsulates with endogenous enzymes 
(lipases and esterases), as well as the physicochemical  transitions that arise, are multifaceted and 
difficult to predict. In vitro tests that mimic the fate of a lipid formulation upon exposure to the 
gastrointestinal and enzymatic environment of the body are therefore heavily relied upon to 
rationalise formulation development of biodegradable drug delivery systems. 
 
Under simulated lipolysis in vitro, two stable cubic phases incorporating tetrahydrolipstatin 
formulated from monoolein or monopalmitolein have been designed and investigated. Both 
systems displayed controlled degradation with at least a 4-fold improvement compared to the blank 
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systems; a stability that can be tuned by varying the concentration of the incorporated inhibitor, 
thereby presenting a framework from which formulators can select the most promising formulation 
approach for a specific drug to be delivered over a desired duration. In these systems, sustained 
release is achieved by interrupting the interactions of lipolytic enzymes at the lipid/water interface 
through the introduction of a molecule that competes for their active site at this boundary impeding 
the hydrolysis. A hydrophobic, and industrially relevant small molecule drug, a clofazimine citrate 
salt, was selected to demonstrate the feasibility of this approach by means of gravimetric and 
dissolution studies under simulated lipolysis. Both lipid systems demonstrated extended stability, 
and subsequently coordinated prolonged release over 30 days with a direct relationship between 
the rate of lipid digestion and molecule release observed. This novel formulation is achieved 
without negatively affecting the structure of the matrix itself, as shown by comprehensive small-
angle X-ray scattering experiments. By adjusting the concentration of the lipase inhibitor, one 
could potentially tailor a system with desired stability for any given drug delivery applications 
where hydrophobic drugs are required. Tetrahydralipstatin is a potent inhibitor of many other 
lipolytic enzymes additional to the pancreatic lipase studied here. These include gastric lipase, and 
carboxyl ester lipases. Thus, the concept studied described here may have a more far-reaching 
relevance, especially for the rapidly degraded dispersions of the cubic phase that may be suitable 
for oral delivery. 
 
The number of new chemical entities identified annually is rising with thanks to progress in 
automated synthesis, combinatorial chemistry, and high throughput screening. However, a 
disproportionate number of these molecules in drug development display poor solubility [106, 495, 
496] and significant efforts are required to improve their bioavailability [492] if they are to 
progress to commercialization. The BCS class IV drugs [4] includes a large number of poorly 
soluble, high molecular weight drug candidates with presumed poor ability to permeate biological 
membranes [491]. The promise of biodegradable lipid-based drug delivery systems such as LCP 
in improving the solubilization and bioavailability of  these difficult lipophilic drugs has been 
discussed at length [120, 297-301]. They have the potential to do so by stimulating the secretion 
of endogenous lipids (bile salts and phospholipids), by assembling micellar structures, and by 
improving enterocyte-based transport including inhibition of the P-gp efflux system [109, 110]. In 
the third chapter of this thesis a BCS class IV drug paclitaxel, a clinically relevant antineoplastic 
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agent, has been selected as a model drug to asses lipid cubic systems with the ultimate aim of  
designing a system for improving the in vivo behaviour of hydrophobic drugs by exploiting the 
intestinal absorption pathways of dietary glycerides. For this particular application, the 
mesophase’s autonomous assembly is independent of organic solvent and so is an additional 
attractive feature for the delivery of PTX as it eradicates the need for harmful carriers such as 
polyethoxylated castor oil commonly used in their formulation. SAXS and cryo-TEM confirmed 
that the incorporation of THL and PTX in the cubic phase and its dispersions did not negatively 
influence the formation of the Q""# mesophase.  
 
Paclitaxel, like most water-immiscible drugs, inhabits the lipid bilayer of the cubic network. The 
liberation of the molecule from the mesophase has been studied and the hydrolysis rate of the 
surrounding lipid matrix has been proven as the rate limiting step, in a similar way to that observed 
for CFZ. In the initial lipolysis studies the action of lipases on the lipid mesophase and how this 
could be controlled by THL to regulate the release of the drug payload has been clearly 
demonstrated. Further to this investigation, the third body of work within this thesis sought to 
clarify this modulation by unravelling the impact and mode of action of lipase inhibitors, relevant 
lipase cofactors (colipase and calcium ions) and the hydrophobic therapeutic agent itself on the 
enzymatic activity of lipases. In doing so, it was possible to decipher the impact on the digestion 
rate of the matrix and subsequent release of the encapsulated PTX model drug that was extended 
almost 4-fold to 30 days.  
 
Through a combination of gravimetric mass monitoring, high-resolution characterisation 
techniques and in silico approaches, the significant inhibition of pancreatic lipase by THL has been 
explained at a molecular level. The PTX-loaded LCP samples were exposed to lipase alone, and a 
mixture of lipase and its co-factor colipase to monitor their lipolysis in the presence and absence 
of THL by a simple gravimetric approach. The inhibitor-containing samples exposed only to lipase 
demonstrated a biphasic digestion, with a delayed start followed by a rapid loss in mass. Although 
an accelerated mass loss was observed in the samples exposed to the enzyme-cofactor mix in the 
initial stages of the study, the THL appeared to coordinate a more controlled lipolysis when 
colipase was present. This pattern of digestion is more attractive in controlled drug delivery where 
the risk of burst release and possible toxicities associated with same are minimised by delivering 
consistent concentrations of drug as the lipid vehicle is digested. As expected [518-520], improved 
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lipase activation was illustrated through supplementation of the digestion media with calcium in 
the form of CaCl2 across both THL and inhibitor free samples. To compliment experimental data, 
MD simulations were utilized and confirmed that the catalytic triad of the pancreatic lipase is more 
accessible to the natural substrate MO than the inhibitor THL, where a surface loop exposes the 
active site to its lipid substrate while the mobile flap domain closes to hinder access of THL to the 
catalytic pocket of the enzyme. Interestingly however, a more favourable binding at this Ser153-
Asp177-His264 catalytic triad is presented to the inhibitor compared to that of its lipid substrate. 
Additionally, when overall binding is taken into account, beyond the isolation of the catalytic triad, 
our simulations identified a more favourable predicted binding of the inhibitor compared to its 
lipid counterpart. These findings agreed nicely with those of our digestion studies. The data 
reported within this study highlights the capabilities of the inhibitor system to modulate and extend 
the degradation-controlled release properties of the PTX from lipid cubic mesophases. This 
approach has far-reaching relevance, where our novel systems have the potential control and 
sustain the release of these molecules to overcome issues of bioavailability associated with the 
notorious BCS IV drug along with others that present similar challenges in drug delivery 
applications. 
 
The final consideration of this thesis was in bridging the gap between fundamental science and 
applying the concepts in a clinical setting. The highly viscous and stiff nature of the fully swollen 
bulk lipid cubic phase may waive, or at least hamper, its application in parenteral drug delivery. 
Notwithstanding these limitations, alternative delivery strategies have been presented for these 
fascinating systems. For one, the transitional nature of liquid crystalline phases presents an 
opportunity for capitalizing on the fluid-like consistency of the lamellar phase to easily deliver the 
reconstituted drug to target delivery sites where they can self-assemble into the cubic symmetries 
upon hydration by biological fluids. The MAG cubic phase’s sensitivity to temperature between 
RT and body temperature, further facilitates this putative in situ gelling system. An important 
consideration where in situ gelling is desired, is the impact of biologically relevant ions, 
endogenous proteins, and sterols on the structure of the desired phase. Here, by means of SAXS 
the collective impact of ionic effect and media composition on the lattice parameter and subsequent 
water uptake of the Q""# cubic phase using three biologically relevant media (PBS buffer at pH ~ 
7.4, SNF at pH 6.4 or FaSSGF at pH ~ 1.6) has been demonstrated. In good agreement with the 
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literature, the pH and ionic composition of the swelling media was shown to alter the lattice 
parameters and  internal dimensions of the phase, potentially owing to ionization of fatty acids. By 
clarifying these effects on the phase behaviour of this complex system, our data may facilitate 
predictions on the in vivo stability and performance of these systems from a biological and medical 
viewpoint.  
 
With the aim of presenting a suitable set up for rapidly forming the cubic phase of MO and MPL 
in potential medical applications, the feasibility of a single-use double-barrelled syringe equipped 
with a mixer unit has also been demonstrated. This straight-forward approach overcomes the need 
for storage of the easily dehydrated lipid cubic phase system while effectively and efficiently 
assembling a Q""#  cubic phase with the versatility of encapsulating hydrophobic or hydrophilic 
drugs or proteins.  
 
6.2 Final words and future directions 
 
The lipid cubic phase has yet to reach the market in a drug delivery application. However, the 
results and data presented in this work enriches the existing knowledge of drug reconstitution in 
lipid cubic mesophases, confirming the potential of bicontinuous cubic phase as a versatile and 
useful biological membrane mimic for safe and effective controlled drug delivery. Furthermore, 
our novel approach to exploit and control the biodegradation of the mucoadhesive matrix in 
lipolytic environments presents a general strategy for the design of tailorable release systems for 
troublesome lipophilic molecules. Nevertheless, further investigations should seek to study the 
success of this approach for extending the stability of rapidly digested cubosomes. This may 
include a combination of pH-stat or HPLC experiments to extract and quantify liberated fatty acids, 
with high resolution techniques like SAXS and cryo-TEM to track changes in size and internal 
structure of the systems. Elucidating this response, and coupled with the data already presented in 
this thesis, may guide us towards the design of a broadly applicable, tunable carrier systems for 
countless drug payloads, while overcoming the issues of instability and administration associated 
with the lipid mesophase. Providing these predictions serves to rationalise formulation 
development to improve bioavailability and reduce attrition rates of otherwise shelved NCEs. 
Further, as the majority of stabilizers are believed to predominantly coat the outer surface of 
cubosomes, they present a means for targeting cells of interest. For example, biotin- [567] and 
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folate- [605] modified F108 stabilizer has been shown to increase the uptake of cubosomes in 
HeLa cancer cell lines that overexpress biotin and folate receptors to improve the 
chemotherapeutic activity of anticancer agents. In this context, the influence of different stabilizers 











































1. Kulkarni, C.V., et al., Monoolein: a magic lipid? Physical Chemistry Chemical Physics, 2011. 13(8): 
p. 3004-3021. 
2. Wade, A. and P. Weller, Lactose. 2 ed. Handbook of Pharmaceutical Excipients, 2nd edn. 
Pharmaceutical Press, London. 1994. 252-261. 
3. Kola, I. and J. Landis, Can the pharmaceutical industry reduce attrition rates? Nature reviews Drug 
discovery, 2004. 3(8): p. 711-716. 
4. Amidon, G.L., et al., A theoretical basis for a biopharmaceutic drug classification: the correlation 
of in vitro drug product dissolution and in vivo bioavailability. Pharmaceutical research, 1995. 
12(3): p. 413-420. 
5. Laxminarayan, R., et al., Drug resistance, in Disease Control Priorities in Developing Countries. 2nd 
edition. 2006, The International Bank for Reconstruction and Development/The World Bank. 
6. Naik, A., Y.N. Kalia, and R.H. Guy, Transdermal drug delivery: overcoming the skin’s barrier function. 
Pharmaceutical science & technology today, 2000. 3(9): p. 318-326. 
7. Yang, R., et al., Getting drugs across biological barriers. Advanced Materials, 2017. 29(37): p. 
1606596. 
8. Patel, M.M., et al., Getting into the brain. CNS drugs, 2009. 23(1): p. 35-58. 
9. Prausnitz, M.R., S. Mitragotri, and R. Langer, Current status and future potential of transdermal 
drug delivery. Nature reviews Drug discovery, 2004. 3(2): p. 115-124. 
10. Hadgraft, J. and R.H. Guy, Transdermal drug delivery: Developmental issues and research 
initiatives. Drugs and the pharmaceutical sciences, 1989. 35. 
11. Bronaugh, R.L. and H.I. Maibach, Percutaneous absorption: drugs--cosmetics--mechanisms--
methodology: drugs--cosmetics--mechanisms--methodology. 1999: CRC Press. 
12. Viswanathan, P., Y. Muralidaran, and G. Ragavan, Challenges in oral drug delivery: a nano-based 
strategy to overcome, in Nanostructures for oral medicine. 2017, Elsevier. p. 173-201. 
13. Radomsky, M.L., et al., Controlled vaginal delivery of antibodies in the mouse. Biology of 
reproduction, 1992. 47(1): p. 133-140. 
14. Greenblatt, D.J., Intramuscular injection of drugs. New England Journal of Medicine, 1976. 
295(10): p. 542-546. 
15. ZELMAN, S., Notes on techniques of intramuscular injection. The avoidance of needless pain and 
morbidity. The American journal of the medical sciences, 1961. 241: p. 563-574. 
16. Xiao, L., et al., Subcutaneous injection of botulinum toxin a is beneficial in postherpetic neuralgia. 
Pain Medicine, 2010. 11(12): p. 1827-1833. 
17. Mathaes, R., et al., Subcutaneous injection volume of biopharmaceuticals—pushing the 
boundaries. Journal of pharmaceutical sciences, 2016. 105(8): p. 2255-2259. 
18. Türker, S., E. Onur, and Y. Ózer, Nasal route and drug delivery systems. Pharmacy world and 
Science, 2004. 26(3): p. 137-142. 
19. Marttin, E., et al., Nasal mucociliary clearance as a factor in nasal drug delivery. Advanced drug 
delivery reviews, 1998. 29(1-2): p. 13-38. 
20. Sarkar, M.A., Drug metabolism in the nasal mucosa. Pharmaceutical research, 1992. 9(1): p. 1-9. 
21. Arora, P., S. Sharma, and S. Garg, Permeability issues in nasal drug delivery. Drug discovery today, 
2002. 7(18): p. 967-975. 
22. Patton, J.S., Mechanisms of macromolecule absorption by the lungs. Advanced drug delivery 
reviews, 1996. 19(1): p. 3-36. 
23. Sung, J.C., B.L. Pulliam, and D.A. Edwards, Nanoparticles for drug delivery to the lungs. Trends in 
biotechnology, 2007. 25(12): p. 563-570. 
 198 
24. Yang, W., J.I. Peters, and R.O. Williams III, Inhaled nanoparticles—a current review. International 
journal of pharmaceutics, 2008. 356(1-2): p. 239-247. 
25. Athamneh, T., et al., Alginate and hybrid alginate-hyaluronic acid aerogel microspheres as 
potential carrier for pulmonary drug delivery. The journal of supercritical fluids, 2019. 150: p. 49-
55. 
26. Emami, F., S.J.M. Yazdi, and D.H. Na, Poly (lactic acid)/poly (lactic-co-glycolic acid) particulate 
carriers for pulmonary drug delivery. Journal of Pharmaceutical Investigation, 2019: p. 1-16. 
27. Courrier, H., N. Butz, and T.F. Vandamme, Pulmonary drug delivery systems: recent developments 
and prospects. Critical Reviews™ in Therapeutic Drug Carrier Systems, 2002. 19(4-5). 
28. Chen, Q.Z., I.D. Thompson, and A.R. Boccaccini, 45S5 Bioglass®-derived glass–ceramic scaffolds 
for bone tissue engineering. Biomaterials, 2006. 27(11): p. 2414-2425. 
29. Maquet, V. and R. Jerome. Design of macroporous biodegradable polymer scaffolds for cell 
transplantation. in Materials Science Forum. 1997. Trans Tech Publ. 
30. Hutmacher, D.W., Scaffolds in tissue engineering bone and cartilage. Biomaterials, 2000. 21(24): 
p. 2529-2543. 
31. Hirabayashi, H. and J. Fujisaki, Bone-specific drug delivery systems. Clinical pharmacokinetics, 
2003. 42(15): p. 1319-1330. 
32. Torchilin, V.P., Drug targeting. European Journal of Pharmaceutical Sciences, 2000. 11: p. S81-S91. 
33. Langer, R., Where a pill won’t reach. Scientific American, 2003. 288(4): p. 50-57. 
34. Kostarelos, K., Rational design and engineering of delivery systems for therapeutics: biomedical 
exercises in colloid and surface science. Advances in colloid and interface science, 2003. 106(1-3): 
p. 147-168. 
35. Langer, R., Drugs on target. Science, 2001. 293(5527): p. 58-59. 
36. LaVan, D.A., D.M. Lynn, and R. Langer, Moving smaller in drug discovery and delivery. Nature 
Reviews Drug Discovery, 2002. 1(1): p. 77-84. 
37. Langer, R., Drug delivery and targeting. NATURE-LONDON-, 1998: p. 5-10. 
38. Langer, R., New methods of drug delivery. Science, 1990. 249(4976): p. 1527-1533. 
39. Yang, W.-W. and E. Pierstorff, Reservoir-based polymer drug delivery systems. Journal of 
laboratory automation, 2012. 17(1): p. 50-58. 
40. Van Duong, T. and G. Van den Mooter, The role of the carrier in the formulation of pharmaceutical 
solid dispersions. Part I: crystalline and semi-crystalline carriers. Expert opinion on drug delivery, 
2016. 13(11): p. 1583-1594. 
41. Van Duong, T. and G. Van den Mooter, The role of the carrier in the formulation of pharmaceutical 
solid dispersions. Part II: amorphous carriers. Expert opinion on drug delivery, 2016. 13(12): p. 
1681-1694. 
42. Chasin, M., Biodegradable polymers as drug delivery systems. Vol. 45. 1990: Informa Health Care. 
43. Adeoye, O. and H. Cabral-Marques, Cyclodextrin nanosystems in oral drug delivery: a mini review. 
International journal of pharmaceutics, 2017. 531(2): p. 521-531. 
44. Devi, K. and U. Bhosale, Formulation and optimization of polymeric nano drug delivery system of 
acyclovir using 3² full factorial design. Int. J. PharmTech Res, 2009. 1(3): p. 644-653. 
45. Singh, S., Nanomedicine–nanoscale drugs and delivery systems. Journal of nanoscience and 
nanotechnology, 2010. 10(12): p. 7906-7918. 
46. Crommelin, D.J. and A.T. Florence, Towards more effective advanced drug delivery systems. 
International journal of pharmaceutics, 2013. 454(1): p. 496-511. 
47. Yan Lee, P. and K. KY Wong, Nanomedicine: a new frontier in cancer therapeutics. Current drug 
delivery, 2011. 8(3): p. 245-253. 
48. Heidel, J.D. and M.E. Davis, Clinical developments in nanotechnology for cancer therapy. 
Pharmaceutical research, 2011. 28(2): p. 187-199. 
 199 
49. Ansari, S., F. Islam, and M. Sameem, Influence of nanotechnology on herbal drugs: A Review. 
Journal of advanced pharmaceutical technology & research, 2012. 3(3): p. 142. 
50. Mukerjee, A. and J.K. Vishwanatha, Formulation, characterization and evaluation of curcumin-
loaded PLGA nanospheres for cancer therapy. Anticancer research, 2009. 29(10): p. 3867-3875. 
51. Taylor, M., et al., Six bioabsorbable polymers: in vitro acute toxicity of accumulated degradation 
products. Journal of applied biomaterials, 1994. 5(2): p. 151-157. 
52. Hasırcı, V., et al., Versatility of biodegradable biopolymers: degradability and an in vivo application. 
Journal of biotechnology, 2001. 86(2): p. 135-150. 
53. Mura, S., J. Nicolas, and P. Couvreur, Stimuli-responsive nanocarriers for drug delivery. Nature 
materials, 2013. 12(11): p. 991-1003. 
54. Gulzar, A., et al., Stimuli responsive drug delivery application of polymer and silica in biomedicine. 
Journal of Materials Chemistry B, 2015. 3(44): p. 8599-8622. 
55. Chilkoti, A., M.R. Dreher, and D.E. Meyer, Design of thermally responsive, recombinant 
polypeptide carriers for targeted drug delivery. Advanced drug delivery reviews, 2002. 54(8): p. 
1093-1111. 
56. RahanyanKägi, N., et al., StimuliResponsive Lipidic Cubic Phase: Triggered Release and 
Sequestration of Guest Molecules. ChemistryA European Journal, 2015. 21(5): p. 1873-1877. 
57. Fong, W.-K., et al., Alkylation of spiropyran moiety provides reversible photo-control over 
nanostructured soft materials. Biointerphases, 2012. 7(1-4): p. 3. 
58. Negrini, R. and R. Mezzenga, pH-responsive lyotropic liquid crystals for controlled drug delivery. 
Langmuir, 2011. 27(9): p. 5296-5303. 
59. Gupta, P., K. Vermani, and S. Garg, Hydrogels: from controlled release to pH-responsive drug 
delivery. Drug discovery today, 2002. 7(10): p. 569-579. 
60. Bolla, P.K., et al., A review on pH and temperature responsive gels and other less explored drug 
delivery systems. Journal of Drug Delivery Science and Technology, 2018. 46: p. 416-435. 
61. AlvarezLorenzo, C., L. Bromberg, and A. Concheiro, Lightsensitive intelligent drug delivery 
systems. Photochemistry and photobiology, 2009. 85(4): p. 848-860. 
62. Linsley, C.S. and B.M. Wu, Recent advances in light-responsive on-demand drug-delivery systems. 
Therapeutic delivery, 2017. 8(2): p. 89-107. 
63. Madan, M., et al., In situ forming polymeric drug delivery systems. Indian journal of 
pharmaceutical sciences, 2009. 71(3): p. 242. 
64. Li, J. and D.J. Mooney, Designing hydrogels for controlled drug delivery. Nature Reviews Materials, 
2016. 1(12): p. 1-17. 
65. Ganji, F. and F.E. VASHEGHANI, Hydrogels in controlled drug delivery systems. 2009. 
66. Hoare, T.R. and D.S. Kohane, Hydrogels in drug delivery: Progress and challenges. Polymer, 2008. 
49(8): p. 1993-2007. 
67. Ishii, S., J. Kaneko, and Y. Nagasaki, Development of a long-acting, protein-loaded, redox-active, 
injectable gel formed by a polyion complex for local protein therapeutics. Biomaterials, 2016. 84: 
p. 210-218. 
68. Miyazaki, S., et al., In situ gelling xyloglucan formulations for sustained release ocular delivery of 
pilocarpine hydrochloride. International journal of pharmaceutics, 2001. 229(1-2): p. 29-36. 
69. Smart, J., I. Kellaway, and H. Worthington, An invitro investigation of mucosaadhesive 
materials for use in controlled drug delivery. Journal of Pharmacy and Pharmacology, 1984. 36(5): 
p. 295-299. 
70. Ruel-Gariepy, E. and J.-C. Leroux, In situ-forming hydrogels—review of temperature-sensitive 
systems. European Journal of Pharmaceutics and Biopharmaceutics, 2004. 58(2): p. 409-426. 
 200 
71. Thilek Kumar, M., et al., Ph-lnduced in situ gelling systems of indomethacin for sustained ocular 
delivery. Indian journal of pharmaceutical sciences, 2005. 67(3): p. 327-333. 
72. Gao, W., et al., Nanoparticle-hydrogel: a hybrid biomaterial system for localized drug delivery. 
Annals of biomedical engineering, 2016. 44(6): p. 2049-2061. 
73. Eckmann, D., et al., Nanogel carrier design for targeted drug delivery. Journal of Materials 
Chemistry B, 2014. 2(46): p. 8085-8097. 
74. Basso, J., et al., Hydrogel-based drug delivery nanosystems for the treatment of brain tumors. Gels, 
2018. 4(3): p. 62. 
75. Shah, S., P.K. Sasmal, and K.-B. Lee, Photo-triggerable hydrogel–nanoparticle hybrid scaffolds for 
remotely controlled drug delivery. Journal of Materials Chemistry B, 2014. 2(44): p. 7685-7693. 
76. Shin, S. and L.D. Shea, Lentivirus immobilization to nanoparticles for enhanced and localized 
delivery from hydrogels. Molecular Therapy, 2010. 18(4): p. 700-706. 
77. Oh, J.K., et al., The development of microgels/nanogels for drug delivery applications. Progress in 
Polymer Science, 2008. 33(4): p. 448-477. 
78. Chacko, R.T., et al., Polymer nanogels: a versatile nanoscopic drug delivery platform. Advanced 
drug delivery reviews, 2012. 64(9): p. 836-851. 
79. Gothwal, A., I. Khan, and U. Gupta, Polymeric micelles: recent advancements in the delivery of 
anticancer drugs. Pharmaceutical research, 2016. 33(1): p. 18-39. 
80. Lu, Y. and K. Park, Polymeric micelles and alternative nanonized delivery vehicles for poorly soluble 
drugs. International journal of pharmaceutics, 2013. 453(1): p. 198-214. 
81. Behl, C., et al., Optimization of systemic nasal drug delivery with pharmaceutical excipients. 
Advanced drug delivery reviews, 1998. 29(1-2): p. 117-133. 
82. Patil, S.B. and K.K. Sawant, Development, optimization and in vitro evaluation of alginate 
mucoadhesive microspheres of carvedilol for nasal delivery. Journal of microencapsulation, 2009. 
26(5): p. 432-443. 
83. Illum, L., et al., Bioadhesive microspheres as a potential nasal drug delivery system. International 
journal of pharmaceutics, 1987. 39(3): p. 189-199. 
84. Björk, E. and P. Edman, Characterization of degradable starch microspheres as a nasal delivery 
system for drugs. International journal of pharmaceutics, 1990. 62(2-3): p. 187-192. 
85. Salem, H.F., et al., Nanosized nasal emulgel of resveratrol: preparation, optimization, in vitro 
evaluation and in vivo pharmacokinetic study. Drug development and industrial pharmacy, 2019. 
45(10): p. 1624-1634. 
86. Mahajan, H.S., S.K. Shah, and S.J. Surana, Nasal in situ gel containing hydroxy propyl β-cyclodextrin 
inclusion complex of artemether: development and in vitro evaluation. Journal of Inclusion 
Phenomena and Macrocyclic Chemistry, 2011. 70(1-2): p. 49-58. 
87. Aspden, T.J., et al., Chitosan as a nasal delivery system: the effect of chitosan solutions on in vitro 
and in vivo mucociliary transport rates in human turbinates and volunteers. Journal of 
pharmaceutical sciences, 1997. 86(4): p. 509-513. 
88. Carvalho, F.C., et al., Mucoadhesive drug delivery systems. Brazilian Journal of Pharmaceutical 
Sciences, 2010. 46(1): p. 1-17. 
89. Khutoryanskiy, V.V., Advances in mucoadhesion and mucoadhesive polymers. Macromolecular 
bioscience, 2011. 11(6): p. 748-764. 
90. Li, H., R.J. Hardy, and X. Gu, Effect of drug solubility on polymer hydration and drug dissolution 
from polyethylene oxide (PEO) matrix tablets. AAPS PharmSciTech, 2008. 9(2): p. 437-443. 
91. Elgadir, M., et al., Impact of chitosan composites and chitosan nanoparticle composites on various 
drug delivery systems: A review. Journal of food and drug analysis, 2015. 23(4): p. 619. 
92. Mufamadi, M.S., et al., A review on composite liposomal technologies for specialized drug delivery. 
Journal of drug delivery, 2011. 2011. 
 201 
93. Hadjiargyrou, M. and J.B. Chiu, Enhanced composite electrospun nanofiber scaffolds for use in 
drug delivery. Expert opinion on drug delivery, 2008. 5(10): p. 1093-1106. 
94. Lasserre, A. and P.K. Bajpai, Ceramic drug-delivery devices. Critical Reviews™ in Therapeutic Drug 
Carrier Systems, 1998. 15(1). 
95. Bajpai, P.K. and G.A. Graves, Porous ceramic carriers for controlled release of proteins, polypeptide 
hormones, and other substances within human and/or other mamillian species and method. 1980, 
Google Patents. 
96. Yi, Z., et al., Hierarchical porous hydroxyapatite fibers with a hollow structure as drug delivery 
carriers. Ceramics International, 2016. 42(16): p. 19079-19085. 
97. Parent, M., et al., Design of calcium phosphate ceramics for drug delivery applications in bone 
diseases: A review of the parameters affecting the loading and release of the therapeutic 
substance. Journal of Controlled Release, 2017. 252: p. 1-17. 
98. Morris, L.M. and P.K. Bajpai, Development of a resorbable tricalcium phosphate (TCP) amine 
antibiotic composite. MRS Online Proceedings Library Archive, 1987. 110. 
99. Mouriño, V. and A.R. Boccaccini, Bone tissue engineering therapeutics: controlled drug delivery in 
three-dimensional scaffolds. Journal of the Royal Society Interface, 2010. 7(43): p. 209-227. 
100. Meenach, S.A., J.Z. Hilt, and K.W. Anderson, Poly (ethylene glycol)-based magnetic hydrogel 
nanocomposites for hyperthermia cancer therapy. Acta Biomaterialia, 2010. 6(3): p. 1039-1046. 
101. Gobbo, O.L., et al., Magnetic nanoparticles in cancer theranostics. Theranostics, 2015. 5(11): p. 
1249. 
102. Wu, M. and S. Huang, Magnetic nanoparticles in cancer diagnosis, drug delivery and treatment. 
Molecular and clinical oncology, 2017. 7(5): p. 738-746. 
103. Williams, H.M., The application of magnetic nanoparticles in the treatment and monitoring of 
cancer and infectious diseases. Bioscience Horizons: The International Journal of Student Research, 
2017. 10. 
104. Shin, J., et al., Hollow manganese oxide nanoparticles as multifunctional agents for magnetic 
resonance imaging and drug delivery. Angewandte Chemie International Edition, 2009. 48(2): p. 
321-324. 
105. Strickley, R.G., Currently marketed oral lipid-based dosage forms: drug products and excipients. 
Drugs and the Pharmaceutical sciences, 2007. 170: p. 1. 
106. Vithani, K., et al., Colloidal aspects of dispersion and digestion of self-dispersing lipid-based 
formulations for poorly water-soluble drugs. Advanced drug delivery reviews, 2019. 142: p. 16-34. 
107. Gigliobianco, M., et al., Nanocrystals of poorly soluble drugs: Drug bioavailability and 
physicochemical stability. Pharmaceutics, 2018. 10(3): p. 134. 
108. Ghadi, R. and N. Dand, BCS class IV drugs: Highly notorious candidates for formulation 
development. Journal of Controlled Release, 2017. 248: p. 71-95. 
109. Porter, C.J., N.L. Trevaskis, and W.N. Charman, Lipids and lipid-based formulations: optimizing the 
oral delivery of lipophilic drugs. Nature reviews Drug discovery, 2007. 6(3): p. 231-248. 
110. O’Driscoll, C.M., Lipid-based formulations for intestinal lymphatic delivery. European Journal of 
Pharmaceutical Sciences, 2002. 15(5): p. 405-415. 
111. Rane, S.S. and B.D. Anderson, What determines drug solubility in lipid vehicles: is it predictable? 
Advanced drug delivery reviews, 2008. 60(6): p. 638-656. 
112. Chakraborty, S., et al., Lipid–an emerging platform for oral delivery of drugs with poor 
bioavailability. European Journal of Pharmaceutics and Biopharmaceutics, 2009. 73(1): p. 1-15. 
113. Kalepu, S., M. Manthina, and V. Padavala, Oral lipid-based drug delivery systems–an overview. 
Acta Pharmaceutica Sinica B, 2013. 3(6): p. 361-372. 
 202 
114. Pouton, C.W., Lipid formulations for oral administration of drugs: non-emulsifying, self-
emulsifying and ‘self-microemulsifying’drug delivery systems. European journal of pharmaceutical 
sciences, 2000. 11: p. S93-S98. 
115. Pouton, C.W., Formulation of poorly water-soluble drugs for oral administration: physicochemical 
and physiological issues and the lipid formulation classification system. European journal of 
pharmaceutical sciences, 2006. 29(3-4): p. 278-287. 
116. Anton, N. and T.F. Vandamme, Nano-emulsions and micro-emulsions: clarifications of the critical 
differences. Pharmaceutical research, 2011. 28(5): p. 978-985. 
117. Nigade, P.M., S.L. Patil, and S.S. Tiwari, Self emulsifying drug delivery system (SEDDS): A review. 
International Journal of Pharmacy and Biological Sciences, 2012. 2(2): p. 42-52. 
118. Beloqui, A., et al., Mechanism of transport of saquinavir-loaded nanostructured lipid carriers 
across the intestinal barrier. Journal of Controlled Release, 2013. 166(2): p. 115-123. 
119. Nazaruk, E., E. Górecka, and R. Bilewicz, Enzymes and mediators hosted together in lipidic 
mesophases for the construction of biodevices. Journal of colloid and interface science, 2012. 
385(1): p. 130-136. 
120. Peltier, S., et al., Enhanced oral paclitaxel bioavailability after administration of paclitaxel-loaded 
lipid nanocapsules. Pharmaceutical Research, 2006. 23(6): p. 1243-1250. 
121. Jain, S., et al., Ethosomes: a novel vesicular carrier for enhanced transdermal delivery of an antiHIV 
agent. Indian journal of pharmaceutical sciences, 2004. 66(1): p. 72. 
122. Lasic, D.D. and D. Papahadjopoulos, Medical applications of liposomes. 1998: Elsevier. 
123. Shah, J.C., Y. Sadhale, and D.M. Chilukuri, Cubic phase gels as drug delivery systems. Advanced 
Drug Delivery Reviews, 2001. 47(2-3): p. 229-250. 
124. Tardieu, A. and V. Luzzati, A novel cubic phase—a cage-like network of rods with enclosed spherical 
micelles. Biochimica et Biophysica Acta (BBA)-Biomembranes, 1970. 219(1): p. 11-17. 
125. Larsson, K., K. Fontell, and N. Krog, Structural relationships between lamellar, cubic and hexagonal 
phases in monoglyceride-water systems. Possibility of cubic structures in biological systems. 
Chemistry and Physics of Lipids, 1980. 27(4): p. 321-328. 
126. Ericsson, B., et al., Cubic phases as delivery systems for peptide drugs. 1991, ACS Publications. 
127. Rizwan, S., et al., Characterisation of bicontinuous cubic liquid crystalline systems of phytantriol 
and water using cryo field emission scanning electron microscopy (cryo FESEM). Micron, 2007. 
38(5): p. 478-485. 
128. Kumar, R. and A. Philip, Modified transdermal technologies: Breaking the barriers of drug 
permeation via the skin. Tropical Journal of Pharmaceutical Research, 2007. 6(1): p. 633-644. 
129. Chien, Y.W., Logics of transdermal controlled drug administration. Drug Development and 
Industrial Pharmacy, 1983. 9(4): p. 497-520. 
130. Cevc, G., Drug delivery across the skin. Expert opinion on investigational drugs, 1997. 6(12): p. 
1887-1937. 
131. Woo, J.S., et al., Enhanced oral bioavailability of paclitaxel by coadministration of the P-
glycoprotein inhibitor KR30031. Pharmaceutical research, 2003. 20(1): p. 24-30. 
132. Butani, D., C. Yewale, and A. Misra, Amphotericin B topical microemulsion: formulation, 
characterization and evaluation. Colloids and Surfaces B: Biointerfaces, 2014. 116: p. 351-358. 
133. Yan, Y.-D., et al., Effect of dose and dosage interval on the oral bioavailability of docetaxel in 
combination with a curcumin self-emulsifying drug delivery system (SEDDS). European journal of 
drug metabolism and pharmacokinetics, 2012. 37(3): p. 217-224. 
134. Garg, B., et al., Systematic development of solid self-nanoemulsifying oily formulations (S-SNEOFs) 
for enhancing the oral bioavailability and intestinal lymphatic uptake of lopinavir. Colloids and 
Surfaces B: Biointerfaces, 2016. 141: p. 611-622. 
 203 
135. Jaafar-Maalej, C., et al., Ethanol injection method for hydrophilic and lipophilic drug-loaded 
liposome preparation. Journal of liposome research, 2010. 20(3): p. 228-243. 
136. Nii, T. and F. Ishii, Encapsulation efficiency of water-soluble and insoluble drugs in liposomes 
prepared by the microencapsulation vesicle method. International journal of pharmaceutics, 2005. 
298(1): p. 198-205. 
137. Rathore, A., et al., Mannosylated liposomes bearing Amphotericin B for effective management of 
visceral Leishmaniasis. Journal of liposome research, 2011. 21(4): p. 333-340. 
138. Vural, I., C. Sarisozen, and S.S. Olmez, Chitosan coated furosemide liposomes for improved 
bioavailability. Journal of biomedical nanotechnology, 2011. 7(3): p. 426-430. 
139. Das, B., et al., Transferosomal gel for transdermal delivery of risperidone: Formulation 
optimization and ex vivo permeation. Journal of Drug Delivery Science and Technology, 2017. 38: 
p. 59-71. 
140. Mehnert, W. and K. Mäder, Solid lipid nanoparticles: production, characterization and applications. 
Advanced drug delivery reviews, 2012. 64: p. 83-101. 
141. Negi, J.S., et al., Development and evaluation of glyceryl behenate based solid lipid nanoparticles 
(SLNs) using hot self-nanoemulsification (SNE) technique. Archives of pharmacal research, 2014. 
37(3): p. 361-370. 
142. Ravi, P.R., et al., A hybrid design to optimize preparation of lopinavir loaded solid lipid 
nanoparticles and comparative pharmacokinetic evaluation with marketed lopinavir/ritonavir 
coformulation. Journal of Pharmacy and Pharmacology, 2014. 66(7): p. 912-926. 
143. Arai, T., et al., Novel local drug delivery system using thermoreversible gel in combination with 
polymeric microspheres or liposomes. Anticancer research, 2010. 30(4): p. 1057-1064. 
144. Bastiancich, C., Vanvarenberg, K., Ucakar, B., Pitorre, M., Bastiat, G., Lagarce, F., Préat, V. and 
Danhier, F.,, Lauroyl-gemcitabine-loaded lipid nanocapsule hydrogel for the treatment of 
glioblastoma. Journal of Controlled Release, 2016. 225: p. 283-293. 
145. Caffrey, M., A comprehensive review of the lipid cubic phase or in meso method for crystallizing 
membrane and soluble proteins and complexes. Acta Crystallographica Section F: Structural 
Biology Communications, 2015. 71(1): p. 3-18. 
146. Larsson, K., Cubic lipid-water phases: structures and biomembrane aspects. The Journal of Physical 
Chemistry, 1989. 93(21): p. 7304-7314. 
147. Gruner, S.M., et al., Lipid polymorphism: the molecular basis of nonbilayer phases. Annual review 
of biophysics and biophysical chemistry, 1985. 14(1): p. 211-238. 
148. Luzzati, V., T. Gulik-Krzywicki, and A. Tardieu, Polymorphism of lecithins. Nature, 1968. 218(5146): 
p. 1031-1034. 
149. Cherezov, V., H. Fersi, and M. Caffrey, Crystallization screens: compatibility with the lipidic cubic 
phase for in meso crystallization of membrane proteins. Biophysical journal, 2001. 81(1): p. 225-
242. 
150. Chung, H. and M. Caffrey, The curvature elastic-energy function of the lipid-water cubic 
mesophase. Nature, 1994. 368(6468): p. 224. 
151. Anderson, D.M., S.M. Gruner, and S. Leibler, Geometrical aspects of the frustration in the cubic 
phases of lyotropic liquid crystals. Proceedings of the National Academy of Sciences, 1988. 85(15): 
p. 5364-5368. 
152. Duesing, P., R. Templer, and J. Seddon, Quantifying packing frustration energy in inverse lyotropic 
mesophases. Langmuir, 1997. 13(2): p. 351-359. 
153. Shearman, G.C., et al., Calculations of and evidence for chain packing stress in inverse lyotropic 
bicontinuous cubic phases. Langmuir, 2007. 23(13): p. 7276-7285. 
154. Salim, M., et al., Amphiphilic designer nano-carriers for controlled release: from drug delivery to 
diagnostics. MedChemComm, 2014. 5(11): p. 1602-1618. 
 204 
155. Israelachvili, J.N., Intermolecular and surface forces. 2015: Academic press. 
156. Mouritsen, O.G., Lipidology and lipidomics––quo vadis? A new era for the physical chemistry of 
lipids. Physical Chemistry Chemical Physics, 2011. 13(43): p. 19195-19205. 
157. Seddon, J.M. and R.H. Templer, Cubic phases of self-assembled amphiphilic aggregates. 
Philosophical Transactions of the Royal Society of London. Series A: Physical and Engineering 
Sciences, 1993. 344(1672): p. 377-401. 
158. Zabara, A., et al., The nanoscience behind the art of in-meso crystallization of membrane proteins. 
Nanoscale, 2017. 9(2): p. 754-763. 
159. Delacroix, H., Crystallographic analysis of freeze-fracture electron micrographs: application to the 
structure determination of cubic lipid-water phases. Journal of microscopy, 1998. 192: p. 280-292. 
160. Razumas, V., et al., Effects of distearoylphosphatidylglycerol and lysozyme on the structure of the 
monoolein-water cubic phase: X-ray diffraction and Raman scattering studies. Chemistry and 
physics of lipids, 1996. 84(2): p. 123-138. 
161. Eriksson, P.-O. and G. Lindblom, Lipid and water diffusion in bicontinuous cubic phases measured 
by NMR. Biophysical journal, 1993. 64(1): p. 129-136. 
162. Lindblom, G. and L. Rilfors, Cubic phases and isotropic structures formed by membrane lipids—
possible biological relevance. Biochimica et Biophysica Acta (BBA)-Reviews on Biomembranes, 
1989. 988(2): p. 221-256. 
163. Cribier, S., et al., Cubic Phase of Lipid-containing Systems: A Translational Diffusion Study by 
Fluorescence Recovery After Photobleaching. Journal of molecular biology, 1993. 229(2): p. 517-
525. 
164. Small, D.M., Physical chemistry of lipids. 1986: Plenum Press. 
165. Landau, E.M. and J.P. Rosenbusch, Lipidic cubic phases: a novel concept for the crystallization of 
membrane proteins. Proceedings of the National Academy of Sciences, 1996. 93(25): p. 14532-
14535. 
166. Demurtas, D., et al., Direct visualization of dispersed lipid bicontinuous cubic phases by cryo-
electron tomography. Nature communications, 2015. 6(1): p. 1-8. 
167. Barauskas, J. and T. Landh, Phase behavior of the phytantriol/water system. Langmuir, 2003. 
19(23): p. 9562-9565. 
168. Clogston, J., Applications of the lepidic cubic phase: from controlled release and uptake to in meso 
crystallization of membrane proteins. 2005, The Ohio State University. 
169. Wyatt, D. and D. Dorschel, A cubic-phase delivery system composed of glyceryl monooleate and 
water for sustained release of water-soluble drugs. Pharmaceutical technology, 1992. 16(10): p. 
116-116. 
170. Clogston, J. and M. Caffrey, Controlling release from the lipidic cubic phase. Amino acids, peptides, 
proteins and nucleic acids. Journal of controlled release, 2005. 107(1): p. 97-111. 
171. Angelov, B., et al., Identification of large channels in cationic PEGylated cubosome nanoparticles 
by synchrotron radiation SAXS and Cryo-TEM imaging. Soft Matter, 2015. 11(18): p. 3686-3692. 
172. Chung, H. and M. Caffrey, Polymorphism, mesomorphism, and metastability of monoelaidin in 
excess water. Biophysical journal, 1995. 69(5): p. 1951-1963. 
173. Briggs, J., The phase behavior of hydrated monoacylglycerols and the design of an X-ray 
compatible scanning calorimeter. 1994, The Ohio State University. 
174. Norling, T., et al., Formulation of a drug delivery system based on a mixture of monoglycerides and 
triglycerides for use in the treatment of periodontal disease. Journal of clinical periodontology, 
1992. 19(9): p. 687-692. 
175. Hato, M., et al., Phase behavior of phytanyl-chained akylglycoside/water systems. Trends in 
Colloid and Interface Science XVI, 2004: p. 56-60. 
 205 
176. Hasenhuettl, G.L., Food emulsifiers and their applications, G.L. Hasenhuettl and R.W. Hartel, 
Editors. 2008, Springer Science and Business Media. 
177. Qiu, H. and M. Caffrey, The phase diagram of the monoolein/water system: metastability and 
equilibrium aspects. Biomaterials, 2000. 21(3): p. 223-234. 
178. Takahashi, H., I. Hatta, and P.J. Quinn, Cubic phases in hydrated 1: 1 and 1: 2 
dipalmitoylphosphatidylcholine-dipalmitoylglycerol mixtures. Biophysical journal, 1996. 70(3): p. 
1407-1411. 
179. Aleandri, S., et al., Design of light-triggered lyotropic liquid crystal mesophases and their 
application as molecular switches in “on demand” release. Langmuir, 2015. 31(25): p. 6981-6987. 
180. Ganem-Quintanar, A., D. Quintanar-Guerrero, and P. Buri, Monoolein: A review of the 
pharmaceutical applications. Drug Development and Industrial Pharmacy, 2000. 26(8): p. 809-820. 
181. Fong, W.-K., et al., Responsive self-assembled nanostructured lipid systems for drug delivery and 
diagnostics. Journal of colloid and interface science, 2016. 484: p. 320-339. 
182. Caffrey, M. and V. Cherezov, Crystallizing membrane proteins using lipidic mesophases. Nature 
protocols, 2009. 4(5): p. 706-731. 
183. Burdock, G.A., Fenaroli's handbook of flavor ingredients. 2016: CRC press. 
184. Seddon, J.M., Structure of the inverted hexagonal (HII) phase, and non-lamellar phase transitions 
of lipids. Biochimica et Biophysica Acta (BBA)-Reviews on Biomembranes, 1990. 1031(1): p. 1-69. 
185. Qiu, H. and M. Caffrey, Lyotropic and thermotropic phase behavior of hydrated monoacylglycerols: 
structure characterization of monovaccenin. The Journal of Physical Chemistry B, 1998. 102(24): 
p. 4819-4829. 
186. Wagner, E., Panthenol und Phytantriol in der Kosmetik. Parfümerie und Kosmetik, 1994. 75(4). 
187. Ribier, A. and B. Biatry, Cosmetic or dermatological composition in the form of an aqueous and 
stable dispersion of cubic gel particles based on phytanetriol and containing a surface-active agent 
which has a fatty chain, as dispersing and stabilizing agent. 1998, Google Patents. 
188. Shi, X., et al., Comparative studies on glycerol monooleate-and phytantriol-based cubosomes 
containing oridonin in vitro and in vivo. Pharmaceutical development and technology, 2017. 22(3): 
p. 322-329. 
189. Wadsten-Hindrichsen, P., et al., Aqueous self-assembly of phytantriol in ternary systems: effect of 
monoolein, distearoylphosphatidylglycerol and three water-miscible solvents. Journal of colloid 
and interface science, 2007. 315(2): p. 701-713. 
190. Lagerwall, J.P. and G. Scalia, A new era for liquid crystal research: Applications of liquid crystals in 
soft matter nano-, bio-and microtechnology. Current Applied Physics, 2012. 12(6): p. 1387-1412. 
191. Antognini, L.M., et al., Quantifying the transport properties of lipid mesophases by theoretical 
modelling of diffusion experiments. The Journal of chemical physics, 2016. 145(8): p. 084903. 
192. Guillot, S., et al., Direct and indirect thermal transitions from hexosomes to emulsified micro-
emulsions in oil-loaded monoglyceride-based particles. Colloids and Surfaces A: Physicochemical 
and Engineering Aspects, 2006. 291(1-3): p. 78-84. 
193. Siekmann, B., et al., Preparation and structural investigations of colloidal dispersions prepared 
from cubic monoglyceride–water phases. International journal of pharmaceutics, 2002. 244(1-2): 
p. 33-43. 
194. Attama, A.A. and C.C. Müller-Goymann, Effect of beeswax modification on the lipid matrix and 
solid lipid nanoparticle crystallinity. Colloids and Surfaces A: Physicochemical and Engineering 
Aspects, 2008. 315(1-3): p. 189-195. 
195. Forbes, R., A. Cooper, and H. Mitchell, The composition of the adult human body as determined 
by chemical analysis. J Biol Chem, 1953. 203(1): p. 359-366. 
196. Engström, S., et al., A study of polar lipid drug systems undergoing a thermoreversible lamellar-
to-cubic phase transition. International journal of pharmaceutics, 1992. 86(2-3): p. 137-145. 
 206 
197. Caboi, F., et al., Addition of hydrophilic and lipophilic compounds of biological relevance to the 
monoolein/water system. I. Phase behavior. Chemistry and physics of lipids, 2001. 109(1): p. 47-
62. 
198. Costa, P. and J.M.S. Lobo, Modeling and comparison of dissolution profiles. European journal of 
pharmaceutical sciences, 2001. 13(2): p. 123-133. 
199. Gouda, R., H. Baishya, and Z. Qing, Application of mathematical models in drug release kinetics of 
carbidopa and levodopa ER tablets. J. Dev. Drugs, 2017. 6(02): p. 1-8. 
200. Wagner, J.G., Interpretation of percent dissolved-time plots derived from in vitro testing of 
conventional tablets and capsules. Journal of pharmaceutical sciences, 1969. 58(10): p. 1253-1257. 
201. Hixson, A. and J. Crowell, Dependence of reaction velocity upon surface and agitation. Industrial 
& Engineering Chemistry, 1931. 23(8): p. 923-931. 
202. Siepmann, J. and N.A. Peppas, Higuchi equation: derivation, applications, use and misuse. 
International journal of pharmaceutics, 2011. 418(1): p. 6-12. 
203. Korsmeyer, R.W., et al., Mechanisms of solute release from porous hydrophilic polymers. 
International journal of pharmaceutics, 1983. 15(1): p. 25-35. 
204. Ritger, P.L. and N.A. Peppas, A simple equation for description of solute release II. Fickian and 
anomalous release from swellable devices. Journal of controlled release, 1987. 5(1): p. 37-42. 
205. Peppas, N.A. and J.J. Sahlin, A simple equation for the description of solute release. III. Coupling of 
diffusion and relaxation. International journal of pharmaceutics, 1989. 57(2): p. 169-172. 
206. Mikac, U., et al., Dynamics of water and xanthan chains in hydrogels studied by NMR relaxometry 
and their influence on drug release. International journal of pharmaceutics, 2019. 563: p. 373-383. 
207. Sheikh, F.A., et al., Linseed hydrogel based floating drug delivery system for fluoroquinolone 
antibiotics: Design, in vitro drug release and in vivo real-time floating detection. Saudi 
Pharmaceutical Journal, 2020. 28(5): p. 538-549. 
208. Caccavo, D., An overview on the mathematical modeling of hydrogels’ behavior for drug delivery 
systems. International journal of pharmaceutics, 2019. 560: p. 175-190. 
209. Bender, J., et al., Lipid cubic phases for improved topical drug delivery in photodynamic therapy. 
Journal of Controlled Release, 2005. 106(3): p. 350-360. 
210. Nielsen, L.S., L. Schubert, and J. Hansen, Bioadhesive drug delivery systems: I. Characterisation of 
mucoadhesive properties of systems based on glyceryl mono-oleate and glyceryl monolinoleate. 
European journal of pharmaceutical sciences, 1998. 6(3): p. 231-239. 
211. Kossena, G.A., et al., A novel cubic phase of medium chain lipid origin for the delivery of poorly 
water soluble drugs. Journal of controlled release, 2004. 99(2): p. 217-229. 
212. Szlezak, M., et al., Monoolein cubic phase gels and cubosomes doped with magnetic 
nanoparticles–hybrid materials for controlled drug release. ACS applied materials & interfaces, 
2017. 9(3): p. 2796-2805. 
213. Gan, L., et al., Recent advances in topical ophthalmic drug delivery with lipid-based nanocarriers. 
Drug discovery today, 2013. 18(5-6): p. 290-297. 
214. Boyd, B.J., et al., A lipid-based liquid crystalline matrix that provides sustained release and 
enhanced oral bioavailability for a model poorly water soluble drug in rats. International journal 
of pharmaceutics, 2007. 340(1-2): p. 52-60. 
215. Chang, C.-M. and R. Bodmeier, Effect of dissolution media and additives on the drug release from 
cubic phase delivery systems. Journal of Controlled Release, 1997 46(3): p. 215-222. 
216. Burrows, R., J. Collett, and D. Attwood, The release of drugs from monoglyceride-water liquid 
crystalline phases. International journal of pharmaceutics, 1994. 111(3): p. 283-293. 
217. Chang, C.M. and R. Bodmeier, Swelling of and drug release from monoglyceridebased drug 
delivery systems. Journal of pharmaceutical sciences, 1997 86(6): p. 747-752. 
 207 
218. Sadhale, Y. and J.C. Shah, Stabilization of insulin against agitation-induced aggregation by the 
GMO cubic phase gel. International journal of pharmaceutics, 1999. 191(1): p. 51-64. 
219. Lee, K.W., et al., Nanostructure of liquid crystalline matrix determines in vitro sustained release 
and in vivo oral absorption kinetics for hydrophilic model drugs. International journal of 
pharmaceutics, 2009. 365(1-2): p. 190-199. 
220. Almsherqi, Z.A., S.D. Kohlwein, and Y. Deng, Cubic membranes: a legend beyond the Flatland* of 
cell membrane organization. The Journal of cell biology, 2006. 173(6): p. 839-844. 
221. Drummond, C.J. and C. Fong, Surfactant self-assembly objects as novel drug delivery vehicles. 
Current opinion in colloid & interface science, 1999. 4(6): p. 449-456. 
222. Sadhale, Y. and J.C. Shah, Glyceryl monooleate cubic phase gel as chemical stability enhancer of 
cefazolin and cefuroxime. Pharmaceutical development and technology, 1998. 3(4): p. 549-556. 
223. Engstrom, S., B. Lindman, and K. Larsson, Method of preparing controlled-release preparations for 
biologically active materials and resulting compositions. 1992, Google Patents. 
224. van Dalsen, L., et al., 9.8 MAG: A New Host Lipid for In Meso (Lipid Cubic Phase) Crystallization of 
Integral Membrane Proteins. Crystal Growth & Design, 2020. 21(1): p. 490-500. 
225. Osornio, Y.M., et al., Design and synthesis of lipids for the fabrication of functional lipidic cubic-
phase biomaterials. The Journal of organic chemistry, 2012. 77(23): p. 10583-10595. 
226. Nazaruk, E., et al., Charged additives modify drug release rates from lipidic cubic phase carriers by 
modulating electrostatic interactions. Journal of Electroanalytical Chemistry, 2018. 819: p. 269-
274. 
227. Andersson, S.J., M.; Lidin, S.; Larsson, K., Structure of the cubosome - a closed lipid bilayer 
aggregate. Zeitschrift für Kristallographie-Crystalline Materials, 1995. 210(5): p. 315-318. 
228. Yaghmur, A. and O. Glatter, Characterization and potential applications of nanostructured 
aqueous dispersions. Advances in colloid and interface science, 2009. 147: p. 333-342. 
229. Karami, Z. and M. Hamidi, Cubosomes: remarkable drug delivery potential. Drug discovery today, 
2016. 21(5): p. 789-801. 
230. Garg, G., S. Saraf, and S. Saraf, Cubosomes: an overview. Biological and Pharmaceutical Bulletin, 
2007. 30(2): p. 350-353. 
231. Luzzati, V. and F. Husson, The structure of the liquid-crystalline phases of lipid-water systems. The 
Journal of cell biology, 1962. 12(2): p. 207-219. 
232. Peng, X., et al., Characterization of cubosomes as a targeted and sustained transdermal delivery 
system for capsaicin. Drug design, development and therapy, 2015. 9: p. 4209. 
233. Gustafsson, J., et al., Cubic lipid− water phase dispersed into submicron particles. Langmuir, 1996. 
12(20): p. 4611-4613. 
234. Gustafsson, J., et al., Submicron particles of reversed lipid phases in water stabilized by a nonionic 
amphiphilic polymer. Langmuir, 1997. 13(26): p. 6964-6971. 
235. Spicer, P.T., et al., Novel process for producing cubic liquid crystalline nanoparticles (cubosomes). 
Langmuir, 2001. 17(19): p. 5748-5756. 
236. Rizwan, S., et al., Preparation of phytantriol cubosomes by solvent precursor dilution for the 
delivery of protein vaccines. European Journal of Pharmaceutics and Biopharmaceutics, 2011. 
79(1): p. 15-22. 
237. Boge, L., et al., Cubosomes post-loaded with antimicrobial peptides: characterization, bactericidal 
effect and proteolytic stability. International journal of pharmaceutics, 2017. 526(1-2): p. 400-412. 
238. Cervin, C., et al., A combined in vitro and in vivo study on the interactions between somatostatin 
and lipid-based liquid crystalline drug carriers and bilayers. European journal of pharmaceutical 
sciences, 2009. 36(4-5): p. 377-385. 
239. Pan, X., et al., Nanostructed cubosomes as advanced drug delivery system. Current pharmaceutical 
design, 2013. 19(35): p. 6290-6297. 
 208 
240. Esposito, E., et al., Cubosome dispersions as delivery systems for percutaneous administration of 
indomethacin. Pharmaceutical research, 2005. 22(12): p. 2163-2173. 
241. Chung, H., et al., Self-assembled “nanocubicle” as a carrier for peroral insulin delivery. 
Diabetologia, 2002. 45(3): p. 448-451. 
242. Angelova, A., et al., Self-assembled multicompartment liquid crystalline lipid carriers for protein, 
peptide, and nucleic acid drug delivery. Accounts of chemical research, 2010. 44(2): p. 147-156. 
243. Landau, E.M., et al., Crystallization of a polar protein and small molecules from the aqueous 
compartment of lipidic cubic phases. The Journal of Physical Chemistry B, 1997. 101(11): p. 1935-
1937. 
244. Lai, J., et al., Pharmacokinetics and enhanced oral bioavailability in beagle dogs of cyclosporine A 
encapsulated in glyceryl monooleate/poloxamer 407 cubic nanoparticles. International journal of 
nanomedicine, 2010. 5: p. 13. 
245. Diepold, R., et al., Distribution of poly-hexyl-2-cyano-[3-14C] acrylate nanoparticles in healthy and 
chronically inflamed rabbit eyes. International journal of pharmaceutics, 1989. 54(2): p. 149-153. 
246. Duncan, R., T.A. Connors, and H. Meada, Drug targeting in cancer therapy: the magic bullet, what 
next? 1996, Taylor & Francis. 
247. Monsky, W.L., et al., Augmentation of transvascular transport of macromolecules and 
nanoparticles in tumors using vascular endothelial growth factor. Cancer Research, 1999. 59(16): 
p. 4129-4135. 
248. Boyd, B.J., Characterisation of drug release from cubosomes using the pressure ultrafiltration 
method. International journal of pharmaceutics, 2003. 260(2): p. 239-247. 
249. Kaasgaard, T. and C.J. Drummond, Ordered 2-D and 3-D nanostructured amphiphile self-assembly 
materials stable in excess solvent. Physical Chemistry Chemical Physics, 2006. 8(43): p. 4957-4975. 
250. Sagalowicz, L., R. Mezzenga, and M.E. Leser, Investigating reversed liquid crystalline mesophases. 
Current opinion in colloid & interface science, 2006. 11(4): p. 224-229. 
251. Milak, S., et al., Vancomycin Loaded Glycerol Monooleate Liquid Crystalline Phases Modified with 
Surfactants. Pharmaceutics, 2020. 12(6): p. 521. 
252. Boyd, B.J., et al., Lyotropic liquid crystalline phases formed from glycerate surfactants as sustained 
release drug delivery systems. International journal of pharmaceutics, 2006. 309(1-2): p. 218-226. 
253. Lopes, L.B., F.F. Speretta, and M.V.L. Bentley, Enhancement of skin penetration of vitamin K using 
monoolein-based liquid crystalline systems. European Journal of Pharmaceutical Sciences, 2007. 
32(3): p. 209-215. 
254. Cohen-Avrahami, M., A. Aserin, and N. Garti, HII mesophase and peptide cell-penetrating 
enhancers for improved transdermal delivery of sodium diclofenac. Colloids and Surfaces B: 
Biointerfaces, 2010. 77(2): p. 131-138. 
255. Swarnakar, N.K., et al., Enhanced oromucosal delivery of progesterone via hexosomes. 
Pharmaceutical research, 2007. 24(12): p. 2223-2230. 
256. Li, Y., et al., PH responsiveness of hexosomes and cubosomes for combined delivery of Brucea 
javanica oil and doxorubicin. Langmuir, 2019. 35(45): p. 14532-14542. 
257. Borné, J., T. Nylander, and A. Khan, Effect of lipase on different lipid liquid crystalline phases 
formed by oleic acid based acylglycerols in aqueous systems. Langmuir, 2002. 18(23): p. 8972-
8981. 
258. Wallin, R. and T. Arnebrant, The activity of lipase at the cubic liquid-crystalline phase/water 
interface. Journal of colloid and interface science, 1994. 164(1): p. 16-20. 
259. Campos, J., et al., On the interaction between adsorbed layers of monoolein and the lipase action 
on the formed layers. Colloids and Surfaces B: Biointerfaces, 2002. 26(1-2): p. 172-182. 
260. Verger, R. and G.H. De Haas, Interfacial enzyme kinetics of lipolysis. Annual review of biophysics 
and bioengineering, 1976. 5(1): p. 77-117. 
 209 
261. Maylie, M.-F., M. Charles, and P. Desnuelle, Action of organophosphates and sulfonyl halides on 
porcine pancreatic lipase. Biochimica et Biophysica Acta (BBA)-Enzymology, 1972. 276(1): p. 162-
175. 
262. Winkler, F., A. d'Arcy, and W. Hunziker, Structure of human pancreatic lipase. Nature, 1990. 
343(6260): p. 771. 
263. Chang, J.W., et al., Highly selective inhibitors of monoacylglycerol lipase bearing a reactive group 
that is bioisosteric with endocannabinoid substrates. Chemistry & biology, 2012. 19(5): p. 579-588. 
264. Borgström, B. and C. Erlanson, Pancreatic juice co-lipase: physiological importance. Biochimica et 
biophysica acta, 1971. 242(2): p. 509. 
265. Golding, M. and T.J. Wooster, The influence of emulsion structure and stability on lipid digestion. 
Current Opinion in Colloid & Interface Science, 2010. 15(1-2): p. 90-101. 
266. Patton, J.S., et al., Binding of porcine pancreatic lipase and colipase in the absence of substrate 
studies by two-phase partition and affinity chromatography. Journal of Biological Chemistry, 1978. 
253(12): p. 4195-4202. 
267. Lowe, M.E., Pancreatic triglyceride lipase and colipase: insights into dietary fat digestion. 
Gastroenterology, 1994. 107(5): p. 1524-1536. 
268. Liao, T.H., P. Hamosh, and M. Hamosh, Fat digestion by lingual lipase: mechanism of lipolysis in 
the stomach and upper small intestine. Pediatric research, 1984. 18(5): p. 402-409. 
269. Hamosh, M., Lingual and gastric lipases. Nutrition (Burbank, Los Angeles County, Calif.), 1990. 
6(6): p. 421-428. 
270. Borovicka, J., et al., Regulation of gastric and pancreatic lipase secretion by CCK and cholinergic 
mechanisms in humans. American Journal of Physiology-Gastrointestinal and Liver Physiology, 
1997. 273(2): p. G374-G380. 
271. Fredenberg, S., et al., The mechanisms of drug release in poly (lactic-co-glycolic acid)-based drug 
delivery systems—a review. International journal of pharmaceutics, 2011. 415(1-2): p. 34-52. 
272. Frankel, E.N., Lipid oxidation. 2014: Elsevier. 
273. Rhoades, R.A. and D.R. Bell, Medical phisiology: Principles for clinical medicine. 2012: Lippincott 
Williams & Wilkins. 
274. Keller, P.J. and B.J. Allan, The protein composition of human pancreatic juice. Journal of Biological 
Chemistry, 1967. 242(2): p. 281-287. 
275. Embleton, J.K. and C.W. Pouton, Structure and function of gastro-intestinal lipases. Advanced 
Drug Delivery Reviews, 1997. 25(1): p. 15-32. 
276. Phan, C.T. and P. Tso, Intestinal lipid absorption and transport. Front Biosci, 2001. 6(5): p. D299-
D319. 
277. Iqbal, J. and M.M. Hussain, Intestinal lipid absorption. American Journal of Physiology-
Endocrinology and Metabolism, 2009. 296(6): p. E1183-E1194. 
278. Tso, P., A. Nauli, and C.-M. Lo, Enterocyte fatty acid uptake and intestinal fatty acid-binding 
protein. 2004, Portland Press Ltd. 
279. Simmonds, W., The role of micellar solubilization in lipid absorption. Australian Journal Of 
Experimental Biology And Medical Science, 1972. 50(4): p. 403-421. 
280. Hofmann, A.F. and B. Borgström, The intraluminal phase of fat digestion in man: the lipid content 
of the micellar and oil phases of intestinal content obtained during fat digestion and absorption. 
The Journal of clinical investigation, 1964. 43(2): p. 247-257. 
281. Hoffman, N., The relationship between uptake in vitro of oleic acid and micellar solubilization. 
Biochimica et Biophysica Acta (BBA)-Biomembranes, 1970. 196(2): p. 193-203. 
282. Abumrad, N.A. and N.O. Davidson, Role of the gut in lipid homeostasis. Physiological reviews, 2012. 
92(3): p. 1061-1085. 
 210 
283. Risovic, V., et al., Effect of various lipid-based oral formulations on plasma and tissue 
concentrations and renal toxicity of amphotericin B within male rats. Antimicrob Agents 
Chemother, 2003. 47: p. 3339-3342. 
284. Bogman, K., et al., The role of surfactants in the reversal of active transport mediated by multidrug 
resistance proteins. Journal of pharmaceutical sciences, 2003. 92(6): p. 1250-1261. 
285. Hugger, E.D., et al., A comparison of commonly used polyethoxylated pharmaceutical excipients 
on their ability to inhibit Pglycoprotein activity in vitro. Journal of pharmaceutical sciences, 2002. 
91(9): p. 1991-2002. 
286. Johnson, B.M., W.N. Charman, and C.J. Porter, An in vitro examination of the impact of 
polyethylene glycol 400, pluronic P85, and vitamin E da-tocopheryl polyethylene glycol 1000 
succinate on P-glycoprotein efflux and enterocyte-based metabolism in excised rat intestine. AAPS 
pharmsci, 2002. 4(4): p. 193-205. 
287. Wandel, C., R.B. Kim, and C.M. Stein, “Inactive” excipients such as Cremophor can affect in vivo 
drug disposition. Clinical Pharmacology & Therapeutics, 2003. 73(5): p. 394-396. 
288. Risovic, V., et al., Potential mechanisms by which Peceol® increases the gastrointestinal absorption 
of amphotericin B. Drug development and industrial pharmacy, 2004. 30(7): p. 767-774. 
289. Agellon, L.B., M.J. Toth, and A.B. Thomson, Intracellular lipid binding proteins of the small intestine, 
in Cellular Lipid Binding Proteins. 2002, Springer. p. 79-82. 
290. Thompson, J., et al., The liver fatty acid binding protein-comparison of cavity properties of 
intracellular lipid-binding proteins. Molecular and cellular biochemistry, 1999. 192(1-2): p. 9-16. 
291. Storch, J. and A.E. Thumser, Tissue-specific functions in the fatty acid-binding protein family. 
Journal of Biological Chemistry, 2010. 285(43): p. 32679-32683. 
292. Mansbach, C.M. and S.A. Siddiqi, The biogenesis of chylomicrons. Annual review of physiology, 
2010. 72: p. 315-333. 
293. Pan, X. and M.M. Hussain, Gut triglyceride production. Biochimica et Biophysica Acta (BBA)-
Molecular and Cell Biology of Lipids, 2012. 1821(5): p. 727-735. 
294. Demignot, S., F. Beilstein, and E. Morel, Triglyceride-rich lipoproteins and cytosolic lipid droplets 
in enterocytes: key players in intestinal physiology and metabolic disorders. Biochimie, 2014. 96: 
p. 48-55. 
295. Sturley, S.L. and M.M. Hussain, Lipid droplet formation on opposing sides of the endoplasmic 
reticulum. Journal of lipid research, 2012. 53(9): p. 1800-1810. 
296. Hernell, O., J.E. Staggers, and M.C. Carey, Physical-chemical behavior of dietary and biliary lipids 
during intestinal digestion and absorption. 2. Phase analysis and aggregation states of luminal 
lipids during duodenal fat digestion in healthy adult human beings. Biochemistry, 1990. 29(8): p. 
2041-2056. 
297. Kaukonen, A.M., et al., Drug solubilization behavior during in vitro digestion of suspension 
formulations of poorly water-soluble drugs in triglyceride lipids. Pharmaceutical research, 2004. 
21(2): p. 254-260. 
298. Kaukonen, A.M., et al., Drug solubilization behavior during in vitro digestion of simple triglyceride 
lipid solution formulations. Pharmaceutical research, 2004. 21(2): p. 245-253. 
299. Larsen, A., et al., Lipid-based formulations for danazol containing a digestible surfactant, Labrafil 
M2125CS: in vivo bioavailability and dynamic in vitro lipolysis. Pharmaceutical research, 2008. 
25(12): p. 2769-2777. 
300. Porter, C.J., et al., Enhancing intestinal drug solubilisation using lipid-based delivery systems. 
Advanced drug delivery reviews, 2008. 60(6): p. 673-691. 
301. Caliph, S.M., W.N. Charman, and C.J. Porter, Effect of short, medium, and longchain fatty 
acidbased vehicles on the absolute oral bioavailability and intestinal lymphatic transport of 
 211 
halofantrine and assessment of mass balance in lymphcannulated and noncannulated rats. 
Journal of pharmaceutical sciences, 2000. 89(8): p. 1073-1084. 
302. Narangifard, A., et al., Human skin barrier formation takes place via a cubic to lamellar lipid phase 
transition as analyzed by cryo-electron microscopy and EM-simulation. Experimental cell research, 
2018. 366(2): p. 139-151. 
303. Best, C.H., et al., The nature of the vasodilator constituents of certain tissue extracts. The 
Journal of physiology, 1927. 62(4): p. 397-417. 
304. Loew, E.R. and O. Chickering, Gastric secretion in dogs treated with histamine antagonist, 
thymoxyethyldiethylamine. Proceedings of the Society for Experimental Biology and Medicine, 
1941. 48(1): p. 65-68. 
305. Black, J., et al., Definition and antagonism of histamine H2-receptors. Nature, 1972. 236: p. 385-
390. 
306. Wollenberg, A. and K. Feichtner, Atopic dermatitis and skin allergies–update and outlook. Allergy, 
2013. 68(12): p. 1509-1519. 
307. Hide, M., et al., Autoantibodies against the high-affinity IgE receptor as a cause of histamine 
release in chronic urticaria. New England Journal of Medicine, 1993. 328(22): p. 1599-1604. 
308. Walch, H., Topical application of cetirizine and loratadine. 2004, Google Patents. 
309. Heinrich, J., et al., European health survey in adults (ECRHS). Pneumologie, 2002. 56(5): p. 297-
303. 
310. World Allergy Organization (WAO), White book on allergy: update 2013, W.a. organization, Editor. 
2013: Milwaukee, WI. 
311. Simons, F.E.R. and K.J. Simons, Histamine and H1-antihistamines: celebrating a century of progress. 
Journal of Allergy and Clinical Immunology, 2011. 128(6): p. 1139-1150. e4. 
312. Leurs, R., M. Church, and M. Taglialatela, H1 antihistamines: inverse agonism, anti
inflammatory actions and cardiac effects. Clinical & Experimental Allergy, 2002. 32(4): p. 489-498. 
313. Simons, F.E.R., The antiallergic effects of antihistamines (H1-receptor antagonists). Journal of 
allergy and clinical immunology, 1992. 90(4): p. 705-715. 
314. Simons, F.E.R., Advances in H1-antihistamines. New England Journal of Medicine, 2004. 351(21): 
p. 2203-2217. 
315. Bakker, R.A., et al., Histamine H1-receptor activation of nuclear factor-κB: roles for Gβγ-and 
Gαq/11-subunits in constitutive and agonist-mediated signaling. Molecular pharmacology, 2001. 
60(5): p. 1133-1142. 
316. Weller, K. and M. Maurer, Desloratadine inhibits human skin mast cell activation and histamine 
release. The Journal of investigative dermatology, 2009. 129(11): p. 2723. 
317. Chishty, M., et al., Affinity for the P-glycoprotein efflux pump at the blood-brain barrier may 
explain the lack of CNS side-effects of modern antihistamines. Journal of drug targeting, 2001. 
9(3): p. 223-228. 
318. Timmerman, H., Factors involved in the absence of sedative effects by the second-generation 
antihistamines. ALLERGY-COPENHAGEN-SUPPLEMENT-, 2000. 55: p. 5-10. 
319. Chen, C., et al., P-glycoprotein limits the brain penetration of nonsedating but not sedating H1-
antagonists. Drug Metabolism and Disposition, 2003. 31(3): p. 312-318. 
320. Machado, O.L.T., D.M. de CamposMesquita, and T. PachecoSoares, Antihistaminic Treatment, 
Allergen Specific Immunotherapy, and Blockade of IgE as Alternative Allergy Treatments. 
Allergen, 2017: p. 67. 
321. Church, M.K. and D.S. Church, Pharmacology of antihistamines. Indian journal of dermatology, 
2013. 58(3): p. 219. 
 212 
322. Tashiro, M., et al., Roles of histamine in regulation of arousal and cognition: functional 
neuroimaging of histamine H1 receptors in human brain. Life sciences, 2002. 72(4-5): p. 409-414. 
323. Gelotte, C.K., B.A. Zimmerman, and G.A. Thompson, SingleDose Pharmacokinetic Study of 
Diphenhydramine HCl in Children and Adolescents. Clinical pharmacology in drug development, 
2018. 7(4): p. 400-407. 
324. BD Simplist, Diphenhydramine Hydrochloride Injection, USP. 2010. 
325. Banerji, A., A.A. Long, and C.A. Camargo Jr. Diphenhydramine versus nonsedating antihistamines 
for acute allergic reactions: A literature review. in Allergy & Asthma Proceedings. 2007. 
326. Edwards, R.J., C.-T. Huang, and N.-M. Pui, Long acting dual release product containing 
carbinoxamine and pseudoephedrine. 2016, Google Patents. 
327. Food and Drug Administration, HIGHLIGHTS OF PRESCRIBING INFORMATION: Karbinal ER. 2013. 
328. FDA. Arbinoxa Oral Solution. 2020; Available from: https://www.drugs.com/pro/arbinoxa-oral-
solution.html. 
329. Goindi, S., B. Dhatt, and A. Kaur, Ethosomes-based topical delivery system of antihistaminic drug 
for treatment of skin allergies. Journal of microencapsulation, 2014. 31(7): p. 716-724. 
330. Zemtsov, A. and H. Hosier, A Novel Vehicle Formulation for Treatment of Inflammatory Skin 
Diseases. Journal of Cosmetics, Dermatological Sciences and Applications, 2013. 3(01): p. 18. 
331. Salib, R.J. and P.H. Howarth, Safety and tolerability profiles of intranasal antihistamines and 
intranasal corticosteroids in the treatment of allergic rhinitis. Drug Safety, 2003. 26(12): p. 863-
893. 
332. Hampel, F.C., et al., Double-blind, placebo-controlled study of azelastine and fluticasone in a single 
nasal spray delivery device. Annals of Allergy, Asthma & Immunology, 2010. 105(2): p. 168-173. 
333. Food and Drug Administration, ASTELIN - azelastine hydrochloride spray, metered 2011. 
334. Shin, S.-C. and M.-K. Yoon, Application of TPX polymer membranes for the controlled release of 
triprolidine. International journal of pharmaceutics, 2002. 232(1-2): p. 131-137. 
335. Hindmarch, I. and Z. Shamsi, Antihistamines: models to assess sedative properties, assessment of 
sedation, safety and other sideeffects. Clinical & Experimental Allergy, 1999. 29: p. 133-142. 
336. Jain, G.K., A. Rampal, and H. Sen, Process for the preparation of a controlled drug delivery system 
containing pseudoephedrine and a long acting antihistamine. 2001, Google Patents. 
337. Rabinowitz, J.D. and A.C. Zaffaroni, Delivery of antihistamines through an inhalation route. 2004, 
Google Patents. 
338. Gu, X., et al., Evaluation and comparison of five matrix excipients for the controlled release of 
acrivastine and pseudoephedrine. Drug development and industrial pharmacy, 2004. 30(10): p. 
1009-1017. 
339. Rossi, A., et al., A preliminary study on topical cetirizine in the therapeutic management of 
androgenetic alopecia. Journal of Dermatological Treatment, 2018. 29(2): p. 149-151. 
340. Elzainy, A.A., et al., Cetirizine from topical phosphatidylcholine-hydrogenated liposomes: 
evaluation of peripheral antihistaminic activity and systemic absorption in a rabbit model. The 
AAPS journal, 2004. 6(3): p. 7-12. 
341. Shin, S.-C. and H.-J. Lee, Controlled release of triprolidine using ethylene-vinyl acetate membrane 
and matrix systems. European journal of pharmaceutics and biopharmaceutics, 2002. 54(2): p. 
201-206. 
342. Ramachandran, S., S. Nandhakumar, and M.D. Dhanaraju, Formulation and characterization of 
glutaraldehyde cross-linked chitosan biodegradable microspheres loaded with famotidine. 
Tropical Journal of Pharmaceutical Research, 2011. 10(3). 
 213 
343. Bize, C., et al., Bioactive Formulations with SugarDerived Surfactants: A New Approach for 
Photoprotection and Controlled Release of Promethazine. ChemPhysChem, 2013. 14(6): p. 1126-
1131. 
344. Dian, L., et al., Cubic phase nanoparticles for sustained release of ibuprofen: formulation, 
characterization, and enhanced bioavailability study. International journal of nanomedicine, 2013. 
8: p. 845. 
345. Hundekar, Y.R., et al., Preparation and evaluation of diclofenac sodium cubosomes for 
percutaneous administration. World journal of pharmacy and pharmaceutical sciences, 2014. 
3(1): p. 523-539. 
346. Müller, R., E. Souto, and M. Radtke, Medicament vehicle for the controlled administration of an 
active agent, produced from lipid matrix-medicament conjugates, in WO00/67800. 2000. 
347. Chang, C.-M. and R. Bodmeier, Monoglyceride based liquid crystalline topical drug delivery 
systems. Pharm. Res., 1994. 11: p. S185. 
348. Du Buske, L.M., Clinical comparison of histamine H1–receptor antagonist drugs. Journal of allergy 
and clinical immunology, 1996. 98(6): p. S307-S318. 
349. Wu, H., et al., A novel small Odorranalectin-bearing cubosomes: Preparation, brain delivery and 
pharmacodynamic study on amyloid-β25–35-treated rats following intranasal administration. 
European Journal of Pharmaceutics and Biopharmaceutics, 2012. 80(2): p. 368-378. 
350. Boge, L., Lipid-based liquid crystals as drug delivery vehicles for antimicrobial peptides. 2018: 
Department of Chemistry and Chemical Engineering, Chalmers University of …. 
351. Filik, J., et al., Processing two-dimensional X-ray diffraction and small-angle scattering data in 
DAWN 2. Journal of applied crystallography, 2017. 50(3): p. 959-966. 
352. Briggs, J., H. Chung, and M. Caffrey, The temperature-composition phase diagram and mesophase 
structure characterization of the monoolein/water system. Journal de Physique II, 1996. 6(5): p. 
723-751. 
353. Zhou, X.E., et al., X-ray laser diffraction for structure determination of the rhodopsin-arrestin 
complex. Scientific data, 2016. 3: p. 160021. 
354. Turner, D.C., et al., Structural study of the inverted cubic phases of di-dodecyl alkyl-β-D-
glucopyranosyl-rac-glycerol. Journal de Physique II, 1992. 2(11): p. 2039-2063. 
355. Prosperi-Porta, G., et al., Phenylboronic-acid-based polymeric micelles for mucoadhesive anterior 
segment ocular drug delivery. Biomacromolecules, 2016. 17(4): p. 1449-1457. 
356. Martinac, A., et al., Development and bioadhesive properties of chitosan-ethylcellulose 
microspheres for nasal delivery. International journal of pharmaceutics, 2005. 291(1-2): p. 69-77. 
357. Farid, R.M., et al., Formulation and in vitro evaluation of salbutamol sulphate in situ gelling nasal 
inserts. Aaps Pharmscitech, 2013. 14(2): p. 712-718. 
358. Hasan, S., et al., Controlled-release formulation of antihistamine based on cetirizine zinc-layered 
hydroxide nanocomposites and its effect on histamine release from basophilic leukemia (RBL-2H3) 
cells. International Journal of Nanomedicine, 2012. 7: p. 3351. 
359. Nazaruk, E., et al., Design and assembly of pH-sensitive lipidic cubic phase matrices for drug release. 
Langmuir, 2014. 30(5): p. 1383-1390. 
360. Caboi, F., et al., Structural effects, mobility, and redox behavior of vitamin K1 hosted in the 
monoolein/water liquid crystalline phases. Langmuir, 1997. 13(20): p. 5476-5483. 
361. Yaghmur, A., et al., Tuning curvature and stability of monoolein bilayers by designer lipid-like 
peptide surfactants. PLoS One, 2007. 2(5). 
362. Borné, J., T. Nylander, and A. Khan, Phase behavior and aggregate formation for the aqueous 
monoolein system mixed with sodium oleate and oleic acid. Langmuir, 2001. 17(25): p. 7742-7751. 
363. Hyde, S., et al., The language of shape: the role of curvature in condensed matter: physics, 
chemistry and biology. 1996: Elsevier. 
 214 
364. Kim, H., Z. Song, and C. Leal, Super-swelled lyotropic single crystals. Proceedings of the National 
Academy of Sciences, 2017. 114(41): p. 10834-10839. 
365. Larsson, K. and F. Tiberg, Periodic minimal surface structures in bicontinuous lipid–water phases 
and nanoparticles. Current opinion in colloid & interface science, 2005. 9(6): p. 365-369. 
366. Hyde, S.T., Bicontinuous structures in lyotropic liquid crystals and crystalline hyperbolic surfaces. 
Current Opinion in Solid State and Materials Science, 1996. 1(5): p. 653-662. 
367. Johnsson, M., J. Barauskas, and F. Tiberg, Cubic phases and cubic phase dispersions in a 
phospholipid-based system. Journal of the American Chemical Society, 2005. 127(4): p. 1076-1077. 
368. Tenchov, B., R. Koynova, and G. Rapp, Accelerated formation of cubic phases in 
phosphatidylethanolamine dispersions. Biophysical journal, 1998. 75(2): p. 853-866. 
369. Angelov, B., et al., Long-living intermediates during a lamellar to a diamond-cubic lipid phase 
transition: a small-angle X-ray scattering investigation. Langmuir, 2009. 25(6): p. 3734-3742. 
370. Nakano, M., et al., Small-angle X-ray scattering and 13C NMR investigation on the internal 
structure of “cubosomes”. Langmuir, 2001. 17(13): p. 3917-3922. 
371. Yaghmur, A., et al., Self-assembly in monoelaidin aqueous dispersions: direct vesicles to 
cubosomes transition. PLoS One, 2008. 3(11). 
372. Nakano, M., et al., Dispersions of liquid crystalline phases of the monoolein/oleic acid/Pluronic 
F127 system. Langmuir, 2002. 18(24): p. 9283-9288. 
373. Sagalowicz, L., et al., Crystallography of dispersed liquid crystalline phases studied by cryo
transmission electron microscopy. Journal of microscopy, 2006. 221(2): p. 110-121. 
374. Falchi, A.M., et al., Effects of monoolein-based cubosome formulations on lipid droplets and 
mitochondria of HeLa cells. Toxicology Research, 2015. 4(4): p. 1025-1036. 
375. Mozafari, M., Nanoliposomes: preparation and analysis, in Liposomes. 2010, Springer. p. 29-50. 
376. Sou, K., Electrostatics of carboxylated anionic vesicles for improving entrapment capacity. 
Chemistry and physics of lipids, 2011. 164(3): p. 211-215. 
377. Han, S., et al., Novel vehicle based on cubosomes for ophthalmic delivery of flurbiprofen with low 
irritancy and high bioavailability. Acta Pharmacologica Sinica, 2010. 31(8): p. 990-998. 
378. Levy, M., et al., Characterization of diazepam submicron emulsion interface: role of oleic acid. 
Journal of microencapsulation, 1994. 11(1): p. 79-92. 
379. Freitas, C. and R.H. Müller, Effect of light and temperature on zeta potential and physical stability 
in solid lipid nanoparticle (SLN™) dispersions. International journal of pharmaceutics, 1998. 
168(2): p. 221-229. 
380. Barriga, H.M., M.N. Holme, and M.M. Stevens, Cubosomes: the next generation of smart lipid 
nanoparticles? Angewandte Chemie International Edition, 2019. 58(10): p. 2958-2978. 
381. Tilley, A.J., C.J. Drummond, and B.J. Boyd, Disposition and association of the steric stabilizer 
Pluronic® F127 in lyotropic liquid crystalline nanostructured particle dispersions. Journal of colloid 
and interface science, 2013. 392: p. 288-296. 
382. Guo, C., et al., Lyotropic liquid crystal systems in drug delivery. Drug discovery today, 2010. 15(23-
24): p. 1032-1040. 
383. Nafee, N., et al., Relevance of the colloidal stability of chitosan/PLGA nanoparticles on their 
cytotoxicity profile. International journal of pharmaceutics, 2009. 381(2): p. 130-139. 
384. Selvi, R.B., et al., ATP driven clathrin dependent entry of carbon nanospheres prefer cells with 
glucose receptors. Journal of nanobiotechnology, 2012. 10(1): p. 35. 
385. Chung, T.-H., et al., The effect of surface charge on the uptake and biological function of 
mesoporous silica nanoparticles in 3T3-L1 cells and human mesenchymal stem cells. Biomaterials, 
2007. 28(19): p. 2959-2966. 
 215 
386. Zhang, D., et al., The morphology and surface charge-dependent cellular uptake efficiency of 
upconversion nanostructures revealed by single-particle optical microscopy. Chemical science, 
2018. 9(23): p. 5260-5269. 
387. Wilhelm, C., et al., Intracellular uptake of anionic superparamagnetic nanoparticles as a function 
of their surface coating. Biomaterials, 2003. 24(6): p. 1001-1011. 
388. Lorenz, M.R., et al., Uptake of functionalized, fluorescent-labeled polymeric particles in different 
cell lines and stem cells. Biomaterials, 2006. 27(14): p. 2820-2828. 
389. Sahay, G., D.Y. Alakhova, and A.V. Kabanov, Endocytosis of nanomedicines. Journal of controlled 
release, 2010. 145(3): p. 182-195. 
390. Martins, S., et al., Solid lipid nanoparticles as intracellular drug transporters: an investigation of 
the uptake mechanism and pathway. International journal of pharmaceutics, 2012. 430(1-2): p. 
216-227. 
391. Ravi, P.R., et al., Lipid nanoparticles for oral delivery of raloxifene: optimization, stability, in vivo 
evaluation and uptake mechanism. European journal of pharmaceutics and biopharmaceutics, 
2014. 87(1): p. 114-124. 
392. Kam, N.W.S., Z. Liu, and H. Dai, Carbon nanotubes as intracellular transporters for proteins and 
DNA: an investigation of the uptake mechanism and pathway. Angewandte Chemie International 
Edition, 2006. 45(4): p. 577-581. 
393. Thurn, K.T., et al., Endocytosis of titanium dioxide nanoparticles in prostate cancer PC-3M cells. 
Nanomedicine: Nanotechnology, Biology and Medicine, 2011. 7(2): p. 123-130. 
394. Yang, Z., et al., Evaluating the potential of cubosomal nanoparticles for oral delivery of 
amphotericin B in treating fungal infection. International journal of nanomedicine, 2014. 9: p. 327. 
395. Prange, J.A., et al., Overcoming endocytosis deficiency by cubosome nanocarriers. ACS Applied Bio 
Materials, 2019. 2(6): p. 2490-2499. 
396. Luo, Q., et al., A novel glyceryl monoolein-bearing cubosomes for gambogenic acid: preparation, 
cytotoxicity and intracellular uptake. International journal of pharmaceutics, 2015. 493(1-2): p. 
30-39. 
397. Fröhlich, E., The role of surface charge in cellular uptake and cytotoxicity of medical nanoparticles. 
International journal of nanomedicine, 2012. 7: p. 5577. 
398. Pelle, E., et al., Identification of histamine receptors and reduction of squalene levels by an 
antihistamine in sebocytes. Journal of investigative dermatology, 2008. 128(5): p. 1280-1285. 
399. Snyder, R.D. and J.W. Green, A review of the genotoxicity of marketed pharmaceuticals. Mutation 
Research/Reviews in Mutation Research, 2001. 488(2): p. 151-169. 
400. Ellegaard, A.-M., et al., Repurposing cationic amphiphilic antihistamines for cancer treatment. 
EBioMedicine, 2016. 9: p. 130-139. 
401. Salimi, A., M. Razian, and J. Pourahmad, Analysis of toxicity effects of buspirone, cetirizine and 
olanzapine on human blood lymphocytes: in vitro model. Current clinical pharmacology, 2018. 
13(2): p. 120-127. 
402. Rosa, A., et al., Monoolein-based cubosomes affect lipid profile in HeLa cells. Chemistry and 
physics of lipids, 2015. 191: p. 96-105. 
403. Eldem, T. and P. Speiser, Intestinal fat absorption and its relevance in lipid drug delivery systems. 
Pharmazie, 1989. 44(7): p. 444-447. 
404. Illum, L., Nasal drug delivery—possibilities, problems and solutions. Journal of controlled release, 
2003. 87(1-3): p. 187-198. 
405. Mura, P., et al., In situ mucoadhesive-thermosensitive liposomal gel as a novel vehicle for nasal 
extended delivery of opiorphin. European Journal of Pharmaceutics and Biopharmaceutics, 2018. 
122: p. 54-61. 
 216 
406. Campbell, C., et al., Drug development of intranasally delivered peptides. Therapeutic Delivery, 
2012. 3(4): p. 557-568. 
407. Ghori, M.U., et al., Nasal drug delivery systems: an overview. American Journal of Pharmacological 
Sciences, 2015. 3(5): p. 110-119. 
408. Lochhead, J.J. and R.G. Thorne, Intranasal delivery of biologics to the central nervous system. 
Advanced drug delivery reviews, 2012. 64(7): p. 614-628. 
409. Kim, Y.S. and S.B. Ho, Intestinal goblet cells and mucins in health and disease: recent insights and 
progress. Current gastroenterology reports, 2010. 12(5): p. 319-330. 
410. Bøgh, M., et al., Mucosal drug delivery: barriers, in vitro models and formulation strategies. 
Journal of Drug Delivery Science and Technology, 2013. 23(4): p. 383-391. 
411. Thornton, D.J. and J.K. Sheehan, From mucins to mucus: toward a more coherent understanding 
of this essential barrier. Proceedings of the American Thoracic Society, 2004. 1(1): p. 54-61. 
412. Li, L.D., et al., Spatial configuration and composition of charge modulates transport into a mucin 
hydrogel barrier. Biophysical journal, 2013. 105(6): p. 1357-1365. 
413. Bravo-Osuna, I., et al., Interfacial interaction between transmembrane ocular mucins and adhesive 
polymers and dendrimers analyzed by surface plasmon resonance. Pharmaceutical research, 2012. 
29(8): p. 2329-2340. 
414. Joergensen, L., et al., New insights into the mucoadhesion of pectins by AFM roughness 
parameters in combination with SPR. International journal of pharmaceutics, 2011. 411(1-2): p. 
162-168. 
415. Zeng, W., et al., Hyaluronic acid-coated niosomes facilitate tacrolimus ocular delivery: 
Mucoadhesion, precorneal retention, aqueous humor pharmacokinetics, and transcorneal 
permeability. Colloids and Surfaces B: Biointerfaces, 2016. 141: p. 28-35. 
416. Bansil, R., E. Stanley, and J.T. LaMont, Mucin biophysics. Annual review of physiology, 1995. 57(1): 
p. 635-657. 
417. Bhaskar, K.R., et al., Viscous fingering of HCI through gastric mucin. Nature, 1992. 360(6403): p. 
458-461. 
418. Ugwoke, M.I., et al., Nasal mucoadhesive drug delivery: background, applications, trends and 
future perspectives. Advanced drug delivery reviews, 2005. 57(11): p. 1640-1665. 
419. Jiang, L., et al., The application of mucoadhesive polymers in nasal drug delivery. Drug 
development and industrial pharmacy, 2010. 36(3): p. 323-336. 
420. Morita, Y., N. Koyama, and S. Ohsawa, Methods employing stable preparation containing 
azelastine hydrochloride. 2000, Google Patents. 
421. Wang, C., S. Hu, and C.C. Sun, Expedited development of diphenhydramine orally disintegrating 
tablet through integrated crystal and particle engineering. Molecular pharmaceutics, 2017. 
14(10): p. 3399-3408. 
422. Van Eeckhaut, A., et al., Influence of methanol on the enantioresolution of antihistamines with 
carboxymethylcyclodextrin in capillary electrophoresis. Electrophoresis, 2004. 25(16): p. 
2838-2847. 
423. Bajerski, L., et al., Determination of cetirizine in tablets and compounded capsules: comparative 
study between CE and HPLC. Química Nova, 2010. 33(1): p. 114-118. 
424. Wang, C., et al., Relationships among crystal structures, mechanical properties, and tableting 
performance probed using four salts of diphenhydramine. Crystal Growth & Design, 2017. 17(11): 
p. 6030-6040. 
425. Reddy, M., et al., Polymorphic forms of dihydrochloride salts of cetirizine and processes for 
preparation thereof. 2004, Google Patents. 
426. Maccaroni, E., et al., Azelastine hydrochloride: A powder diffraction and 13C CPMAS NMR study 
of its anhydrous and solvated forms. Crystal Growth and Design, 2009. 9(1): p. 517-524. 
 217 
427. Deng, Y., et al., Studies on the in vitro ion exchange kinetics and thermodynamics and in vivo 
pharmacokinetics of the carbinoxamine-resin complex. International Journal of Pharmaceutics, 
2020. 588: p. 119779. 
428. Dully, M., et al., Modulating the Release of Pharmaceuticals from Lipid Cubic Phases using a Lipase 
Inhibitor. Journal of Colloid and Interface Science, 2020(573): p. 176-192. 
429. Hatefi, Y. and W. Hanstein, Destabilization of membranes with chaotropic ions, in Methods in 
enzymology. 1974, Elsevier. p. 770-790. 
430. Hyde, A.M., et al., General principles and strategies for salting-out informed by the Hofmeister 
series. Organic Process Research & Development, 2017. 21(9): p. 1355-1370. 
431. Lo Nostro, P. and B.W. Ninham, Hofmeister phenomena: an update on ion specificity in biology. 
Chemical reviews, 2012. 112(4): p. 2286-2322. 
432. Brasnett, C., et al., Effects of cations on the behaviour of lipid cubic phases. Scientific reports, 2017. 
7(1): p. 1-7. 
433. Nguyen, T.-H., et al., Nanostructured liquid crystalline particles provide long duration sustained-
release effect for a poorly water soluble drug after oral administration. Journal of controlled 
release, 2011. 153(2): p. 180-186. 
434. Vervaeck, A., et al., Prilling of fatty acids as a continuous process for the development of controlled 
release multiparticulate dosage forms. European journal of pharmaceutics and biopharmaceutics, 
2013. 85(3): p. 587-596. 
435. Clogston, J., et al., Controlling release from the lipidic cubic phase by selective alkylation. Journal 
of controlled release, 2005. 102(2): p. 441-461. 
436. Togias, A.G., et al., Demonstration of inhibition of mediator release from human mast cells by 
azatadine base: in vivo and in vitro evaluation. JAMA, 1986. 255(2): p. 225-229. 
437. Lichtenstein, L.M. and E. Gillespie, The effects of the H1 and H2 antihistamines on" allergic" 
histamine release and its inhibition by histamine. Journal of Pharmacology and Experimental 
Therapeutics, 1975. 192(2): p. 441-450. 
438. Nadler, M., et al., Signal transduction by the high-affinity immunoglobulin E receptor FcRI: 
coupling form to function. Adv. Immunol, 2000. 76: p. 325-355. 
439. Kitani, S., et al., Inhibition of IgE-mediated histamine release by myosin light chain kinase inhibitors. 
Biochemical and biophysical research communications, 1992. 183(1): p. 48-54. 
440. Hanifin, J.M., The role of antihistamines in atopic dermatitis. Journal of allergy and clinical 
immunology, 1990. 86(4): p. 666-669. 
441. Michel, L., C. De Vos, and L. Dubertret, Cetirizine effects on the cutaneous allergic reaction in 
humans. Annals of allergy, 1990. 65(6): p. 512. 
442. Church, M.K. and C.F. GRADIDGE, Inhibition of histamine release from human lung in vitro by 
antihistamines and related drugs. British journal of pharmacology, 1980. 69(4): p. 663-667. 
443. Vannieuwenhuyse, E., et al., Double-blind placebo-controlled clinical evaluation of oxatimide (R 
35443). A novel potent anti-allergic drug in the treatment of hay fever. Acta allergologica, 1977. 
32(4): p. 278-289. 
444. De Clerck, F., et al., Oxatomide protectsTrichinella spiralis infected mice from lethal anaphylaxis. 
Agents and actions, 1978. 8(6): p. 568-571. 
445. Little, M.M. and T.B. Casale, Azelastine inhibits IgE-mediated human basophil histamine release. 
Journal of allergy and clinical immunology, 1989. 83(5): p. 862-865. 
446. Katayama, S., Anti-allergic effect of azelastine hydrochloride on immediate type hypersensitivity 
reactions in vivo and in vitro. 1981. 
447. Chand, N., et al., Inhibition of IgE-mediated allergic histamine release from rat peritoneal mast 
cells by azelastine and selected antiallergic drugs. Agents and actions, 1985. 16(5): p. 318-322. 
 218 
448. Fischer, B. and W. Schmutzler, Inhibition by azelastine of the immunologically induced histamine 
release from isolated guinea pig mast cells. Arzneimittel-forschung, 1981. 31(8): p. 1193-1195. 
449. Seddon, J., Inverse cubic phases of membrane-lipids, and their relevance to the static and dynamic 
structure of biomembranes. Acta Pharm, 1992. 42(4): p. 255-62. 
450. Blijleven, J.S., et al. Mechanisms of influenza viral membrane fusion. in Seminars in cell & 
developmental biology. 2016. Elsevier. 
451. Michaelsen, M.H., et al., The effect of digestion and drug load on halofantrine absorption from 
self-nanoemulsifying drug delivery system (SNEDDS). The AAPS journal, 2016. 18(1): p. 180-186. 
452. Feeney, O.M., et al., ‘Stealth’lipid-based formulations: poly (ethylene glycol)-mediated digestion 
inhibition improves oral bioavailability of a model poorly water soluble drug. Journal of Controlled 
Release, 2014. 192: p. 219-227. 
453. Tran, T., et al., In vitro and in vivo performance of monoacyl phospholipid-based self-emulsifying 
drug delivery systems. Journal of Controlled Release, 2017. 255: p. 45-53. 
454. Li, Y. and D.J. McClements, Inhibition of lipase-catalyzed hydrolysis of emulsified triglyceride oils 
by low-molecular weight surfactants under simulated gastrointestinal conditions. European 
journal of pharmaceutics and biopharmaceutics, 2011. 79(2): p. 423-431. 
455. Wulff-Pérez, M., et al., Controlling lipolysis through steric surfactants: new insights on the 
controlled degradation of submicron emulsions after oral and intravenous administration. 
International journal of pharmaceutics, 2012. 423(2): p. 161-166. 
456. Hadvary, P., H. Lengsfeld, and H. Wolfer, Inhibition of pancreatic lipase in vitro by the covalent 
inhibitor tetrahydrolipstatin. Biochemical Journal, 1988. 256(2): p. 357-361. 
457. Gargouri, Y., et al., Inactivation of pancreatic and gastric lipases by THL and C12: 0-TNB: a kinetic 
study with emulsified tributyrin. Biochimica et Biophysica Acta (BBA)-Lipids and Lipid Metabolism, 
1991. 1085(3): p. 322-328. 
458. Heck, A.M., J.A. Yanovski, and K.A. Calis, Orlistat, a new lipase inhibitor for the management of 
obesity. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2000. 20(3): 
p. 270-279. 
459. Drent, M.L. and E.A. van der Veen, First clinical studies with orlistat: a short review. Obesity 
research, 1995. 3(S4): p. 623S-625S. 
460. Lee, M.W., F.B. Kraemer, and D.L. Severson, Characterization of a partially purified diacylglycerol 
lipase from bovine aorta. Biochimica et Biophysica Acta (BBA)-Lipids and Lipid Metabolism, 1995. 
1254(3): p. 311-318. 
461. McNeely, W. and P. Benfield, Orlistat. Drugs, 1998. 56(2): p. 241-9; discussion 250. 
462. Lookene, A., N. Skottova, and G. Olivecrona, Interactions of lipoprotein lipase with the active
site inhibitor tetrahydrolipstatin (Orlistat) R. European journal of biochemistry, 1994. 222(2): p. 
395-403. 
463. Lawson, D., A. Brzozowski, and G. Dodson, Lifting the lid off lipases. Curr. Biol, 1992. 2: p. 473-475. 
464. Hadvary, P., et al., The lipase inhibitor tetrahydrolipstatin binds covalently to the putative active 
site serine of pancreatic lipase. Journal of Biological Chemistry, 1991. 266(4): p. 2021-2027. 
465. Lüthi-Peng, Q., H.P. Märki, and P. Hadváry, Identification of the active-site serine in human 
pancreatic lipase by chemical modification with tetrahydrolipstatin. FEBS letters, 1992. 299(1): p. 
111-115. 
466. Borgström, B., Mode of action of tetrahydrolipstatin: a derivative of the naturally occurring lipase 
inhibitor lipstatin. Biochimica et Biophysica Acta (BBA)-Lipids and Lipid Metabolism, 1988. 962(3): 
p. 308-316. 
467. Carrière, F., et al., Inhibition of gastrointestinal lipolysis by Orlistat during digestion of test meals 
in healthy volunteers. American Journal of Physiology-Gastrointestinal and Liver Physiology, 2001. 
281(1): p. G16-G28. 
 219 
468. Human Metabolome Database (HMDB). Orlistat. Available from: 
http://www.hmdb.ca/metabolites/HMDB0015215. 
469. Tiss, A., et al., Transfer of orlistat through oil–water interfaces. Chemistry and physics of lipids, 
2002. 119(1-2): p. 41-49. 
470. Tiss, A., et al., Surface behaviour of bile salts and tetrahydrolipstatin at air/water and oil/water 
interfaces. Chemistry and physics of lipids, 2001. 111(1): p. 73-85. 
471. Bannigan, P., et al., Role of biorelevant dissolution media in the selection of optimal Salt forms of 
oral drugs: maximizing the gastrointestinal solubility and in vitro activity of the antimicrobial 
molecule, clofazimine. ACS omega, 2017. 2(12): p. 8969-8981. 
472. Shakeel, F. and W. Ramadan, Transdermal delivery of anticancer drug caffeine from water-in-oil 
nanoemulsions. Colloids and Surfaces B: Biointerfaces, 2010. 75(1): p. 356-362. 
473. Azhari, H., et al., Stabilising cubosomes with Tween 80 as a step towards targeting lipid 
nanocarriers to the blood–brain barrier. European Journal of Pharmaceutics and 
Biopharmaceutics, 2016. 104: p. 148-155. 
474. Dombrowski, R., Microscopy techniques for analyzing the phase nature and morphology of 
biomaterials, in Characterization of Biomaterials. 2013, Elsevier. p. 1-33. 
475. Lutton, E., Phase behavior of aqueous systems of monoglycerides. Journal of the American Oil 
Chemists Society, 1965. 42(12): p. 1068-1070. 
476. Conn, C.E., et al., High-throughput analysis of the structural evolution of the monoolein cubic 
phase in situ under crystallogenesis conditions. Soft Matter, 2012. 8(7): p. 2310-2321. 
477. Cherezov, V., K.M. Riedl, and M. Caffrey, Too hot to handle? Synchrotron X-ray damage of lipid 
membranes and mesophases. Journal of synchrotron radiation, 2002. 9(6): p. 333-341. 
478. van‘t Hag, L., et al., Lyotropic liquid crystal engineering moving beyond binary compositional 
space–ordered nanostructured amphiphile self-assembly materials by design. Chemical society 
reviews, 2017. 46(10): p. 2705-2731. 
479. Rand, R., et al., Membrane curvature, lipid segregation, and structural transitions for 
phospholipids under dual-solvent stress. Biochemistry, 1990. 29(1): p. 76-87. 
480. Templer, R.H., B.J. Khoo, and J.M. Seddon, Gaussian curvature modulus of an amphiphilic 
monolayer. Langmuir, 1998. 14(26): p. 7427-7434. 
481. Edwards, H.G., et al., Metamorphosis of caffeine hydrate and anhydrous caffeine. Journal of the 
Chemical Society, Perkin Transactions 2, 1997(10): p. 1985-1990. 
482. Patton, J.S., et al., The light microscopy of triglyceride digestion. Food Structure, 1985. 4(1): p. 5. 
483. Kirchgessner, T.G., et al., Organization of the human lipoprotein lipase gene and evolution of the 
lipase gene family. Proceedings of the National Academy of Sciences, 1989. 86(24): p. 9647-9651. 
484. Mukherjee, M., Human digestive and metabolic lipases—a brief review. Journal of Molecular 
Catalysis B: Enzymatic, 2003. 22(5-6): p. 369-376. 
485. Warren, D.B., et al., Real time evolution of liquid crystalline nanostructure during the digestion of 
formulation lipids using synchrotron small-angle X-ray scattering. Langmuir, 2011. 27(15): p. 
9528-9534. 
486. Lynch, M.L., et al., Enhanced loading of water-soluble actives into bicontinuous cubic phase liquid 
crystals using cationic surfactants. Journal of colloid and interface science, 2003. 260(2): p. 404-
413. 
487. Lindell, K., et al., Influence of a charged phospholipid on the release pattern of timolol maleate 
from cubic liquid crystalline phases. The Colloid Science of Lipids, 1998. 108: p. 111-118. 
488. Patel, V. and A. Misra, Encapsulation and stability of clofazimine liposomes. Journal of 
microencapsulation, 1999. 16(3): p. 357-367. 
 220 
489. O'Reilly, J.R., O.I. Corrigan, and C.M. O'Driscoll, The effect of simple micellar systems on the 
solubility and intestinal absorption of clofazimine (B663) in the anaesthetised rat. International 
journal of pharmaceutics, 1994. 105(2): p. 137-146. 
490. Azhari, H., Surface modified cubosomes for drug delivery across the blood-brain barrier. 2018, 
University of Otago. 
491. Stegemann, S., et al., When poor solubility becomes an issue: from early stage to proof of concept. 
European journal of pharmaceutical sciences, 2007. 31(5): p. 249-261. 
492. Kerns, E.H. and L. Di, Pharmaceutical profiling in drug discovery. Drug discovery today, 2003. 8(7): 
p. 316-323. 
493. Takagi, T., et al., A provisional biopharmaceutical classification of the top 200 oral drug products 
in the United States, Great Britain, Spain, and Japan. Molecular pharmaceutics, 2006. 3(6): p. 631-
643. 
494. Lipinski, C.A., et al., Experimental and computational approaches to estimate solubility and 
permeability in drug discovery and development settings. Advanced drug delivery reviews, 1997. 
23(1-3): p. 3-25. 
495. Di, L., P.V. Fish, and T. Mano, Bridging solubility between drug discovery and development. Drug 
discovery today, 2012. 17(9-10): p. 486-495. 
496. Di, L., E.H. Kerns, and G.T. Carter, Drug-like property concepts in pharmaceutical design. Current 
pharmaceutical design, 2009. 15(19): p. 2184-2194. 
497. Vo, C.L.-N., C. Park, and B.-J. Lee, Current trends and future perspectives of solid dispersions 
containing poorly water-soluble drugs. European journal of pharmaceutics and biopharmaceutics, 
2013. 85(3): p. 799-813. 
498. Fong, W.-K., T. Hanley, and B.J. Boyd, Stimuli responsive liquid crystals provide ‘on-demand’drug 
delivery in vitro and in vivo. Journal of Controlled Release, 2009. 135(3): p. 218-226. 
499. Fong, W.-K., et al., Plasmonic nanorods provide reversible control over nanostructure of self-
assembled drug delivery materials. Langmuir, 2010. 26(9): p. 6136-6139. 
500. Kwon, T.K. and J.-C. Kim, Monoolein cubic phase containing acidic proteinoid: pH-dependent 
release. Drug development and industrial pharmacy, 2011. 37(1): p. 56-61. 
501. Angelov, B., et al., Small-angle neutron and X-ray scattering from amphiphilic stimuli-responsive 
diamond-type bicontinuous cubic phase. Journal of the American Chemical Society, 2007. 129(44): 
p. 13474-13479. 
502. Liu, Z., et al., Cytotoxic and anti-angiogenic paclitaxel solubilized and permeation-enhanced by 
natural product nanoparticles. Anti-cancer drugs, 2015. 26(2): p. 167. 
503. Kavallaris, M., Microtubules and resistance to tubulin-binding agents. Nature Reviews Cancer, 
2010. 10(3): p. 194-204. 
504. Liggins, R.T., W. Hunter, and H.M. Burt, Solid-state characterization of paclitaxel. Journal of 
pharmaceutical sciences, 1997. 86(12): p. 1458-1463. 
505. Yao, H.-J., et al., The antitumor efficacy of functional paclitaxel nanomicelles in treating resistant 
breast cancers by oral delivery. Biomaterials, 2011. 32(12): p. 3285-3302. 
506. Chae, S.W., et al., Intestinal Pglycoprotein inhibitors, benzoxanthone analogues. Journal of 
Pharmacy and Pharmacology, 2018. 70(2): p. 234-241. 
507. Amin, M.L., P-glycoprotein inhibition for optimal drug delivery. Drug target insights, 2013. 7: p. 
DTI. S12519. 
508. Zeng, N., et al., Preparation and characterization of paclitaxel-loaded DSPE-PEG-liquid crystalline 
nanoparticles (LCNPs) for improved bioavailability. International journal of pharmaceutics, 2012. 
424(1-2): p. 58-66. 
 221 
509. Zeng, N., et al., Lipid-based liquid crystalline nanoparticles as oral drug delivery vehicles for poorly 
water-soluble drugs: cellular interaction and in vivo absorption. International journal of 
nanomedicine, 2012. 7: p. 3703. 
510. Green, M., et al., Abraxane®, a novel Cremophor®-free, albumin-bound particle form of paclitaxel 
for the treatment of advanced non-small-cell lung cancer. Annals of Oncology, 2006. 17(8): p. 
1263-1268. 
511. Zhang, J., et al., Polymeric nanoparticles based on chitooligosaccharide as drug carriers for co-
delivery of all-trans-retinoic acid and paclitaxel. Carbohydrate polymers, 2015. 129: p. 25-34. 
512. He, Y., et al., Mesoporous silica nanoparticles as potential carriers for enhanced drug solubility of 
paclitaxel. Materials Science and Engineering: C, 2017. 78: p. 12-17. 
513. Lundberg, B., et al., A lipophilic paclitaxel derivative incorporated in a lipid emulsion for parenteral 
administration. Journal of Controlled Release, 2003. 86(1): p. 93-100. 
514. Yang, X.-y., et al., Hyaluronic acid-coated nanostructured lipid carriers for targeting paclitaxel to 
cancer. Cancer letters, 2013. 334(2): p. 338-345. 
515. Yuan, H., et al., Cellular uptake of solid lipid nanoparticles and cytotoxicity of encapsulated 
paclitaxel in A549 cancer cells. International journal of pharmaceutics, 2008. 348(1-2): p. 137-145. 
516. Zhai, J., et al., Paclitaxel-loaded self-assembled lipid nanoparticles as targeted drug delivery 
systems for the treatment of aggressive ovarian cancer. ACS applied materials & interfaces, 2018. 
10(30): p. 25174-25185. 
517. Briggs, J., The phase behavior of hydrated monoacylglycerols and the design of an X-ray 
compatible scanning calorimeter. 1994, The Ohio State University. 
518. Lairon, D., et al., Effects of bile lipids on the adsorption and activity of pancreatic lipase on 
triacylglycerol emulsions. Biochimica et Biophysica Acta (BBA)-Lipids and Lipid Metabolism, 1980. 
618(1): p. 119-128. 
519. Kimura, H., et al., Activation of human pancreatic lipase activity by calcium and bile salts. The 
Journal of Biochemistry, 1982. 92(1): p. 243-251. 
520. Alvarez, F.J. and V.J. Stella, The role of calcium ions and bile salts on the pancreatic lipase-catalyzed 
hydrolysis of triglyceride emulsions stabilized with lecithin. Pharmaceutical research, 1989. 6(6): 
p. 449-457. 
521. Bläckberg, L., et al., Colipase enhances hydrolysis of dietary triglycerides in the absence of bile salts. 
The Journal of clinical investigation, 1979. 64(5): p. 1303-1308. 
522. Borgstrom, B., Binding of pancreatic colipase to interfaces: effects of detergents. FEBS Lett, 1976. 
71: p. 201-204. 
523. Vandermeers, A., et al., Effect of colipase on adsorption and activity of rat pancreatic lipase on 
emulsified tributyrin in the presence of bile salt. FEBS letters, 1975. 49(3): p. 334-337. 
524. Nilsson, C., et al., SPECT/CT imaging of radiolabeled cubosomes and hexosomes for potential 
theranostic applications. Biomaterials, 2013. 34(33): p. 8491-8503. 
525. Mealey, D., et al., Influence of solvent on crystal nucleation of risperidone. Faraday discussions, 
2015. 179: p. 309-328. 
526. Zeglinski, J., et al., Crystal nucleation of tolbutamide in solution: Relationship to solvent, solute 
conformation, and solution structure. Chemistry–A European Journal, 2018. 24(19): p. 4916-4926. 
527. Padrela, L., J. Zeglinski, and K.M. Ryan, Insight into the role of additives in controlling polymorphic 
outcome: A CO2-antisolvent crystallization process of carbamazepine. Crystal Growth & Design, 
2017. 17(9): p. 4544-4553. 
528. Grimme, S., S. Ehrlich, and L. Goerigk, Effect of the damping function in dispersion corrected 
density functional theory. Journal of computational chemistry, 2011. 32(7): p. 1456-1465. 
529. Rassolov, V.A., et al., 631G* basis set for thirdrow atoms. Journal of Computational Chemistry, 
2001. 22(9): p. 976-984. 
 222 
530. Goerigk, L. and S. Grimme, Efficient and Accurate Double-Hybrid-Meta-GGA Density Functionals
  Evaluation with the Extended GMTKN30 Database for General Main Group Thermochemistry, 
Kinetics, and Noncovalent Interactions. Journal of chemical theory and computation, 2011. 7(2): 
p. 291-309. 
531. Weigend, F. and R. Ahlrichs, Balanced basis sets of split valence, triple zeta valence and quadruple 
zeta valence quality for H to Rn: Design and assessment of accuracy. Physical Chemistry Chemical 
Physics, 2005. 7(18): p. 3297-3305. 
532. Hermoso, J., et al., Lipase activation by nonionic detergents. The crystal structure of the porcine 
lipase-colipase-tetraethylene glycol monooctyl ether complex. J Biol Chem, 1996. 271(30): p. 
18007-16. 
533. Khan, F.I., et al., The Lid Domain in Lipases: Structural and Functional Determinant of Enzymatic 
Properties. Front Bioeng Biotechnol, 2017. 5: p. 16. 
534. Lowe, M.E., Colipase stabilizes the lid domain of pancreatic triglyceride lipase. J Biol Chem, 1997. 
272(1): p. 9-12. 
535. Lowe, M.E., The catalytic site residues and interfacial binding of human pancreatic lipase. J Biol 
Chem, 1992. 267(24): p. 17069-73. 
536. Morris, G.M., et al., AutoDock4 and AutoDockTools4: Automated docking with selective receptor 
flexibility. J Comput Chem, 2009. 30(16): p. 2785-91. 
537. Editorial: ChemSpider--a tool for Natural Products research. Nat Prod Rep, 2015. 32(8): p. 1163-4. 
538. Morris, G.M., et al., Automated docking using a Lamarckian genetic algorithm and an empirical 
binding free energy function. Journal of computational chemistry, 1998. 19(14): p. 1639-1662. 
539. Huang, J., et al., CHARMM36m: an improved force field for folded and intrinsically disordered 
proteins. Nat Methods, 2017. 14(1): p. 71-73. 
540. Vanommeslaeghe, K., et al., CHARMM general force field: A force field for drug-like molecules 
compatible with the CHARMM all-atom additive biological force fields. J Comput Chem, 2010. 
31(4): p. 671-90. 
541. Yu, W., et al., Extension of the CHARMM General Force Field to sulfonyl-containing compounds 
and its utility in biomolecular simulations. J Comput Chem, 2012. 33(31): p. 2451-68. 
542. MacKerell, A.D., et al., All-atom empirical potential for molecular modeling and dynamics studies 
of proteins. J Phys Chem B, 1998. 102(18): p. 3586-616. 
543. Berendsen, H.J., D. van der Spoel, and R. van Drunen, GROMACS: a message-passing parallel 
molecular dynamics implementation. Computer physics communications, 1995. 91(1-3): p. 43-56. 
544. Van Der Spoel, D., et al., GROMACS: fast, flexible, and free. J Comput Chem, 2005. 26(16): p. 1701-
18. 
545. Hockney, R.W., The potential calculation and some applications. Methods Comput. Phys., 1970. 
9: p. 136. 
546. Hess, B., et al., LINCS: A linear constraint solver for molecular simulations. Journal of 
Computational Chemistry, 1997. 18(12): p. 1463-1472. 
547. Miyamoto, S. and P.A. Kollman, Settle: An analytical version of the SHAKE and RATTLE algorithm 
for rigid water models. Journal of Computational Chemistry, 1992. 13(8): p. 952-962. 
548. Darden, T., D. York, and L. Pedersen, Particle mesh Ewald: An N⋅ log (N) method for Ewald sums in 
large systems. The Journal of chemical physics, 1993. 98(12): p. 10089-10092. 
549. Bussi, G., D. Donadio, and M. Parrinello, Canonical sampling through velocity rescaling. J Chem 
Phys, 2007. 126(1): p. 014101. 
550. Berendsen, H.J., et al., Molecular dynamics with coupling to an external bath. The Journal of 
chemical physics, 1984. 81(8): p. 3684-3690. 
551. Parrinello, M. and A. Rahman, Polymorphic transitions in single crystals: A new molecular 
dynamics method. Journal of Applied Physics, 1981. 52(12): p. 7182-7190. 
 223 
552. Humphrey, W., A. Dalke, and K. Schulten, VMD: visual molecular dynamics. J Mol Graph, 1996. 
14(1): p. 33-38. 
553. Pettersen, E.F., et al., UCSF Chimera--a visualization system for exploratory research and analysis. 
J Comput Chem, 2004. 25(13): p. 1605-12. 
554. Kollman, P.A., et al., Calculating structures and free energies of complex molecules: combining 
molecular mechanics and continuum models. Acc Chem Res, 2000. 33(12): p. 889-97. 
555. Kumari, R., et al., g_mmpbsa--a GROMACS tool for high-throughput MM-PBSA calculations. J 
Chem Inf Model, 2014. 54(7): p. 1951-62. 
556. Aleksandrov, A., D. Thompson, and T. Simonson, Alchemical free energy simulations for biological 
complexes: powerful but temperamental. J Mol Recognit, 2010. 23(2): p. 117-27. 
557. Reyes, P., et al., Taxane coatings for implantable medical devices. 2012, Google Patents. 
558. Caboi, F., et al., NMR investigation on Melaleuca alternifolia essential oil dispersed in the 
monoolein aqueous system: phase behavior and dynamics. Langmuir, 2002. 18(21): p. 7916-7922. 
559. Bernstein, J., Polymorphism in Molecular Crystals 2e. Vol. 30. 2020: International Union of Crystal. 
560. Hilfiker, R., Polymorphism in the pharmaceutical industry. Vol. 308. 2006: Wiley Online Library. 
561. Yu, K., et al., Role of four different kinds of polyethylenimines (PEIs) in preparation of polymeric 
lipid nanoparticles and their anticancer activity study. Journal of Cancer, 2016. 7(7): p. 872. 
562. Pyo, S.-H., et al., Preparation and dissolution profiles of the amorphous, dihydrated crystalline, 
and anhydrous crystalline forms of paclitaxel. Drying Technology, 2007. 25(10): p. 1759-1767. 
563. Lv, Q., et al., Development and evaluation of penciclovir-loaded solid lipid nanoparticles for topical 
delivery. International journal of pharmaceutics, 2009. 372(1-2): p. 191-198. 
564. Liu, M., et al., Characterization and release of triptolide-loaded poly (D, L-lactic acid) nanoparticles. 
European polymer journal, 2005. 41(2): p. 375-382. 
565. Venkateswarlu, V. and K. Manjunath, Preparation, characterization and in vitro release kinetics of 
clozapine solid lipid nanoparticles. Journal of controlled release, 2004. 95(3): p. 627-638. 
566. Lee, J.H., et al., Preparation and characterization of solvent induced dihydrated, anhydrous, and 
amorphous paclitaxel. Bulletin of the Korean Chemical Society, 2001. 22(8): p. 925-928. 
567. Aleandri, S., et al., Biotinylated cubosomes: a versatile tool for active targeting and codelivery of 
paclitaxel and a fluorescein-based lipid dye. Langmuir, 2015. 31(46): p. 12770-12776. 
568. Yaghmur, A., et al., Emulsified microemulsions and oil-containing liquid crystalline phases. 
Langmuir, 2005. 21(2): p. 569-577. 
569. Barauskas, J., et al., Cubic phase nanoparticles (cubosome): principles for controlling size, structure, 
and stability. Langmuir, 2005. 21(6): p. 2569-2577. 
570. Sagalowicz, L., et al., Study of liquid crystal space groups using controlled tilting with cryogenic 
transmission electron microscopy. Langmuir, 2007. 23(24): p. 12003-12009. 
571. van Tilbeurgh, H., et al., Interfacial activation of the lipase-procolipase complex by mixed micelles 
revealed by X-ray crystallography. Nature, 1993. 362(6423): p. 814-20. 
572. Kratz, A., et al., Normal reference laboratory values. New England Journal of Medicine, 2004. 
351(15): p. 1548-1563. 
573. Olbrich, W.M. and R. Müller. Development of an in vitro degradation assay for solid lipid 
nanoparticles. in Proceeding 2 th world Meeting APGI/APV, Paris. 1998. 
574. Olbrich, C. and R. Müller, Enzymatic degradation of SLN—effect of surfactant and surfactant 
mixtures. International journal of pharmaceutics, 1999. 180(1): p. 31-39. 
575. Scow, R.O., Effect of sodium taurodeoxycholate, CaCl2 and albumin on the action of pancreatic 
lipase on droplets of trioleoylglycerol and the release of lipolytic products into aqueous media. 
Biochimie, 1988. 70(9): p. 1251-1261. 
 224 
576. Zangenberg, N.H., et al., A dynamic in vitro lipolysis model: I. Controlling the rate of lipolysis by 
continuous addition of calcium. European Journal of Pharmaceutical Sciences, 2001. 14(2): p. 115-
122. 
577. Hu, M., et al., Role of calcium and calcium-binding agents on the lipase digestibility of emulsified 
lipids using an in vitro digestion model. Food Hydrocolloids, 2010. 24(8): p. 719-725. 
578. Benzonana, G. and P. Desnuelle, Action of some effectors on the hydrolysis of long-chain 
triglycerides by pancreatic lipase. Biochimica et Biophysica Acta (BBA)-Lipids and Lipid Metabolism, 
1968. 164(1): p. 47-58. 
579. Wenk, M.R., et al., Paclitaxel partitioning into lipid bilayers. Journal of pharmaceutical sciences, 
1996. 85(2): p. 228-231. 
580. Alani, A.W., et al., Polymeric micelles for the pH-dependent controlled, continuous low dose 
release of paclitaxel. Biomaterials, 2010. 31(7): p. 1765-1772. 
581. Abouelmagd, S.A., et al., Release kinetics study of poorly water-soluble drugs from nanoparticles: 
are we doing it right? Molecular pharmaceutics, 2015. 12(3): p. 997-1003. 
582. Kulkarni, C.V., et al., Self-assembled lipid cubic phase and cubosomes for the delivery of aspirin as 
a model drug. Langmuir, 2017. 33(38): p. 9907-9915. 
583. Nazaruk, E., et al., Lyotropic cubic phases for drug delivery: diffusion and sustained release from 
the mesophase evaluated by electrochemical methods. Langmuir, 2015. 31(46): p. 12753-12761. 
584. Bender, J., et al., Lipid cubic phases in topical drug delivery: visualization of skin distribution using 
two-photon microscopy. Journal of Controlled Release, 2008. 129(3): p. 163-169. 
585. Lopes, L.B., et al., Liquid crystalline phases of monoolein and water for topical delivery of 
cyclosporin A: characterization and study of in vitro and in vivo delivery. European Journal of 
Pharmaceutics and Biopharmaceutics, 2006. 63(2): p. 146-155. 
586. Kar, M., et al., Current Developments in Excipient Science: Implication of Quantitative Selection of 
Each Excipient in Product Development, in Basic Fundamentals of Drug Delivery. 2019, Elsevier. p. 
29-83. 
587. Cheng, A., et al., A simple mechanical mixer for small viscous lipid-containing samples. Chemistry 
and Physics of Lipids, 1998. 95(1): p. 11-21. 
588. Caffrey, M. and C. Porter, Crystallizing membrane proteins for structure determination using lipidic 
mesophases. JoVE (Journal of Visualized Experiments), 2010(45): p. e1712-e1712. 
589. Nunes, K.M., et al., The Monoglyceride Content Affects the Self-Assembly Behavior, Rheological 
Properties, Syringeability, and Mucoadhesion of In Situ–Gelling Liquid Crystalline Phase. Journal 
of pharmaceutical sciences, 2016. 105(8): p. 2355-2364. 
590. Pham, A.C., et al., In vivo formation of cubic phase in situ after oral administration of cubic phase 
precursor formulation provides long duration gastric retention and absorption for poorly water-
soluble drugs. Molecular pharmaceutics, 2016. 13(1): p. 280-286. 
591. Esposito, E., et al., Comparative analysis of tetracycline-containing dental gels: poloxamer-and 
monoglyceride-based formulations. International journal of pharmaceutics, 1996. 142(1): p. 9-23. 
592. Geraghty, P.B., et al., The in vitro release of some antimuscarinic drugs from monoolein/water 
lyotropic liquid crystalline gels. Pharmaceutical research, 1996. 13(8): p. 1265-1271. 
593. Takahashi, H., A. Matsuo, and I. Hatta, Effects of chaotropic and kosmotropic solutes on the 
structure of lipid cubic phase: Monoolein-water systems. Molecular Crystals and Liquid Crystals 
Science and Technology. Section A. Molecular Crystals and Liquid Crystals, 2000. 347(1): p. 231-
238. 
594. Clogston, J., et al., Phase behavior of a monoacylglycerol:(myverol 18-99K)/water system. 
Chemistry and physics of lipids, 2000. 107(2): p. 191-220. 
595. Collins, K.D. and M.W. Washabaugh, The Hofmeister effect and the behaviour of water at 
interfaces. Quarterly reviews of biophysics, 1985. 18(4): p. 323-422. 
 225 
596. Sanderson, P.W., et al., The Hofmeister effect in relation to membrane lipid phase stability. 
Biochimica et Biophysica Acta (BBA)-Biomembranes, 1991. 1067(1): p. 43-50. 
597. Takahashi, H., H. Ohmae, and I. Hatta, Trehalose-induced destabilization of interdigitated gel 
phase in dihexadecylphosphatidylcholine. Biophysical journal, 1997. 73(6): p. 3030-3038. 
598. Hyde, S., Microstructure of bicontinuous surfactant aggregates. The Journal of physical chemistry, 
1989. 93(4): p. 1458-1464. 
599. Rapp, G., et al., X-ray diffraction studies on the effect of additives on the phase behaviour of lipids, 
in Lipid Bilayers. 2001, Springer. p. 165-187. 
600. Marcus, Y., Ions in Solution and their Solvation. 2015: John Wiley & Sons. 
601. Moelbert, S., B. Normand, and P. De Los Rios, Kosmotropes and chaotropes: modelling preferential 
exclusion, binding and aggregate stability. Biophysical chemistry, 2004. 112(1): p. 45-57. 
602. Gater, D.L., et al., Hydrogen bonding of cholesterol in the lipidic cubic phase. Langmuir, 2013. 
29(25): p. 8031-8038. 
603. Shojaei, A.H., B. Berner, and X. Li, Transbuccal delivery of acyclovir: I. In vitro determination of 
routes of buccal transport. Pharmaceutical research, 1998. 15(8): p. 1182-1188. 
604. Kanda, T., et al., Inhibitory effects of apple polyphenol on induced histamine release from RBL-2H3 
cells and rat mast cells. Bioscience, biotechnology, and biochemistry, 1998. 62(7): p. 1284-1289. 














































































Figure A.1.1. Calibration curves for 1st generation antihistamines Carbinoxamine maleate (CBX) 
and Diphenhydramine hydrochloride (DPH) obtained by HPLC 












































Figure A.1.2. Calibration curves for 2nd generation antihistamines Cetirizine dihydrochloride 



























































A.2. Host lipid selection 
 
A number of different monoacylglyerols were investigated for their ability to form the cubic phase 
in the presence of water. 8 lipids were selected and a range of water-lipid ratios under selected 
conditions of temperature were investigated. The lipid phases were prepared in accordance with 
the bulk preparation method. The lipids were weighed in their molten state and known volumes of 
water were carefully layered on top to allow for the diffusion of water and assembly of the 
lyotropic liquid crystals. 
 
 
Figure A.2.1 Chemical structures of the lipids used in this investigation 
 
The 8 lipids selected, whose structures are shown in figure A.2.1 were as follows: Phytantriol 
(3,7,11,15-Tetramethyl-1,2,3-hexadecanetriol); 7.7 MAG (1-(7Z-tetradecenoyl)-rac-glycerol), 7.8 
MAG (1-(7Z-pentadecenoyl)-rac-glycerol) and 7.9 MAG (1-(7Z-hexadecenoyl)-rac-glycerol); 
Monoolein 9.9 MAG (1-(9Z-octadecenoyl)-rac-glycerol), Monopalmitolein 9.7 MAG (1-(9Z-
hexadecenoyl)-rac-glycerol), Monovaccenin 11.7 MAG (1-(11Z-octadecenoyl)-rac-glycerol) and  
Monoeicosenoin 11.9 MAG (1-(11Z-eicosenoyl)-rac-glycerol). 
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Table A.2.1. Experimental conditions trialled for accessing the lipid cubic phase of various MAG 
lipids 






























RT 45 Clear/Viscous N Y 
RT 55 Clear/Viscous N Y 
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RT 45 Crystals Y N 
RT 55 Crystals Y N 












37 60 Kaleidoscope 
effect 
Y N 
37 65 Kaleidoscope 
effect 
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37 60 Clear/Viscous N Y 
37 55 Clear/Viscous N Y 







RT 50 Kaleidoscope 
effect 
Y N 
37 40 Kaleidoscope 
effect 
Y N 
Monoolein 9.9 Wax 40 40 Clear/Viscous N Y 
 RT 40 Clear/Viscous N Y 
Phytantriol N/A Wax RT 27 Clear/Viscous N Y 
 
A kaleidoscope effect was observed on the microscope for 7.7 and 7.9 MAG which would 
indicate the formation of the hexagonal phase. 11.9 MAG is a very waxy lipid at room temperature, 
with a relatively high melting point compared to the others on the list. The transportation of water 
into more waxy lipids when solid is much slower. The lipid began to solidify much more rapidly 
 232 
and this may have impeded the movement of water within the membrane even further and would 
require much higher temperatures for cubic phase formation. Those processes that would demand 
extended hold time at high temperatures to prepare cubic phases would be very costly, and from 
an economical perspective would be highly impractical. For this reason 11.9 MAG was ruled out 




Figure A.2.2. example CPLM images aquired on the Zeiss AxioScope Optical microscope at 10x 
magnification showing different phases of liquid crystalline systems: Hexagonal phase for 7.9 













Figure A.3.1. Micrograph of RBL-2H3 cells cultured in Eagle's Minimum Essential Medium 
(EMEM) 
 
A.4. Mucoadhesion Studies: MP-SPR investigation 
 
 
Figure A.4.1. MP-SPR sensogram from adsorption of mucin onto clean Au sensor registered at 
two wavelengths (670 and 785 nm). Mucin (100 ug/ml in PBS) was injected into 2 channels at a 
flow rate of 30ul/min. 
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Figure A.4.2. Typical kinetics fitting resulted obtained for MO-AZL from TraceDrawer™ 
software according to One-to-Two interaction model. Blue curve is the measured data while black 




















Figure A.4.3. Kinetics of adsorption to mucin as measured by MP-SPR: overlay of triplicate 















































































































































Figure A.6.1. 1D azimuthally integrated SAXS patterns of monoolein (MO) cubic mesophases 
formulated with or without antihistamines. The peaks of the patterns have been indexed according 






Figure A.6.2. 1D azimuthally integrated SAXS patterns of monopalmitolein (MPL) cubic 
mesophases formulated with or without antihistamines. The peaks of the patterns have been 
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Scheme B.1. Lipase attack on the ester bond present on the Monoacylglycerol lipid chain bridging 
the oleic acid component to the glycerol backbone breaking the lipid down into its constituents. 
Adapted from [1]. 





Scheme B.2. Schematic of Tetrahydrolipstatin’s reversible inhibitory action on the lipase 
demonstrating a nucleophilic attack of the β-lactone ring of THL by the serine residue at the lipase 
active site (a) producing an inactive acyl-enzyme complex product (b). Ultimately, hydrolysis of 
this covalent linkage frees the active enzyme (c) resulting in a carboxylic acid which may then be 























Figure B.1. 1D azimuthally integrated SAXS patterns of fresh monoolein blank/THL loaded cubic 
mesophases. Repetitions recorded sequentially demonstrate no impact on the phase from radiation 
exposure at a single location. Patterns are plotted from first scan at the bottom to last scan at the 
top. 












Figure B.2. 1D azimuthally integrated SAXS patterns of fresh monopalmitolein blank/THL loaded 
cubic mesophases. Repetitions recorded sequentially demonstrate no impact on the phase from 
radiation exposure at a single location. Patterns are plotted from first scan at the bottom to last 






















Figure B.3. 1D azimuthally integrated SAXS patterns of fresh monoolein and monopalmitolein 
caffeine loaded cubic mesophases with/without THL. Vertical lines indicate the position of the 













      
MO_Caffeine_1 wt. % MO_Caffeine_3 wt. % 
MPL_Caffeine_1 wt. % MPL_Caffeine_3 wt. % 
MPL_THL_Caffeine_1 wt. % MO_THL_Caffeine_1 wt. % 
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indices at each line corresponding to a Miller plane from the space group. $44
5  indicates a Diamond 
cubic phase and $44






Figure B.4. 1D azimuthally integrated SAXS patterns of fresh monoolein and monopalmitolein 
clofazimine citrate loaded cubic mesophases with/without THL. Vertical lines indicate the position 
of the peaks of the mesophase(s) present in the system as detailed in the legend, with the squares 
MO_CFZ-Citrate_1 wt. % MO_CFZ-Citrate_3 wt. % 
MPL_CFZ-Citrate_1 wt. % MPL_CFZ-Citrate_3 wt. % 
MPL_THL_CFZ-Citrate_1 wt. % 
MO_THL_CFZ-Citrate_1 wt. % 
 247 
of the indices at each line corresponding to a Miller plane from the space group. $44
5  indicates a 
Diamond cubic phase and $44




Figure B.5. 1D azimuthally integrated SAXS patterns of fresh monoolein and monopalmitolein 
cubic mesophases with/without THL showing the impact of lipase exposure on the phase. Vertical 
lines indicate the position of the peaks of the mesophase(s) present in the system as detailed in the 
legend, with the squares of the indices at each line corresponding to a Miller plane from the space 
group. $44
5  indicates a Diamond cubic phase and $44
6  the Gyroid phase. 
MO_Blank MO_THL_1.5 wt. % 




Figure B.6. 1D azimuthally integrated SAXS patterns of monoolein (MO) and monopalmitolein 
(MPL) cubic mesophases swelled in a variety of bio-relevant media of varied pH. The peaks of 




















































































Mathematical model plots for kinetics of release of CFZ-citrate 
Table B.1. Release kinetic modelling of CFZ-citrate from LCP gels 
 
Gel Sample 













MO 0.949 0.778 0.827 0.851 0.938 0.641 
MO_THL 0.885 0.896 0.955 0.893 0.945 0.517 
MPL 0.905 0.724 0.792 0.804 0.976 0.783 
MPL_THL 0.97 0.951 0.897 0.959 0.971 0.58 
 
Drug release from the cubic phase is usually diffusion-controlled and follows square root of time 
kinetics. This is shown by a linear relationship between the cumulative % of drug released and the 
square root of time (Higuchi model) for all of the LCP formulations. This is indicated by the 
relatively high correlation coefficient values. The linear relationship was stronger in the case of 
those samples prepared with the enzyme inhibitor where the correlation coefficient was closer to 
unity (0.897 and 0.955). The method describes a rate of release in a case where the drug loading 
in the matrix exceeds that of its solubility in a given media. 
 
Carrier systems that obey zero-order kinetics are considered gold-star in terms of their prolonged 
release capabilities. When the release data was fitted to the zero-order kinetic equation (cumulative 
% of drug released versus time), the relatively high r2 values suggested that the release kinetics 
from the system followed the zero-order model releasing CFZ-citrate at a constant rate per unit 
time, while the dissolution results were found not to fit as well with first order kinetics in the case 
of the gels in the absence of THL. This highlights the potential of the THL as a controlled release 
mediator underpinned of course by its ability to maintain an in-tact matrix for a greatly extended 
period of time. 
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Furthermore, to reiterate the hypothesis that erosion of the gels had a part to play in the release 
kinetics, and could be controlled by the introduction of THL, the data was fitted to the Hixson-
Crowell model (cube root % total drug - cube root of % unreleased drug v time (min)) which 
describes diffusion controlled release that is partly influenced by the change in size of the matrix 
system. The correlation coefficients were relatively high in the cases of all formulations (0.8 to 
0.96), again slightly higher in those containing THL. The linear relationships observed confirm 
that the digestion of the gels likely influenced the release of the CFZ-citrate salt from the phase. 
 
The data was then fitted to a Korsemeyer-Peppas model. The diffusion coefficients for all 
formulations was estimated from the linear regression of the Korsmeyer-Peppas model. This 
allows for further confirmation of the contribution of gel erosion to the release of CFZ-citrate upon 
determination of the diffusion coefficient (n). All formulations, showed coefficient values larger 
than 0.45. This would indicate an anomalous non-fickian diffusion transport that is both diffusion 
and swelling/erosion controlled. In this case, an n ≤ 0.45 indicates a Fickian diffusion mechanism 
and 0.45 < n < 0.89 corresponds to non-Fickian transport [6]. The diffusion coefficient is generally 
larger for those release systems driven by the erosion of the matrix, compared to the observed n 
values less than 0.89 indicative of diffusive release ([7]. Incorporating THL resulted in a decrease 
of the averaged diffusion coefficient of CFZ embedded in the LCP systems as expected, as the 
degradation of the phase was slow and thus it was possible for the drug to penetrate the aqueous 

















Figure B.8. Kinetic model plots for the release of CFZ-citrate from monoolein LCP formulated 








































































































































Figure B.9. Kinetic model plots for the release of CFZ-citrate from monoolein LCP in the presence 
of Lipase fitted to different mathematical models 
 
 































































































































Figure B.10. Kinetic model plots for the release of CFZ-citrate from monopalmitolein LCP 
formulated with 1.5 wt. % THL in the presence of Lipase fitted to different mathematical models 
 



























































































































Figure B.11. Kinetic model plots for the release of CFZ-citrate from monopalmitolein LCP THL 
in the presence of Lipase fitted to different mathematical models 
 



























































































































Mathematical model plots for kinetics of release of caffeine 
Table B.2. Release kinetic modelling of caffeine from LCP gels 
 
Gel Sample 













MO 0.761 0.96 0.955 0.905 0.917 0.44 
MO_THL 0.3961 0.952 0.901 0.875 0.943 0.274 
MPL 0.508 0.341 0.805 0.79 0.75 0.208 
MPL_THL 0.495 0.903 0.797 0.762 0.894 0.163 
 
The Higuchi square root of time release kinetics defines the release of pharmaceuticals from the 
cubic phase [8]. The Higuchi equation is based on a pseudo-steady-state approach and provides a 
mathematical means of demonstrating a direct proportionality between the total quantity of 
released drug and the square root of time, allowing one to understand the release mechanism of a 
material [9]. An exchange of water from the media into the internal matrix and simultaneous 
transfer of incorporated drug and water from the matrix to the external environment are the 
proposed events occurring during hydrophilic drug release from the cubic phase [8]. The calculated 
r2 values shown here present strong linear relationships between the cumulative % of drug released 
in the first 8 hours and the square root of time. These results indicate that the caffeine does indeed 
partitions predominantly into the aqueous channel network from which it diffuses into the media 
with little influence from the swelling and breakdown of the matrix itself. This data was 
complemented by fitting the release to a Korsemeyer-Peppas model as previously described. The 
various formulations yielded n values of ≤ 0.45. This is indicative of the simplest diffusion-
controlled process that is a Fickian diffusion mechanism corresponding to Fick’s law [6]. 
 
In contrast to the kinetics of CFZ release, when the release data from the various Caffeine 
systems were fitted to the zero-order kinetic equation, the relatively small regression values 
suggested that the system did not obey the model. However, the dissolution results were found to 
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have a better fit with first order kinetics. The correlation coefficient in this case was closest to 
unity suggesting that the release of caffeine from LCP most likely follows first order kinetics. This 
data strongly confirms the expected diffusion-controlled kinetics. In first-order release, the rate of 

































Figure B.12. Kinetic model plots for the release of caffeine from monoolein LCP formulated with 




























Zero-order kinetics model plot

























Higuchi model plot 
























First-order kinetics model plot
























































Figure B.13. Kinetic model plots for the release of caffeine from monoolein LCP in the presence 
of Lipase fitted to different mathematical models 
 
 



















































Higuchi model plot 

















































































Figure B.14. Kinetic model plots for the release of caffeine from monopalmitolein LCP 
formulated with 1.5 wt. % THL in the presence of Lipase fitted to different mathematical models 
 
 



































































































































Figure B.15. Kinetic model plots for the release of caffeine from monopalmitolein LCP in the 
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Probing the mechanism behind inhibitor-
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Figure C.1. (A) 2.8 Å resolution crystal structure (PDB code 1ETH [524]) of porcine pancreatic 
lipase showing one subunit out of the two identical subunits used for computation. The catalytic 
triad in the active site are shown in ball and stick representation coloured green for Ser153, red for 
 266 
Asp177 and blue for His264. The colipase is shown in ball and stick which controls the opening 
and closing of the flap/lid shown in orange (Cys238-Cys262). The secondary structures are 
represented as violet – a-helix, yellow – b-sheet/strand and grey – random coil. (B) 3D structures 
of the inhibitor Tetrahydrolipstatin (THL) and MAG lipid substrate Monoolein (MO). (C) Initial 
setup for docking with AutoDock 4.2 [528] with the grid box of dimensions 50 nm X 50 nm X 50 
nm around the catalytic residue Asp153 at the centre. (D) Four best docked THL-lipase complex 
poses ranked according to their binding energies (see Table C1). The same colour coding for the 
catalytic triad is followed. (E) Four best docked MO-lipase complex poses (Table C2). (F-I) Time 




Figure C.2. Time evolution of the total interaction energies (Coulomb electrostatics + vdW) of 
THL-catalytic pocket and MO-catalytic pocket (A) without colipase and (B) with colipase. The 
 268 
running average traces of energies are computed over every 2000 time points. (C) Representative 
snapshot of MO interacting with His264 of the lipase catalytic pocket via electrostatic interactions. 
(D) Interaction energies of the mobile flap domain with colipase. Residue-wise energy 
contributions towards the total binding energy of inhibitor and lipid substrate with lipase. 
Difference in energy contributions between THL and MO binding from residues of (E) lipase 
without colipase and (F) lipase with colipase. The residues forming the catalytic triad are annotated 
as green for S153, red for D177 and blue for His264, and residues encompassing the mobile flap 
(Cys238-Cys262) domain is shaded in orange. (G) Contributions from THL and MO towards the 
total binding energy. (H) Difference in energy contributions between THL and MO binding from 






























































Figure C.3. Optimized geometry of MO-THL-MO. Binding energy in kJ mol-1. Hydrogen – 
white, carbon – grey, oxygen – red, nitrogen – blue; intra and inter molecular hydrogen bonds are 











Figure C.4. Degradation behaviour of blank monoolein lipid controlled-release formulations in  
lipase-containing PBS at 37°C and 200 rpm. 
 
Table C.3. Calculated solubility of PTX in dissolution media through HPLC analysis 
(N=3) 
Dissolution Media Calculated Concentration 
(mg/mL) 
1X PBS pH 7.4 TLTD 
1X PBS pH 5.8 TLTD 
10X PBS pH 5.8 TLTD 
Deionised water TLTD 
Acetonitrile 48.2  
2 % HCD (Heptakis(2,6-di-O-
methyl)-β-cyclodextrin) 
71.5  
Ethanol 31.5  
Methanol 28.3  
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